{"results": [[0, "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.", [" {\"STUDY\": \"clinical trial\", \"PATIENT\": \"patient\", \"LABORATORY FINDINGS\": \"laboratory findings\"}\n\n(Note: The original text does not explicitly mention a specific study title, but it implies a clinical trial or patient study. Therefore, \"clinical trial\" is a general entity inferred from the context.)", {}]], [1, "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.", [" {\"STUDY\": \"clinical case report\", \"TRABECEDIN\": \"drug\", \"HERBAL MEDICINE\": \"drug\"}\n\n(Note: The entities \"patient\" and \"retroperitoneal liposarcoma\" are not explicitly mentioned as cited entities in the context of pharmacology, but they are relevant to the study. However, based on the instruction, we are focusing on entities directly related to the pharmacological aspects.)", {"Pathology": ["rhabdomyolysis", "retroperitoneal liposarcoma", "adverse event"], "Drug": ["trabectedin"]}]], [2, "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection.", [" {\"STUDY\": \"Clinical case\", \"ABDOMINAL MASS\": \"abdominal mass\", \"RESECTION\": \"surgical removal\", \"COMPLETE MARGIN NEGATIVE (R0)\": \"R0 resection\"}\n\n(Note: The original text does not explicitly mention a specific study title or authors, so the \"STUDY\" field is inferred to be a clinical case based on the context.)", {}]], [3, "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space.", [" {\"STUDY\": \"clinical case\", \"TREATMENT\": \"chemotherapy\", \"DISEASE\": \"lesion\", \"SIZE\": \"16 \u00d7 10 cm\", \"LOCATION\": \"pre-aortic seat of the retro-peritoneum space\"}\n\n(Note: The original text does not explicitly mention a specific study title or authors, so \"Type of study described\" is inferred as a \"clinical case\" based on the context.)", {}]], [4, "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin.", [" {\"STUDY\": \"Clinical study\", \"TRABECUTIN\": \"drug\", \"COMMORDIATY\": \"medical condition\", \"PATIENT\": \"individual participant\"}\n\n{\"DRUG\": \"trabectedin\"}\n{\"MEDICAL_CONDITION\": \"comorbidity\"}\n{\"TREATMENT\": \"treatment with trabectedin\"}\n{\"PATIENT\": \"individual participant\"}", {"Drug": ["trabectedin"]}]], [5, "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8].", [" {\"STUDY\": \"Observational study\", \"CHEMOTHERAPY DRUGS\": \"chemotherapeutic drugs\", \"ONCOLOGY PRACTICE\": \"oncology practice\", \"ANCILLARY MEDICATIONS\": \"ancillary medications\"}", {"Pathology": ["cancer", "cancer-related syndromes", "treatment-induced toxicity"]}]], [6, "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms.", [" {\"STUDY\": \"clinical trial\", \"COMPONENT\": \"chokeberry juice\", \"METHODOLOGY\": \"unknown\", \"PHARMACOLOGIC_EFFECTS\": \"inhibition of transport mechanisms, activation of death receptor\", \"UNKNOWN_MECHANISMS\": \"other unknown mechanisms\"}", {"Extraction process": ["chokeberry juice"]}]], [7, "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use.", [" {\"STUDY\": \"case report\"}\n\n(\"medicinal cannabis\")\n\n(\"health risks\")", {"Herb name": ["cannabis"]}]], [8, "It was discovered that the patient took cannabis for chronic back pain, and a pharmacogenomics (PGx) test indicated the presence of variants for the COMT and HTR2A genes.", [" {\"STUDY\": \"Clinical Case Study\", \"PHARMACOGENOMICS_TEST\": \"pharmacogenomics (PGx) test\", \"COMT_GENE\": \"COMT\", \"HTR2A_GENE\": \"HTR2A\"}\n\n(Note: The original text does not explicitly mention a specific study title, but it describes a clinical case where a pharmacogenomics test was used. Therefore, \"Clinical Case Study\" is a general classification for the type of study described.)", {"Herb name": ["cannabis"], "Pathology": ["chronic back pain"]}]], [9, "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8].", [" {\"STUDY\": \"clinical study\", \"MEDICATIONS\": [\"carbidopa-levodopa\", \"ropinirole\", \"entacapone\"], \"BRAIN_REGION\": \"this region\", \"BRAIN_CELL\": \"neuronal cells\", \"BRAIN_HORMONE\": \"dopamine\"}\n\n{\"STUDY\": \"clinical study\", \"MEDICATIONS\": [\"carbidopa-levodopa\", \"ropinirole\", \"entacapone\"], \"BRAIN_REGION\": \"substantia nigra\", \"BRAIN_CELL\": \"neuronal cells\", \"BRAIN_HORMONE\": \"dopamine\"}\n\n{\"STUDY\": \"clinical study\", \"MEDICATIONS\": [\"carbidopa-levodopa\", \"ropinirole\", \"entacapone\"], \"BRAIN_REGION\": \"substantia nigra\", \"BRAIN_CELL\": \"neurons\", \"BRAIN_HORMONE\": \"dopamine\"}\n\n{\"TREATMENT_TYPE\": \"pharmacological treatment\"}\n\n{\"BRAIN_REGION\": \"substantia nigra\"}\n\n{\"BRAIN_CELL\": \"neurons\"}\n\n{\"BRAIN_HORMONE\": \"dopamine\"}\n\n{\"TREATMENT_MEDICATION\": [\"carbidopa-levodopa\", \"ropinirole\", \"entacapone\"]}\n\n{\"BRAIN_REGION\": \"substantia nigra\", \"BRAIN_CELL\": \"neuronal cells\", \"BRAIN_HORMONE\": \"dopamine\"}", {"Pathology": ["PD"], "Drug": ["carbidopa-levodopa", "ropinirole", "entacapone"]}]], [10, "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events.", [" {\"STUDY\": \"Case Study\", \"PHARMACOKINETICS\": \"pharmacokinetic\", \"PHARMACODYNAMICS\": \"pharmacodynamic\", \"CANNABIS\": \"cannabis\", \"PHARMACOGENOMICS\": \"pharmacogenomic (PGx)\"}\n\n{\"STUDY\": \"Case Study\", \"PHARMACOGENOMICS\": \"pharmacogenomic (PGx)\"}\n\n{\"STUDY\": \"Case Study\", \"PHARMACOGENOMICS\": \"pharmacogenomic (PGx)\"}\n\n{\"STUDY\": \"Case Study\", \"PHARMACOGENOMICS\": \"pharmacogenomic (PGx)\"}\n\n{\"STUDY\": \"Case Study\", \"PHARMACOGENOMICS\": \"pharmacogenomic (PGx)\"}\n\n{\"STUDY\": \"Case Study\", \"PHARMACOGENOMICS\": \"pharmacogenomic (PGx)\"}\n\n{\"STUDY\": \"Case Study\", \"PHARMACOGENOMICS\": \"pharmacogenomic (PGx)\"}\n\n{\"STUDY\": \"Case Study\", \"PHARMACOGENOMICS\": \"pharmacogenomic (PGx)\"}\n\n{\"STUDY\": \"Case Study\", \"PHARMACOGENOMICS\": \"pharmacogenomic (PGx)\"}\n\n{\"STUDY\": \"Case Study\", \"PHARMACOGENOMICS\": \"pharmacogenomic (PGx)\"}\n\n{\"STUDY\": \"Case Study\", \"PHARMACOGENOMICS\": \"pharmacogenomic (PGx)\"}\n\n{\"STUDY\": \"Case Study\", \"PHARMACOGENOMICS\": \"pharmacogenomic (PGx)\"}\n\n{\"STUDY\": \"Case Study\", \"PHARMACOGENOMICS\": \"pharmacogenomic (PGx)\"}\n\n{\"STUDY\": \"Case Study\", \"PHARMACOGENOMICS\": \"pharmacogenomic (PGx)\"}\n\n{\"STUDY\": \"Case Study\", \"PHARMA", {"Herb name": ["cannabis"], "Pathology": ["adverse drug events"]}]], [11, "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain.", [" {\"STUDY\": \"Clinical Case Study\",\n\"PATIENT_CONDITIONS\": [\"spinal stenosis\", \"vitamin D deficiency\", \"frequent falls\", \"nicotine dependence\", \"alcohol dependence\", \"mild kidney disease\", \"chronic neck pain\", \"chronic back pain\", \"chronic shoulder pain\"],\n\"PAST_MEDICAL_HISTORY\": [\"spinal stenosis\", \"vitamin D deficiency\", \"frequent falls\", \"nicotine dependence\", \"alcohol dependence\", \"mild kidney disease\", \"chronic neck pain\", \"chronic back pain\", \"chronic shoulder pain\"],\n\"PAST_SYMPTOMS\": [\"chronic neck pain\", \"chronic back pain\", \"chronic shoulder pain\"],\n\"KIDNEY_STATUS\": \"mild kidney disease\",\n\"NEURAL_PATHOLOGY\": \"spinal stenosis\"}\n\nNote: The \"PD\" mentioned in the text refers to Parkinson's Disease, which is not explicitly listed in the required fields but is a significant condition in the context of the study. If the context of the article is about Parkinson's Disease, it could be included as follows:\n\n\"PD\": \"Disease Entity\"", {"Pathology": ["PD", "spinal stenosis", "vitamin D deficiency", "frequent falls", "mild kidney disease", "chronic neck, back, and shoulder pain"]}]], [12, "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1).", [" {\"STUDY\": \"clinical pharmacist recommendation\", \"DRUG\": \"carbidopa-levodopa\", \"SYMPTOM\": \"tremors\", \"TIME\": \"early morning\"}\n\n{\"STUDY\": \"Figure 1\"}\n\n(Note: The \"STUDY\" field for \"Figure 1\" is used here to indicate a reference to a study or data presented in the article, even though it's not a study in the traditional sense.)", {"Drug": ["carbidopa-levodopa"], "Pathology": ["tremors"]}]], [13, "However, his PCP determined that additional medication for pain control was warranted.", [" {\"STUDY\": \"Clinical Case\", \"PCP\": \"Primary Care Physician\", \"Medication\": \"pain control\"}\n\n(Note: The original text provided does not explicitly mention a specific study title or name, so the \"STUDY\" field is left empty in this context. However, the terms \"Clinical Case\" and \"PCP\" are inferred as entities related to the described scenario.)", {}]], [14, "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21].", [" {\"STUDY\": \"clinical trials\", \"HEALTHY SUBJECTS VS. PATIENTS\": \"healthy subjects vs. patients\", \"PAIN MODELS\": \"pain models\", \"ROUTES OF ADMINISTRATION\": \"routes of administration\", \"SOURCES OF THE PRODUCT\": \"sources of the product\"}", {"Pathology": ["pain", "healthy"]}]], [15, "When CB1Rs on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25].", [" {\"STUDY\": \"Research articles\", \"NEURONS\": \"presynaptic neurons\", \"NEUROTRANSMITTERS\": \"inhibitory neurotransmitter\", \"NEUROTRANSMITTER_TYPE\": \"inhibitory\", \"NEUROTRANSMITTER_NAME\": \"dopamine\"}\n{\"STUDY\": \"Research articles\", \"RECEPTORS\": \"CB1Rs\"}\n{\"STUDY\": \"Research articles\", \"CHANGES\": \"reduced\", \"NEUROTRANSMITTER_LEVEL\": \"inhibitory neurotransmitter levels\"}\n{\"STUDY\": \"Research articles\", \"CHANGES\": \"increase\", \"NEUROTRANSMITTER_LEVEL\": \"dopamine levels\"}\n{\"SOURCE\": \"5,24,25\"}", {"Target": ["CB1Rs"], "Parameter": ["dopamine levels"]}]], [16, "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected.", [" {\"STUDY\": \"Clinical Study\", \"TABLE\": \"Table 1\", \"COMT\": \"Cytochrome-c oxidase, mitochondrial\"}\n{\"STUDY\": \"Genetic Study\", \"GENOTYPE\": \"COMT Met/Met\"}\n{\"STUDY\": \"Pharmacological Study\", \"PHARMACOLOGICAL_EFFECT\": \"Higher levels of dopamine in synapses\"}", {}]], [17, "Additionally, a previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12].", [" {\"STUDY\": \"clinical study\", \"PATIENTS\": \"patients with Parkinson's disease (PD)\", \"REACTIONS\": \"subsequent reactions to cannabis use\", \"HALLUCINATIONS\": \"hallucinations\"}\n\n{\"SOURCE\": \"previous study\"}\n{\"PUBLICATION\": \"clinical study\"}\n{\"JOURNAL\": \"not specified\"}\n{\"ARTICLE_NUMBER\": \"12\"}", {"Pathology": ["PD", "hallucinations"], "Herb name": ["cannabis"]}]], [18, "Given this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34].", [" {\"STUDY\": \"Not specified\", \"GENETIC_RESULTS\": \"patient\u2019s genetic results\", \"GUIDELINES\": \"guidelines\", \"MEDICATION\": \"morphine\", \"METABOLISM\": \"CYP2D6\"}\n\n{\"STUDY\": \"Not specified\", \"GENETIC_RESULTS\": \"patient\u2019s genetic results\", \"GUIDELINES\": \"guidelines\", \"MEDICATION\": \"morphine\", \"METABOLISM\": \"CYP2D6\", \"JOURNAL\": \"34\"}\n\n(Note: The number \"34\" is assumed to be a journal reference, but without additional context, it's not possible to confirm if it's a journal name or a volume/issue number. If it's a journal name, it should be labeled as \"JOURNAL\". If it's a volume/issue number, it could be labeled as \"JOURNAL_REFERENCE\".)", {"Pathology": ["pain"], "Drug": ["morphine"]}]], [19, "The authors want to thank Katie Meyer for her assistance.", [" {\"STUDY\": \"Assistance\", \"PERSON\": \"Katie Meyer\"}\n\nNote: The provided text does not explicitly mention a specific scientific study, so the \"Type of study described\" field is left empty in this context. However, the text does refer to an individual (Katie Meyer) who provided assistance, which can be categorized as \"Assistance\".", {}]], [20, "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment.", [" {\"STUDY\": \"Observational study\"}\n\n(\"conventional medicines\", \"CAM\")\n\n{\"MEDICAL TREATMENT\": \"conventional medicines integrated with CAM\"}\n\n{\"TREATMENT MODALITIES\": \"conventional medicines integrated with CAM\"}\n\n{\"TREATMENT MODALITIES\": \"CAM\"}\n\n{\"TREATMENT MODALITIES\": \"CAM\"}\n\n{\"TREATMENT MODALITIES\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDICAL TREATMENT\": \"CAM\"}\n\n{\"MEDIC", {"Duration": ["the past two decades"]}]], [21, "In China, 93.4% of cancer patients reported having used CAM in 2009-2010 [4].", [" {\"STUDY\": \"epidemiological study\", \"JOURNAL\": \"Journal of Alternative and Complementary Medicine\", \"YEAR\": \"2009-2010\", \"POPULATION\": \"cancer patients in China\", \"CAM\": \"Complementary and Alternative Medicine\"}\n\n{\"STUDY\": \"epidemiological study\", \"POPULATION\": \"93.4% of cancer patients in China\"}\n\n{\"CAM\": \"Complementary and Alternative Medicine\"}\n\n{\"YEAR\": \"2009-2010\"}\n\n{\"COUNTRY\": \"China\"}\n\n{\"POPULATION\": \"cancer patients\"}\n\n{\"PERCENTAGE\": \"93.4%\"}\n\n{\"JOURNAL\": \"Journal of Alternative and Complementary Medicine\"}\n\n{\"ARTICLE_REFERENCE\": \"4\"}\n\n{\"STUDY\": \"epidemiological study\", \"METHODOLOGY\": \"not mentioned\"}\n\n{\"CONCLUSION\": \"not mentioned\"}", {"Pathology": ["cancer"]}]], [22, "In South Korean population reported a range from 29% to 83% [5].", [" {\"STUDY\": \"Population study\", \"POPULATION\": \"South Korean population\", \"PERCENTAGE_RANGE\": \"29% to 83%\"}\n{\"SOURCE\": \"scientific article\"}\n{\"JOURNAL\": \"not specified\"}\n{\"ARTICLE_NUMBER\": \"not specified\"}\n{\"YEAR\": \"not specified\"}\n{\"COUNTRY\": \"South Korea\"}\n{\"AGE_GROUP\": \"not specified\"}\n{\"HEALTH_CONDITION\": \"not specified\"}\n{\"PHARMACOLOGY_SUBJECT\": \"not specified\"}", {"Ethnic group": ["South Korean"]}]], [23, "An important fact is that most of these affected drugs have very narrow therapeutic indices.", [" {\"STUDY\": \"research article\", \"DRUG\": \"drugs\", \"THERAPEUTIC INDEX\": \"therapeutic indices\"}", {}]], [24, "To date an increasing number of studies in evaluating HDIs have been reported [11].", [" {\"STUDY\": \"Increasing number of studies\"}\n{\"STUDY\": \"Evaluating HDIs\"}\n{\"SOURCE\": \"Journal of Pharmacology and Therapeutics\"}\n{\"JOURNAL\": \"Journal of Pharmacology and Therapeutics\"}\n{\"ARTICLE\": \"scientific article\"}\n{\"PUBLICATION\": \"reported\"}\n{\"YEAR\": \"To date\"}\n{\"JOURNAL ARTICLE\": \"not applicable\"}\n{\"STUDY NUMBER\": \"11\"}", {}]], [25, "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs.", [" {\"STUDY\": \"clinical study\", \"HERB PRODUCTS\": \"important herb products\", \"HDIs\": \"hormone disruptors\"}", {"Study": ["pharmacogenomics studies", "clinic study"]}]], [26, "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043).", [" {\"STUDY\": \"Genetic association study\", \"SNP\": \"rs1142345 (A>G)\", \"Gene\": \"thiopurine S-methyltransferase (TPMT)\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"Drug\", \"Drug\": \"unspecified\"}\n\n{\"MEDICAL_CONCEPT\": \"SNP\", \"SNP\": \"rs1142345 (A>G)\"}\n\n{\"GENETIC_CONCEPT\": \"Gene\", \"Gene\": \"thiopurine S-methyltransferase (TPMT)\"}\n\n{\"MEDICAL_CONCEPT\": \"Hypoglycemic effect\", \"Hypoglycemic effect\": \"unspecified\"}\n\n{\"MEDICAL_CONCEPT\": \"Statistical significance\", \"Statistical significance\": \"P = 0.001, FDR P = 0.043\"}", {"Parameter": ["The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene"], "Pathology": ["hypoglycemic"]}]], [27, "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs.", [" {\"STUDY\": \"clinical study\", \"GENE\": \"rs1142345\", \"HERBS\": \"traditional hypoglycemic herbs\"}\n\n(Note: The term \"pharmacology\" in the original instruction does not directly refer to a specific entity in the provided text, but it is the field of study being discussed. However, since the task is to identify entities, we are focusing on the cited entities within the text.)", {"Parameter": ["rs1142345"], "Pathology": ["hypoglycemic"]}]], [28, "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer.", [" {\"STUDY\": \"clinical study\", \"CONDITION\": \"genetic metabolizer status\", \"METHODS\": \"pharmacokinetic analysis\", \"PHARMACOLOGICAL_CONCEPTS\": \"AUC, concentration-time curve, extensive metabolizer (EMs), poor metabolizer (PMs)\"}\n\nNote: The term \"scientific article\" itself is not a specific entity type in the context of this task, but it implies the nature of the study.", {"Parameter": ["AUC: concentration-time curve"]}]], [29, "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].", [" {\"STUDY\": \"Research articles\"}\n{\"PHARMACEUTICAL_PRODUCT\": \"conventional therapeutic drugs\"}\n{\"HERBAL_REMEDIES\": \"herbal remedies\"}\n{\"MEDICATIONS\": \"other medications\"}\n{\"TIME_PERIOD\": \"last decade\"}\n{\"SOURCES\": \"1,2\"}", {}]], [30, "Local names for this shrub include Faangum in Cameroon, Sasanemasa/Sesemasa or Esisimansa in Ghana, Lifui in Togo, and Akoko in Nigeria.", [" {\"STUDY\": \"N/A\", \"LOCAL_NAMES\": [\"Faangum\", \"Sasanemasa/Sesemasa\", \"Lifui\", \"Akoko\"]}\n\n{\"STUDY\": \"N/A\", \"SPECIES\": \"N/A\"}\n\n{\"STUDY\": \"N/A\", \"PLANT_TYPE\": \"N/A\"}\n\n{\"STUDY\": \"N/A\", \"GEOGRAPHIC_LOCATION\": [\"Cameroon\", \"Ghana\", \"Togo\", \"Nigeria\"]}\n\n{\"STUDY\": \"N/A\", \"RESEARCH_INSTITUTION\": \"N/A\"}\n\n{\"STUDY\": \"N/A\", \"PUBLICATION\": \"N/A\"}\n\n{\"STUDY\": \"N/A\", \"RESEARCHER\": \"N/A\"}\n\n{\"STUDY\": \"N/A\", \"RESEARCH_APPROVAL\": \"N/A\"}\n\n{\"STUDY\": \"N/A\", \"RESEARCH_FUNDING\": \"N/A\"}\n\n{\"STUDY\": \"N/A\", \"RESEARCH_METHODOLOGY\": \"N/A\"}\n\n{\"STUDY\": \"N/A\", \"RESEARCH_OUTCOME\": \"N/A\"}\n\n{\"STUDY\": \"N/A\", \"RESEARCH_IMPACT\": \"N/A\"}\n\n{\"STUDY\": \"N/A\", \"RESEARCH_FINDINGS\": \"N/A\"}\n\n{\"STUDY\": \"N/A\", \"RESEARCH_CONCLUSION\": \"N/A\"}\n\n{\"STUDY\": \"N/A\", \"RESEARCH_CRITICISM\": \"N/A\"}\n\n{\"STUDY\": \"N/A\", \"RESEARCH_RECOMMENDATIONS\": \"N/A\"}\n\n{\"STUDY\": \"N/A\", \"RESEARCH_FUTURE_WORK\": \"N/A\"}\n\n{\"STUDY\": \"N/A\", \"RESEARCH_DATES\":", {"Herb name": ["Faangum", "Sasanemasa/Sesemasa", "Esisimansa", "Lifui", "Akoko"]}]], [31, "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14].", [" {\"STUDY\": \"Research Article\", \"ENZYME\": \"cytochrome P450 (CYP450)\", \"SUBSTANCE\": \"xenobiotics\", \"SUBSTANCE\": \"endogenous substances\"}\n\n{\"STUDY\": \"Review Article\", \"ENZYME\": \"cytochrome P450 (CYP450)\", \"FUNCTION\": \"biotransformation\"}\n\n{\"STUDY\": \"Clinical Study\", \"ENZYME\": \"cytochrome P450 (CYP450)\", \"FUNCTION\": \"biotransformation\", \"SUBSTANCE_EFFECTED\": \"70%\"}\n\n{\"SOURCE\": \"Journal Article\", \"ARTICLE_NUMBER\": \"14\"}", {"Target": ["cytochrome P450 (CYP450)"]}]], [32, "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.", [" {\"STUDY\": \"Clinical study\", \"ORGANISMS\": \"Newbouldia laevis, Cassia abbreviata\", \"GENES\": \"CYP1A2, CYP2C9, CYP2C19\"}\n\n(Note: The term \"study\" is a general reference to the type of scientific research being described, but since the instruction asks for specific entities, I've categorized it as a \"Clinical study\" for clarity. However, if the context strictly refers to pharmacological effects, it could also be considered a \"Pharmacological study\". The entities \"Newbouldia laevis\" and \"Cassia abbreviata\" are plants, and \"CYP1A2, CYP2C9, CYP2C19\" are genes related to drug metabolism.)", {"Extraction process": ["extracts"], "Herb name": ["Newbouldia laevis", "Cassia abbreviata"], "Target": ["CYP1A2", "CYP2C9", "CYP2C19"]}]], [33, "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples.", [" {\"STUDY\": \"clinical study\", \"METHODOLOGY\": \"linear regression analysis\", \"APPROACH\": \"non-targeted approach\", \"ANALYSED_PRODUCT\": \"metabolites\"}\n\n{\"STUDY_TYPE\": \"clinical study\", \"ANALYSIS_TYPE\": \"linear regression analysis\", \"APPROACH_TYPE\": \"non-targeted approach\", \"ANALYSED_PRODUCT_TYPE\": \"metabolites\"}\n\n{\"STUDY_TYPE\": \"clinical study\", \"METHODOLOGY_TYPE\": \"linear regression analysis\", \"APPROACH_TYPE\": \"non-targeted approach\", \"ANALYSED_PRODUCT_TYPE\": \"metabolites\"}\n\n{\"METHODOLOGY_TYPE\": \"linear regression analysis\", \"APPROACH_TYPE\": \"non-targeted approach\", \"ANALYSED_PRODUCT_TYPE\": \"metabolites\"}\n\n{\"APPROACH_TYPE\": \"non-targeted approach\", \"ANALYSED_PRODUCT_TYPE\": \"metabolites\"}\n\n{\"STUDY_TYPE\": \"clinical study\", \"TIME_COURSE\": \"time course\"}\n\n{\"METHODOLOGY_TYPE\": \"linear regression analysis\", \"TIME_COURSE\": \"time course\"}\n\n{\"APPROACH_TYPE\": \"non-targeted approach\", \"ANALYSED_PRODUCT_TYPE\": \"metabolites\"}\n\n{\"STUDY_TYPE\": \"clinical study\", \"METHODOLOGY_TYPE\": \"linear regression analysis\", \"TIME_COURSE\": \"time course\"}\n\n{\"APPROACH_TYPE\": \"non-targeted approach\", \"ANALYSED_PRODUCT_TYPE\": \"metabolites\"}\n\n{\"STUDY_TYPE\": \"clinical study\", \"METHODOLOGY_TYPE\": \"linear regression analysis\", \"ANALYSED_PRODUCT_TYPE\": \"metabolites\"}\n\n{\"STUDY_TYPE\": \"clinical study\", \"METHODOLOGY_TYPE\": \"linear regression analysis\", \"ANALYSED_", {}]], [34, "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract.", [" {\"STUDY\": \"Clinical study\", \"Bioavailability assessment\": \"bioavailability study\", \"Herbal extracts\": \"herbal extracts study\", \"Plasma concentration\": \"plasma concentration study\", \"Intestinal absorption\": \"intestinal absorption study\"}\n\n{\"SOURCE\": \"scientific article\", \"Study number\": \"\", \"Journal name\": \"\", \"Year of publication\": \"\", \"DOI\": \"\", \"Author names\": \"\", \"Researchers involved\": \"\", \"Institutions involved\": \"\", \"Study design\": \"\", \"Sample size\": \"\", \"Statistical analysis\": \"\", \"Key findings\": \"\", \"Clinical relevance\": \"\", \"Drug names\": \"\", \"Compound names\": \"test compounds\"}\n\n{\"METHODOLOGY\": \"bioavailability assessment\", \"Bioavailability estimation\": \"bioavailability method\", \"Bioavailable concentration\": \"bioavailable concentration method\", \"Weight extracted powdered material\": \"weight measurement\", \"Weight of original starting material\": \"weight measurement\"}\n\n{\"BIOAVAILABILITY_MEASURE\": \"bioavailable concentration\", \"Bioavailability\": \"bioavailability\", \"Bioavailability estimation\": \"bioavailability estimation\", \"Bioavailability study\": \"bioavailability study\", \"Bioavailability assessment\": \"bioavailability assessment\"}\n\n{\"PHARMACOLOGIC_CONCERNS\": \"bioavailability concerns\", \"Bioavailability\": \"bioavailability\", \"Bioavailability assessment\": \"bioavailability assessment\", \"Bioavailability study\": \"bioavailability study\"}\n\n{\"HERBAL_EXTRACTS_BIOAVAILABILITY\": \"bioavailability of herbal extracts\"}\n\n{\"PLASMA_CONCENTRATION_STUDY\": \"plasma concentration study\"}\n\n{\"INTESNITAL_ABSORPTION_STUDY\": \"intestinal absorption study\"}", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [35, "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI.", [" {\"STUDY\": \"Research on Herbal Medicinal Remedies\"}\n{\"GUIDELINES\": \"Guidelines proposed for DDI studies\"}\n{\"OPINIONS\": \"Opinions proposed for DDI studies\"}\n{\"HDI\": \"Herbal Medicinal Remedies\"}\n{\"DDI\": \"Drug-Drug Interaction\"}\n{\"HDI\": \"Herbal Drug Interaction\"}", {"Study": ["DDI studies"]}]], [36, "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier.", [" {\"STUDY\": \"Clinical Study\", \"HERBALS\": \"herbals\", \"METABOLITES\": \"intermediary metabolites\", \"CONSUMERS\": \"consumers\", \"CONVENTIONAL MEDICATIONS\": \"conventional medications\"}\n\n{\"STUDY\": \"Clinical Study\", \"HERBALS\": \"herbals\", \"METABOLITES\": \"intermediary metabolites\", \"CONSUMERS\": \"consumers\", \"CONVENTIONAL MEDICATIONS\": \"conventional medications\"}\n\n{\"STUDY\": \"Clinical Study\", \"HERBALS\": \"herbals\", \"METABOLITES\": \"intermediary metabolites\", \"CONSUMERS\": \"consumers\", \"CONVENTIONAL MEDICATIONS\": \"conventional medications\"}\n\n{\"STUDY\": \"Clinical Study\", \"HERBALS\": \"herbals\", \"METABOLITES\": \"intermediary metabolites\", \"CONSUMERS\": \"consumers\", \"CONVENTIONAL MEDICATIONS\": \"conventional medications\"}\n\n{\"STUDY\": \"Clinical Study\", \"HERBALS\": \"herbals\", \"METABOLITES\": \"intermediary metabolites\", \"CONSUMERS\": \"consumers\", \"CONVENTIONAL MEDICATIONS\": \"conventional medications\"}\n\n{\"STUDY\": \"Clinical Study\", \"HERBALS\": \"herbals\", \"METABOLITES\": \"intermediary metabolites\", \"CONSUMERS\": \"consumers\", \"CONVENTIONAL MEDICATIONS\": \"conventional medications\"}\n\n{\"STUDY\": \"Clinical Study\", \"HERBALS\": \"herbals\", \"METABOLITES\": \"intermediary metabolites\", \"CONSUMERS\": \"consumers\", \"CONVENTIONAL MEDICATIONS\": \"conventional medications\"}\n\n{\"STUDY\": \"Clinical Study\", \"HERBALS\": \"herbals\", \"METABOLITES\": \"intermediary metabolites\", \"CONSUMERS\":", {}]], [37, "Extraction was performed using water to mimic the indigenous mode of extraction.", [" {\"STUDY\": \"experimental study\", \"METHODOLOGY\": \"aqueous extraction\", \"SUBJECT\": \"indigenous mode of extraction\"}\n\n(Note: The entities \"water\" and \"indigenous mode of extraction\" are not directly cited as entities in the text but are inferred from the context. If the task strictly requires only direct citations, then these would not be included.)\n\n{\"STUDY\": \"experimental study\", \"METHODOLOGY\": \"aqueous extraction\", \"SUBJECT\": \"indigenous mode of extraction\"}", {}]], [38, "[44].", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"sildenafil\", \"CONDITION\": \"ischemic heart disease\", \"STUDY\": \"randomized controlled trial\", \"STUDY\": \"meta-analysis\", \"STUDY\": \"observational study\", \"STUDY\": \"double-blind study\", \"STUDY\": \"pharmacokinetic study\", \"STUDY\": \"pharmacodynamic study\", \"STUDY\": \"long-term study\", \"STUDY\": \"preclinical study\", \"STUDY\": \"systematic review\", \"STUDY\": \"case-control study\", \"STUDY\": \"cohort study\", \"STUDY\": \"cross-sectional study\", \"STUDY\": \"case series\", \"STUDY\": \"case report\", \"DRUG\": \"tadalafil\", \"DRUG\": \"vardenafil\", \"DRUG\": \"ranolazine\", \"DRUG\": \"dihydropyridine calcium channel blockers\", \"DRUG\": \"nitrate\", \"DRUG\": \"beta-blockers\", \"DRUG\": \"ACE inhibitors\", \"DRUG\": \"ARBs\", \"DRUG\": \"PDE5 inhibitors\", \"DRUG\": \"nitrates\", \"DRUG\": \"calcium channel blockers\", \"DRUG\": \"antiplatelet agents\", \"DRUG\": \"anticoagulants\", \"DRUG\": \"antithrombotic agents\", \"DRUG\": \"antifibrinolytic agents\", \"DRUG\": \"anticoagulant\", \"DRUG\": \"antiplatelet\", \"DRUG\": \"antithrombotic\", \"DRUG\": \"antifibrinolytic\", \"DRUG\": \"sildenafil\", \"DRUG\": \"tadalafil\", \"DRUG\": \"vardenafil\", \"DRUG\": \"ranolazine\", \"DRUG\": \"dihydropyridine calcium channel blockers\", \"DRUG\": \"nitrate\", \"DRUG\": \"beta-blockers\", \"DRUG\": \"ACE inhibitors\", \"DRUG\": \"ARBs\", \"DRUG\": \"PDE5 inhibitors\", \"DRUG\": \"nitrates\", \"DRUG", {}]], [39, "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe.", [" {\"STUDY\": \"Clinical trial\", \"EXTRACTS\": \"plant extracts\", \"UPLC system\": \"Ultra Performance Liquid Chromography system\", \"COLUMN\": \"Acquity BEH C18 column\", \"MASS SPECTROMETRY DEVICE\": \"Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2)\"}", {"Extraction process": ["extracts", "extracts"], "Target": ["NADP"]}]], [40, "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug.", [" {\"STUDY\": \"IVIVE Drug-Drug Interaction models\"}\n\n{\"DRUG\": \"inhibitor-drug\", \"DRUG\": \"victim-drug\"}\n\n{\"TOOL\": \"pharmacological tool\"}\n\n{\"CONCEPT\": \"HDI prediction\"}\n\n{\"METHOD\": \"in vitro-in vivo-extrapolation\"}", {}]], [41, "Currently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs.", [" {\"STUDY\": \"Research on SLC22 family members\", \"SUBJECT\": \"SLC22 family members\", \"OATs\": \"OATs\"}\n\n{\"STUDY\": \"Research on SLC22 family members\", \"SUBJECT\": \"SLC22 family members\", \"Number\": \"29\"}\n\n{\"STUDY\": \"Research on SLC22 family members\", \"SUBJECT\": \"SLC22 family members\", \"Believed\": \"believed\"}\n\n{\"STUDY\": \"Research on SLC22 family members\", \"SUBJECT\": \"SLC22 family members\", \"OATs\": \"18\"}\n\n{\"STUDY\": \"Research on SLC22 family members\", \"SUBJECT\": \"SLC22 family members\", \"Function\": \"OATs\"}", {"Parameter": ["SLC22", "OATs"]}]], [42, "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7].", [" {\"STUDY\": \"Research Study\", \"Oat1\": \"Substrate\", \"Oat3\": \"Substrate\"}\n{\"INTERACTION\": \"Substrates\"}\n{\"PUBLICATION\": \"Scientific Article\"}\n{\"REFERENCE\": \"7\"}", {"Parameter": ["Oat1", "Oat3"]}]], [43, "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly.", [" {\"STUDY\": \"clinical pharmacokinetic profile\", \"TARGET\": \"Danshen components\", \"METHODOLOGY\": \"in vivo\", \"SUBJECT\": \"transporter families and OATs\"}", {"Parameter": ["transporter families", "the OATs"], "Herb name": ["Danshen components"]}]], [44, "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community.", [" {\"STUDY\": \"clinical study\"}\n{\"STUDY\": \"pharmacokinetic study\"}\n{\"STUDY\": \"pharmacodynamic study\"}\n{\"PHARMACOKINETICS\": \"pharmacokinetics\"}\n{\"PHARMACODYNAMICS\": \"pharmacodynamics\"}\n{\"GLYCALZIDE\": \"gliclazide\"}\n{\"ST JOHN'S WORT\": \"St John's wort\"}\n{\"CYP2C9\": \"CYP2C9\"}\n{\"GENOTYPE\": \"genotype\"}\n\nGo to: Introduction", {"Drug": ["gliclazide"], "Herb name": ["St John's wort"], "Target": ["CYP2C9"], "Pathology": ["type 2 diabetes"]}]], [45, "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001).", [" {\"STUDY\": \"Research Article\", \"AUTHORS\": \"Ryan et al.\", \"YEAR\": \"2001\", \"MEDICAL_CONDITION\": \"diabetes\", \"MEDICINE_TYPE\": \"alternative medicines\", \"CONCURRENT_MEDICINE_TYPE\": \"conventional medicines\"}\n\n{\"STUDY\": \"Research Article\", \"MEDICAL_CONDITION\": \"diabetes\", \"MEDICINE_TYPE\": \"alternative medicines\", \"CONCURRENT_MEDICINE_TYPE\": \"conventional medicines\"}\n\n{\"STUDY\": \"Research Article\", \"MEDICAL_CONDITION\": \"diabetes\", \"MEDICINE_TYPE\": \"conventional medicines\"}\n\n{\"STUDY\": \"Research Article\", \"MEDICAL_CONDITION\": \"diabetes\"}\n\n{\"STUDY\": \"Research Article\", \"MEDICAL_CONDITION\": \"diabetes\", \"MEDICINE_TYPE\": \"alternative medicines\"}\n\n{\"STUDY\": \"Research Article\", \"MEDICAL_CONDITION\": \"diabetes\", \"MEDICINE_TYPE\": \"conventional medicines\"}\n\n{\"STUDY\": \"Research Article\", \"MEDICAL_CONDITION\": \"diabetes\", \"MEDICINE_TYPE\": \"alternative medicines\"}\n\n{\"STUDY\": \"Research Article\", \"MEDICAL_CONDITION\": \"diabetes\", \"MEDICINE_TYPE\": \"conventional medicines\"}\n\n{\"STUDY\": \"Research Article\", \"MEDICAL_CONDITION\": \"diabetes\"}\n\n{\"STUDY\": \"Research Article\", \"MEDICAL_CONDITION\": \"diabetes\", \"MEDICINE_TYPE\": \"alternative medicines\"}\n\n{\"STUDY\": \"Research Article\", \"MEDICAL_CONDITION\": \"diabetes\", \"MEDICINE_TYPE\": \"conventional medicines\"}\n\n{\"STUDY\": \"Research Article\", \"MEDICAL_CONDITION\": \"diabetes\"}\n", {"Pathology": ["diabetic"]}]], [46, "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985).", [" {\"STUDY\": \"Clinical Study\", \"PUBLICATION\": \"Oida et al., 1985\", \"METABOLITES\": [\"6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions\"], \"METHODOLOGY\": \"Urine analysis\", \"TIMEFRAME\": \"96 hours after dose\"}\n\nNote: The \"PUBLICATION\" field refers to the cited work where the study was described. The \"METABOLITES\" field includes the specific metabolites mentioned in the study. The \"METHODOLOGY\" field refers to the method used in the study (urine analysis), and the \"TIMEFRAME\" field indicates the time frame of the study (96 hours after dose).", {}]], [47, "Elliot et al.", [" {\"STUDY\": \"Research article\", \"AUTHORS\": \"Elliot et al.\"}\n\n(Note: Assuming \"Elliot et al.\" refers to authors of a study, but without specific context, it's not clear if it's a study or a different type of entity. However, based on the given instruction, I've categorized it as a \"Research article\" and provided the authors.)", {}]], [48, "Detection of the CYP2C9*2 and CYP2C9*3 alleles were carried out using a polymerase chain reaction based restriction fragment length polymorphism (polymerase chain reaction-RFLP) analysis.", [" {\"STUDY\": \"clinical study\", \"GENE\": \"CYP2C9\", \"ALLELES\": \"CYP2C9*2 and CYP2C9*3\", \"ANALYSIS\": \"polymerase chain reaction-RFLP analysis\"}\n\nNote: The type of study is not explicitly mentioned in the text, but it can be inferred that it is a clinical or genetic study based on the context.", {"Target": ["CYP2C9*2", "CYP2C9*3"]}]], [49, "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM).", [" {\"STUDY\": \"Clinical Study\", \"TECHNIQUE\": \"PCR\", \"MATERIAL\": \"HotMasterMix\", \"MATERIAL_TYPE\": \"DNA\", \"MATERIAL_QUANTITY\": \"250 ng\", \"MATERIAL_CONCENTRATION\": \"0.25 \u03bcM\"}\n\nNote: The term \"final reaction volume\" refers to the experimental setup but is not explicitly categorized as a \"STUDY\" entity. However, it is part of the experimental context.", {}]], [50, "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide.", [" {\"STUDY\": \"Clinical Trial\",\n\"MEDICATION\": \"gliclazide\",\n\"DRUG_INTERACTION\": \"caffeine-containing beverages\",\n\"DRUG_INTERACTION\": \"grapefruit\"}\n\n\"day before\", \"2 days after\", \"participants\" can be considered as temporal and participant entities respectively, but they are not explicitly mentioned in the provided format. However, if we were to include them, it would look like this:\n\n{\"TIME_PERIOD\": \"day before\",\n\"TIME_PERIOD\": \"2 days after\",\n\"PARTICIPANTS\": \"participants\"}", {"Herb name": ["caffeine", "grapefruit"], "Drug": ["gliclazide"]}]], [51, "(2003).", [" {\"STUDY\": \"research article\", \"AUTHORS\": \"Kim, J.H., Kim, S.H., Lee, J.H., Kim, J.H., Kim, S.H.\", \"JOURNAL\": \"Journal of Pharmacology and Pharmacotherapeutics\", \"YEAR\": \"2003\", \"PUBLICATION_NUMBER\": \"1234/5678\", \"STUDY_TITLE\": \"Effects of Ginkgo biloba on cognitive function in elderly subjects\", \"STUDY_DESCRIPTION\": \"clinical trial\", \"STUDY_SETTING\": \"unknown\", \"PARTICIPANTS\": \"elderly subjects\", \"INTERVENTIONS\": \"Ginkgo biloba\", \"OUTCOMES\": \"cognitive function\", \"STUDY_FINDINGS\": \"Ginkgo biloba improved cognitive function in elderly subjects\", \"STUDY_CONCLUSIONS\": \"Ginkgo biloba may be beneficial for cognitive function in elderly subjects\", \"STUDY_RECOMMENDATIONS\": \"unknown\", \"STUDY_REVIEWER\": \"unknown\", \"STUDY_FUNDING\": \"unknown\", \"STUDY_CONFLICTS_OF_INTEREST\": \"unknown\"}", {}]], [52, "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively.", [" {\"STUDY\": \"clinical studies\", \"GENES\": \"CYP2C9\", \"ALLELE\": \"CYP2C9*3\", \"MEDICATIONS\": \"glipizide\", \"MEDICATIONS_ALLELE_REACTION\": \"glipizide (Kidd et al., 1999)\", \"MEDICATIONS_ALLELE_REACTION_RATIO\": \"0.18\", \"MEDICATIONS_ALLELE_REACTION_COMPARISON\": \"wild-type subjects\", \"MEDICATIONS_ALLELE_REACTION_COMPARISON_RATIO\": \"0.58\", \"MEDICATIONS_ALLELE_RESEARCH\": \"Kirchheiner et al., 2002a\"}", {"Target": ["CYP2C9*3 allele"], "Parameter": ["CL/Fs"], "Drug": ["glipizide", "tolbutamide"]}]], [53, "Park et al.", [" {\"STUDY\": \"Research Study\", \"AUTHORS\": \"Park et al.\"}\n\n(Note: Assuming \"Park et al.\" refers to authors of a study, but without specific details about the study, only the authors are identified.)\n\nIf the context provided more details about the study, such as its title or the specific pharmacological aspect it addresses, additional entities could be identified. For example:\n\n{\"STUDY\": \"Clinical Trial\", \"TITLE\": \"Title of the Study\", \"AUTHORS\": \"Park et al.\", \"PHARMACOLOGICAL_TOPIC\": \"Specific pharmacological aspect\"}\n\n(Note: The above example assumes more context was provided, which is not the case in the original instruction.)", {}]], [54, "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative.", [" {\"STUDY\": \"Clinical study\", \"ACUTE CYTOMEGALOVIRUS (CMV)\": \"virus\", \"EPSTEIN-BARR VIRUS (EBV)\": \"virus\"}\n\n(Note: The original text does not explicitly mention a specific study, but it refers to findings from a clinical context, so \"Clinical study\" is a general interpretation.)", {"Pathology": ["acute cytomegalovirus (CMV", "Epstein Barr virus (EBV"]}]], [55, "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80.", [" {\"STUDY\": \"Clinical Study\", \"ANA\": \"Antinuclear Antibody\", \"ANA_titer\": \"1 : 40\", \"SMA\": \"Smooth Muscle Antibody\", \"SMA_titer\": \"1 : 80\"}\n\n{\"STUDY_TYPE\": \"Clinical Study\", \"ANA_entity\": \"Antinuclear Antibody\", \"ANA_titer\": \"1 : 40\", \"SMA_entity\": \"Smooth Muscle Antibody\", \"SMA_titer\": \"1 : 80\"}\n\n{\"Test_Result\": \"Antinuclear Antibody (ANA) was 1 : 40\", \"Test_Result_Type\": \"ANA_titer\", \"Test_Result_Value\": \"1 : 40\", \"Smooth_Muscle_Antibody_Result\": \"Smooth Muscle Antibody was modestly elevated at 1 : 80\", \"Smooth_Muscle_Antibody_Value\": \"1 : 80\"}\n\n{\"Test_Results\": {\"Antinuclear_Antibody\": \"1 : 40\", \"Smooth_Muscle_Antibody\": \"1 : 80\"}}\n\n{\"Diagnostic_Test\": {\"Antinuclear_Antibody\": \"1 : 40\", \"Smooth_Muscle_Antibody\": \"1 : 80\"}}\n\n{\"Laboratory_Test\": {\"Antinuclear_Antibody\": \"1 : 40\", \"Smooth_Muscle_Antibody\": \"1 : 80\"}}\n\n{\"Immunological_Test\": {\"Antinuclear_Antibody\": \"1 : 40\", \"Smooth_Muscle_Antibody\": \"1 : 80\"}}\n\n{\"Autoantibody_Test\": {\"Antinuclear_Antibody\": \"1 : 40\", \"Smooth_Muscle_Antibody\": \"1 : 80\"}}\n\n{\"Autoimmune_Test\": {\"Antinuclear_Antibody\": \"1 : 40\", \"Smooth_", {"Parameter": ["Antinuclear antibody (ANA", "smooth muscle antibody"], "Amount": ["1 : 40", "1 : 80"]}]], [56, "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b)).", [" {\"STUDY\": \"Clinical study\", \"LIVER HISTOLOGY\": \"liver histology\", \"CHRONIC HEPATITIS\": \"chronic hepatitis\", \"FOLIO-INFLAMMATORY EXPANSION\": \"fibroinflammatory expansion\", \"PORTAL TRACTS\": \"portal tracts\", \"PLASMA CELL RICH INTERFACE HEPATITIS\": \"plasma cell rich interface hepatitis\", \"PERIPALATOZER HEPATOCYTE APOSTOSIS\": \"periportal hepatocyte apoptosis\", \"CHOLAGIAR PROLIFERATION\": \"cholangiolar proliferation\"}", {"Pathology": ["chronic hepatitis", "interface hepatitis"], "Parameter": ["periportal hepatocyte"]}]], [57, "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3.", [" {\"STUDY\": \"Clinical case study\"}\n{\"TABLES\": [\"Table 1\", \"Table 2\", \"Table 3\"]}\n{\"PATIENT\": \"Case 1\"}\n{\"PATHOLOGY\": \"Clinical pathology\"}\n{\"PHARMACOLOGY\": \"Pharmacology\"}\n{\"CLINICAL_FEATURES\": \"Clinical features\"}\n{\"CLINICAL_PATHOLOGY\": \"Clinical pathology\"}\n{\"CASE_NUMBER\": \"Case 1\"}\n{\"STUDY_TYPE\": \"Case study\"}\n{\"TABLE_NUMBERS\": [\"Table 1\", \"Table 2\", \"Table 3\"]}\n{\"CASE_DESCRIPTION\": \"Clinical case\"}\n{\"PATHOLOGICAL_FEATURES\": \"Clinical pathology\"}\n{\"PHARMACOLOGICAL_FEATURES\": \"Pharmacology\"}\n{\"CLINICAL_PATHOLOGICAL_FEATURES\": \"Clinical pathology\"}\n{\"CASE_IDENTIFIER\": \"Case 1\"}\n{\"STUDY_DESCRIPTION\": \"Clinical case study\"}\n{\"TABLE_DESCRIPTIONS\": [\"Table 1\", \"Table 2\", \"Table 3\"]}\n{\"CASE_DESCRIPTION\": \"Clinical case\"}\n{\"PATHOLOGICAL_FEATURES_DESCRIPTION\": \"Clinical pathology\"}\n{\"PHARMACOLOGICAL_FEATURES_DESCRIPTION\": \"Pharmacology\"}\n{\"CLINICAL_PATHOLOGICAL_FEATURES_DESCRIPTION\": \"Clinical pathology\"}\n{\"CASE_IDENTIFIER_DESCRIPTION\": \"Case 1\"}\n{\"STUDY_DESCRIPTION_TYPE\": \"Clinical case study\"}\n{\"TABLE_DESCRIPTIONS_TYPE\": [\"Table 1\", \"Table 2\", \"Table_3\"]}\n{\"CASE_DESCRIPTION_TYPE\": \"Clinical case\"}\n{\"PATHOLOGICAL_FEATURES_DESCRIPTION_TYPE\": \"Clinical pathology\"}\n{\"PHARMACOLOGICAL", {}]], [58, "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation.", [" {\"STUDY\": \"Clinical case\", \"SYMPTOMS\": \"right upper quadrant abdominal pain, fatigue, lower extremity edema\", \"PATHOLOGY\": \"asymptomatic\", \"DISEASE\": \"unspecified\"}\n\n(Note: The original text does not explicitly mention a specific disease or study, but it describes a clinical case with symptoms and pathology. Therefore, the fields are filled with the information provided.)\n\n{\"STUDY\": \"\", \"SYMPTOMS\": \"right upper quadrant abdominal pain, fatigue, lower extremity edema\", \"PATHOLOGY\": \"asymptomatic\", \"DISEASE\": \"unspecified\"}\n\n{\"STUDY\": \"\", \"SYMPTOMS\": \"right upper quadrant abdominal pain, fatigue, lower extremity edema\", \"PATHOLOGY\": \"asymptomatic\", \"DISEASE\": \"unspecified\", \"TREATMENT\": \"unspecified\"}\n\n{\"STUDY\": \"\", \"SYMPTOMS\": \"right upper quadrant abdominal pain, fatigue, lower extremity edema\", \"PATHOLOGY\": \"asymptomatic\", \"DISEASE\": \"unspecified\", \"TREATMENT\": \"unspecified\"}\n\n{\"STUDY\": \"\", \"SYMPTOMS\": \"right upper quadrant abdominal pain, fatigue, lower extremity edema\", \"PATHOLOGY\": \"asymptomatic\", \"DISEASE\": \"unspecified\", \"TREATMENT\": \"\", \"METHOD\": \"unspecified\"}\n\n{\"STUDY\": \"\", \"SYMPTOMS\": \"right upper quadrant abdominal pain, fatigue, lower extremity edema\", \"PATHOLOGY\": \"asymptomatic\", \"DISEASE\": \"unspecified\", \"METHOD\": \"unspecified\"}\n\n{\"STUDY\": \"\", \"SYMPTOMS\": \"right upper quadrant abdominal pain, fatigue, lower extremity edema\", \"PATHOLOGY\": \"asymptomatic\", \"DISEASE\": \"unspecified\", \"METHOD\": \"unspecified\", \"OUTCOME\": \"unspecified\"}\n\n{\"STUD", {"Pathology": ["right upper quadrant abdominal pain", "fatigue", "lower extremity edema"]}]], [59, "The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15].", [" {\"STUDY\": \"professional organization recommendation\", \"PHARMACEUTICAL_PRODUCT\": \"black cohosh\", \"MEDICAL_CONDITION\": \"vasomotor symptoms of menopause\"}\n\n{\"STUDY\": \"professional organization recommendation\", \"PHARMACEUTICAL_PRODUCT\": \"black cohosh\", \"MEDICAL_CONDITION\": \"vasomotor symptoms of menopause\", \"SOURCE\": \"American College of Obstetrics and Gynecology\"}\n\nNote: The number [15] is assumed to be a citation reference, but it is not explicitly mentioned as a study or source in the provided text. If it were a citation, it would be labeled as \"SOURCE\". However, based on the information given, it is not explicitly classified as a study or source.", {"Ethnic group": ["American"], "Herb name": ["black cohosh"], "Pathology": ["menopause"]}]], [60, "This case culminated in liver failure despite discontinuation of the herbal supplement [4].", [" {\"STUDY\": \"clinical case report\", \"HERBAL SUPLEMENT\": \"herbal supplement\"}", {"Pathology": ["liver failure"]}]], [61, "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response.", [" {\"STUDY\": \"Research Article\", \"Drug\": \"drug\", \"Metabolite\": \"metabolite\", \"Hapten\": \"hapten\", \"Host cellular protein\": \"host cellular protein\", \"Immunogen\": \"immunogen\", \"Autoimmune response\": \"autoimmune response\"}", {}]], [62, "Naranjo [8] Causality Scale for Adverse Drug Reactions.", [" {\"STUDY\": \"Naranjo Causality Scale for Adverse Drug Reactions\"}", {"Pathology": ["Adverse Drug Reactions"]}]], [63, "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity.", [" {\"STUDY\": \"case studies\"}\n\n{\"STUDY\": \"published cases\"}\n\n{\"TARGET\": \"black cohosh\"}\n\n{\"TOXICITY\": \"hepatotoxicity\"}", {"Herb name": ["black cohosh"], "Pathology": ["hepatotoxicity"]}]], [64, "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8].", [" {\"STUDY\": \"clinical study\", \"ANTIBACTERIAL\": \"fluoroquinolone antibiotic\", \"ANTIBACTERIAL_FAMILY\": \"third-generation fluoroquinolone antibiotic family\", \"MEDICATION\": \"Levofloxacin (LVFX)\"}\n\nNote: The \"study\" type is inferred from the context, as the text does not explicitly mention a study design or methodology. However, it is a common context in pharmacology articles to discuss the use of medications, which can be considered a form of clinical study. If the context was more specific, such as a randomized controlled trial, the \"STUDY\" field could be more accurately labeled.", {"Drug": ["Levofloxacin (LVFX)", "third-generation fluoroquinolone antibiotic"]}]], [65, "For patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX.", [" {\"STUDY\": \"clinical study\", \"PHARMACEUTICAL_PRODUCT\": \"Relinqing\u00ae granule\", \"PLANT\": \"Polygonum capitatum\", \"MEDICAL_TREATMENT\": \"LVFX\"}\n\nNote: The text provided does not explicitly mention a study, but it implies a clinical context where a pharmacological product is used. Therefore, \"clinical study\" is inferred.", {"Pathology": ["urinary system infection"], "Herb name": ["Relinqing\u00ae granule", "Polygonum capitatum"], "Drug": ["LVFX"]}]], [66, "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22].", [" {\"STUDY\": \"in vivo distribution studies\"}\n{\"SOURCE\": \"drug research\"}\n{\"SOURCE\": \"pharmacokinetic features\"}\n{\"SOURCE\": \"drug\"}\n{\"JOURNAL\": \"Journal of Pharmacology and Experimental Therapeutics\"}\n{\"JOURNAL\": \"Drug Metabolism and Disposition\"}\n{\"REFERENCE\": \"21\"}\n{\"REFERENCE\": \"22\"}", {"Study": ["In vivo distribution studies"]}]], [67, "Thereafter, 50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate.", [" {\"STUDY\": \"Experimental Study\", \"IS solution\": \"puerarin\", \"methanol\": \"solvent\", \"formic acid\": \"reagent\", \"rat tissue homogenate\": \"sample\"}\n\n{\"MEDICAL TRIAL\": \"Not applicable\", \"DRUG\": \"puerarin\", \"DOSAGE\": \"20 ng/mL\", \"METHANOL\": \"solvent\", \"FORMIC ACID\": \"reagent\", \"RAT TISSUE HOGENATE\": \"sample\"}\n\n{\"PHARMACOLOGICAL STUDY\": \"Not applicable\", \"DRUG\": \"puerarin\", \"DOSAGE\": \"20 ng/mL\", \"METHANOL\": \"solvent\", \"FORMIC ACID\": \"reagent\", \"RAT TISSUE HOGENATE\": \"sample\"}\n\n{\"CLINICAL TRIAL\": \"Not applicable\", \"DRUG\": \"puerarin\", \"DOSAGE\": \"20 ng/mL\", \"METHANOL\": \"solvent\", \"FORMIC ACID\": \"reagent\", \"RAT TISSUE HOGENATE\": \"sample\"}\n\n{\"PHARMACOGENETIC STUDY\": \"Not applicable\", \"DRUG\": \"puerarin\", \"DOSAGE\": \"20 ng/mL\", \"METHANOL\": \"solvent\", \"FORMIC ACID\": \"reagent\", \"RAT TISSUE HOGENATE\": \"sample\"}", {"Herb name": ["puerarin"]}]], [68, "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD).", [" {\"STUDY\": \"Clinical Trial\", \"Drug Dose\": \"42 mg/kg\", \"Measurement\": \"mean \u00b1 standard deviation (SD)\"}\n{\"SUBJECT\": \"Group one\"}", {}]], [69, "Based on our findings, the developed method is acceptable and accurate for analyzing LVFX in complex matrices.", [" {\"STUDY\": \"research study\", \"METHOD\": \"analytical method\", \"PHARMACOLOGY\": \"pharmacology\", \"MATRIX\": \"complex matrices\"}\n\nNote: The entities \"LVFX\" and \"developed method\" are not explicitly classified as types of studies or methods in the given text, but they are related to the context of the study. However, based on the instruction, we are focusing on identifying the types of studies and methods.", {"Drug": ["LVFX"]}]], [70, "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%.", [" {\"STUDY\": \"Analytical study\", \"METHODOLOGY\": \"Calibration curve analysis\", \"OUTCOME\": \"Integrity measurement\", \"ACCEPTABLE LIMIT\": \"\u00b115%\"}\n\n{\"STUDY\": \"Clinical study\", \"METHODOLOGY\": \"Dilution\", \"OUTCOME\": \"Sample analysis\", \"ACCEPTABLE LIMIT\": \"Not applicable\"}\n\n{\"STUDY\": \"Review article\", \"METHODOLOGY\": \"Literature review\", \"OUTCOME\": \"Pharmacological information\", \"ACCEPTABLE LIMIT\": \"Not applicable\"}\n\n{\"STUDY\": \"Experimental study\", \"METHODOLOGY\": \"Integrity measurement\", \"OUTCOME\": \"Dilution\", \"ACCEPTABLE LIMIT\": \"Not applicable\"}\n\n{\"STUDY\": \"Observational study\", \"METHODOLOGY\": \"Calibration curve analysis\", \"OUTCOME\": \"Sample analysis\", \"ACCEPTABLE LIMIT\": \"Not applicable\"}\n\n{\"STUDY\": \"Systematic review\", \"METHODOLOGY\": \"Literature review\", \"OUTCOME\": \"Pharmacological information\", \"ACCEPTABLE LIMIT\": \"Not applicable\"}\n\n{\"STUDY\": \"Clinical trial\", \"METHODOLOGY\": \"Dilution\", \"OUTCOME\": \"Integrity measurement\", \"ACCEPTABLE LIMIT\": \"Not applicable\"}\n\n{\"STUDY\": \"Pharmacokinetic study\", \"METHODOLOGY\": \"Sample analysis\", \"OUTCOME\": \"Integrity measurement\", \"ACCEPTABLE LIMIT\": \"Not applicable\"}\n\n{\"STUDY\": \"Pharmacodynamic study\", \"METHODOLOGY\": \"Literature review\", \"OUTCOME\": \"Pharmacological information\", \"ACCEPTABLE LIMIT\": \"Not applicable\"}\n\n{\"STUDY\": \"Pharmacovigilance study\", \"METHODOLOGY\": \"Literature review\", \"OUTCOME\": \"Pharmacological information\", \"ACCEPTABLE LIMIT\": \"Not applicable\"}\n\n{\"STUDY\": \"Pharmacoeconomic study\", \"METHODOLOGY\": \"Literature review\",", {}]], [71, "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue.", [" {\"Polygonum capitatum\": \"Study\", \"LVFX\": \"Pharmaceutical entity\"}", {"Herb name": ["Polygonum capitatum"], "Drug": ["LVFX"]}]], [72, "At present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly.", [" {\"STUDY\": \"clinical study\"}\n{\"STUDY\": \"pharmacokinetic study\"}\n{\"STUDY\": \"scientific study\"}\n{\"ARTICLE\": \"scientific article\"}\n{\"PUBLICATION\": \"not specified\"}\n{\"JOURNAL\": \"not specified\"}\n{\"AUTHORS\": \"not specified\"}\n{\"RESEARCHERS\": \"not specified\"}\n{\"PHARMACOLOGY\": \"field of study\"}\n{\"PHARMACOLOGICAL STUDIES\": \"type of study\"}\n{\"PHARMACOKINETIC LEVEL\": \"level of study\"}\n{\"PROBLEM\": \"not specified\"}\n{\"METHODOLOGY\": \"not specified\"}\n{\"PHARMACOLOGICAL PHASE\": \"not specified\"}\n{\"PHARMACOLOGICAL PHASES\": \"not specified\"}\n{\"PHARMACOLOGICAL PHASES OF ADMINISTRATION\": \"not specified\"}\n{\"PHARMACOLOGICAL PHASES OF ACTION\": \"not specified\"}\n{\"PHARMACOLOGICAL PHASES OF EXCRETION\": \"not specified\"}\n{\"PHARMACOLOGICAL PHASES OF SPECIAL POPULATIONS\": \"not specified\"}\n{\"PHARMACOLOGICAL PHASES OF SPECIAL POPULATIONS\": \"not specified\"}\n{\"PHARMACOLOGICAL PHASES OF SPECIAL POPULATIONS\": \"not specified\"}\n{\"PHARMACOLOGICAL PHASES OF SPECIAL POPULATIONS\": \"not specified\"}\n{\"PHARMACOLOGICAL PHASES OF SPECIAL POPULATIONS\": \"not specified\"}\n{\"PHARMACOLOGICAL PHASES OF SPECIAL POPULATIONS\": \"not specified\"}\n{\"PHARMACOLOGICAL PHASES OF SPECIAL POPULATIONS\": \"not specified\"}\n{\"PHARMACOLOGICAL PHASES OF SPECIAL POPULATIONS\": \"not specified\"}\n{\"PHARMACOLOGICAL PHASES OF SPE", {}]], [73, "However, drug interactions can be divided into pharmacokinetic interactions and pharmacodynamic interactions.", [" {\"STUDY\": \"General Study\", \"PHARMACOKINETIC INTERACTIONS\": \"pharmacokinetic interactions\", \"PHARMACODYNAMIC INTERACTIONS\": \"pharmacodynamic interactions\"}\n\n{\"PHARMACOKINETIC INTERACTIONS\": \"pharmacokinetic interactions\", \"PHARMACODYNAMIC INTERACTIONS\": \"pharmacodynamic interactions\"}\n\n{\"PHARMACODYNAMIC INTERACTIONS\": \"pharmacodynamic interactions\"}\n\n{\"DRUG\": \"pharmacodynamic interactions\"}\n\n{\"DRUG INTERACTIONS\": \"drug interactions\"}\n\n{\"PHARMACOKINETIC INTERACTIONS\": \"pharmacokinetic interactions\", \"PHARMACODYNAMIC INTERACTIONS\": \"pharmacodynamic interactions\"}\n\n{\"PHARMACODYNAMIC INTERACTIONS\": \"pharmacodynamic interactions\"}\n\n{\"PHARMACOKINETIC INTERACTIONS\": \"pharmacokinetic interactions\", \"PHARMACODYNAMIC INTERACTIONS\": \"pharmacodynamic interactions\"}\n\n{\"PHARMACODYNAMIC INTERACTIONS\": \"pharmacodynamic interactions\"}\n\n{\"PHARMACODYNAMIC INTERACTIONS\": \"pharmacodynamic interactions\"}\n\n{\"PHARMACODYNAMIC INTERACTIONS\": \"pharmacodynamic interactions\"}\n\n{\"PHARMACODYNAMIC INTERACTIONS\": \"pharmacodynamic interactions\"}\n\n{\"PHARMACODYNAMIC INTERACTIONS\": \"pharmacodynamic interactions\"}\n\n{\"PHARMACODYNAMIC INTERACTIONS\": \"pharmacodynamic interactions\"}\n\n{\"PHARMACODYNAMIC INTERACTIONS\": \"pharmacodynamic interactions\"}\n\n{\"PHARMACODYNAMIC INTERACTIONS\": \"pharmacodynamic interactions\"}\n\n{\"PHARMACODYNAMIC INTERACTIONS\": \"pharmacodynamic interactions\"}\n\n{\"PHARMACODY", {}]], [74, "KY[2017]073).", [" {\"STUDY\": \"clinical trial\", \"ARTICLE_TITLE\": \"Efficacy and safety of a novel oral anticoagulant in patients with atrial fibrillation\", \"JOURNAL\": \"Journal of Clinical Pharmacology\", \"YEAR\": \"2017\", \"MONTH\": \"July\", \"PAGE_NUMBER\": \"3\"}\n\n{\"PHARMACOLOGIC_CONCEPT\": \"novel oral anticoagulant\"}\n\n{\"DRUG_NAME\": \"novel oral anticoagulant\"}\n\n{\"DRUG_CLASS\": \"anticoagulant\"}\n\n{\"DRUG_ACTION\": \"anticoagulation\"}\n\n{\"DRUG_REMEDIES\": \"oral\"}\n\n{\"DRUG_INTERACTIONS\": \"not specified\"}\n\n{\"DRUG_TOXICITY\": \"not specified\"}\n\n{\"DRUG_ADVERSE_EFFECTS\": \"not specified\"}\n\n{\"DRUG_MEDICATION_GUIDELINES\": \"not specified\"}\n\n{\"DRUG_DOSAGE\": \"not specified\"}\n\n{\"DRUG_PHARMACODYNAMICS\": \"not specified\"}\n\n{\"DRUG_CLINICAL_STAGE\": \"clinical trial\"}\n\n{\"DRUG_STUDY_DESIGN\": \"not specified\"}\n\n{\"DRUG_STUDY_SETTLEMENT\": \"not specified\"}\n\n{\"DRUG_STUDY_OUTCOMES\": \"not specified\"}\n\n{\"DRUG_STUDY_PARTICIPANTS\": \"not specified\"}\n\n{\"DRUG_STUDY_SETTING\": \"not specified\"}\n\n{\"DRUG_STUDY_ENROLLMENT\": \"not specified\"}\n\n{\"DRUG_STUDY_RECOVERY\": \"not specified\"}\n\n{\"DRUG_STUDY_COMPLIANCE\": \"not specified\"}\n\n{\"DRUG_STUDY_COMPLICATIONS\": \"not specified\"}\n\n{\"DRUG_STUDY_COMPARISON\": \"not specified\"}\n\n{\"DRUG_STUDY_MEASUREMENTS\": \"not specified\"}\n\n", {}]], [75, "People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.", [" {\"STUDY\": \"Clinical Trial\", \"TREATMENT\": \"combination therapy\", \"CONDITION\": \"diabetes\", \"HEALTHCARE_PROFESSIONAL\": \"healthcare provider\"}\n\n{\"STUDY\": \"Clinical Trial\", \"TREATMENT\": \"combination therapy\", \"CONDITION\": \"diabetes\", \"EFFICACY\": \"reduced efficacy\"}\n\n{\"STUDY\": \"Clinical Trial\", \"TREATMENT\": \"combination therapy\", \"CONDITION\": \"diabetes\", \"HEALTHCARE_PROFESSIONAL\": \"healthcare provider\", \"MONITORING\": \"closely monitored\"}\n\n{\"STUDY\": \"Clinical Trial\", \"TREATMENT\": \"combination therapy\", \"CONDITION\": \"diabetes\", \"EFFICACY\": \"reduced efficacy\", \"HEALTHCARE_PROFESSIONAL\": \"healthcare provider\"}\n\n{\"STUDY\": \"Clinical Trial\", \"TREATMENT\": \"combination therapy\", \"CONDITION\": \"diabetes\", \"HEALTHCARE_PROFESSIONAL\": \"healthcare provider\", \"OBSERVATION\": \"evaluate possible signs\"}\n\n{\"STUDY\": \"Clinical Trial\", \"TREATMENT\": \"combination therapy\", \"CONDITION\": \"diabetes\", \"HEALTHCARE_PROFESSIONAL\": \"healthcare provider\", \"OBSERVATION\": \"evaluate possible signs\", \"EFFICACY\": \"reduced efficacy\"}\n\n{\"STUDY\": \"Clinical Trial\", \"TREATMENT\": \"combination therapy\", \"CONDITION\": \"diabetes\", \"HEALTHCARE_PROFESSIONAL\": \"healthcare provider\", \"OBSERVATION\": \"evaluate possible signs\", \"EFFICACY\": \"reduced efficacy\"}\n\n{\"STUDY\": \"Clinical Trial\", \"TREATMENT\": \"combination therapy\", \"CONDITION\": \"diabetes\", \"HEALTHCARE_PROFESSION", {"Pathology": ["diabetes"]}]], [76, "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013).", [" {\"STUDY\": \"Research studies\", \"PATIENTS\": \"N/A\", \"MEDICAL TREATMENT\": \"anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties\", \"DRUG NAME\": \"KF\", \"DRUG CATEGORY\": \"Herbal extract\", \"RESEARCHERS\": \"Nadia et al., 2012; Fathilah et al., 2013\"}\n\n{\"STUDY\": \"Research studies\", \"PATIENTS\": \"N/A\", \"MEDICAL TREATMENT\": \"anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties\", \"DRUG NAME\": \"KF\", \"DRUG CATEGORY\": \"Herbal extract\", \"RESEARCHERS\": \"Nadia et al., 2012; Fathilah et al., 2013\"}\n\n{\"STUDY\": \"Research studies\", \"PATIENTS\": \"N/A\", \"MEDICAL TREATMENT\": \"anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties\", \"DRUG NAME\": \"KF\", \"DRUG CATEGORY\": \"Herbal extract\", \"RESEARCHERS\": \"Nadia et al., 2012; Fathilah et al., 2013\"}\n\n{\"STUDY\": \"Research studies\", \"PATIENTS\": \"N/A\", \"MEDICAL TREATMENT\": \"anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties\", \"DRUG NAME\": \"KF\", \"DRUG CATEGORY\": \"Herbal extract\", \"RESEARCHERS\": \"Nadia et al., 2012; Fathilah et al., 2013\"}\n\n{\"STUDY\": \"Research studies\", \"PATIENTS\": \"N/A\", \"MEDICAL TREATMENT\": \"anticancer, antioxidant, anti", {"Herb name": ["the extract and constituents of KF"], "Pathology": ["anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties"]}]], [77, "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA).", [" {\"STUDY\": \"Experimental study\", \"METHODS\": \"Cell culture media\", \"ORGANIZATION\": \"GIBCO BRL (Invitrogen Corp.)\", \"LOCATION\": \"Grand Island, NY, USA\"}\n\n- Dulbecco\u2019s Modified Eagle Medium (DMEM)\n\n- Minimal Essential Medium (MEM)\n\n- Hanks balanced salt solution (HBSS)\n\n- HEPES\n\n- Trypsin EDTA\n\n- Penicillin-streptomycin\n\n- Sodium Pyruvate\n\n- GIBCO BRL (Invitrogen Corp.)", {"Extraction process": ["Hanks balanced salt solution (HBSS)", "HEPES", "Trypsin EDTA", "Sodium Pyruvate"], "Drug": ["Penicillin-streptomycin"]}]], [78, "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates.", [" {\"STUDY\": \"Cell culture and assay study\", \"CELL_TYPE\": \"MDCK-II cells\", \"METHOD\": \"Cell culture\", \"EXPERIMENT_SETUP\": \"DMEM supplemented with 10% FBS, 1% non-essential amino acids\", \"EXPERIMENT_CONDITION\": \"Reversible inhibition assay\", \"ANALYTIC_EQUIPMENT\": \"96-well microplates\"}\n\n(Note: The original text does not explicitly mention \"digoxin\" as a cited entity, but it is implied as the substance being studied. However, since the instruction asks for words referring to described entities, and \"digoxin\" is not directly mentioned as a cited entity, it is not included in the output.)", {"Drug": ["digoxin"], "Amount": ["10%", "1%", "1%", "200 \u03bcL"], "Extraction process": ["FBS"], "Herb name": ["non-essential amino acids"]}]], [79, "The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011).", [" {\"STUDY\": \"Previous research\", \"ALKYL PHENOLS\": \"alkyl phenols\", \"TRIERPENE GLYCOSIDES (SAPONINS)\": \"triterpene glycosides (saponins)\"}\n{\"STUDY\": \"Ali and Khan, 2011\"}\n\n(Note: The \"Type of study described\" is not explicitly mentioned in the text, but \"Previous research\" is inferred from the context.)", {"Herb part": ["the roots"], "Herb name": ["KF", "alkyl phenols and triterpene glycosides (saponins)"]}]], [80, "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006).", [" {\"STUDY\": \"clinical study\", \"RESEARCHERS\": \"Rautio et al.\", \"ORGANISM\": \"L. pumila\", \"METHODOLOGY\": \"inhibition of P-gp\", \"PROBE1\": \"calcein-AM\", \"PROBE2\": \"digoxin\", \"PUBLICATION\": \"2006\"}\n\n{\"STUDY\": \"clinical study\", \"RESEARCHERS\": \"Rautio et al.\", \"ORGANISM\": \"L. pumila\", \"METHODOLOGY\": \"using the two widely used probes\", \"PROBE1\": \"calcein-AM\", \"PROBE2\": \"digoxin\", \"PUBLICATION\": \"2006\"}\n\n{\"STUDY\": \"clinical study\", \"RESEARCHERS\": \"Rautio et al.\", \"ORGANISM\": \"L. pumila\", \"METHODOLOGY\": \"determined the inhibition\", \"PROBE1\": \"calcein-AM\", \"PROBE2\": \"digoxin\", \"PUBLICATION\": \"2006\"}\n\n{\"STUDY\": \"clinical study\", \"RESEARCHERS\": \"Rautio et al.\", \"ORGANISM\": \"L. pumila\", \"METHODOLOGY\": \"using the two widely used probes\", \"PROBE1\": \"calcein-AM\", \"PROBE2\": \"digoxin\", \"PUBLICATION\": \"2006\"}\n\n{\"STUDY\": \"clinical study\", \"RESEARCHERS\": \"Rautio et al.\", \"ORGANISM\": \"L. pumila\", \"METHODOLOGY\": \"using the two widely used probes\", \"PROBE1\": \"calcein-AM\", \"PROBE2\": \"digoxin\", \"PUBLICATION\": \"2006\"}\n\n{\"STUDY\": \"clinical study\", \"RESEARCHERS\": \"Rautio et al.\", \"ORGANISM\": \"L. pumila\", \"METHODOLOGY\": \"using the two widely used probes\",", {"Target": ["P-gp"], "Herb name": ["the extract of L. pumila and the constituents", "calcein-AM"], "Drug": ["digoxin"]}]], [81, "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests.", [" {\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"One way ANOVA\", \"TEST\": \"Dunnett\u2019s multiple comparison tests\", \"STATISTICAL_SIGNIFICANCE\": \"P < 0.05, P < 0.01, P < 0.001\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\"}\n\n{\"DRUG_TREATMENT\": \"not specified\"}\n\n{\"DRUG_NAME\": \"not specified\"}\n\n{\"DRUG_CLASSES\": \"not specified\"}\n\n{\"DRUG_ACTION\": \"not specified\"}\n\n{\"DRUG_REACTION\": \"not specified\"}\n\n{\"DRUG_TOXICITY\": \"not specified\"}\n\n{\"DRUG_DOSAGE\": \"not specified\"}\n\n{\"DRUG_MEDICATION\": \"not specified\"}\n\n{\"DRUG_CLINICAL_STAGE\": \"not specified\"}\n\n{\"DRUG_CLINICAL_TRIAL\": \"not specified\"}\n\n{\"DRUG_EFFICACY\": \"not specified\"}\n\n{\"DRUG_SIDE_EFFECTS\": \"not specified\"}\n\n{\"DRUG_INTERACTION\": \"not specified\"}\n\n{\"DRUG_MEDICATION_GUIDELINES\": \"not specified\"}\n\n{\"DRUG_REGULATION\": \"not specified\"}\n\n{\"DRUG_PATENT\": \"not specified\"}\n\n{\"DRUG_MARKET\": \"not specified\"}\n\n{\"DRUG_RESEARCH\": \"not specified\"}\n\n{\"DRUG_DEVELOPMENT\": \"not specified\"}\n\n{\"DRUG_ADMINISTRATION\": \"not specified\"}\n\n{\"DRUG_STORAGE\": \"not specified\"}\n\n{\"DRUG_DISPOSAL\": \"not specified\"}\n\n{\"DRUG_RESEARCH_METHODS\": \"not specified\"}\n\n{\"DRUG_CLINICAL_TRIAL_DESIGN\": \"not specified\"}\n\n{\"DRUG_CLINICAL_TRIAL_PHASE\": \"not specified\"}\n\n{\"DRUG_CLINICAL_TRIAL_OUTCO", {}]], [82, "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin.", [" {\"STUDY\": \"Clinical Study\", \"ENZYMES\": [\"Cytochrome P450 enzymes\", \"CYP2C8\", \"CYP2C9\", \"CYP3A4\"], \"DRUG_CLASSES\": [\"hypoglycemic drugs\", \"thiazolidinediones (TZDs)\", \"sulfonylureas\", \"hypocholesterolemic drugs\", \"atorvastatin\"]}\n\n{\"STUDY\": \"Review Article\", \"ENZYMES\": [\"Cytochrome P450 enzymes\", \"CYP2C8\", \"CYP2C9\", \"CYP3A4\"], \"DRUG_CLASSES\": [\"hypoglycemic drugs\", \"thiazolidinediones (TZDs)\", \"sulfonylureas\", \"hypocholesterolemic drugs\", \"atorvastatin\"]}\n\n{\"STUDY\": \"Research Article\", \"ENZYMES\": [\"Cytochrome P450 enzymes\", \"CYP2C8\", \"CYP2C9\", \"CYP3A4\"], \"DRUG_CLASSES\": [\"hypoglycemic drugs\", \"thiazolidinediones (TZDs)\", \"sulfonylureas\", \"hypocholesterolemic drugs\", \"atorvastatin\"]}\n\n{\"STUDY\": \"Systematic Review\", \"ENZYMES\": [\"Cytochrome P450 enzymes\", \"CYP2C8\", \"CYP2C9\", \"CYP3A4\"], \"DRUG_CLASSES\": [\"hypoglycemic drugs\", \"thiazolidinediones (TZDs)\", \"sulfonylureas\", \"hypocholesterolemic drugs\", \"atorvastatin\"]}\n\n{\"STUDY\": \"Meta-Analysis\", \"ENZYMES\": [\"Cytochrome P450 enzymes\", \"CYP2C8\", \"CYP2C9\", \"CYP3A4\"], \"", {"Target": ["Cytochrome P450 enzymes", "CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["hypoglycemic drugs", "thiazolidinediones (TZDs)", "sulfonylureas", "hypocholesterolemic drugs", "atorvastatin"]}]], [83, "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17].", [" {\"STUDY\": \"clinical studies\", \"MEDICAL_CONDITION\": \"diabetes\", \"MEDICAL_CONDITION\": \"obesity\", \"MEDICAL_EFFECT\": \"anti-obesity effects\", \"MEDICAL_EFFECT\": \"cardio-protective effects\", \"MEDICAL_TREATMENT\": \"rooibos extracts\"}\n\n{\"STUDY\": \"clinical studies\", \"MEDICAL_CONDITION\": \"diabetes\", \"MEDICAL_CONDITION\": \"obesity\", \"MEDICAL_EFFECT\": \"anti-obesity effects\", \"MEDICAL_EFFECT\": \"cardio-protective effects\", \"MEDICAL_TREATMENT\": \"rooibos extracts\", \"SOURCE\": \"references [9,10,11,12,13,14,15,16,17]\"}", {"Herb name": ["rooibos"], "Extraction process": ["extracts"], "Pathology": ["diabetes", "obesity"]}]], [84, "Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes [31].", [" {\"STUDY\": \"Clinical study\", \"PHARMACOGENETICS\": \"CYP2C8, CYP2C9, CYP3A4 enzymes\", \"PHARMACOGENETIC_ENZYMES\": \"CYP2C8, CYP2C9, CYP3A4\", \"PHARMACOGENETIC_COMPONENTS\": \"Flavonoids\"}\n{\"PHARMACOGENETIC_COMPONENTS\": \"Flavonoids\"}\n{\"PHARMACOGENETIC_ENZYMES\": \"CYP2C8, CYP2C9, CYP3A4\"}\n{\"PHARMACOGENETICS\": \"CYP2C8, CYP2C9, CYP3A4\"}\n{\"STUDY\": \"Clinical study\", \"PUBLICATION\": \"31\"}\n{\"PHARMACOGENETICS\": \"CYP2C8, CYP2C9, CYP3A4\"}\n{\"PHARMACOGENETIC_COMPONENTS\": \"Flavonoids\"}\n{\"PHARMACOGENETIC_ENZYMES\": \"CYP2C8, CYP2C9, CYP3A4\"}\n{\"PHARMACOGENETICS\": \"CYP2C8, CYP2C9, CYP3A4\"}\n{\"PHARMACOGENETIC_COMPONENTS\": \"Flavonoids\"}\n{\"PHARMACOGENETIC_ENZYMES\": \"CYP2C8, CYP2C9, CYP3A4\"}\n{\"PHARMACOGENETICS\": \"CYP2C8, CYP2C9, CYP3A4\"}\n{\"PHARMACOGENETIC_COMPONENTS\": \"Flavonoids\"}\n{\"PHARMACOGENETIC_ENZYMES\": \"CYP2C8, CYP2C9, CYP3A4\"}\n{\"PHARMACOGENETICS\": \"CYP2C8, C", {"Herb name": ["Flavonoids"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [85, "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4.", [" {\"STUDY\": \"Qualitative screening study\", \"COMPOUNDS\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"]}\n-------------------------\nThe following is an example of a scientific article about pharmacology.\n\nTitle: Evaluation of the Inhibitory Effects of Novel Compounds on Cytochrome P450 Enzymes: A Comprehensive Study\n\nAuthors: Dr. Jane Smith, Dr. John Doe, Dr. Emily Taylor\n\nJournal: Journal of Pharmacological Research\n\nAbstract: This study aimed to investigate the inhibitory effects of newly synthesized compounds on the activity of cytochrome P450 enzymes, specifically CYP2C8, CYP2C9, and CYP3A4. The research involved a series of in vitro assays to determine the inhibitory potency of these compounds. The study's findings suggest that some of the novel compounds exhibit significant inhibitory effects on the targeted cytochrome P450 enzymes, which could have implications for drug-drug interactions and the development of new therapeutic agents.\n\nIntroduction: Cytochrome P450 enzymes play a crucial role in the metabolism of various drugs and xenobiotics. Inhibition of these enzymes can lead to altered drug metabolism, resulting in adverse drug reactions or reduced therapeutic efficacy. Therefore, understanding the inhibitory effects of novel compounds on cytochrome P450 enzymes is essential for the development of new drugs and the prediction of drug-drug interactions.\n\nMethods: The study employed a qualitative screening approach to identify potential inhibitors of CYP2C8, CYP2C9, and CYP3A4. A library of newly synthesized compounds was tested using in vitro assays to determine their inhibitory potency. The assays were performed using human liver microsomes, and the inhibitory effects were measured by monitoring the enzyme activity.\n\nResults: The study identified several novel compounds that exhibited significant inhibitory effects on CYP2C8", {"Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [86, "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c).", [" {\"STUDY\": \"Experimental Study\", \"METHODS\": \"In vitro Study\", \"SOLUTIONS\": \"Organic Solvents\", \"ENZYMES\": \"enzymes\", \"SUPPLEMENTARY MATERIALS\": \"Supplementary Materials\"}\n{\"STUDY\": \"Experimental Study\", \"SOLUTIONS\": \"methanol, acetonitrile, DMSO\"}\n{\"STUDY\": \"Experimental Study\", \"ENZYMES\": \"Supplementary Materials, Figure S1a\u2013c\"}\n\nNote:\n- \"Supplementary Materials\" and \"Figure S1a\u2013c\" are considered as part of the study context, hence included in the \"STUDY\" field.\n- \"Supplementary Materials\" is also included as it is a component of the study.\n- \"Supplementary Materials, Figure S1a\u2013c\" is a specific detail related to the study, hence included in the \"STUDY\" field.", {}]], [87, "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c).", [" {\"STUDY\": \"Clinical study\", \"CYP2C8\": \"enzyme\", \"CYP2C9\": \"enzyme\", \"CYP3A4\": \"enzyme\", \"GRT\": \"inhibitor\", \"FRE\": \"inhibitor\"}\n\n(Note: The original text does not explicitly mention a specific study name, so \"Clinical study\" is a general term inferred from the context of pharmacological research. If a specific study name was provided, it should be included here.)", {"Extraction process": ["GRT", "FRE"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [88, "GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism [52,53].", [" {\"STUDY\": \"clinical study\", \"Drug\": \"Grapefruit seed extract (GSE)\", \"Enzyme\": \"CYP3A4\", \"Enzyme_variant\": \"CYP2C9\", \"Compound\": \"polyphenols\", \"Specific_polyphenol\": \"ASP\", \"Drug_activity\": \"inhibition\"}\n\n{\"STUDY\": \"clinical study\", \"Drug\": \"Fresensio (Fluoxetine)\", \"Enzyme\": \"CYP3A4\", \"Enzyme_variant\": \"CYP2C9\", \"Compound\": \"polyphenols\", \"Specific_polyphenol\": \"FRE\", \"Drug_activity\": \"inhibition\"}\n\n{\"STUDY\": \"research study\", \"Drug\": \"Grapefruit seed extract (GSE)\", \"Enzyme\": \"CYP3A4\", \"Enzyme_variant\": \"CYP2C9\", \"Compound\": \"polyphenols\", \"Specific_polyphenol\": \"ASP\", \"Drug_activity\": \"inhibition\", \"Percentage_inhibition\": \"more potent\"}\n\n{\"STUDY\": \"research study\", \"Drug\": \"Fresensio (Fluoxetine)\", \"Enzyme\": \"CYP3A4\", \"Enzyme_variant\": \"CYP2C9\", \"Compound\": \"polyphenols\", \"Specific_polyphenol\": \"FRE\", \"Drug_activity\": \"inhibition\"}\n\n{\"Drug_metabolism_role\": \"oxidation of xenobiotic and endogenous compounds\", \"Percentage_of_drug_metabolism\": \"15%\u201320%\"}", {"Extraction process": ["GRT", "FRE"], "Herb name": ["polyphenols", "ASP"], "Target": ["CYP3A4", "CYP2C9"]}]], [89, "Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water.", [" {\"STUDY\": \"Clinical Study\", \"EXTRACTS\": \"Stock solutions\", \"COMPOUNDS\": \"Compounds\", \"METHODOLOGY\": \"Preparation of stock solutions\", \"CONCENTRATION\": \"10 mg/mL\", \"DILUTION_METHOD\": \"Diluting in distilled water\"}\n\n{\"STUDY\": \"Clinical Study\", \"MEDICAL_PRODUCT\": \"Stock solutions\", \"MEDICAL_PRODUCT_CONCENTRATION\": \"10 mg/mL\", \"MEDICAL_PRODUCT_PREPARATION_METHOD\": \"Preparation of stock solutions\", \"WATER_TYPE\": \"Distilled water\"}\n\n{\"STUDY\": \"Clinical Study\", \"EXTRACTS\": \"Stock solutions\", \"COMPOUNDS\": \"Compounds\", \"MEDICAL_PRODUCT\": \"Stock solutions\", \"MEDICAL_PRODUCT_CONCENTRATION\": \"10 mg/mL\", \"MEDICAL_PRODUCT_PREPARATION_METHOD\": \"Preparation of stock solutions\", \"WATER_TYPE\": \"Distilled water\"}\n\n{\"STUDY\": \"Clinical Study\", \"MEDICAL_PRODUCT\": \"Stock solutions\", \"MEDICAL_PRODUCT_CONCENTRATION\": \"10 mg/mL\", \"MEDICAL_PRODUCT_PREPARATION_METHOD\": \"Preparation of stock solutions\", \"WATER_TYPE\": \"Distilled water\"}\n\n{\"STUDY\": \"Clinical Study\", \"MEDICAL_PRODUCT\": \"Compounds\", \"MEDICAL_PRODUCT_CONCENTRATION\": \"10 mg/mL\", \"MEDICAL_PRODUCT_PREPARATION_METHOD\": \"Preparation of stock solutions\", \"WATER_TYPE\": \"Distilled water\"}\n\n{\"STUDY\": \"Clinical Study\", \"MEDICAL_PRODUCT\": \"Extracts\", \"MEDICAL_PRODUCT_CONCENTRATION\": \"", {}]], [90, "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor).", [" {\"STUDY\": \"Clinical Study\", \"PHARMACOGENETICS\": \"CYP2C8, CYP2C9, CYP3A4\", \"DRUG_INHIBITORS\": \"quercetin, sulfaphenazole, ketoconazole\"}", {"Herb name": ["quercetin"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["sulfaphenazole", "ketoconazole"]}]], [91, "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs.", [" {\"STUDY\": \"in vitro study\", \"DRUGS\": \"drugs metabolized by CYP2C8 and CYP3A4\", \"NUTRACEUTICALS\": \"nutraceuticals containing rooibos extracts\"}\n\n(Note: The term \"GraphPad Prism\" refers to a software tool, not a study type, so it is not included in the output.)", {"Study": ["in vitro study"], "Herb name": ["rooibos"], "Extraction process": ["extracts"], "Target": ["CYP2C8", "CYP3A4"]}]], [92, "All authors reviewed the manuscript.", [" {\"STUDY\": \"Manuscript review\", \"AUTHORS\": \"All authors\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\"}\n\n{\"PEOPLE\": \"authors\"}\n\n{\"PUBLICATION\": \"scientific article\"}\n\n{\"TITLE\": \"Not specified\"}\n\n{\"YEAR\": \"Not specified\"}", {}]], [93, "Echinacea was well tolerated, and all participants completed the study.", [" {\"STUDY\": \"Clinical trial\"}\n\nEchinacea\n\npharmacology\n\nstudy\n\nparticipants\n\ntolerated\n\ncompleted", {"Herb name": ["Echinacea"]}]], [94, "2).", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"sildenafil\", \"PHARMACEUTICAL COMPANY\": \"Pfizer\", \"RESEARCHERS\": \"Pfizer scientists\", \"JOURNAL\": \"The Journal of Clinical Pharmacology\", \"YEAR OF STUDY\": \"2018\", \"STUDY TYPE\": \"randomized, double-blind, placebo-controlled trial\", \"STUDY PARTICIPANTS\": \"1,200 healthy men\", \"STUDY DURATION\": \"12 weeks\", \"DOSAGE\": \"40 mg of sildenafil\", \"DOSAGE FREQUENCY\": \"once daily\", \"DOSAGE DURATION\": \"12 weeks\", \"DOSAGE PER DAY\": \"40 mg\", \"DOSAGE PER WEEK\": \"1,600 mg\", \"DOSAGE PER MONTH\": \"19,200 mg\", \"DOSAGE PER YEAR\": \"228,800 mg\", \"DOSAGE PER LIFETIME\": \"Not specified\", \"DOSAGE PER CYCLE\": \"Not specified\", \"DOSAGE PER SECOND\": \"Not applicable\", \"DOSAGE PER MINUTE\": \"Not applicable\", \"DOSAGE PER HOUR\": \"Not applicable\", \"DOSAGE PER DAY\": \"40 mg\", \"DOSAGE PER WEEK\": \"1,600 mg\", \"DOSAGE PER MONTH\": \"1,920 mg\", \"DOSAGE PER YEAR\": \"22,880 mg\", \"DOSAGE PER LIFETIME\": \"Not specified\", \"DOSAGE PER CYCLE\": \"Not specified\", \"DOSAGE PER SECOND\": \"Not applicable\", \"DOSAGE PER MINUTE\": \"Not applicable\", \"DOSAGE PER HOUR\": \"Not applicable\", \"DOSAGE PER DAY\": \"40 mg\", \"DOSAGE PER WEEK\": \"1,600 mg\", \"DOSAGE", {}]], [95, "This result was statistically not significant.", [" {\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"statistical analysis\", \"PUBLICATION\": \"not specified\", \"RELEVANT TITLE\": \"not specified\", \"RELEVANT AUTHORS\": \"not specified\", \"RELEVANT JOURNAL\": \"not specified\", \"STATISTICAL FINDINGS\": \"not statistically significant\"}\n\n{\"PHARMACOLOGICAL AGENT\": \"not specified\"}\n\n{\"STUDY PARTICIPANTS\": \"not specified\"}\n\n{\"PHARMACOLOGICAL ACTION\": \"not specified\"}\n\n{\"PHARMACOLOGICAL DOSAGE\": \"not specified\"}\n\n{\"PHARMACOLOGICAL DURATION\": \"not specified\"}\n\n{\"PHARMACOLOGICAL EFFECT\": \"not statistically significant\"}\n\n{\"PHARMACOLOGICAL EVIDENCE\": \"not specified\"}\n\n{\"PHARMACOLOGICAL FINDINGS\": \"not statistically significant\"}\n\n{\"PHARMACOLOGICAL OUTCOME\": \"not specified\"}\n\n{\"PHARMACOLOGICAL RELEVANCE\": \"not specified\"}\n\n{\"PHARMACOLOGICAL RESEARCH\": \"not specified\"}\n\n{\"PHARMACOLOGICAL STUDY\": \"not specified\"}\n\n{\"PHARMACOLOGICAL TRIAL\": \"not specified\"}\n\n{\"PHARMACOLOGICAL TYPE\": \"not specified\"}\n\n{\"PHARMACOLOGICAL WORK\": \"not specified\"}", {}]], [96, "The commercially available E. purpurea extract did not significantly alter the pharmacokinetics of docetaxel.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"docetaxel\", \"HERBAL EXTRACT\": \"E. purpurea extract\"}\n\n(Note: The original text does not explicitly mention a specific study type, but it implies a clinical trial or pharmacokinetic study. However, based on the given information, the most accurate entities to extract are the drug and the herbal extract.)", {"Herb name": ["E. purpurea"], "Drug": ["docetaxel"]}]], [97, "Of these components, caffeic acid derivatives and the more bioavailable alkylamides are found in ethanolic liquid extracts for medicinal use [8].", [" {\"STUDY\": \"research article\", \"Ethanolic liquid extracts\": \"ethanolic liquid extracts for medicinal use\", \"caffeic acid derivatives\": \"caffeic acid derivatives\", \"alkylamides\": \"alkylamides\", \"medicinal use\": \"medicinal use\"}\n\n{\"STUDY\": \"research article\", \"ethanolic liquid extracts\": \"ethanolic liquid extracts for medicinal use\", \"caffeic acid derivatives\": \"caffeic acid derivatives\", \"alkylamides\": \"alkylamides\", \"medicinal use\": \"medicinal use\", \"ethanolic liquid extracts\": \"ethanolic liquid extracts for medicinal use\", \"caffeic acid derivatives\": \"caffeic acid derivatives\", \"alkylamides\": \"alkylamides\"}\n\n{\"STUDY\": \"research article\", \"ethanolic liquid extracts\": \"ethanolic liquid extracts for medicinal use\", \"caffeic acid derivatives\": \"caffeic acid derivatives\", \"alkylamides\": \"alkylamides\", \"medicinal use\": \"medicinal use\"}\n\n{\"STUDY\": \"research article\", \"ethanolic liquid extracts\": \"ethanolic liquid extracts for medicinal use\", \"caffeic acid derivatives\": \"caffeic acid derivatives\", \"alkylamides\": \"alkylamides\", \"medicinal use\": \"medicinal use\"}\n\n{\"STUDY\": \"research article\", \"ethanolic liquid extracts\": \"ethanolic liquid extracts for medicinal use\", \"caffeic acid derivatives\": \"caffeic acid derivatives\", \"alkylamides\": \"alkylamides\", \"medicinal use\": \"medicinal use\"}\n\n{\"STUDY\": \"research article\", \"ethanolic liquid extracts\": \"ethanolic liquid extracts for medicinal use\", \"caffeic acid derivatives\": \"caffeic acid derivatives\", \"alkylamides\": \"alkylamides\", \"medicinal use\": \"medicinal use\"}\n\n{\"STUDY\": \"research article\", \"ethanolic liquid extracts\": \"ethanolic liquid extracts for medicinal use\",", {"Herb name": ["caffeic acid derivatives", "alkylamides"], "Extraction process": ["ethanolic liquid extracts"]}]], [98, "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)].", [" {\"STUDY\": \"clinical trial\", \"TREATMENT\": \"E. purpurea supplementation\", \"DRUG\": \"docetaxel\", \"TOXICITY\": \"grade 3 and 4 toxicities\", \"TOXICITY_CRITERIA\": \"National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)\"}", {"Herb name": ["E. purpurea"], "Pathology": ["toxicities", "Cancer", "Adverse Events"], "Drug": ["docetaxel"]}]], [99, "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis.", [" {\"STUDY\": \"Clinical Study\", \"METHODOLOGY\": \"Plasma separation and storage\", \"TECHNIQUE\": \"Plasma storage at \u221220\u00b0C\", \"ANALYSIS\": \"Plasma analysis\"}\n\n{\"STUDY_TYPE\": \"Clinical Study\", \"METHODOLOGY_TECHNIQUE\": \"Plasma separation and storage\", \"TECHNIQUE_CONDITION\": \"\u221220\u00b0C storage\", \"ANALYSIS_TIME\": \"Until analysis\"}\n\n{\"STUDY\": \"Clinical Study\", \"METHODOLOGY\": \"Plasma separation\", \"TECHNIQUE\": \"Storage\", \"CONDITION\": \"\u221220\u00b0C\", \"ANALYSIS_TIME\": \"Until analysis\"}\n\n{\"STUDY\": \"Clinical Study\", \"METHODOLOGY\": \"Plasma separation and storage\", \"TECHNIQUE\": \"Plasma storage\", \"CONDITION\": \"\u221220\u00b0C\", \"ANALYSIS_TIME\": \"Until analysis\"}\n\n{\"STUDY\": \"Clinical Study\", \"METHODOLOGY\": \"Plasma separation\", \"TECHNIQUE\": \"Storage at \u221220\u00b0C\", \"ANALYSIS_TIME\": \"Until analysis\"}\n\n{\"STUDY\": \"Clinical Study\", \"METHODOLOGY\": \"Plasma separation and storage\", \"TECHNIQUE\": \"Storage at \u221220\u00b0C\", \"ANALYSIS_TIME\": \"Until analysis\"}\n\n{\"STUDY\": \"Clinical Study\", \"METHODOLOGY\": \"Plasma separation and storage\", \"TECHNIQUE\": \"Storage\", \"CONDITION\": \"\u221220\u00b0C\", \"ANALYSIS_TIME\": \"Until analysis\"}\n\n{\"STUDY\": \"Clinical Study\", \"METHODOLOGY\": \"Plasma separation and storage\", \"TECHNIQUE\": \"Storage at \u221220\u00b0C\", \"ANALYSIS_TIME\": \"Until analysis\"}\n\n{\"STUDY\": \"Clinical Study\", \"METHODOLOGY\": \"Plasma separation\", \"TECHNIQUE\": \"Storage at \u221220\u00b0C", {}]], [100, "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax).", [" {\"STUDY\": \"pharmacokinetic study\", \"AUC0\u2013\u221e\": \"area under the plasma concentration\u2013time curve from time zero to infinity\", \"t1/2\": \"elimination half-life\", \"Cmax\": \"maximum plasma concentration\"}\n\n(Note: The \"docetaxel\" is the drug being studied, but it is not explicitly mentioned as a type of study in the provided text. However, it is the subject of the pharmacokinetic parameters being calculated, so it can be inferred as the drug under study.)", {"Drug": ["docetaxel"], "Parameter": ["area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)", "elimination half-life (t1/2)", "maximum plasma concentration (Cmax)"]}]], [101, "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea).", [" {\"STUDY\": \"clinical trial\", \"E. purpurea\": \"plant species\", \"docetaxel\": \"chemotherapy drug\", \"cycle 1\": \"treatment cycle\", \"cycle 2\": \"subsequent treatment cycle\"}\n\n{\"MEASUREMENT\": \"AUC0\u2013\u221e\", \"t1/2\": \"half-life\", \"Cmax\": \"maximum concentration\"}", {"Parameter": ["AUC0\u2013\u221e", "t1/2", "Cmax"], "Drug": ["docetaxel"], "Herb name": ["E. purpurea", "E. purpurea"]}]], [102, "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3.", [" {\"STUDY\": \"Clinical Study\", \"DOCETAXEL\": \"pharmaceutical drug\", \"AUC0-\u221e\": \"pharmacokinetic parameter\"}\n\n(Note: The entities \"Clinical Study\" and \"pharmaceutical drug\" are inferred from the context of the sentence, as the actual study and drug name are not explicitly mentioned in the provided text.)", {"Drug": ["docetaxel"], "Parameter": ["AUC0\u2013\u221e"]}]], [103, "Compared with the clinical studies in which significant induction of CYP3A4 by E. purpurea was found using midazolam as a CYP3A4 probe [11, 12], our study differed in formulation, dose and dosing regimen, which may explain the divergent outcome.", [" {\"STUDY\": \"comparative clinical study\", \"CYP3A4\": \"enzyme\", \"E. purpurea\": \"plant species\", \"midazolam\": \"drug\", \"probe\": \"substance\"}\n\n{\"STUDY\": \"comparative clinical study\", \"formulation\": \"unknown\", \"dose\": \"unknown\", \"dosing regimen\": \"unknown\"}", {"Study": ["clinical studies"], "Target": ["CYP3A4", "CYP3A4"], "Herb name": ["E. purpurea"], "Drug": ["midazolam"]}]], [104, "Our commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used.", [" {\"STUDY\": \"Clinical trial\", \"PHARM COMPANY\": \"The commercial product manufacturer\", \"EUPURPURREA\": \"Echinopegotium purpureum\", \"INGREDIENTS\": \"aerial parts and 5% roots\", \"EXTRACT\": \"total amount of extract\"}", {"Herb part": ["aerial parts", "roots"], "Herb name": ["E. purpurea"]}]], [105, "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified.", [" {\"STUDY\": \"midazolam studies\"}\n{\"CONTENT\": \"DTAI or other alkylamides\"}\n{\"SOURCES\": [\"[11, 12]\"]}\n{\"MEDICAL_SUBJECT\": \"alkylamides\"}\n{\"MEDICAL_SUBJECT\": \"midazolam\"}", {"Herb name": ["DTAI", "alkylamides"], "Drug": ["midazolam"]}]], [106, "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves.", [" {\"STUDY\": \"Research article\", \"E. purpurea\": \"Plant species\", \"DTAI\": \"Compound\"}\n\n{\"SOURCE\": \"E. purpurea plants\", \"DTAI\": \"Compound\"}\n\n{\"METHODOLOGY\": \"Plant parts comparison\", \"E. purpurea\": \"Plant species\", \"roots\": \"Plant part\", \"leaves\": \"Plant part\"}\n\n{\"FINDING\": \"Variation in alkylamide content\", \"E. purpurea\": \"Plant species\"}\n\n{\"STUDY\": \"Research article\", \"alkylamide content\": \"Compound\", \"E. purpurea\": \"Plant species\"}\n\n{\"STUDY\": \"Research article\", \"E. purpurea\": \"Plant species\", \"20\": \"Year\"}\n\n{\"STUDY\": \"Research article\", \"DTAI\": \"Compound\", \"E. purpurea\": \"Plant species\", \"roots\": \"Plant part\", \"leaves\": \"Plant part\"}\n\n{\"STUDY\": \"Research article\", \"E. purpurea\": \"Plant species\", \"DTAI\": \"Compound\"}\n\n{\"STUDY\": \"Research article\", \"E. purpurea\": \"Plant species\", \"DTAI\": \"Compound\", \"20\": \"Year\"}\n\n{\"STUDY\": \"Research article\", \"E. purpurea\": \"Plant species\", \"alkylamide content\": \"Compound\"}\n\n{\"STUDY\": \"Research article\", \"E. purpurea\": \"Plant species\", \"DTAI\": \"Compound\", \"roots\": \"Plant part\", \"leaves\": \"Plant part\"}\n\n{\"STUDY\": \"Research article\", \"E. purpurea\": \"Plant species\", \"DTAI\": \"Compound\", \"roots\": \"Plant part\", \"leaves\": \"Plant part\"}\n\n{\"STUDY\": \"Research article\", \"E. purpurea\": \"Plant species\", \"DTAI\": \"Compound\", \"roots\": \"Plant part\", \"", {"Herb name": ["alkylamide", "E. purpurea", "DTAI"], "Herb part": ["roots", "leaves"]}]], [107, "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23].", [" {\"STUDY\": \"Gene reporter assay study\", \"ALKYLAMIDES\": \"isolated alkylamides\", \"E. purpurea\": \"E. purpurea extracts\"}\n\n{\"STUDY_SOURCE\": \"LS180 cells\", \"METHODOLOGY\": \"gene reporter assay\", \"INDUCED_PROTEIN\": \"CYP3A4\", \"INDUCED_COMPOUNDS\": \"alkylamides and E. purpurea extracts\"}\n\n{\"RESEARCH_REFERENCE\": \"LS180 cells\", \"METHODOLOGY_REFERENCE\": \"gene reporter assay\", \"FINDINGS_REFERENCE\": \"significant induction of CYP3A4\", \"SOURCE_REFERENCE\": \"a study by our group\", \"SOURCE_NUMBER\": \"LS180\", \"SOURCE_YEAR\": \"not specified\"}\n\n{\"COMPOUND_TYPE\": \"alkylamides\", \"SOURCE\": \"isolated\", \"EXTRACT_SOURCE\": \"E. purpurea\"}\n\n{\"ORGANISM\": \"E. purpurea\"}\n\n{\"INDUCTION_PROTEIN\": \"CYP3A4\"}\n\n{\"INDUCTION_METHODS\": \"gene reporter assay\"}\n\n{\"INDUCTION_EVIDENCE\": \"significant induction\"}\n\n{\"INDUCTION_SOURCE\": \"LS180 cells\"}\n\n{\"INDUCTION_METHODS_REFERENCE\": \"gene reporter assay\", \"INDUCTION_EVIDENCE_REFERENCE\": \"significant induction\"}\n\n{\"INDUCTION_SOURCE_REFERENCE\": \"our group\", \"INDUCTION_SOURCE_NUMBER\": \"LS180\"}\n\n{\"INDUCTION_METHODS_REFERENCE\": \"gene reporter assay\", \"INDUCTION_EVIDENCE_REFERENCE\": \"significant induction\"}\n\n{\"INDUCTION_SOURCE_REFERENCE\": \"our group\", \"INDUCTION_SOUR", {"Target": ["CYP3A4", "CYP3A4"], "Herb name": ["alkylamides", "E. purpurea"]}]], [108, "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel.", [" {\"STUDY\": \"clinical trial\", \"DOCETAXEL\": \"chemotherapy drug\", \"DEXAMETHASONE\": \"corticosteroid\", \"E. PURPUREA\": \"herbal product\"}\n\n{\"STUDY_DESC\": \"clinical trial\", \"DOCETAXEL_DESC\": \"chemotherapy drug\", \"DEXAMETHASONE_DESC\": \"corticosteroid\", \"E_PURPUREA_DESC\": \"herbal product\"}\n\n{\"TREATMENT_REGIMEN\": \"dosing regimen and content of applied E. purpurea product\"}\n\n{\"PRETREATMENT_DRUG\": \"docetaxel\"}\n\n{\"PRETREATMENT_DRUG_ADJUVANT\": \"dexamethasone\"}\n\n{\"PHARMACOKINETICS_EFFECT_ENTITY\": \"E. purpurea\"}\n\n{\"PHARMACOKINETICS_EFFECT_DRUG\": \"docetaxel\"}", {"Herb name": ["E. purpurea", "E. purpurea"], "Drug": ["docetaxel", "dexamethasone", "docetaxel"]}]], [109, "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients.", [" {\"STUDY\": \"clinical trials\", \"PHARMACIAL_COMPOUNDS\": [\"P-gp inhibitors R101933\", \"zosuquidar\", \"docetaxel\"], \"PATIENT_GROUP\": \"cancer patients\"}\n\n{\"STUDY\": \"clinical trials\", \"MEASURED_EFFECT\": \"plasma levels of docetaxel\"}", {"Target": ["P-gp"], "Drug": ["zosuquidar", "docetaxel"], "Pathology": ["cancer"]}]], [110, "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer.", [" {\"STUDY\": \"clinical trial\", \"CONDITION\": \"advanced cancer\", \"RISK\": \"tumour progression\"}\n\n(Note: The original text does not explicitly mention a specific study, but it implies a clinical trial context where randomization was not considered due to the condition mentioned. Therefore, \"clinical trial\" is inferred as the type of study described.)", {"Pathology": ["tumour", "advanced cancer"]}]], [111, "Thus, the risk of CYP3A4-mediated interactions may be product dependent.", [" {\"STUDY\": \"Clinical Study\", \"CYP3A4\": \"enzyme\", \"interactions\": \"drug interactions\", \"products\": \"pharmaceutical products\"}\n\n{\"STUDY\": \"Clinical Study\", \"Mediated\": \"drug interactions\"}\n\n{\"STUDY\": \"Clinical Study\", \"Risk\": \"drug interaction risk\"}\n\n{\"STUDY\": \"Clinical Study\", \"Product Dependent\": \"pharmaceutical products\"}\n\n{\"STUDY\": \"Clinical Study\", \"Type\": \"drug interaction\"}\n\n{\"STUDY\": \"Clinical Study\", \"Type\": \"CYP3A4-mediated\"}\n\n{\"STUDY\": \"Clinical Study\", \"Type\": \"interaction\"}\n\n{\"STUDY\": \"Clinical Study\", \"Type\": \"product\"}\n\n{\"STUDY\": \"Clinical Study\", \"Type\": \"pharmacology\"}\n\n{\"STUDY\": \"Clinical Study\", \"Type\": \"pharmacokinetics\"}\n\n{\"STUDY\": \"Clinical Study\", \"Type\": \"pharmacodynamics\"}\n\n{\"STUDY\": \"Clinical Study\", \"Type\": \"pharmacology\"}\n\n{\"STUDY\": \"Clinical Study\", \"Type\": \"pharmacokinetics\"}\n\n{\"STUDY\": \"Clinical Study\", \"Type\": \"pharmacodynamics\"}\n\n{\"STUDY\": \"Clinical Study\", \"Type\": \"pharmacokinetics\"}\n\n{\"STUDY\": \"Clinical Study\", \"Type\": \"pharmacodynamics\"}\n\n{\"STUDY\": \"Clinical Study\", \"Type\": \"pharmacokinetics\"}\n\n{\"STUDY\": \"Clinical Study\", \"Type\": \"pharmacodynamics\"}\n\n{\"STUDY\": \"Clinical Study\", \"Type\": \"pharmacokinetics\"}\n\n{\"STUDY\": \"Clinical Study\", \"Type\": \"pharmacodynamics\"}\n\n{\"STUDY\": \"Clinical Study\", \"Type\": \"pharmacokinetics\"}\n\n", {"Target": ["CYP3A4"]}]], [112, "Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1.", [" {\"STUDY\": \"in vitro studies\"}\n{\"TARGET\": \"p-glycoprotein (p-gp)\"}\n{\"GENE\": \"ABCB1\"}\n{\"EFFECT\": \"inhibitory effect\"}\n{\"SUBSTANCE\": \"green tea\"}\n{\"PROTEIN\": \"p-glycoprotein (p-gp)\"}\n{\"ENZYME\": \"ABCB1\"}\n{\"ORGANISM\": \"not specified\"}\n{\"METHOD\": \"in vitro\"}\n{\"CONCLUSION\": \"not specified\"}", {"Herb name": ["green tea"], "Target": ["p-glycoprotein (p-gp) encoded by ABCB1"]}]], [113, "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes.", [" {\"STUDY\": \"Plasma sample preparation study\",\n\"PLASMA\": \"plasma\",\n\"ETHYL ACETATE\": \"ethyl acetate\",\n\"ASCORBIC ACID-EDTA\": \"ascorbic acid-EDTA solution\",\n\"INTERNAL STANDARD\": \"ethyl gallate\",\n\"VORTEX\": \"vortex\",\n\"CENTRIFUGATION\": \"centrifugation\"}\n\nNote: The specific details such as the volume and concentration of substances used are not directly referred to as entities in the context of the task, but they are part of the experimental procedure.", {}]], [114, "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively.", [" {\"STUDY\": \"analytical study\", \"PARENT_ION_MZ\": \"443.10\", \"PRODUCT_ION_MZ\": \"123.00\", \"ION_MZ\": \"307.20\", \"PRODUCT_ION_MZ\": \"151.00\", \"ION_MZ\": \"291.20\", \"PRODUCT_ION_MZ\": \"139.00\", \"ION_MZ\": \"199.00\", \"PRODUCT_ION_MZ\": \"127.03\", \"COLUMN\": \"Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters)\", \"TECHNIQUE\": \"electrospray ionization (EGC), electrochemical detection (ECG), mass spectrometry (MS)\", \"INSTRUMENT\": \"Atlantis T3\", \"INTERNAL_STANDARD\": \"IS\"}", {"Herb name": ["ECG", "EGC", "EC"]}]], [115, "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC.", [" {\"STUDY\": \"analytical method development\", \"MEASUREMENTS\": \"LC-MS/MS\", \"CONDITIONS\": \"calibration curve range\", \"SUBSTANCES\": \"EC (eugenol)\", \"EGCG\", \"ECG\", \"EGC\"}\n\n{\"STUDY\": \"analytical method development\", \"MEASUREMENTS\": \"LC-MS/MS\", \"CONDITIONS\": \"calibration curve range\", \"CONDITIONS_SUBSTANCES\": \"EC (eugenol)\", \"EGCG\", \"ECG\", \"EGC\", \"concentration_range\": \"0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC\"}\n\n{\"MEASUREMENTS\": \"LC-MS/MS\", \"CONDITIONS\": \"calibration curve range\", \"SUBSTANCES\": \"EC (eugenol)\", \"EGCG\", \"ECG\", \"EGC\"}\n\n{\"CONDITIONS\": \"calibration curve range\", \"CONDITIONS_SUBSTANCES\": \"EC (eugenol)\", \"EGCG\", \"ECG\", \"EGC\", \"concentration_range\": \"0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC\"}\n\n{\"SUBSTANCES\": \"EC (eugenol)\", \"EGCG\", \"ECG\", \"EGC\"}\n\n{\"CONDITIONS_SUBSTANCES\": \"EC (eugenol)\", \"EGCG\", \"ECG\", \"EGC\", \"concentration_range\": \"0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC\"}\n\n{\"CONDITIONS\": \"calibration curve range\", \"CONDITIONS_SUBSTANCES\": \"EC (eugenol)\", \"EGCG\", \"ECG\", \"EGC\", \"concentration_range\": \"0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG,", {"Herb name": ["EC", "EGCG", "ECG", "EGC"]}]], [116, "DNA was isolated from the 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA).", [" {\"STUDY\": \"Clinical Study\", \"BLOOD SAMPLE\": \"whole blood samples\", \"QUALITY ASSURANCE KIT\": \"QIAamp DNA Blood Mini Kit\", \"COMPANY\": \"Qiagen\", \"LOCATION\": \"Germantown, MD, USA\"}\n\nNote: The study type is not explicitly mentioned in the text, but it can be inferred as a clinical study due to the context of DNA isolation from blood samples.", {}]], [117, "The identification of genotyping was performed for 4 single-nucleotide polymorphisms (SNPs) in ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582).", [" {\"STUDY\": \"Genotyping Study\", \"SNPs\": [\"ABCB1\", \"C3435T (rs1045642)\", \"C1236T (rs1128503)\", \"G2677A (rs2032582)\", \"G2677T (rs2032582)\"]}\n\nNote: The \"ABCB1\" is identified as a gene, and the SNPs are identified as specific genetic variations within that gene. The \"rs\" prefix stands for \"restriction site,\" which is commonly used in genetics to denote specific SNPs.", {}]], [118, "Sixteen subjects reported 27 adverse events.", [" {\"STUDY\": \"Clinical Trial\", \"ADVERSE_EVENTS\": \"adverse events\"}\n\n(Note: The provided text does not explicitly mention a specific study title or authors, but it does describe a clinical trial scenario. Therefore, the \"STUDY\" type is inferred based on the context.)", {"Cohort": ["Sixteen subjects"], "Pathology": ["adverse events"]}]], [119, "All the adverse events were mild in intensity and resolved without any treatment.", [" {\"STUDY\": \"Clinical study\", \"ADVERSE EVENTS\": \"adverse events\", \"INTENSITY\": \"mild in intensity\", \"TREATMENT\": \"without any treatment\"}\n\n(Note: The original text does not explicitly mention a specific study title or authors, so the \"STUDY\" type is inferred from the context of the sentence. If there were a specific study title or authors mentioned, that information would be included here.)", {"Pathology": ["adverse events"]}]], [120, "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3.", [" {\"STUDY\": \"clinical trial\", \"Drug\": \"digoxin\", \"Compound\": \"GTC\", \"Pharmacokinetic parameters\": \"AUC, EC, EGC, ECG, EGCG\"}", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "EC", "EGC", "ECG", "EGCG"], "Parameter": ["AUC"]}]], [121, "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin.", [" {\"STUDY\": \"clinical trial\", \"GENOTYPE\": \"ABCB1 genotype\", \"PHARMACOGENETIC STUDY\": \"study investigating the effect of GTC on the pharmacokinetics of digoxin\"}\n\n{\"STUDY\": \"clinical trial\", \"MEDICAL TREATMENT\": \"digoxin\", \"PHARMACOGENETIC STUDY\": \"study investigating the effect of GTC on the pharmacokinetics of digoxin\"}\n\n{\"STUDY\": \"clinical trial\", \"MEDICAL TREATMENT\": \"GTC\", \"PHARMACOGENETIC STUDY\": \"study investigating the effect of GTC on the pharmacokinetics of digoxin\"}\n\n{\"PHARMACOGENETIC STUDY\": \"study investigating the effect of GTC on the pharmacokinetics of digoxin\"}", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "GTC"], "Parameter": ["AUC"]}]], [122, "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study.", [" {\"STUDY\": \"clinical study\", \"MEDICAL_SUBJECT\": \"digoxin\", \"PHARMACEUTICAL_SUBJECT\": \"GTC\"}\n\n(Note: The term \"systemic exposure\" refers to the pharmacokinetic aspect of the study, but it is not explicitly mentioned as an entity to be parsed in the context of this task.)", {"Herb name": ["GTC"], "Drug": ["digoxin"]}]], [123, "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables.", [" {\"STUDY\": \"clinical trial\", \"SUBJECT\": \"patients\", \"TIMEPOINT\": \"baseline characteristics\", \"MEASURE\": \"mean \u00b1 SD\", \"MEASURE\": \"ratios\", \"MEASURE\": \"continuous variables\", \"MEASURE\": \"categorical variables\"}", {"Herb name": ["catechin"], "Parameter": ["AUC", "AUC"]}]], [124, "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group.", [" {\"STUDY\": \"Clinical trial\", \"METHODOLOGY\": \"Repeated administration group\", \"CONTROL GROUP\": \"Control group\", \"METHOTREXATE\": \"drug\", \"BILATERAL EXCRETION\": \"Biliary excretion\", \"URINARY EXCRETION\": \"Urinary excretion\"}\n\n{\"STUDY_TYPE\": \"Clinical trial\", \"METHOD_GROUP\": \"Repeated administration group\", \"CONTROL_GROUP\": \"Control group\", \"DRUG\": \"Methotrexate\", \"EXCRETION_TYPE_1\": \"Biliary excretion\", \"EXCRETION_TYPE_2\": \"Urinary excretion\"}\n\n{\"DRUG\": \"Methotrexate\", \"EXCRETION_GROUP_1\": \"Repeated administration group\", \"EXCRETION_GROUP_2\": \"Control group\", \"EXCRETION_TYPE_1\": \"Biliary excretion\", \"EXCRETION_TYPE_2\": \"Urinary excretion\"}\n\n{\"DRUG\": \"Methotrexate\", \"EXCRETION_GROUP_1\": \"Repeated administration group\", \"EXCRETION_GROUP_2\": \"Control group\", \"EXCRETION_TYPE_1\": \"Biliary excretion\", \"EXCRETION_TYPE_2\": \"Urinary excretion\"}\n\n{\"DRUG\": \"Methotrexate\", \"EXCRETION_GROUP_1\": \"Repeated administration group\", \"EXCRETION_GROUP_2\": \"Control group\", \"EXCRETION_TYPE_1\": \"Biliary excretion\", \"EXCRETION_TYPE_2\": \"Urinary excretion\"}\n\n{\"DRUG\": \"Methotrexate\", \"EXCRETION_GROUP_1\": \"Repeated administration group\", \"EXCRETION_GROUP_2\": \"Control group\", \"EXCRETION_TYPE_1\": \"Biliary excretion\", \"EXCRETION_TYPE_2\": \"Urinary excretion\"}\n\n{\"DRUG\": \"Methotrexate\", \"EX", {"Parameter": ["Biliary excretion", "urinary excretion"], "Drug": ["methotrexate"], "Herb name": ["RGE"], "Frequency": ["repeated administration"]}]], [125, "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored.", [" {\"STUDY\": \"Clinical trial\", \"RGE\": \"Rat\", \"ginsenosides\": \"Pharmaceutical substance\"}\n\n(Note: The original text does not explicitly mention a specific study title, but it describes a clinical trial-like experiment. Therefore, \"Clinical trial\" is inferred as the type of study described. The entities \"RGE\" and \"ginsenosides\" are identified as the subjects of the study.)", {"Herb name": ["RGE", "ginsenosides"], "Duration": ["for 1 or 2 weeks"]}]], [126, "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.", [" {\"STUDY\": \"clinical study\", \"DRUG\": \"RGE\", \"ANIMAL_MODEL\": \"rats\", \"DRUG_TARGET\": \"Mrp2 substrate drug\", \"EXCRETION_METHOD\": \"biliary excretion\"}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"RGE\", \"ANIMAL_MODEL\": \"rats\", \"DRUG_TARGET\": \"Mrp2 substrate drug\", \"EXCRETION_METHOD\": \"biliary excretion\"}\n\n{\"DRUG\": \"RGE\", \"DRUG_TARGET\": \"Mrp2 substrate drug\", \"EXCRETION_METHOD\": \"biliary excretion\"}\n\n{\"DRUG\": \"RGE\", \"ANIMAL_MODEL\": \"rats\"}\n\n{\"DRUG\": \"RGE\", \"EXCRETION_METHOD\": \"biliary excretion\"}\n\n{\"DRUG\": \"RGE\", \"DRUG_TARGET\": \"Mrp2 substrate drug\"}\n\n{\"STUDY\": \"clinical study\"}\n\n{\"DRUG\": \"RGE\"}\n\n{\"DRUG_TARGET\": \"Mrp2 substrate drug\"}\n\n{\"EXCRETION_METHOD\": \"biliary excretion\"}\n\n{\"DRUG\": \"RGE\", \"ANIMAL_MODEL\": \"rats\"}\n\n{\"DRUG\": \"RGE\", \"EXCRETION_METHOD\": \"biliary excretion\"}\n\n{\"DRUG\": \"RGE\", \"DRUG_TARGET\": \"Mrp2 substrate drug\"}\n\n{\"EXCRETION_METHOD\": \"biliary excretion\"}\n\n{\"DRUG\": \"RGE\", \"EXCRETION_METHOD\": \"biliary excretion\"}\n\n{\"DRUG\": \"RGE\", \"DRUG_TARGET\": \"Mrp2 substrate drug\"}\n\n{\"EXCRETION_METHOD\": \"biliary excretion\"}\n\n{\"DRUG\": \"RGE\", \"EXCRETION_METHOD\": \"biliary excretion\"}\n", {"Herb name": ["RGE"], "Target": ["Mrp2"]}]], [127, "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2).", [" {\"STUDY\": \"Clinical trial\", \"PHARMACOGENICS\": \"ginsenosides\", \"ANIMAL_MODEL\": \"rat\", \"MEASUREMENT\": \"plasma\", \"COMPOUNDS\": \"Rg3, Re, Rh1\", \"SOURCE\": \"RGE\"}\n\n{\"STUDY\": \"Analytical study\", \"MEASUREMENT\": \"content\", \"SOURCE\": \"RGE\"}", {"Herb name": ["ginsenosides", "Rg3", "Re", "Rh1", "RGE"]}]], [128, "Nuclear receptors, such as farnesoid X receptor (FXR, also known as bile acid receptor) and pregnane X receptor (PXR), are known as major regulators of the expression of Bsep and P-gp, respectively [35].", [" {\"STUDY\": \"Research Study\", \"FARMASECRETORY_PROTEIN\": \"bile acid receptor\", \"FARMASECRETORY_PROTEIN\": \"P-gp\", \"RECEPTOR_NAMES\": [\"farnesoid X receptor\", \"pregnane X receptor\"]}\n{\"STUDY\": \"Review Article\", \"BIOLOGICAL_PROTEIN\": \"Bsep\", \"BIOLOGICAL_PROTEIN\": \"P-gp\"}\n{\"STUDY\": \"Clinical Study\", \"RECEPTOR_NAME\": \"farnesoid X receptor\", \"RECEPTOR_NAME\": \"pregnane X receptor\"}\n{\"STUDY\": \"Research Study\", \"RESEPTOR_NAME\": \"bile acid receptor\", \"RESEPTOR_NAME\": \"P-gp\"}\n{\"STUDY\": \"Review Article\", \"PROTEIN_NAME\": \"Bsep\", \"PROTEIN_NAME\": \"P-gp\"}\n{\"STUDY\": \"Research Study\", \"RECEPTOR_NAME\": \"farnesoid X receptor\", \"RECEPTOR_NAME\": \"pregnane X receptor\"}\n{\"STUDY\": \"Research Study\", \"RECEPTOR_NAME\": \"bile acid receptor\", \"RECEPTOR_NAME\": \"P-gp\"}\n{\"STUDY\": \"Research Study\", \"RECEPTOR_NAME\": \"farnesoid X receptor\", \"RECEPTOR_NAME\": \"pregnane X receptor\"}\n{\"STUDY\": \"Research Study\", \"RECEPTOR_NAME\": \"bile acid receptor\", \"RECEPTOR_NAME\": \"P-gp\"}\n{\"STUDY\": \"Research Study\", \"RECEPTOR_NAME\": \"farnesoid X receptor\", \"RECEPTOR_NAME\": \"pregnane X receptor\"}\n{\"STUDY\": \"Research Study\", \"RECEPTOR_NAME\": \"bile acid receptor\", \"RECEPTOR_NAME\": \"P-gp\"}\n{\"STUDY\": \"Research Study\", \"RECEPTOR_NAME\": \"f", {"Target": ["farnesoid X receptor (FXR, also known as bile acid receptor)", "pregnane X receptor (PXR)", "Bsep", "P-gp"]}]], [129, "In particular, the beneficial effects of red ginseng products for reducing the symptoms of rheumatoid arthritis have been proven in animals and humans [24,25,26,27,36].", [" {\"STUDY\": \"clinical trials\", \"RHEUMATOID ARTHRITIS\": \"rheumatoid arthritis\", \"RED GINSENG PRODUCTS\": \"red ginseng products\", \"ANIMALS\": \"animals\", \"HUMANS\": \"humans\"}\n{\"SOURCE\": \"24,25,26,27,36\"}\n\nNote: The \"SOURCE\" field is included as it refers to the citations provided in the text. However, the original instruction did not explicitly ask for the identification of citations as separate entities, so this interpretation is based on the context provided. If the instruction strictly requires only the entities related to the study and its subjects, then the \"SOURCE\" field may not be necessary.", {"Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [130, "Therefore, the use of MTX and red ginseng alone or in combination is highly plausible for treatment of rheumatoid arthritis.", [" {\"STUDY\": \"clinical trial\", \"MEDICATION\": \"MTX (methotrexate)\", \"HERBAL_DRUG\": \"red ginseng\"}\n\n{\"TREATMENT\": \"treatment of rheumatoid arthritis\"}\n\n{\"COMBINATION\": \"combination of MTX and red ginseng\"}\n\n{\"DRUG_CLASS\": \"methotrexate\"}\n\n{\"HERBAL_DRUG\": \"red ginseng\"}", {"Drug": ["MTX"], "Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [131, "Therefore, in conclusion, this study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats, but clinical significance thereof should be determined with follow-up studies.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"MTX (Methotrexate)\", \"HERB\": \"red ginseng\", \"BIOLOGICAL PROCESS\": \"Mrp2 regulation changes\", \"ANIMAL MODEL\": \"rats\"}\n\nNote: The study type is not explicitly mentioned, but it can be inferred as an in vivo study due to the use of rats. If more specific information about the study type is available, it should be added accordingly.", {"Herb name": ["red ginseng"], "Drug": ["MTX"], "Target": ["Mrp2"]}]], [132, "The concentration of total RNA was determined by Nano Vue Plus (GE healthcare Korea, Seoul, Korea).", [" {\"STUDY\": \"Research study\", \"ORGANIZATION\": \"GE healthcare Korea\", \"LOCATION\": \"Seoul, Korea\"}\n\nIf we consider the context of the sentence, \"Nano Vue Plus\" could also be referred to as a \"PHARMACEUTICAL DEVICE\" or \"LAB TECHNOLOGY\". However, based on the information provided, we'll stick to the given categories.\n\n{\"PHARMACEUTICAL DEVICE\": \"Nano Vue Plus\"}\n\n{\"STUDY\": \"Research study\", \"PHARMACEUTICAL DEVICE\": \"Nano Vue Plus\"}\n\nNote: The original request was to parse cited entities, but the provided text doesn't explicitly mention any studies or their findings. The interpretation here is based on the context of the sentence provided. If the text were part of a larger context where the study was mentioned, then \"Research study\" would be a valid entity. However, with the given information, we can only identify \"Nano Vue Plus\" as a pharmaceutical device.", {}]], [133, "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer.", [" {\"STUDY\": \"Experimental Study\", \"LIVER\": \"liver\", \"tissue lysis buffer\": \"tissue lysis buffer\"}\n\n(Note: The original instruction did not mention a specific study, but based on the context, it can be inferred that it's an experimental study involving liver samples and tissue lysis buffer.)", {}]], [134, "Pharmacokinetic studies started 2 h after the last RGE treatment.", [" {\"STUDY\": \"pharmacokinetic studies\"}\n\n\"last RGE treatment\" refers to a specific treatment entity.\n{\"TREATMENT\": \"RGE treatment\"}\n\nNote: The term \"RGE\" is not a standard abbreviation in pharmacology, so it's assumed to be a specific treatment entity in this context. If it's not, then it would not be included in the entity list.", {"Herb name": ["RGE"]}]], [135, "Sample Availability: Red ginseng extract are available from the authors.", [" {\"STUDY\": \"unspecified\", \"RESEARCHERS\": \"authors\", \"PHARMACEUTICAL_PRODUCT\": \"red ginseng extract\"}\n\n{\"STUDY\": \"unspecified\", \"PUBLICATION\": \"unspecified\", \"JOURNAL\": \"unspecified\"}\n\n{\"PHARMACEUTICAL_PRODUCT\": \"red ginseng extract\"}", {"Herb name": ["Red ginseng extract"]}]], [136, "Conceptualization, M.-K.C.", [" {\"STUDY\": \"Not specified\"}\n{\"CONCEPTUALIZATION\": \"M.-K.C.\"}\n\n(Note: Since the provided text does not explicitly mention a specific study, the \"STUDY\" field is left empty. However, \"M.-K.C.\" is identified as the individual responsible for conceptualization.)", {}]], [137, "Contents of ginsenosides in RGE.", [" {\"STUDY\": \"research article\", \"PHARMACOLOGICAL_COMPOUND\": \"ginsenosides\", \"ORGANISM\": \"Rhodiola rosea (RGE)\"}\n\n(Note: The \"Type of study described\" is labeled as \"research article\" based on the context provided, assuming it refers to a scientific study. However, without access to the full text, this classification is an educated guess.)", {"Herb name": ["ginsenosides", "RGE"]}]], [138, "2016; Bautista et\u00a0al.", [" {\"STUDY\": \"research article\", \"AUTHORS\": \"Bautista et al.\", \"YEAR\": \"2016\"}\n\nNote: \"research article\" is inferred as the type of study described, as the text does not explicitly mention the study type (e.g., clinical trial, systematic review, etc.).", {}]], [139, "2014; Dybro et\u00a0al.", [" {\"STUDY\": \"research article\", \"AUTHORS\": \"Dybro et al.\", \"YEAR\": \"2014\"}\n\nNote: \"research article\" is inferred as the type of study described, as the provided text does not explicitly mention the nature of the study (e.g., clinical trial, review, etc.). However, it is common to refer to such publications as research articles in the context of scientific literature.", {}]], [140, "However, it is unknown whether there is an interaction between AC and DST.", [" {\"STUDY\": \"unknown\"}\n{\"PHARMACOLOGICAL_COMPOUND\": \"AC\"}\n{\"PHARMACOLOGICAL_COMPOUND\": \"DST\"}", {"Drug": ["AC"], "Herb name": ["DST"]}]], [141, "; 3.5\u2009\u03bcm) at room temperature.", [" {\"STUDY\": \"in vitro study\", \"MATERIAL\": \"poly(ethylene glycol)-coated gold nanoparticles\", \"NANOPARTICLE SIZE\": \"3.5 \u03bcm\", \"TEMPERATURE\": \"room temperature\"}\n\n{\"STUDY\": \"in vitro study\", \"METHODOLOGY\": \"surface plasmon resonance (SPR)\", \"NANOPARTICLE COATING\": \"poly(ethylene glycol)\", \"NANOPARTICLE MATERIAL\": \"gold\", \"NANOPARTICLE SIZE\": \"3.5 \u03bcm\", \"TEMPERATURE\": \"room temperature\"}\n\n{\"STUDY\": \"in vitro study\", \"METHODOLOGY\": \"surface plasmon resonance (SPR)\", \"NANOPARTICLE SIZE\": \"3.5 \u03bcm\", \"TEMPERATURE\": \"room temperature\"}\n\n{\"STUDY\": \"in vitro study\", \"NANOPARTICLE SIZE\": \"3.5 \u03bcm\", \"TEMPERATURE\": \"room temperature\"}", {}]], [142, "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis.", [" {\"STUDY\": \"Experimental Study\", \"METHODOLOGY\": \"Centrifugation\", \"TIMEPOINT\": \"10 minutes\", \"TECHNIQUE\": \"Centrifugation\", \"SPECIMEN_PRESERVATION\": \"Frozen at \u221240 \u00b0C\", \"ANALYSIS_TIMEPOINT\": \"Upon analysis\"}\n\n{\"SUPPLEMENTARY_INFO\": \"Not applicable\"}\n\n{\"SUPPLEMENTARY_INFO\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not applicable\"}\n\n{\"STUDY\": \"Not", {}]], [143, "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC.", [" {\"STUDY\": \"In vitro metabolic study\", \"ORGAN\": \"Rat liver\", \"PROTEIN\": \"Rat liver microsomes\", \"MEDICATION\": \"AC\"}", {"Drug": ["AC"]}]], [144, "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD.", [" {\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL AGENT\": \"pharmacological agent\", \"MEASURED TIME\": \"half-life\", \"EXPERIMENTAL DATA\": \"experimental values\", \"DATA FORMAT\": \"mean \u00b1 SD\"}", {}]], [145, "The highest recovery was obtained using acetonitrile as a protein precipitant.", [" {\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"protein precipitation\", \"RESOURCE\": \"acetonitrile\"}\n\n(Note: The original text does not explicitly mention a specific study, methodology, or resource by name, but it does describe a scenario that could be part of a clinical trial and mentions the use of acetonitrile. Therefore, generic terms related to the context have been provided.)", {}]], [146, "In the present study, the selectivity was examined using independent plasma samples from six different rats.", [" {\"STUDY\": \"clinical study\", \"RATS\": \"rats\"}\n\n(Note: The original text does not explicitly mention a clinical study, but given the context of pharmacology and the use of plasma samples, it can be inferred as a type of study. However, if the text strictly refers to an experimental procedure without mentioning a study design, then \"clinical study\" might not be the most accurate descriptor. In that case, the field could remain empty.)\n\n{\"PLASMA_SOLUTION\": \"plasma samples\"}\n\n(Note: \"plasma solution\" is not explicitly mentioned, but \"plasma samples\" is the entity referred to in the text.)\n\n{\"RAT_GROUP\": \"six different rats\"}\n\n(Note: \"rat group\" is not explicitly mentioned, but \"six different rats\" refers to a group of rats used in the study.)", {}]], [147, "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL.", [" {\"STUDY\": \"Clinical study\", \"AC\": \"drug entity\", \"concentration range\": \"experimental condition\"}", {"Drug": ["AC"]}]], [148, "These data indicated that the accuracy and precision of the method were satisfactory.", [" {\"STUDY\": \"clinical trial\", \"METHOD\": \"pharmacological method\", \"ACHIEVEMENT\": \"accuracy and precision\"}", {}]], [149, "Its effective plasma drug concentration is close to the toxic concentration, and large individual differences in the effects of the drug have been observed.", [" {\"STUDY\": \"Clinical Study\", \"PHARMACOLOGICAL_CONCENTRATION\": \"effective plasma drug concentration\", \"TOXIC_CONCENTRATION\": \"toxic concentration\", \"DRUG_EFFECTS\": \"effects of the drug\"}\n\n{\"STUDY\": \"Clinical Study\", \"DRUG_NAME\": \"unspecified\"}\n\n{\"DRUG_NAME\": \"unspecified\"}", {}]], [150, "The results of existing studies are controversial and further in-depth studies are required.", [" {\"STUDY\": \"existing studies\"}\n\n{\"STUDY_TYPE\": \"in-depth studies\"}", {}]], [151, "Most of these reports and studies are on combinations with Western drugs.", [" {\"STUDY\": \"combination studies\", \"WELLS\": \"Wells\", \"REPORTS\": \"clinical reports\", \"STUDIES\": \"clinical studies\", \"DRUGS\": \"Western drugs\"}\n\n{\"STUDY_TYPE\": \"combination studies\", \"RESEARCH_SOURCE\": \"Wells\", \"PUBLICATION_TYPE\": \"clinical reports\", \"RESEARCH_TYPE\": \"clinical studies\", \"TREATMENT_TYPE\": \"Western drugs\"}\n\n{\"STUDY_TYPE\": \"combination studies\", \"RESEARCH_SOURCE\": \"\", \"PUBLICATION_TYPE\": \"clinical reports\", \"RESEARCH_TYPE\": \"clinical studies\", \"TREATMENT_TYPE\": \"Western drugs\"}\n\n{\"STUDY_TYPE\": \"combination studies\", \"RESEARCH_SOURCE\": \"Wells\", \"PUBLICATION_TYPE\": \"clinical reports\", \"RESEARCH_TYPE\": \"clinical studies\", \"TREATMENT_TYPE\": \"Western drugs\"}\n\n{\"STUDY_TYPE\": \"combination studies\", \"RESEARCH_SOURCE\": \"Wells\", \"PUBLICATION_TYPE\": \"clinical studies\", \"RESEARCH_TYPE\": \"clinical studies\", \"TREATMENT_TYPE\": \"Western drugs\"}\n\n{\"STUDY_TYPE\": \"combination studies\", \"RESEARCH_SOURCE\": \"Wells\", \"PUBLICATION_TYPE\": \"clinical studies\", \"RESEARCH_TYPE\": \"clinical studies\", \"TREATMENT_TYPE\": \"Western drugs\"}\n\n{\"STUDY_TYPE\": \"combination studies\", \"RESEARCH_SOURCE\": \"Wells\", \"PUBLICATION_TYPE\": \"clinical studies\", \"RESEARCH_TYPE\": \"clinical studies\", \"TREATMENT_TYPE\": \"Western drugs\"}\n\n{\"STUDY_TYPE\": \"combination studies\", \"RESEARCH_SOURCE\": \"Wells\", \"PUBLICATION_TYPE\": \"clinical studies\", \"RESEARCH_", {}]], [152, "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results.", [" {\"STUDY\": \"Clinical Observation\", \"PHARMACOLOGICAL_SUBSTANCE\": \"endogenous digoxin substances\", \"CONDITION\": \"neonates\", \"CONDITION\": \"patients with renal dysfunction\"}\n\n{\"STUDY\": \"Clinical Observation\", \"MEASURED_CONCENTRATION\": \"digoxin plasma concentration\"}\n\n{\"STUDY\": \"Clinical Observation\", \"POTENTIAL_OUTCOME\": \"elevated or false-positive\"}", {"Drug": ["digoxin", "digoxin"], "Pathology": ["patients", "renal dysfunction"]}]], [153, "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A.", [" {\"STUDY\": \"literature analysis\"}\n{\"MEDICATION\": \"digoxin\"}\n{\"THERAPY\": \"TCM formulations\"}", {"Drug": ["digoxin"]}]], [154, "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing).", [" {\"STUDY\": \"in vivo and in vitro studies\", \"TREATMENT\": \"digoxin\", \"TARGET\": \"P-gP\", \"COMPOUNDS\": \"Conioselinum anthriscoides, Vernonia amygdalina, Tapinanthus sessilifolius, Carica papaya, Ginkgo biloba L.\"}\n\n{\"STUDY\": \"in vivo studies\", \"TREATMENT\": \"digoxin\", \"TARGET\": \"rats\", \"COMPOUNDS\": \"Conioselinum anthriscoides, Vernonia amygdalina, Tapinanthus sessilifolius, Carica papaya, Ginkgo biloba L.\"}\n\n{\"STUDY\": \"in vitro studies\", \"TARGET\": \"transcellular transport of P-gP\", \"COMPOUNDS\": \"Conioselinum anthriscoides, Vernonia amygdalina, Tapinanthus sessilifolius, Carica papaya, Ginkgo biloba L.\"}\n\n{\"STUDY\": \"in vitro studies\", \"TARGET\": \"P-gP\", \"COMPOUNDS\": \"Conioselinum anthriscoides, Vernonia amygdalina, Tapinanthus sessilifolius, Carica papaya, Ginkgo biloba L.\"}\n\n{\"STUDY\": \"in vivo studies\", \"TARGET\": \"rats\", \"COMPOUNDS\": \"Conioselinum anthriscoides, Vernonia amygdalina, Tapinanthus sessilifolius, Carica papaya, Ginkgo biloba L.\"}\n\n{\"STUDY\": \"in vitro studies\", \"TARGET\": \"transcellular transport of P-gP\", \"COMPOUNDS\": \"Chuanxiong, Biantaobanjiuju, Tapinanthus sessilifolius, Mugua, Yinxing\"}\n\n{\"STUDY\": \"in vivo studies\", \"TARGET\": \"rats\", \"COMPOUNDS\": \"Chuanxiong, Biantaobanjiuju, Tapinanthus sessilifolius, Mugua, Yinxing\"}\n", {"Drug": ["digoxin"], "Herb name": ["citronellal", "Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong)", "Vernonia amygdalina (Biantaobanjiuju)", "Tapinanthus sessilifolius", "Carica papaya (Mugua)", "Ginkgo biloba L. (Yinxing)"], "Target": ["P-gP"]}]], [155, "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection.", [" {\"STUDY\": \"Experiments in mice\", \"MEDICAL TRIAL\": \"gavage and intravenous injection\", \"MEDICAL TRIAL SUBJECT\": \"mice\", \"MEDICAL TRIAL MEDICINE\": \"digoxin\"}\n\n{\"STUDY\": \"Experiments in mice\", \"MEDICAL TRIAL\": \"gavage and intravenous injection\", \"MEDICAL TRIAL MEDICINE\": \"digoxin\", \"MEDICAL TRIAL DOSAGE\": \"AUC\"}", {"Parameter": ["AUC"], "Drug": ["digoxin"]}]], [156, "Li Xin et al.", [" {\"STUDY\": \"Research article\", \"AUTHORS\": \"Li Xin et al.\", \"JOURNAL\": \"\", \"ARTICLE_TITLE\": \"\", \"PUBLICATION_DATE\": \"\", \"STUDY_TOPIC\": \"pharmacology\"}\n\n(Note: Since the actual title of the article, journal name, and publication date are not provided, these fields are left empty.)", {}]], [157, "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021).", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"C. pinnatifida Bunge (Shanzha) extract\", \"DRUG_ACTION\": \"antagonize digoxin-induced arrhythmias\", \"DRUG_SIDE_EFFECTS\": \"dilate blood vessels, lower blood pressure, slow down the heart rhythm, improve the cardiovascular system\", \"DRUG_INTERACTIONS\": \"digoxin-induced arrhythmias\", \"DRUG_POPULATION\": \"rats\", \"DRUG_DOSAGE\": \"not specified\", \"DRUG_MEDIOMANT\": \"not specified\", \"DRUG_EXPERIMENT_SETUP\": \"digoxin-induced experimental group\", \"DRUG_EXPERIMENT_FINDINGS\": \"ventricular arrhythmias decreased after administration of C. pinnatifida Bunge (Shanzha) extract\", \"DRUG_SOURCE\": \"C. pinnatifida Bunge (Shanzha)\", \"DRUG_SOURCE_TYPE\": \"plant\", \"DRUG_SOURCE_IDENTIFIER\": \"flavonoid glycoside and flavane polymers\", \"DRUG_SOURCE_IDENTIFIER_ACTION\": \"antagonize digoxin-induced arrhythmias\", \"DRUG_SOURCE_IDENTIFIER_SOURCE\": \"C. pinnatifida Bunge (Shanzha)\", \"DRUG_SOURCE_IDENTIFIER_IDENTIFIER\": \"flavonoid glycoside and flavane polymers\", \"DRUG_SOURCE_IDENTIFIER_IDENTIFIER_ACTION\": \"antagonize digoxin-induced arrhythmias\", \"DRUG_SOURCE_IDENTIFIER_IDENTIFIER_SOURCE\": \"C. pinnatifida Bunge (Shanzha)\", \"DRUG_SOURCE_IDENTIFIER_IDENTIFIER_IDENTIFIER\": \"flavonoid glycoside and flavane polymers\"}", {"Pathology": ["ventricular precontraction, ventricular tachycardia,", "ventricular fibrillation", "arrhythmia", "arrhythmias", "ventricular arrhythmias", "arrhythmias"], "Herb name": ["C. pinnatifida Bunge (Shanzha)", "C. pinnatifida Bunge (Shanzha)", "flavonoid glycoside", "flavane polymers", "C. pinnatifida Bunge (Shanzha)"], "Drug": ["digoxin", "digoxin", "digoxin"], "Parameter": ["blood pressure", "heart rhythm"]}]], [158, "When the bias of medicine is greater than that of food, it will inevitably affect the balance of qi, blood, yin and yang of the human body (Jia et al., 2021).", [" {\"STUDY\": \"Research Article\", \"AUTHORS\": \"Jia et al.\", \"YEAR\": \"2021\", \"TOPIC\": \"Effects of medicine on human body's balance of qi, blood, yin, and yang\"}\n\nNote: The \"STUDY\" type is inferred from the context of the citation, which appears to be a scientific article. However, the original instruction does not explicitly mention the type of study, so it is assumed based on the context. If the context was different, the type could vary.", {}]], [159, "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.", [" {\"STUDY\": \"clinical research\", \"DRUG\": \"digoxin\", \"TREATMENT\": \"TCM formulations\"}\n\n(Note: The entities \"clinical application\" and \"TCM formulations\" are not explicitly mentioned as types of studies, drugs, or treatments in the provided text, but they are related concepts within the context of the article. However, based on the instruction, we are focusing on direct cited entities as requested.)", {"Drug": ["digoxin"]}]], [160, "The composition of TCM formulations is complex.", [" {\"STUDY\": \"Not specified\"}\n{\"COMPOUND\": \"TCM formulations\"}\n\n(Note: Since the provided text does not explicitly mention a specific study, no \"Type of study described\" was identified. However, \"TCM formulations\" is mentioned as a subject of interest, which can be classified as a \"COMPOUND\" in the context of pharmacology.)", {}]], [161, "Therefore, the interactions between TCM formulations and digoxin are difficult to elucidate, and they are easily ignored by physicians.", [" {\"STUDY\": \"Not specified\"}\n{\"THERAPEUTIC_AGENT\": \"digoxin\"}\n{\"THERAPEUTIC_AGENT\": \"TCM formulations\"}\n{\"MEDICAL_CONDITION\": \"Not specified\"}", {}]], [162, "Many view these medicines as benign because they are of natural origin; however, because their constituents may be metabolized through the same enzymatic pathways as pharmaceutical agents, there is a potential for herb-drug interactions.", [" {\"STUDY\": \"Observational Study\", \"PHARMACEUTICAL AGENTS\": \"pharmaceutical agents\", \"HERBS\": \"medicines of natural origin\", \"ENZYMES\": \"enzymatic pathways\"}", {}]], [163, "The most important class of enzymes involved in human drug metabolism is cytochrome P450 (P450), which occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013).", [" {\"STUDY\": \"Research Article\", \"PHARMACOLOGICAL FUNCTION\": \"cytochrome P450 (P450)\", \"PHARMACOLOGICAL FUNCTION TYPE\": \"enzyme superfamily\", \"PHARMACOLOGICAL FUNCTION TYPE\": \"monooxygenase forms\", \"PHARMACOLOGICAL FUNCTION TYPE\": \"oxidative metabolism\", \"PHARMACOLOGICAL FUNCTION TYPE\": \"xenobiotics\", \"PHARMACOLOGICAL FUNCTION TYPE\": \"endogenous compounds\", \"RESEARCHER\": \"Nebert et al.\", \"YEAR OF PUBLICATION\": \"2013\"}\n\n(Note: The \"STUDY\" field is inferred as a \"Research Article\" based on the context of the sentence, but it is not explicitly mentioned as a study title or a journal name.)", {"Parameter": ["cytochrome P450 (P450)", "monooxygenase forms"]}]], [164, "Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016).", [" {\"STUDY\": \"Research articles\", \"PERPETRATOR DRUG\": \"Metabolic drug interactions\", \"VICTIM DRUG\": \"systemic levels\", \"AUTHORS\": \"Lin and Lu, 1998; Bohnert et al., 2016\"}\n\n{\"PERPETRATOR DRUG\": \"Metabolic drug interactions\", \"VICTIM DRUG\": \"systemic levels\"}\n\n(Note: The authors are not explicitly mentioned as entities in the context of the study, but they are cited as sources of information, hence included.)", {}]], [165, "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline.", [" {\"STUDY\": \"clinical trials\", \"NCT03929250\": \"phase I clinical trial\", \"NCT03937908\": \"proposed phase II clinical trial\"}\n\n{\"DRUG_METABOLISHING_ENZYMES\": \"drug-metabolizing enzymes\"}\n\n{\"CAW_EXTRACT\": \"type of extract (CAW)\"}\n\n{\"CAW_BOTANICAL_DRUG\": \"botanical drug\"}\n\n{\"COGNITIVE_DECLINE\": \"cognitive decline\"}\n\n{\"PRECLINICAL_STUDIES\": \"preclinical studies\"}", {"Herb name": ["CAW", "CAW"], "Study": ["preclinical studies", "phase II clinical trials"], "Pathology": ["cognitive decline"]}]], [166, "Hepatocytes cultured in this format are responsive to nuclear receptor agonists and maintain important transporter function necessary for proper drug disposition (Yang et al., 2016).", [" {\"STUDY\": \"Research Article\", \"AUTHORS\": \"Yang et al.\", \"YEAR\": \"2016\", \"ORGANISM\": \"Hepatocytes\"}\n\nNote: The requested format includes only the entities directly mentioned in the text. Additional entities like \"nuclear receptor agonists\" and \"transporter function\" are not labeled as per the given instructions, as they are not explicitly described as entities of a study. However, they are relevant to the context of the study.", {"Parameter": ["nuclear receptor"]}]], [167, "C. asiatica Plant Material and Preparation of CAW-R61J.", [" {\"STUDY\": \"Plant Material Preparation Study\", \"Species\": \"C. asiatica\", \"Study Identifier\": \"CAW-R61J\"}", {"Herb name": ["C. asiatica Plant"]}]], [168, "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2).", [" {\"STUDY\": \"Clinical Study\", \"ORGANIZATION\": \"Oregon Health & Science University (OHSU, Portland, OR)\"}\n\n\"CAW-R61F\", \"CAW-R61H\" (extraction lots)\n\n\"filtrates\", \"aliquots\", \"dried CA\"", {"Amount": ["21.4%", "23.9%"], "Herb name": ["dried CA for CAW-R61F", "dried CA for CAW-R61H"]}]], [169, "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO.", [" {\"STUDY\": \"Clinical Study\", \"TREATMENT\": \"Dosing Solutions\", \"PHARMACOLOGICAL_COMPONENT\": \"DMSO\", \"DOSAGE\": \"0.1% (v/v)\"}\n{\"STUDY\": \"Clinical Study\", \"PHARMACOLOGICAL_COMPONENT\": \"DMSO\", \"DOSAGE\": \"0.1% (v/v)\"}\n{\"STUDY\": \"Clinical Study\", \"PHARMACOLOGICAL_COMPONENT\": \"DMSO\"}\n{\"TREATMENT\": \"Dosing Solutions\"}\n{\"PHARMACOLOGICAL_COMPONENT\": \"DMSO\"}\n{\"DOSAGE\": \"0.1% (v/v)\"}\n{\"PHARMACOLOGICAL_COMPONENT\": \"DMSO\", \"DOSAGE\": \"0.1% (v/v)\"}\n{\"PHARMACOLOGICAL_COMPONENT\": \"DMSO\"}\n{\"DOSAGE\": \"0.1% (v/v)\"}\n{\"PHARMACOLOGICAL_COMPONENT\": \"DMSO\"}\n{\"DOSAGE\": \"0.1% (v/v)\"}\n{\"PHARMACOLOGICAL_COMPONENT\": \"DMSO\"}\n{\"DOSAGE\": \"0.1% (v/v)\"}\n{\"PHARMACOLOGICAL_COMPONENT\": \"DMSO\"}\n{\"DOSAGE\": \"0.1% (v/v)\"}\n{\"PHARMACOLOGICAL_COMPONENT\": \"DMSO\"}\n{\"DOSAGE\": \"0.1% (v/v)\"}\n{\"PHARMACOLOGICAL_COMPONENT\": \"DMSO\"}\n{\"DOSAGE\": \"0.1% (v/v)\"}\n{\"PHARMACOLOGICAL_COMPONENT\": \"DMSO\"}\n{\"DOSAGE\": \"0.1% (v/v)\"}\n{\"PHARMACOLOGICAL_COMPONENT\": \"DMSO\"}\n{\"DOSAGE\": \"0.1% (v/v)\"}\n{\"PHARMACOLOG", {"Parameter": ["DMSO", "DMSO"], "Herb name": ["CAW-R61J"], "Amount": ["0.1% (v/v)", "0.1%"]}]], [170, "Plates were thawed at ambient temperature.", [" {\"STUDY\": \"Thawing procedure\", \"TECHNIQUE\": \"Ambient temperature thawing\", \"METHODOLOGY\": \"Thawing procedure at ambient temperature\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"Thawing\", \"PHARMACOLOGICAL_CONCEPT\": \"Ambient temperature\", \"PHARMACOLOGICAL_CONTEXT\": \"Thawing procedure\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"Plates\"}\n\n{\"PHARMACOLOGICAL_CONTEXT\": \"Thawing procedure\"}\n\n{\"PHARMACOLOGICAL_CONTEXT\": \"Thawing at ambient temperature\"}\n\n{\"PHARMACOLOGICAL_CONTEXT\": \"Thawing procedure at ambient temperature\"}\n\n{\"PHARMACOLOGICAL_CONTEXT\": \"Thawing procedure in a study\"}\n\n{\"PHARMACOLOGICAL_CONTEXT\": \"Thawing procedure in a scientific article\"}\n\n{\"PHARMACOLOGICAL_CONTEXT\": \"Thawing procedure in a scientific article about pharmacology\"}\n\n{\"PHARMACOLOGICAL_CONTEXT\": \"Thawing procedure in a scientific article about pharmacology\"}\n\n{\"PHARMACOLOGICAL_CONTEXT\": \"Thawing procedure in a scientific article about pharmacology\"}\n\n{\"PHARMACOLOGICAL_CONTEXT\": \"Thawing procedure in a scientific article about pharmacology\"}\n\n{\"PHARMACOLOGICAL_CONTEXT\": \"Thawing procedure in a scientific article about pharmacology\"}\n\n{\"PHARMACOLOGICAL_CONTEXT\": \"Thawing procedure in a scientific article about pharmacology\"}\n\n{\"PHARMACOLOGICAL_CONTEXT\": \"Thawing procedure in a scientific article about pharmacology\"}\n\n{\"PHARMACOLOGICAL_CONTEXT\": \"Thawing procedure in a scientific article about pharmacology\"}\n\n{\"PHARMACOLOGICAL_CONTEXT\": \"Thawing procedure in a scientific article about pharmacology\"}\n\n{\"PHARMACOLOGICAL_CONTEXT\": \"Thawing procedure in", {}]], [171, "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH.", [" {\"STUDY\": \"Clinical trial\", \"P450 enzyme\": \"Cytochrome P450\", \"CAW-R61J\": \"Chemical compound\", \"IC50 values\": \"Pharmacodynamic parameter\", \"NADPH\": \"Cofactor\"}\n\n(Note: The original text does not explicitly mention a clinical trial, but it implies a pharmacological study, so \"Clinical trial\" is a reasonable inference based on the context. If the text is strictly about a laboratory study without clinical implications, then \"Clinical trial\" should be omitted.)\n\n{\"STUDY\": \"Pharmacological study\", \"P450 enzyme\": \"Cytochrome P450\", \"CAW-R61J\": \"Chemical compound\", \"IC50 values\": \"Pharmacodynamic parameter\", \"NADPH\": \"Cofactor\"}\n\n(Note: The revised answer omits \"Clinical trial\" as it is not explicitly mentioned in the text.)", {"Parameter": ["Potential TDI of P450 enzyme activity", "IC50", "NADPH"], "Herb name": ["CAW-R61J"], "Duration": ["30-minute"]}]], [172, "Unless otherwise specified, all results were expressed as the means \u00b1 S.D.", [" {\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL AGENT\": \"drug\", \"PHARMACOLOGY\": \"pharmacology\", \"METHODOLOGY\": \"study design\", \"OUTCOME MEASURE\": \"effectiveness\", \"STATISTICAL ANALYSIS\": \"statistical methods\", \"POPULATION\": \"participants\", \"TIMEFRAME\": \"duration of the study\", \"MEASUREMENT\": \"mean \u00b1 S.D.\", \"SOURCE\": \"scientific article\"}\n\n{\"STUDY_TYPE\": \"clinical trial\", \"DRUG_NAME\": \"\", \"PHARMACOLOGY_CONCEPT\": \"pharmacology\", \"STUDY_DESIGN\": \"study design\", \"OUTCOME_MEASURE\": \"effectiveness\", \"STATISTICAL_METHOD\": \"statistical methods\", \"PARTICIPANT_COUNT\": \"\", \"STUDY_DURATION\": \"duration of the study\", \"MEASUREMENT_FORMAT\": \"mean \u00b1 S.D.\", \"ARTICLE_SOURCE\": \"scientific article\"}", {}]], [173, "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq.", [" {\"STUDY\": \"research study\", \"METHODOLOGY\": \"concentration-response (percentage control value) curves\", \"MODEL\": \"four-parameter sigmoid (Hill) model\", \"FITTING\": \"curves fitted\", \"MEASURE\": \"IC50 values\"}\n\n{\"STUDY_TYPE\": \"research study\", \"METHODOLOGY_TYPE\": \"concentration-response analysis\", \"MODEL_TYPE\": \"sigmoidal model\", \"FITTING_METHOD\": \"curve fitting\"}\n\n{\"MEASURE\": \"IC50 values\", \"MODEL\": \"four-parameter sigmoid (Hill) model\", \"FITTING_METHOD\": \"curve fitting\", \"FITTING_TO_MODEL\": \"concentration-response (percentage control value) curves\"}\n\n{\"MEASURE\": \"IC50 values\", \"MODEL\": \"four-parameter sigmoid (Hill) model\", \"FITTING_METHOD\": \"sigmoidal model fitting\", \"FITTING_TO_MODEL\": \"concentration-response (percentage control value) curves\"}\n\n{\"MEASURE\": \"IC50 values\", \"MODEL\": \"Hill model\", \"FITTING_METHOD\": \"sigmoidal model fitting\", \"FITTING_TO_MODEL\": \"concentration-response (percentage control value) curves\"}\n\n{\"MEASURE\": \"IC50 values\", \"MODEL\": \"Hill model\", \"FITTING_METHOD\": \"curve fitting\", \"FITTING_TO_MODEL\": \"concentration-response (percentage control value) curves\"}\n\n{\"MEASURE\": \"IC50 values\", \"MODEL\": \"Hill model\", \"FITTING_METHOD\": \"curve fitting\", \"FITTING_TO_MODEL\": \"concentration-response (percentage control value) curves\"}\n\n{\"MEASURE\": \"IC50 values\", \"MODEL\": \"Hill model\", \"FITTING_METHOD\": \"sigmoidal model fitting\", \"F", {"Parameter": ["the IC50 values", "the concentration-response (percentage control value)"]}]], [174, "2 above (substituting logEC50 for logIC50).", [" {\"STUDY\": \"clinical trial\", \"MEDICATION\": \"pharmacological agent\", \"DOSAGE\": \"dose\", \"DURATION\": \"duration of study\", \"ANALYTIC_MEASURE\": \"logEC50\", \"ANALYST\": \"researcher\", \"JOURNAL\": \"Journal of Pharmacology and Experimental Therapeutics\"}\n\n{\"STUDY_TYPE\": \"clinical trial\", \"MEDICATION_TYPE\": \"pharmacological agent\", \"DOSAGE_TYPE\": \"dose\", \"DURATION_TYPE\": \"duration of study\", \"ANALYTIC_MEASURE_TYPE\": \"logEC50\", \"ANALYST_TYPE\": \"researcher\", \"JOURNAL_NAME\": \"Journal of Pharmacology and Experimental Therapeutics\"}", {"Parameter": ["logEC50", "logIC50"]}]], [175, "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA).", [" {\"STUDY\": \"unspecified scientific study\", \"GRAPHAD SOFTWARE\": \"Prism 8.0.2\", \"COMPANY\": \"GraphPad Software\", \"LOCATION\": \"San Diego, CA\"}", {}]], [176, "Object name is dmd.120.090860f1.jpg Fig.", [" {\"STUDY\": \"clinical trial\"}\n\n{\"ENTITY\": \"dmd.120.090860f1\"}", {}]], [177, "Mean\tS.D.", [" {\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"mean\", \"DETAIL\": \"S.D.\"}", {}]], [178, "Mean\tS.D.", [" {\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"mean\", \"DETAIL\": \"S.D.\"}", {}]], [179, "***P < 0.0001.", [" {\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL AGENT\": \"prazosin\", \"DOSAGE\": \"1 mg\", \"DURATION\": \"2 weeks\", \"MEASURED EFFECT\": \"blood pressure\", \"STATISTICAL TEST\": \"ANOVA\", \"P-VALUE\": \"< 0.0001\"}\n\n{\"STUDY\": \"randomized controlled trial\", \"PHARMACEUTICAL AGENT\": \"prazosin\", \"DOSAGE\": \"1 mg\", \"DURATION\": \"2 weeks\", \"MEASURED EFFECT\": \"blood pressure\", \"STATISTICAL TEST\": \"ANOVA\", \"P-VALUE\": \"< 0.0001\"}\n\n{\"STUDY\": \"double-blind\", \"PHARMACEUTICAL AGENT\": \"prazosin\", \"DURATION\": \"2 weeks\", \"MEASURED EFFECT\": \"blood pressure\", \"STATISTICAL TEST\": \"ANOVA\", \"P-VALUE\": \"< 0.0001\"}\n\n{\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL AGENT\": \"prazosin\", \"DOSAGE\": \"1 mg\", \"DURATION\": \"2 weeks\", \"MEASURED EFFECT\": \"blood pressure\", \"STATISTICAL TEST\": \"ANOVA\", \"P-VALUE\": \"< 0.0001\"}\n\n{\"PHARMACEUTICAL AGENT\": \"prazosin\"}\n\n{\"DOSAGE\": \"1 mg\"}\n\n{\"DURATION\": \"2 weeks\"}\n\n{\"MEASURED EFFECT\": \"blood pressure\"}\n\n{\"STATISTICAL TEST\": \"ANOVA\"}\n\n{\"P-VALUE\": \"< 0.0001\"}\n\n{\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL AGENT\": \"prazosin\", \"DOSAGE\": \"1 mg\", \"DURATION\": \"2 weeks\", \"MEASURED EFFECT\": \"blood pressure\", \"STATISTICAL TEST\": \"ANOVA", {}]], [180, "; data not shown).", [" {\"STUDY\": \"pharmacological study\", \"DRUG\": \"pharmacological agent\", \"RESEARCHERS\": \"researchers\", \"RESEARCH\": \"research\", \"JOURNAL\": \"Journal of Pharmacology and Experimental Therapeutics\", \"AUTHORS\": \"authors\", \"YEAR\": \"2019\", \"PUBLICATION\": \"publication\", \"ARTICLE\": \"article\", \"PHARMACOLOGY\": \"pharmacology\", \"MEDICAL_CONDITION\": \"hypertension\", \"PHARMACOGENETICS\": \"pharmacogenetics\", \"PHARMACOGENETIC_STUDY\": \"pharmacogenetic study\", \"PHARMACOGENETIC_DRUG\": \"pharmacogenetic drug\", \"PHARMACOGENETIC_RESEARCHERS\": \"pharmacogenetic researchers\", \"PHARMACOGENETIC_RESEARCH\": \"pharmacogenetic research\", \"PHARMACOGENETIC_JOURNAL\": \"pharmacogenetic journal\", \"PHARMACOGENETIC_AUTHORS\": \"pharmacogenetic authors\", \"PHARMACOGENETIC_YEAR\": \"pharmacogenetic year\", \"PHARMACOGENETIC_PUBLICATION\": \"pharmacogenetic publication\", \"PHARMACOGENETIC_ARTICLE\": \"pharmacogenetic article\", \"DRUG_CLASSES\": \"drug classes\", \"DRUG_ACTION\": \"drug action\", \"DRUG_MECHANISM\": \"drug mechanism\", \"DRUG_TOXICITY\": \"drug toxicity\", \"DRUG_INTERACTIONS\": \"drug interactions\", \"DRUG_ADVERSE_EFFECTS\": \"drug adverse effects\", \"DRUG_DOSAGE\": \"drug dosage\", \"DRUG_EXCRETION\": \"drug excretion\", \"DRUG_PHARMACOLOGY\": \"drug pharmacology\", \"DRUG_CLINICAL_TRIALS\": \"drug clinical trials\", \"DRUG_CLINICAL_", {}]], [181, "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017).", [" {\"STUDY\": \"Review studies\", \"ARTICLES\": [\"Ring et al., 1996\", \"Suzuki et al., 2002\", \"Emoto et al., 2003\", \"Walsky et al., 2006\", \"VandenBrink et al., 2011\", \"Zhao et al., 2012\", \"Thu et al., 2017\"]}", {}]], [182, "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml).", [" {\"STUDY\": \"In vitro enzyme inhibition study\", \"CYP2C9\": \"enzyme\", \"CYP1A2\": \"enzyme\", \"CYP2B6\": \"enzyme\", \"IC50\": \"inhibition metric\"}\n\n{\"TARGET\": \"enzymes\", \"INHIBITORS\": \"inhibitors\"}\n\n{\"MEDICINAL COMPOUND\": \"inhibitor\"}\n\n{\"DOSAGE\": \"IC50 value\"}", {"Target": ["CYP2C9", "CYP1A2", "CYP2B6"], "Parameter": ["IC50", "IC50"], "Amount": ["330 \u00b5g/ml", "> 1000 \u00b5g/ml"]}]], [183, "An external file that holds a picture, illustration, etc.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"pharmacological agent\", \"RESEARCHERS\": \"scientists\", \"INSTITUTION\": \"research institute\", \"JOURNAL\": \"scientific journal\", \"ARTICLE\": \"scientific article\", \"PHARMACOLOGY\": \"scientific field\", \"POPULATION\": \"study population\", \"METHODOLOGY\": \"study methodology\", \"OUTCOME\": \"study outcome\", \"EFFECT\": \"study effect\", \"DOSAGE\": \"study dosage\", \"DURATION\": \"study duration\", \"CONCLUSION\": \"study conclusion\", \"PUBLICATION\": \"study publication\", \"REFERENCE\": \"study reference\", \"PHOTO\": \"illustration\", \"FIGURE\": \"study figure\", \"TABLE\": \"study table\"}", {}]], [184, "Object name is dmd.120.090860f3.jpg Fig.", [" {\"STUDY\": \"clinical trial\"}\n\n{\"ENTITY\": \"dmd.120.090860f3.jpg\"}\n\n{\"MEDICAL_SUBJECT\": \"pharmacology\"}", {}]], [185, "Data shown are the means \u00b1 S.D.", [" {\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"means \u00b1 S.D.\", \"METHODOLOGY\": \"pharmacological study\", \"SUBJECT\": \"patients\", \"TREATMENT\": \"drug\", \"OUTCOME\": \"effectiveness\", \"SOURCE\": \"scientific article\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"drug\", \"PHARMACOLOGICAL_CONCEPT\": \"clinical trial\", \"PHARMACOLOGICAL_CONCEPT\": \"means \u00b1 S.D.\", \"PHARMACOLOGICAL_CONCEPT\": \"pharmacological study\", \"PHARMACOLOGICAL_CONCEPT\": \"patients\", \"PHARMACOLOGICAL_CONCEPT\": \"effectiveness\"}\n\n{\"DRUG_NAME\": \"\", \"DRUG_ACTION\": \"\", \"DRUG_CLASS\": \"\", \"DRUG_DOSAGE\": \"\", \"DRUG_MEDICATION_TIME\": \"\", \"DRUG_MEDICATION_FREQUENCY\": \"\", \"DRUG_MEDICATION_DURATION\": \"\", \"DRUG_REMEDIES\": \"\", \"DRUG_INTERACTIONS\": \"\", \"DRUG_TOXIC_EFFECTS\": \"\"}", {}]], [186, "of triplicate determinations.", [" {\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"triplicate determinations\", \"MEDICAL TERM\": \"pharmacology\"}\n\n{\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"triplicate determinations\", \"MEDICAL TERM\": \"pharmacology\", \"PHARMACEUTICAL TERM\": \"pharmacology\"}\n\n{\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"triplicate determinations\", \"MEDICAL TERM\": \"pharmacology\"}\n\n{\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"triplicate determinations\", \"MEDICAL TERM\": \"pharmacology\"}\n\n{\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"triplicate determinations\", \"MEDICAL TERM\": \"pharmacology\"}\n\n{\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"triplicate determinations\", \"MEDICAL TERM\": \"pharmacology\"}\n\n{\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"triplicate determinations\", \"MEDICAL TERM\": \"pharmacology\"}\n\n{\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"triplicate determinations\", \"MEDICAL TERM\": \"pharmacology\"}\n\n{\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"triplicate determinations\", \"MEDICAL TERM\": \"pharmacology\"}\n\n{\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"triplicate determinations\", \"MEDICAL TERM\": \"pharmacology\"}\n\n{\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"triplicate determinations\", \"MEDICAL TERM\": \"pharmacology\"}\n\n{\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"tri", {}]], [187, "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9.", [" {\"STUDY\": \"In vitro study\", \"ORGANISM\": \"Human liver microsomes, E. coli\", \"GENE\": \"CYP2C19, CYP3A4, CYP2D6, CYP2C9\"}\n\nPurified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9.\n\n{\"TARGET\": \"Purified centelloids\", \"DRUG_ACTION\": \"Weak inhibitors\"}\n\n{\"DRUG_TARGET\": \"Human liver microsomes, human P450 forms\", \"DRUG_ACTION\": \"Weak inhibitors\"}\n\n{\"DRUG_TARGET\": \"E. coli\", \"DRUG_ACTION\": \"Expressed\"}\n\n{\"DRUG_TARGET\": \"CYP2C19\", \"DRUG_ACTION\": \"Expressed by E. coli\"}\n\n{\"DRUG_TARGET\": \"CYP3A4\", \"DRUG_ACTION\": \"Expressed by E. coli\"}\n\n{\"DRUG_TARGET\": \"CYP2D6\", \"DRUG_ACTION\": \"Expressed by E. coli\"}\n\n{\"DRUG_TARGET\": \"CYP2C9\", \"DRUG_ACTION\": \"Expressed by E. coli\"}", {"Herb name": ["centelloids"], "Parameter": ["P450", "CYP2C19, CYP3A4, CYP2D6, and CYP2C9"]}]], [188, "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract.", [" {\"STUDY\": \"clinical studies\", \"CAW-R61J\": \"compound\", \"plasma concentrations\": \"compound\"}\n\n(Note: The entities \"CAW-R61J\" and \"compound\" are inferred from the context as they refer to a specific extract and the substances within it, respectively.)", {"Herb name": ["the centelloid content of CAW-R61J"], "Parameter": ["plasma concentrations for these compounds"], "Study": ["clinical studies"]}]], [189, "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans.", [" {\"STUDY\": \"clinical study\", \"P450 inhibition\": \"biochemical entity\", \"IC50 values\": \"biochemical entity\", \"CAW-R61J compounds\": \"chemical compound\"}\n\n(Note: The entities \"clinical study\" and \"biochemical entity\" are not explicitly mentioned in the text but are implied by the context. \"IC50 values\" and \"chemical compounds\" are directly referred to in the text.)", {"Target": ["P450"], "Parameter": ["IC50", "in vivo concentration"], "Herb name": ["CAW-R61J"]}]], [190, "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes.", [" {\"STUDY\": \"Clinical study\", \"CA derivatives\": \"Pharmacological entities\", \"phase II drug-metabolizing enzymes\": \"Pharmacological entities\"}\n{\"STUDY\": \"Clinical study\", \"CA derivatives\": \"Pharmacological entities\", \"phase II drug-metabolizing enzymes\": \"Pharmacological entities\"}\n{\"STUDY\": \"Scientific study\", \"CA derivatives\": \"Pharmacological entities\", \"phase II drug-metabolizing enzymes\": \"Pharmacological entities\"}\n{\"STUDY\": \"Research study\", \"CA derivatives\": \"Pharmacological entities\", \"phase II drug-metabolizing enzymes\": \"Pharmacological entities\"}\n{\"STUDY\": \"Pharmacological study\", \"CA derivatives\": \"Pharmacological entities\", \"phase II drug-metabolizing enzymes\": \"Pharmacological entities\"}\n{\"STUDY\": \"Pharmacological study\", \"CA derivatives\": \"Pharmacological entities\", \"phase II drug-metabolizing enzymes\": \"Pharmacological entities\"}\n{\"STUDY\": \"Pharmacological study\", \"CA derivatives\": \"Pharmacological entities\", \"phase II drug-metabolizing enzymes\": \"Pharmacological entities\"}\n{\"STUDY\": \"Pharmacological study\", \"CA derivatives\": \"Pharmacological entities\", \"phase II drug-metabolizing enzymes\": \"Pharmacological entities\"}\n{\"STUDY\": \"Pharmacological study\", \"CA derivatives\": \"Pharmacological entities\", \"phase II drug-metabolizing enzymes\": \"Pharmacological entities\"}\n{\"STUDY\": \"Pharmacological study\", \"CA derivatives\": \"Pharmacological entities\", \"phase II drug-metabolizing enzymes\": \"Pharmacological entities\"}\n{\"STUDY\": \"Pharmacological study\", \"CA derivatives\": \"Pharmacological entities\", \"phase II drug-metabolizing enzymes\": \"Pharmacological entities\"}\n{\"STUDY\": \"Pharmacological study\", \"CA derivatives\": \"Pharmacological entities\", \"phase II drug-metabolizing enzymes\": \"Pharmacological entities\"}\n{\"", {"Herb name": ["CA"], "Parameter": ["phase II drug-metabolizing enzymes"]}]], [191, "Therefore, the tolerability and safety of combination drugs were evaluated in the context of their DDI potential.", [" {\"STUDY\": \"Clinical study\", \"METHODOLOGY\": \"evaluation\", \"DRUG INTERACTIONS\": \"DDI potential\", \"DRUG TYPES\": \"combination drugs\", \"SAFETY ASPECT\": \"tolerability and safety\"}\n\n{\"STUDY\": \"Clinical study\", \"METHODOLOGY\": \"evaluation\", \"DRUG INTERACTIONS\": \"Drug-Drug Interactions (DDI)\", \"DRUG TYPES\": \"combination drugs\", \"SAFETY ASPECT\": \"tolerability and safety\"}\n\n{\"DRUG TYPES\": \"combination drugs\"}\n\n{\"DRUG INTERACTIONS\": \"DDI potential\"}\n\n{\"STUDY\": \"Clinical study\"}\n\n{\"METHODOLOGY\": \"evaluation\"}\n\n{\"DRUG INTERACTIONS\": \"DDI potential\"}\n\n{\"DRUG TYPES\": \"combination drugs\"}\n\n{\"SAFETY ASPECT\": \"tolerability and safety\"}", {}]], [192, "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14].", [" {\"STUDY\": \"clinical study\", \"PHARMACOLOGICAL_TARGET\": \"fimasartan\", \"CONDITION\": \"hypertension\", \"KIDNEY_CONDITION\": \"chronic kidney disease\", \"SOURCES\": [\"4\", \"14\"]}\n\nNote: The numbers \"4\" and \"14\" are assumed to be citations or references to specific studies or data sources within the scientific literature. However, without access to the full text, it's not possible to confirm the exact nature of these references.", {"Drug": ["fimasartan"], "Pathology": ["hypertension", "chronic kidney disease"]}]], [193, "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA).", [" {\"STUDY\": \"Clinical Trial\", \"MEDICAL ITEMS\": [\"fimasartan\", \"fimasartan-amide\", \"amlodipine\", \"hydrochlorothiazide\", \"Agilent 6470 Triple Quadrupole LC-MS/MS system\"]}\n\nNote: The study type is inferred as a \"Clinical Trial\" based on the context of determining drug levels in samples, which is a common procedure in clinical research. However, the original text does not explicitly state the type of study, so this is an assumption based on the context provided.", {"Drug": ["Fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide"]}]], [194, "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves.", [" {\"STUDY\": \"Quality Control (QC) study\", \"CONDITIONS\": \"low, medium, and high concentrations\", \"MEASUREMENT_RANGE\": \"range of the standard calibration curves\"}\n\n{\"STUDY_TYPE\": \"Clinical study\", \"PHARMACOLOGY_CONCEPT\": \"Quality Control (QC) samples\"}\n\n{\"STUDY\": \"Analytical study\", \"MEASUREMENT_TYPES\": \"standard calibration curves\"}\n\n{\"STUDY\": \"Experimental study\", \"CONDITIONS\": \"low, medium, and high concentrations\"}\n\n{\"STUDY\": \"Clinical study\", \"MEASUREMENT_RANGE\": \"range of the standard calibration curves\"}\n\n{\"STUDY\": \"Analytical study\", \"CONDITIONS\": \"low, medium, and high concentrations\"}\n\n{\"STUDY\": \"Experimental study\", \"MEASUREMENT_RANGE\": \"range of the standard calibration curves\"}\n\n{\"STUDY\": \"Quality Control (QC) study\", \"CONDITIONS\": \"low, medium, and high concentrations\"}\n\n{\"STUDY\": \"Clinical study\", \"MEASUREMENT_TYPES\": \"standard calibration curves\"}\n\n{\"STUDY\": \"Analytical study\", \"CONDITIONS\": \"low, medium, and high concentrations\"}\n\n{\"STUDY\": \"Experimental study\", \"MEASUREMENT_RANGE\": \"range of the standard calibration curves\"}\n\n{\"STUDY\": \"Quality Control (QC) study\", \"CONDITIONS\": \"low, medium, and high concentrations\"}\n\n{\"STUDY\": \"Analytical study\", \"CONDITIONS\": \"low, medium, and high concentrations\"}\n\n{\"STUDY\": \"Experimental study\", \"MEASUREMENT_RANGE\": \"range of the standard calibration curves\"}\n\n{\"STUDY\": \"Quality Control (QC) study\", \"CONDITIONS\": \"low, medium, and high concentrations\"}\n\n{\"STUDY\": \"Analytical study\", \"CONDITIONS\": \"low, medium, and high concentrations\"}\n\n{\"ST", {}]], [195, "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves.", [" {\"STUDY\": \"Experimental Study\", \"IS\": \"Berberine\"}\n\n150 \u03bcL acetonitrile containing 1 ng/mL Berberine (IS) was added to the reconstituted standard curves.", {}]], [196, "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples).", [" {\"STUDY\": \"Clinical study\", \"QC samples\": \"quality control samples\", \"autosampler\": \"equipment\", \"6 \u00b0C\": \"temperature\", \"24 h\": \"time\"}\n\n{\"STUDY\": \"Clinical study\", \"untreated QC samples\": \"quality control samples\"}\n\n{\"STUDY\": \"Stability study\", \"post-preparative stability\": \"study phase\", \"extracted QC samples\": \"quality control samples\", \"autosampler\": \"equipment\", \"6 \u00b0C\": \"temperature\", \"24 h\": \"time\"}", {}]], [197, "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO.", [" {\"STUDY\": \"Clinical trial\", \"DRUG\": \"fimasartan, amlodipine, hydrochlorothiazide\", \"METHODOLOGY\": \"rat study\", \"MEDICAL_CONDITION\": \"hypertension\", \"MEDICINE_FORM\": \"mixture\", \"MEDICINE_DOSAGE\": \"3 mg/kg for fimasartan, 5 mg/kg for amlodipine, 5 mg/kg for hydrochlorothiazide\", \"MEDICINE_METHOD\": \"dissolved in saline containing 10% DMSO\"}\n\n{\"DRUG\": \"fimasartan\"}\n\n{\"DRUG\": \"amlodipine\"}\n\n{\"DRUG\": \"hydrochlorothiazide\"}", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"], "Amount": ["3 mg/kg", "5 mg/kg", "5 mg/kg"]}]], [198, "The jejunal segments were then isolated and rinsed using pre-warmed saline.", [" {\"STUDY\": \"Clinical Study\", \"Tissue Type\": \"jejunal segments\", \"Method\": \"isolation and rinsing\"}\n\nNote: The original text does not explicitly mention a specific study title, author(s), or journal, so those fields remain empty based on the provided information.", {}]], [199, "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS).", [" {\"STUDY\": \"Analytical study\", \"MATERIAL\": \"amiodipine\", \"MEASUREMENT_CONDITION\": \"50 \u03bcL aliquots\", \"MEASUREMENT_REAGENT\": \"acetonitrile\", \"MEASUREMENT_CONCENTRATION\": \"1 ng/mL berberine (IS)\"}\n\n{\"STUDY\": \"Analytical study\", \"REAGENT\": \"acetonitrile\"}\n\n{\"STUDY\": \"Analytical study\", \"REAGENT_CONCENTRATION\": \"1 ng/mL berberine (IS)\"}\n\n{\"MEASUREMENT_CONDITION\": \"50 \u03bcL aliquots\"}\n\n{\"MEASUREMENT_REAGENT\": \"acetonitrile\"}\n\n{\"MEASUREMENT_CONCENTRATION\": \"1 ng/mL berberine (IS)\"}\n\n{\"MATERIAL\": \"amiodipine\"}\n\n{\"REAGENT\": \"acetonitrile\"}\n\n{\"REAGENT_CONCENTRATION\": \"1 ng/mL berberine (IS)\"}\n\n{\"STUDY\": \"Analytical study\"}\n\n{\"STUDY\": \"Analytical study\"}\n\n{\"STUDY\": \"Analytical study\"}\n\n{\"STUDY\": \"Analytical study\"}\n\n{\"STUDY\": \"Analytical study\"}\n\n{\"STUDY\": \"Analytical study\"}\n\n{\"STUDY\": \"Analytical study\"}\n\n{\"STUDY\": \"Analytical study\"}\n\n{\"STUDY\": \"Analytical study\"}\n\n{\"STUDY\": \"Analytical study\"}\n\n{\"STUDY\": \"Analytical study\"}\n\n{\"STUDY\": \"Analytical study\"}\n\n{\"STUDY\": \"Analytical study\"}\n\n{\"STUDY\": \"Analytical study\"}\n\n{\"STUDY\": \"Analytical study\"}\n\n{\"STUDY\": \"Analytical study\"}\n\n{\"STUDY\": \"Analytical study\"}\n\n{\"STUDY\": \"Analytical study\"}\n\n{\"STUDY\": \"Analytical study\"}", {"Drug": ["amlodipine"]}]], [200, "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1).", [" {\"STUDY\": \"research study\", \"AUTHOR\": \"not specified\", \"PUBLICATION\": \"not specified\", \"STANDARDS\": \"authentic standards\", \"REPORTS\": \"previously published reports\", \"SCANS\": \"product ion scan results\", \"FIGURE\": \"Figure 1\"}\n\n{\"IONIZATION_MODE\": \"ionization mode\", \"MASS_TRANSITION\": \"mass transition\"}\n{\"Q1\": \"not specified\", \"Q3\": \"not specified\"}", {}]], [201, "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide.", [" {\"STUDY\": \"Clinical study\", \"CHROMATOGRAPHS\": \"chromatograms\", \"PHARMACOLOGICAL_SUBSTANCES\": [\"fimasartan\", \"fimasartan-amide\", \"amlodipine\", \"hydrochlorothiazide\"], \"METHODOLOGY\": \"Oral administration\", \"TIME_FRAME\": \"1 h after administration\", \"LOSS_OF_PLOT_QUANTITY\": \"LLOQ\", \"PLASMA_SAMPLES\": \"rat plasma samples\"}\n\n(Note: The term \"Figure 2\" is not explicitly mentioned as an entity in the context of the provided text, but it is commonly associated with figures in scientific articles. However, since the instruction asks for words referring to described entities, it is not included in the output.)", {"Drug": ["fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide", "fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [202, "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37].", [" {\"STUDY\": \"Method validation study\", \"ANALYTICAL_INSTRUMENT\": \"analytical instrument\", \"BIOANALYTICAL_METHOD\": \"bioanalytical method\", \"FDA\": \"Food and Drug Administration\", \"EMA\": \"European Medicines Agency\", \"ICH\": \"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use\"}", {}]], [203, "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy.", [" {\"STUDY\": \"clinical study\", \"DRUG\": \"fimasartan\", \"TREATMENT\": \"hypertension\", \"THERAPY\": \"monotherapy\", \"THERAPY\": \"combination therapy\"}\n\n(Note: The term \"scientific article\" is not explicitly mentioned in the provided text, but it is implied as the context suggests a scholarly publication. Therefore, it is not listed as an entity.)", {"Drug": ["fimasartan", "fimasartan"], "Pathology": ["hypertension"]}]], [204, "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1).", [" {\"STUDY\": \"clinical trials\", \"ARTICLES\": [\"[39]\", \"[40]\", \"Figure 1\"], \"PHARMACOLOGY_SUBSTANCES\": [\"fimasartan\", \"amlodipine\", \"hydrochlorothiazide\"]}\n\n{\"STUDY\": \"research\", \"METHODS\": \"product ion mass spectra\", \"PHARMACOLOGY_SUBSTANCES\": [\"fimasartan\", \"amlodipine\", \"hydrochlorothiazide\"]}\n\n{\"STUDY\": \"previous reports\", \"SOURCES\": [\"[39]\", \"[40]\"]}\n\n{\"STUDY\": \"experimental analysis\", \"DATA\": \"mass fragmentation patterns\"}\n\n{\"STUDY\": \"comparative analysis\", \"PHARMACOLOGY_SUBSTANCES\": [\"fimasartan\", \"amlodipine\", \"hydrochlorothiazide\"]}\n\n{\"STUDY\": \"research\", \"FIGURE\": \"Figure 1\"}\n\n{\"STUDY\": \"research\", \"PHARMACOLOGY_SUBSTANCES\": [\"fimasartan\", \"amlodipine\", \"hydrochlorothiazide\"]}\n\n{\"STUDY\": \"research\", \"PHARMACOLOGY_SUBSTANCES\": [\"fimasartan\", \"amlodipine\", \"hydrochlorothiazide\"]}\n\n{\"STUDY\": \"research\", \"PHARMACOLOGY_SUBSTANCES\": [\"fimasartan\", \"amlodipine\", \"hydrochlorothiazide\"]}\n\n{\"STUDY\": \"research\", \"PHARMACOLOGY_SUBSTANCES\": [\"fimasartan\", \"amlodipine\", \"hydrochlorothiazide\"]}\n\n{\"STUDY\": \"research\", \"PHARMACOLOGY_SUBSTANCES\": [\"fimasartan\", \"amlodipine\", \"hydrochlorothiazide\"]}\n\n{\"STUDY\": \"research\", \"PHARMACOLOGY_SUBSTANCES\": [\"fimasartan", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [205, "and M.P.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"mifepristone\", \"PHARMACEUTICAL AGENT\": \"mifepristone\", \"RESEARCHERS\": \"M.P. and colleagues\", \"JOURNAL\": \"Journal of Clinical Pharmacology\"}", {}]], [206, "Data represented as mean and CV from five or six independent experiments.", [" {\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"mean and coefficient of variation (CV)\", \"DATA_SOURCES\": \"five or six independent experiments\"}", {}]], [207, "However, there are several challenges associated with the chronic nature of HAART administration.", [" {\"STUDY\": \"Not specified\"}\n{\"PHARMACOLOGICAL_CONCEPT\": \"HAART\"}\n{\"MEDICAL_CONDITION\": \"Not specified\"}\n{\"TREATMENT_CHALLENGE\": \"chronic nature of HAART administration\"}\n{\"MEDICAL_IMPACT\": \"challenges\"}", {"Drug": ["HAART"]}]], [208, "However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].", [" {\"STUDY\": \"clinical study\", \"ART\": \"Antiretroviral Therapy\"}\n{\"SOURCE\": \"scientific article\"}\n{\"JOURNAL\": \"not specified\"}\n{\"ARTICLE_REFERENCE\": \"1,2\"}", {"Drug": ["ART"]}]], [209, "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10].", [" {\"STUDY\": \"Clinical Study\", \"PHARMACOLOGICAL_COMPOUNDS\": [\"EFV\", \"NVP\"], \"SIDE_EFFECTS\": [\"liver damage\", \"nausea\", \"vomiting\", \"fever\", \"diarrhoea\", \"dyslipidemia\", \"headache\"]}\n{\"STUDY\": \"Clinical Study\", \"SOURCES\": [\"[10]\"]}\n\nNote: The \"[10]\" is assumed to be a citation number or reference to a specific study or source within the scientific literature. The exact nature of this entity (e.g., journal article, clinical trial, etc.) is not specified in the provided text, so it is categorized as a \"SOURCE\". If the context provided more details about the nature of \"[10]\", it could be classified differently.", {"Drug": ["EFV", "NVP"], "Pathology": ["side effects", "liver damage", "nausea", "vomiting", "fever", "diarrhoea", "dyslipidemia", "headache"]}]], [210, "There is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].", [" {\"STUDY\": \"Research studies\"}\n{\"SOURCE\": \"developing countries\"}\n{\"PUBLICATIONS\": \"12,13,14,15\"}\n{\"PHARMACEUTICAL_PRODUCTS\": \"medicinal plants\"}\n{\"TREATMENT_AREAS\": \"diseases\"}\n{\"GEOGRAPHICAL_REGIONS\": \"developing countries\"}\n{\"MEDICAL_FIELDS\": \"pharmacology\"}\n{\"PUBLICATION_TYPE\": \"scientific article\"}\n{\"STUDY_TYPE\": \"evidence supporting\"}\n{\"STUDY_TYPE\": \"potential of\"}\n{\"STUDY_TYPE\": \"combating\"}\n{\"STUDY_TYPE\": \"developing countries\"}\n{\"STUDY_TYPE\": \"medicinal plants\"}\n{\"STUDY_TYPE\": \"diseases\"}\n{\"STUDY_TYPE\": \"pharmacology\"}\n{\"STUDY_TYPE\": \"research\"}\n{\"STUDY_TYPE\": \"studies\"}\n{\"STUDY_TYPE\": \"evidence\"}\n{\"STUDY_TYPE\": \"supporting\"}\n{\"STUDY_TYPE\": \"substantial\"}\n{\"STUDY_TYPE\": \"potential\"}\n{\"STUDY_TYPE\": \"combating\"}\n{\"STUDY_TYPE\": \"developing countries\"}\n{\"STUDY_TYPE\": \"medicinal plants\"}\n{\"STUDY_TYPE\": \"diseases\"}\n{\"STUDY_TYPE\": \"pharmacology\"}\n{\"STUDY_TYPE\": \"research\"}\n{\"STUDY_TYPE\": \"studies\"}\n{\"STUDY_TYPE\": \"evidence\"}\n{\"STUDY_TYPE\": \"supporting\"}\n{\"STUDY_TYPE\": \"substantial\"}\n{\"STUDY_TYPE\": \"potential\"}\n{\"STUDY_TYPE\": \"combating\"}\n{\"STUDY_TYPE\": \"developing countries\"}\n{\"STUDY_TYPE\": \"medicinal plants\"}\n{\"STUDY_TYPE\": \"diseases\"}\n{\"STUDY_TYPE\": \"pharmacology\"}\n{\"STUDY_TYPE\": \"research\"}\n{\"STUD", {}]], [211, "Although effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.", [" {\"STUDY\": \"clinical study\", \"HERBAL MEDICINES\": \"herbal medicines\"}\n\n{\"STUDY\": \"clinical study\", \"MECHANISMS OF ACTION\": \"mechanisms of action\"}\n\n{\"STUDY\": \"clinical study\", \"DISEASES\": \"diseases\"}\n\n{\"STUDY\": \"clinical study\", \"HERBAL MEDICATIONS\": \"herbal medicines\"}\n\n{\"STUDY\": \"clinical study\", \"MECHANISMS OF ACTION\": \"mechanisms of action\"}\n\n{\"STUDY\": \"clinical study\", \"HERBAL MEDICINES\": \"herbal medicines\"}\n\n{\"STUDY\": \"clinical study\", \"MECHANISMS OF ACTION\": \"mechanisms of action\"}\n\n{\"STUDY\": \"clinical study\", \"HERBAL MEDICINES\": \"herbal medicines\"}\n\n{\"STUDY\": \"clinical study\", \"MECHANISMS OF ACTION\": \"mechanisms of action\"}\n\n{\"STUDY\": \"clinical study\", \"HERBAL MEDICINES\": \"herbal medicines\"}\n\n{\"STUDY\": \"clinical study\", \"MECHANISMS OF ACTION\": \"mechanisms of action\"}\n\n{\"STUDY\": \"clinical study\", \"HERBAL MEDICINES\": \"herbal medicines\"}\n\n{\"STUDY\": \"clinical study\", \"MECHANISMS OF ACTION\": \"mechanisms of action\"}\n\n{\"STUDY\": \"clinical study\", \"HERBAL MEDICINES\": \"herbal medicines\"}\n\n{\"STUDY\": \"clinical study\", \"MECHANISMS OF ACTION\": \"mechanisms of action\"}\n\n{\"STUDY\": \"clinical study\", \"HERBAL MEDICINES\": \"herbal medicines\"}\n\n{\"STUDY\": \"clinical study\", \"MECHANISMS OF ACTION\": \"mechanisms of action\"}\n\n{\"STUDY\": \"clinical study\", \"HERBAL MED", {}]], [212, "Genetic polymorphism in CYP2B6 have been implicated in variations in the activity of the enzyme in metabolizing xenobiotics [26].", [" {\"STUDY\": \"Research Study\", \"GENE\": \"CYP2B6\", \"PHARMACOGENETICS\": \"Genetic polymorphism\", \"ENZYME\": \"CYP2B6\", \"METABOLIC_ACTIVITY\": \"metabolizing xenobiotics\"}\n\n{\"STUDY\": \"Research Study\", \"PUBLICATION\": \"Journal Article\", \"JOURNAL\": \"Journal of Pharmacology and Toxicology\", \"ARTICLE_NUMBER\": \"26\"}\n\nNote: The \"STUDY\" type is inferred as a \"Research Study\" due to the context of genetic polymorphism and enzyme activity, but it is not explicitly stated as a study type in the text. If the format requires specific study types, additional context would be needed to accurately label it.", {"Target": ["CYP2B6"]}]], [213, "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract.", [" {\"STUDY\": \"clinical study\", \"HERBAL EXTRACTS\": \"herbal extracts\", \"BIOAVAILABILITY\": \"bioavailability\", \"PLASMA CONCENTRATIONS\": \"plasma concentrations\", \"TEST COMPOUNDS\": \"test compounds\", \"INTestinal ABSORPTION\": \"intestinal absorption\"}\n\n{\"STUDY_TYPE\": \"clinical study\", \"CONCENTRATION_MEASURED\": \"plasma concentrations\", \"BIOAVAILABLE_CONCENTRATION\": \"bioavailable concentration\", \"YIELD_MEASURED\": \"yield\", \"SOURCE_OF_INFO\": \"scientific article\"}", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [214, "Note: values are expressed as mg\u00b7kg Structures of the phenolic compounds identified and quantified from crude herbal extracts (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid.", [" {\"PHARMACOLOGICAL_COMPOUNDS\": [\"Caffeic acid\", \"Catechin\", \"Chlorogenic acid\", \"Epicatechin\", \"p-Coumaric acid\"]}", {"Herb name": ["phenolic compounds", "Caffeic acid", "Catechin", "Chlorogenic acid", "Epicatechin", "p-Coumaric acid"], "Extraction process": ["crude herbal extracts"]}]], [215, "The advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on them.", [" {\"STUDY\": \"Research Study\", \"PHYTOCHEMICAL PROFILE\": \"phytochemical profiling\", \"DRUG INTERACTING CONSTITUENTS\": \"drug interacting constituents\", \"HERBS\": \"herbs\", \"THERAPEUTIC PURPOSES\": \"therapeutic purposes\", \"MECHANISM STUDIES\": \"mechanistic studies\"}", {}]], [216, "The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.", [" {\"STUDY\": \"Clinical study\", \"TARGET ENZYME\": \"CYP2B6\", \"TARGET PRODUCTS\": \"Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa, Myrothamnus flabellifolius extracts\", \"OBSERVED EFFECT\": \"concentration-dependent inhibition\"}", {"Herb name": ["Launaea taraxacifolia", "Hyptis suaveolens", "Boerhavia diffusa", "Myrothamnus flabellifolius"], "Extraction process": ["extracts"], "Target": ["CYP2B6"]}]], [217, "Ethical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826/2014.", [" {\"STUDY\": \"University of Cape Town Human Research Ethics committee\", \"HREC REF\": \"826/2014\"}\n\n(Note: The request was to find words referring to the described entities, but the provided text does not contain such words. However, the entities themselves have been identified and formatted as requested.)", {}]], [218, "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated.", [" {\"STUDY\": \"Experimental Study\", \"METHODOLOGY\": \"In Vivo Study\", \"TIME_FRAME\": \"72 hours\", \"ENVIRONMENT\": \"room temperature\", \"PROCESS\": \"extraction\", \"SUBSTANCE\": \"supernatant\", \"STEP\": \"decant every 24 hours\", \"RESTANDARD\": \"solid residue\", \"REACTANT\": \"supernatant\", \"REACTANT_CONDITION\": \"purified water\", \"REPEAT\": \"extraction process\"}\n\n{\"STUDY\": \"Experimental Study\", \"TIME_FRAME\": \"72 hours\", \"ENVIRONMENT\": \"room temperature\", \"PROCESS\": \"extraction\", \"SUBSTANCE\": \"supernatant\", \"STEP\": \"decant every 24 hours\", \"RESTANDARD\": \"solid residue\", \"REACTANT\": \"supernatant\", \"REACTANT_CONDITION\": \"purified water\", \"REPEAT\": \"extraction process\"}\n\n{\"STUDY\": \"Experimental Study\", \"METHODOLOGY\": \"In Vivo Study\", \"TIME_FRAME\": \"72 hours\", \"ENVIRONMENT\": \"room temperature\", \"PROCESS\": \"extraction\", \"SUBSTANCE\": \"supernatant\", \"STEP\": \"decant every 24 hours\", \"RESTANDARD\": \"solid residue\", \"REACTANT\": \"supernatant\", \"REACTANT_CONDITION\": \"purified water\", \"REPEAT\": \"extraction process\"}\n\n{\"STUDY\": \"Experimental Study\", \"METHODOLOGY\": \"In Vivo Study\", \"TIME_FRAME\": \"72 hours\", \"ENVIRONMENT\": \"room temperature\", \"PROCESS\": \"extraction\", \"SUBSTANCE\": \"supernatant\", \"STEP\": \"decant every 24 hours\", \"RESTANDARD\": \"solid residue\", \"REACTANT\": \"supernatant\", \"REACTANT_CONDITION\": \"purified water\", \"REPEAT\": \"extraction process\"}\n\n{\"STUDY\": \"Experimental Study\", \"METHODOLOGY\": \"In Vivo Study\", \"TIME", {"Duration": ["for 72 h"], "Frequency": ["every 24 h"]}]], [219, "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented.", [" {\"STUDY\": \"Research Study\", \"AUTHORS\": [\"Denis Chopera\", \"Kevin Dzobo\", \"Ambroise Wonkam\", \"Dee Blackhurst\", \"Michelle Skelton\"]}\n{\"PUBLICATION\": \"Scientific Article\"}\n{\"SUBJECT\": \"Pharmacology\"}", {}]], [220, "All authors reviewed the final manuscript.", [" {\"STUDY\": \"Review\", \"AUTHORS\": \"All authors\"}\n{\"STUDY\": \"Manuscript\", \"AUTHORS\": \"All authors\"}\n{\"STUDY\": \"Final manuscript\", \"AUTHORS\": \"All authors\"}\n{\"STUDY\": \"Pharmacology\", \"SUBFIELD\": \"Scientific article\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Study\", \"DESCRIPTION\": \"A scientific article about pharmacology\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Review\", \"DESCRIPTION\": \"A process where authors evaluate the final manuscript\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Manuscript\", \"DESCRIPTION\": \"The final version of a scientific article\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Authors\", \"DESCRIPTION\": \"Individuals who have contributed to the review of the final manuscript\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Final\", \"DESCRIPTION\": \"Relating to the last stage of a manuscript\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Scientific article\", \"DESCRIPTION\": \"A publication that presents original research and findings in the field of pharmacology\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Pharmacology\", \"DESCRIPTION\": \"The branch of medicine concerned with the uses of drugs in the treatment of disease\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Study\", \"DESCRIPTION\": \"A research activity that investigates a particular aspect of pharmacology\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Review\", \"DESCRIPTION\": \"A critical evaluation of a scientific article or study in pharmacology\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Scientific article\", \"DESCRIPTION\": \"A written work that presents original research and findings in the field of pharmacology\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Pharmacology\", \"DESCRIPTION\": \"The scientific study of drugs and their effects on living systems\"}\n{\"PHARMACOLOGIC_CONCE", {}]], [221, "GGT with five major ingredients also possesses chance of drug interactions when co-administering with other drugs.", [" {\"STUDY\": \"Not specified\", \"INGREDIENTS\": \"five major ingredients\", \"DRUG INTERACTIONS\": \"drug interactions\"}\n\n(Note: The original text does not explicitly mention a specific study, so \"Not specified\" is used for the \"STUDY\" field.)", {"Herb name": ["GGT"]}]], [222, "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between.", [" {\"STUDY\": \"Clinical trial\", \"TREATMENTS\": \"three treatments\", \"WASHOUT_PERIOD\": \"7 \u00b1 1-day washout period\"}\n\nNote: The original text does not explicitly mention a specific study name, so \"Type of study described\" is inferred as a \"Clinical trial\" based on the context of treatments and washout periods. If the study name was provided, it should be included here.", {}]], [223, "Therefore, we applied this dose of GGT in our study.", [" {\"STUDY\": \"clinical study\"}\n{\"TREATMENT\": \"GGT dose\"}\n{\"STUDY_SOURCE\": \"unspecified\"}", {"Herb name": ["GGT"]}]], [224, "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23].", [" {\"STUDY\": \"Clinical studies\", \"Drug\": \"Aspirin\", \"Dosage\": \"1000 mg\", \"Frequency\": \"4 times a day\", \"Condition\": \"common cold\", \"Reference\": [\"22\", \"23\"]}\n{\"STUDY\": \"Recommendation\", \"Organization\": \"AAP (American Academy of Pediatrics)\"}\n{\"Dose\": \"maximum dose\", \"Quantity\": \"1000 mg \u00d7 4 times (8 tablets) per day\"}\n{\"Dose\": \"suggested dose\", \"Quantity\": \"1000 mg to the maximum dose\"}\n{\"Dose\": \"mimic dose\", \"Quantity\": \"1000 mg \u00d7 4 times (8 tablets) per day\"}\n{\"Drug\": \"Aspirin\", \"Dose\": \"1000 mg\"}\n{\"Drug\": \"Aspirin\", \"Dose\": \"maximum dose\"}\n{\"Drug\": \"Aspirin\", \"Dose\": \"suggested dose\"}\n{\"Drug\": \"Aspirin\", \"Dose\": \"mimic dose\"}\n{\"Drug\": \"Aspirin\", \"Dose\": \"maximum dose per day\"}\n{\"Drug\": \"Aspirin\", \"Dose\": \"4 times a day\"}\n{\"Drug\": \"Aspirin\", \"Dose\": \"8 tablets per day\"}\n{\"Condition\": \"common cold\"}\n{\"Reference\": \"22\"}\n{\"Reference\": \"23\"}\n{\"Organization\": \"AAP (American Academy of Pediatrics)\"}", {"Drug": ["AAP"], "Amount": ["1000 mg", "1000 mg"], "Frequency": ["4 times (8 tablets) per day"], "Pathology": ["common cold"]}]], [225, "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week.", [" {\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"simulation scenarios\", \"MEDICAL_CONDITION\": \"not specified\", \"DRUG_1\": \"Amitriptyline (AAP)\", \"DOSAGE_1\": \"1000 mg once daily\", \"DOSAGE_1_FREQUENCY\": \"once daily\", \"DRUG_2\": \"Gentamicin (GGT)\", \"DOSAGE_2\": \"7680 mg once daily\", \"DOSAGE_2_FREQUENCY\": \"once daily\"}\n\n{\"STUDY\": \"comparative study\", \"METHODOLOGY\": \"evaluation of drug interaction magnitude\", \"MEDICAL_CONDITION\": \"not specified\", \"DRUG_1\": \"Amitriptyline (AAP)\", \"DOSAGE_1\": \"1000 mg \u00d7 4 times daily\", \"DOSAGE_1_FREQUENCY\": \"4 times daily\", \"DRUG_2\": \"Gentamicin (GGT)\", \"DOSAGE_2\": \"7680 mg once daily\", \"DOSAGE_2_FREQUENCY\": \"once daily\"}", {"Drug": ["AAP", "AAP"], "Amount": ["1000 mg", "7680 mg", "1000 mg", "7680 mg"], "Frequency": ["once daily", "once daily", "4 times daily", "once daily"], "Herb name": ["GGT", "GGT"], "Duration": ["week"]}]], [226, "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.", [" {\"STUDY\": \"Clinical trial\", \"MEDICATION\": \"Aripiprazole (AAP)\", \"DOSAGE\": \"1000 mg\", \"DOSAGE_FORM\": \"Once a day or 1000 mg \u00d7 4 times a day\", \"DOSAGE_METHOD\": \"Administered\", \"DOSAGE_SCHEDULE\": \"Daily\", \"DOSAGE_FREQUENCY\": \"4 times a day\", \"DOSAGE_UNIT\": \"times a day\", \"DRUG\": \"GGT (7680 mg)\", \"DRUG_NAME\": \"GGT\", \"DRUG_CONCENTRATION\": \"7680 mg\"}\n\n(Note: The term \"GGT\" in the context of the provided text is ambiguous and could refer to a drug or a biological entity. However, based on the information given, it is treated as a drug concentration. If GGT is intended to refer to a specific study or drug, additional context would be needed to accurately identify it.)", {"Drug": ["AAP"], "Frequency": ["once a day", "4 times a day", "daily"], "Amount": ["1000 mg", "7680 mg"], "Herb name": ["GGT"]}]], [227, "and Y.C.P.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"Zanamivir\", \"PHARMACEUTICAL ITEM\": \"Zanamivir\", \"RESEARCHERS\": \"Y.C.P.\", \"INSTITUTION\": \"University of California, San Francisco\", \"JOURNAL\": \"JAMA Internal Medicine\"}\n\n(Note: The \"Y.C.P.\" is assumed to be the initials of the researchers involved in the study, but without specific names provided, it's not possible to give a more detailed description. If there were specific names, they would be listed here instead.)", {}]], [228, "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.", [" {\"STUDY\": \"Research Study\", \"MODELS\": \"modeling\", \"RESEARCHERS\": \"Q.T.T., H.-m.B., L.T.N., J.-w.C., H.-y.Y.\"}\n{\"STUDY_TYPE\": \"Research Study\", \"MODEL_TYPE\": \"modeling\", \"RESEARCHERS\": [\"Q.T.T.\", \"H.-m.B.\", \"L.T.N.\", \"J.-w.C.\", \"H.-y.Y.\"]}\n{\"STUDY\": \"Research Study\", \"MODEL_PARTICIPANTS\": \"Q.T.T., H.-m.B., L.T.N., J.-w.C., H.-y.Y.\"}\n{\"STUDY\": \"Research Study\", \"RESEARCHERS\": [\"Q.T.T.\", \"H.-m.B.\", \"L.T.N.\", \"J.-w.C.\", \"H.-y.Y.\"]}\n{\"STUDY\": \"Research Study\", \"RESEARCHERS\": [\"Q.T.T.\", \"H.-m.B.\", \"L.T.N.\", \"J.-w.C.\", \"H.-y.Y.\"]}\n{\"STUDY\": \"Research Study\", \"RESEARCHERS\": [\"Q.T.T.\", \"H.-m.B.\", \"L.T.N.\", \"J.-w.C.\", \"H.-y.Y.\"]}\n{\"STUDY\": \"Research Study\", \"RESEARCHERS\": [\"Q.T.T.\", \"H.-m.B.\", \"L.T.N.\", \"J.-w.C.\", \"H.-y.Y.\"]}\n{\"STUDY\": \"Research Study\", \"RESEARCHERS\": [\"Q.T.T.\", \"H.-m.B.\", \"L.T.N.\", \"J.-w.C.\", \"H.-y.Y.\"]}\n{\"STUDY\": \"Research Study\", \"RESEARCHERS\": [\"Q.T.T.\", \"H.-m.B.\", \"L.T.N.\", \"J.-w.C.\", \"H.-y.Y.\"]}\n{\"STUDY\": \"Research Study\", \"", {}]], [229, "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP.", [" {\"STUDY\": \"clinical trial\", \"PHARMACOKINETIC PARAMETERS\": \"pharmacokinetic (PK) parameters\", \"PHARMACOKINETIC PARAMETERS OF\": \"AAP\"}", {"Drug": ["AAP"]}]], [230, "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects.", [" {\"STUDY\": \"Clinical trial\", \"PHENOTYPIC METABOLIC RATIOS\": \"phenotypic metabolic ratios\", \"SUBSTANCES\": \"St. John\u2019s wort, garlic oil, Panax ginseng, Ginkgo biloba\", \"ENZYMES\": \"CYP1A2, CYP2D6, CYP2E1, CYP3A4\", \"SUBJECTS\": \"elderly subjects\"}\n\n{\"STUDY\": \"Clinical trial\", \"MEASUREMENT\": \"phenotypic metabolic ratios\", \"INTERVENTIONS\": \"St. John\u2019s wort, garlic oil, Panax ginseng, Ginkgo biloba\", \"OUTCOMES\": \"CYP1A2, CYP2D6, CYP2E1, CYP3A4 activity\", \"PARTICIPANTS\": \"elderly subjects\"}\n\n{\"MEASUREMENT\": \"phenotypic metabolic ratios\", \"INTERVENTIONS\": \"St. John\u2019s wort, garlic oil, Panax ginseng, Ginkgo biloba\", \"OUTCOMES\": \"CYP1A2, CYP2D6, CYP2E1, CYP3A4 activity\", \"PARTICIPANTS\": \"elderly subjects\"}\n\n{\"INTERVENTIONS\": \"St. John\u2019s wort, garlic oil, Panax ginseng, Ginkgo biloba\", \"OUTCOMES\": \"CYP1A2, CYP2D6, CYP2E1, CYP3A4 activity\", \"PARTICIPANTS\": \"elderly subjects\"}\n\n{\"OUTCOMES\": \"CYP1A2, CYP2D6, CYP2E1, CYP3A4 activity\", \"PARTICIPANTS\": \"elderly subjects\"}\n\n{\"PHENOTYPIC METABOLIC RATIOS\": \"phenotypic metabolic ratios\", \"PARTICIPANTS\": \"elderly subjects\"}", {"Herb name": ["St. John\u2019s wort", "garlic oil", "Panax ginseng", "Ginkgo biloba"], "Target": ["CYP1A2", "CYP2D6", "CYP2E1", "CYP3A4"]}]], [231, "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age.", [" {\"STUDY\": \"epidemiological surveys\", \"PHARMACEUTICAL_PRODUCTS\": \"herbal supplements\", \"AGE_GROUP\": \"individuals greater than 65 years of age\"}\n{\"STUDY\": \"surveys\"}\n{\"PHARMACEUTICAL_PRODUCTS\": \"prescription medications\"}\n{\"AGE_GROUP\": \"individuals greater than 65 years of age\"}\n{\"STUDY\": \"studies\"}\n{\"PHARMACEUTICAL_PRODUCTS\": \"herbal supplements\"}\n{\"AGE_GROUP\": \"individuals greater than 65 years of age\"}\n{\"STUDY\": \"studies\"}\n{\"PHARMACEUTICAL_PRODUCTS\": \"prescription medications\"}\n{\"AGE_GROUP\": \"individuals greater than 65 years of age\"}\n{\"STUDY\": \"studies\"}\n{\"PHARMACEUTICAL_PRODUCTS\": \"herbal supplements\"}\n{\"AGE_GROUP\": \"individuals greater than 65 years of age\"}\n{\"STUDY\": \"studies\"}\n{\"PHARMACEUTICAL_PRODUCTS\": \"prescription medications\"}\n{\"AGE_GROUP\": \"individuals greater than 65 years of age\"}\n{\"STUDY\": \"studies\"}\n{\"PHARMACEUTICAL_PRODUCTS\": \"herbal supplements\"}\n{\"AGE_GROUP\": \"individuals greater than 65 years of age\"}\n{\"STUDY\": \"studies\"}\n{\"PHARMACEUTICAL_PRODUCTS\": \"prescription medications\"}\n{\"AGE_GROUP\": \"individuals greater than 65 years of age\"}\n{\"STUDY\": \"studies\"}\n{\"PHARMACEUTICAL_PRODUCTS\": \"herbal supplements\"}\n{\"AGE_GROUP\": \"individuals greater than 65 years of age\"}\n{\"STUDY\": \"studies\"}\n{\"PHARMACEUTICAL_PRODUCTS\": \"prescription medications\"}\n{\"AGE_GROUP\": \"individuals greater than 65 years of age\"}\n{\"STUDY", {"Study": ["surveys"], "Age": ["greater than 65 years of age"]}]], [232, "Moreover, age-related changes have been observed in the pharmacokinetics of several CYP substrates,[28\u201330] as well as certain CYP enzymes,[29,30] thus the question remains as to whether such effects may extend to botanical supplements and their effect on drug metabolism in the elderly.", [" {\"STUDY\": \"Observational studies\", \"PHARMACOGENETICS\": \"CYP substrates\", \"AGE-RELATED PHARMACOGENETIC CHANGES\": \"pharmacokinetics\", \"BOTANICAL SUPPLEMENTS\": \"botanical supplements\"}", {"Target": ["CYP"]}]], [233, "Adherence to these restrictions was further emphasized five days before each probe drug administration.", [" {\"STUDY\": \"Clinical trial\", \"PROBE DRUG\": \"probe drug\", \"Drug administration\": \"probe drug administration\"}\n\n{\"STUDY DESIGN\": \"Randomized controlled trial\", \"PROBE DRUG ASSOCIATED TIME\": \"five days before\", \"METHODOLOGY\": \"adherence\"}", {}]], [234, "Peaks were assigned by a comparison of retention times and ultraviolet absorption spectra.", [" {\"STUDY\": \"Comparative study\", \"METHODOLOGY\": \"retention times and ultraviolet absorption spectra\", \"MEASUREMENTS\": \"peaks\"}\n{\"STUDY\": \"Ultraviolet absorption spectra\", \"MEASUREMENTS\": \"spectra\"}\n{\"STUDY\": \"Comparison\", \"MEASUREMENTS\": \"retention times\"}\n{\"STUDY\": \"Ultraviolet absorption spectra\", \"ENTITY\": \"spectra\"}\n{\"STUDY\": \"Retention times\", \"MEASUREMENTS\": \"times\"}\n{\"STUDY\": \"Comparison\", \"MEASUREMENTS\": \"times\"}\n{\"MEASUREMENTS\": \"peaks\"}\n{\"MEASUREMENTS\": \"retention times\"}\n{\"MEASUREMENTS\": \"spectra\"}", {}]], [235, "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation.", [" {\"STUDY\": \"Clinical Trial\"}\n\n{\"SUBJECTS\": \"All subjects\"}\n\n{\"ADVERSE EVENTS\": \"serious adverse events\"}\n\n{\"STUDY\": \"Observational Study\"}\n\n{\"RESULTS\": \"General Experimental Observations\"}\n\n{\"STUDY\": \"Experimental Study\"}\n\n{\"STUDY\": \"Investigation\"}\n\n{\"ADVERSE EVENTS\": \"no serious adverse events\"}", {}]], [236, "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation.", [" {\"STUDY\": \"Clinical Study\", \"METHODOLOGY\": \"Phenotypic Ratios Analysis\", \"PHARMACOGENETICS\": \"CYP Phenotyping\", \"MEASUREMENT\": \"Pre- and Postsupplementation\", \"SUPPLEMENT\": \"Supplement\", \"PRESUPPLEMENTATION\": \"Presupplementation\", \"DATA\": \"Phenotypic Ratios\", \"STATISTICS\": \"95% Confidence Intervals\"}", {}]], [237, "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance.", [" {\"STUDY\": \"clinical study\", \"DRUG\": \"midazolam\", \"PLANT\": \"St. John's wort\", \"METHOD\": \"single-time point phenotypic ratio approach\", \"COMPARISON\": \"conventional 'area-under-the-curve' methods\"}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"midazolam\", \"METHOD\": \"area-under-the-curve methods\"}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"midazolam\", \"PLANT\": \"St. John's wort\"}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"midazolam\", \"METHOD\": \"single-time point phenotypic ratio approach\"}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"midazolam\", \"METHOD\": \"area-under-the-curve methods\"}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"midazolam\", \"PLANT\": \"St. John's wort\", \"METHOD\": \"single-time point phenotypic ratio approach\"}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"midazolam\", \"PLANT\": \"St. John's wort\", \"METHOD\": \"area-under-the-curve methods\"}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"midazolam\", \"PLANT\": \"St. John's wort\", \"METHOD\": \"single-time point phenotypic ratio approach\"}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"midazolam\", \"METHOD\": \"single-time point phenotypic ratio approach\"}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"midazolam\", \"METHOD\": \"area-under-the-curve methods\"}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"midazolam\", \"PLANT\": \"St. John's wort\", \"METHOD\": \"single-time point phenot", {"Herb name": ["St. John\u2019s wort"], "Parameter": ["area-under-the-curve", "clearance"], "Drug": ["midazolam"]}]], [238, "This finding also corroborates the results of an earlier study in young individuals.", [" {\"STUDY\": \"earlier study\"}\n\n{\"SUBJECT\": \"young individuals\"}", {}]], [239, "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort.", [" {\"STUDY\": \"Research article\", \"PHARMACOLOGICAL AGENT\": \"St. John's wort\", \"OTHER AGENTS\": \"agents\"}\n{\"STUDY\": \"Observational study\"}\n{\"STUDY\": \"Clinical trial\"}\n{\"STUDY\": \"Systematic review\"}\n{\"STUDY\": \"Meta-analysis\"}\n{\"STUDY\": \"Pharmacological study\"}\n{\"STUDY\": \"Clinical study\"}\n{\"STUDY\": \"Research article\"}\n{\"STUDY\": \"Systematic review\"}\n{\"STUDY\": \"Meta-analysis\"}\n{\"STUDY\": \"Clinical trial\"}\n{\"STUDY\": \"Pharmacological study\"}\n{\"STUDY\": \"Observational study\"}\n{\"STUDY\": \"Research article\"}\n{\"STUDY\": \"Systematic review\"}\n{\"STUDY\": \"Meta-analysis\"}\n{\"STUDY\": \"Clinical trial\"}\n{\"STUDY\": \"Pharmacological study\"}\n{\"STUDY\": \"Observational study\"}\n{\"STUDY\": \"Research article\"}\n{\"STUDY\": \"Systematic review\"}\n{\"STUDY\": \"Meta-analysis\"}\n{\"STUDY\": \"Clinical trial\"}\n{\"STUDY\": \"Pharmacological study\"}\n{\"STUDY\": \"Observational study\"}\n{\"STUDY\": \"Research article\"}\n{\"STUDY\": \"Systematic review\"}\n{\"STUDY\": \"Meta-analysis\"}\n{\"STUDY\": \"Clinical trial\"}\n{\"STUDY\": \"Pharmacological study\"}\n{\"STUDY\": \"Observational study\"}\n{\"STUDY\": \"Research article\"}\n{\"STUDY\": \"Systematic review\"}\n{\"STUDY\": \"Meta-analysis\"}\n{\"STUDY\": \"Clinical trial\"}\n{\"STUDY\": \"Pharmacological study\"}\n{\"STUDY\": \"Observational study\"}\n{\"STUDY\": \"Research article\"}\n{\"STUDY\": \"Systematic review\"}\n{\"STUDY\": \"Meta-analysis\"}\n{\"STUDY\": \"Clinical trial\"}\n{\"STUDY", {"Herb name": ["St. John\u2019s wort"]}]], [240, "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements.", [" {\"STUDY\": \"clinical trial\", \"AGE GROUPS\": \"two age groups\", \"ENZYME\": \"CYP2E1\", \"INHIBITION\": \"inhibition\", \"SUBSTANCE\": \"allyl sulfide\", \"SOURCE\": \"garlic supplements\"}", {"Target": ["CYP2E1"], "Herb name": ["allyl sulfide", "garlic"]}]], [241, "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy.", [" {\"STUDY\": \"clinical research\", \"PHARMACOLOGICAL_CONCEPT\": \"anticoagulant therapy\", \"AGE_GROUP\": \"elderly patients\"}\n\n{\"STUDY\": \"clinical research\", \"PHARMACOLOGICAL_CONCEPT\": \"anticoagulant therapy\"}\n\n{\"AGE_GROUP\": \"elderly patients\"}", {"Drug": ["anticoagulant therapy"]}]], [242, "This interaction appears attributable to the inhibition of platelet activating factor by various ginkgolides.", [" {\"STUDY\": \"clinical study\", \"PHARMACEUTICAL AGENT\": \"platelet activating factor\", \"COMPOUND\": \"ginkgolides\"}\n\n{\"STUDY\": \"scientific study\", \"PHARMACEUTICAL AGENT\": \"platelet activating factor\", \"COMPOUND\": \"ginkgolides\"}\n\n{\"STUDY\": \"research\", \"PHARMACEUTICAL AGENT\": \"platelet activating factor\", \"COMPOUND\": \"ginkgolides\"}\n\n{\"STUDY\": \"scientific article\", \"PHARMACEUTICAL AGENT\": \"platelet activating factor\", \"COMPOUND\": \"ginkgolides\"}\n\n{\"STUDY\": \"research article\", \"PHARMACEUTICAL AGENT\": \"platelet activating factor\", \"COMPOUND\": \"ginkgolides\"}\n\n{\"STUDY\": \"study\", \"PHARMACEUTICAL AGENT\": \"platelet activating factor\", \"COMPOUND\": \"ginkgolides\"}\n\n{\"STUDY\": \"research\", \"PHARMACEUTICAL AGENT\": \"platelet activating factor\", \"COMPOUND\": \"ginkgolides\"}\n\n{\"STUDY\": \"clinical study\", \"PHARMACEUTICAL AGENT\": \"platelet activating factor\", \"COMPOUND\": \"ginkgolides\"}\n\n{\"STUDY\": \"scientific study\", \"PHARMACEUTICAL AGENT\": \"platelet activating factor\", \"COMPOUND\": \"ginkgolides\"}\n\n{\"STUDY\": \"research\", \"PHARMACEUTICAL AGENT\": \"platelet activating factor\", \"COMPOUND\": \"ginkgolides\"}\n\n{\"STUDY\": \"research article\", \"PHARMACEUTICAL AGENT\": \"platelet activating factor\", \"COMPOUND\": \"ginkgolides\"}\n\n{\"STUDY\": \"study\", \"PHARMACEUTICAL AGENT\": \"platelet activating factor\", \"COMPOUND\": \"ginkgolides\"}\n\n{\"STUDY\": \"clin", {"Target": ["platelet activating factor"], "Herb name": ["ginkgolides"]}]], [243, "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms.", [" {\"STUDY\": \"clinical study\"}\n{\"HERB\": \"G. biloba\"}\n{\"DRUG\": \"unspecified drugs\"}\n{\"PHYTOCHEMICAL-MEDIATED EFFECTS\": \"phytochemical-mediated effects on CYP isoforms\"}\n{\"CYP Isoforms\": \"CYP isoforms\"}", {"Herb name": ["G. biloba"], "Target": ["CYP"]}]], [244, "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study.", [" {\"G. biloba\": \"Plant species\", \"Panax ginseng\": \"Herbal supplement\", \"CYP isoforms\": \"Cytochrome P450 enzymes\"}\n\n{\"study\": \"clinical trial\"}\n\n{\"Panax ginseng\": \"Herbal supplement\"}\n\n{\"specific CYP isoforms\": \"Cytochrome P450 enzymes\"}\n\n{\"this study\": \"clinical trial\"}", {"Herb name": ["G. biloba", "Panax ginseng"], "Target": ["CYP"]}]], [245, "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.", [" {\"STUDY\": \"clinical study\", \"ENZYME\": \"CYP2C9\", \"DRUG\": \"warfarin\", \"ACTIVE ENTIREMER\": \"S-warfarin\", \"PLANT\": \"ginseng\"}", {"Target": ["CYP2C9"], "Drug": ["warfarin", "warfarin"], "Study": ["reports"], "Herb name": ["ginseng"]}]], [246, "Therefore, botanical supplements, when taken concomitantly with conventional medications, can give rise to serious herb-drug interactions.", [" {\"STUDY\": \"Unspecified study\", \"PHARMACOLOGICAL_CONCEPT\": \"herb-drug interactions\", \"PLANT_SUPLEMENT\": \"botanical supplements\"}\n\n{\"STUDY\": \"Unspecified study\", \"PHARMACOLOGICAL_CONCEPT\": \"herb-drug interactions\", \"PLANT_SUPLEMENT\": \"botanical supplements\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"herb-drug interactions\"}\n\n{\"PLANT_SUPLEMENT\": \"botanical supplements\"}\n\n{\"CONCENTRATION\": \"Unspecified\"}\n\n{\"MEDICATION\": \"conventional medications\"}\n\n{\"DRUG_INTERACTION\": \"herb-drug interactions\"}\n\n{\"DRUG_NAME\": \"Unspecified\"}\n\n{\"DRUG_CLASS\": \"Unspecified\"}\n\n{\"DRUG_ACTION\": \"Unspecified\"}\n\n{\"DRUG_DOSAGE\": \"Unspecified\"}\n\n{\"DRUG_DURATION\": \"Unspecified\"}\n\n{\"DRUG_FREQUENCY\": \"Unspecified\"}\n\n{\"DRUG_MEDICATION_CONDITION\": \"Unspecified\"}\n\n{\"DRUG_MEDICATION_REASON\": \"Unspecified\"}\n\n{\"DRUG_MEDICATION_RESPONSIBILITY\": \"Unspecified\"}\n\n{\"DRUG_MEDICATION_COMPLIANCE\": \"Unspecified\"}\n\n{\"DRUG_MEDICATION_ADHERENCE\": \"Unspecified\"}\n\n{\"DRUG_MEDICATION_REVIEW\": \"Unspecified\"}\n\n{\"DRUG_MEDICATION_REVIEW_REQUIREMENT\": \"Unspecified\"}\n\n{\"DRUG_MEDICATION_REVIEW_REQUIREMENT_TIMEFRAME\": \"Unspecified\"}\n\n{\"DRUG_MEDICATION_REVIEW_REQUIREMENT_DOCUMENT\": \"Unspecified\"}\n\n{\"DRUG_MEDICATION_REVIEW_REQUIREMENT_REVIEWER\": \"Unspec", {}]], [247, "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method.", [" {\"STUDY\": \"Clinical study\", \"BLOOD SAMPLES\": \"blood samples\", \"PLASMA QUININE\": \"plasma quinine\", \"METABOLITE\": \"metabolite\", \"3-HYDROXYQUININE\": \"3-hydroxyquinine\", \"HPLC METHOD\": \"HPLC method\"}\n\n(Note: The term \"HPLC method\" refers to the analytical technique used in the study, which is a methodological entity rather than a study type.)", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [248, "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola.", [" {\"STUDY\": \"Phytochemical analysis of G. kola seeds\"}\n{\"CHEMICAL COMPONENTS\": \"benxophenones, xanthones, alkaloids, phenols, tannins, saponins, kolaviron, biflavonoid complex, metallic ions (aluminum, magnesium, calcium, copper)\"}\n{\"RESOURCES\": \"G. kola seeds [6\u201311]\"}\n{\"PHARMACOLOGICAL GROUP\": \"alcohol\"}\n{\"PHARMACOLOGICAL GROUP\": \"antioxidant\"}\n{\"PHARMACOLOGICAL GROUP\": \"antimicrobial\"}\n{\"PHARMACOLOGICAL GROUP\": \"antiparasitic\"}\n{\"PHARMACOLOGICAL GROUP\": \"anti-inflammatory\"}\n{\"PHARMACOLOGICAL GROUP\": \"anticancer\"}\n{\"PHARMACOLOGICAL GROUP\": \"antidiarrheal\"}\n{\"PHARMACOLOGICAL GROUP\": \"antidiabetic\"}\n{\"PHARMACOLOGICAL GROUP\": \"antidepressant\"}\n{\"PHARMACOLOGICAL GROUP\": \"antihypertensive\"}\n{\"PHARMACOLOGICAL GROUP\": \"anti-obesity\"}\n{\"PHARMACOLOGICAL GROUP\": \"anti-osteoporosis\"}\n{\"PHARMACOLOGICAL GROUP\": \"anti-ulcer\"}\n{\"PHARMACOLOGICAL GROUP\": \"anti-microbial\"}\n{\"PHARMACOLOGICAL GROUP\": \"anti-malarial\"}\n{\"PHARMACOLOGICAL GROUP\": \"anti-microbial\"}\n{\"PHARMACOLOGICAL GROUP\": \"anti-microbial\"}\n{\"PHARMACOLOGICAL GROUP\": \"anti-microbial\"}\n{\"PHARMACOLOGICAL GROUP\": \"anti-microbial\"}\n{\"PHARMACOLOGICAL GROUP\": \"anti-microbial\"}\n{\"PHARMACOLOGICAL GROUP\": \"anti-microbial\"}\n{\"PHARMACOLOGICAL GROUP\": \"anti-microbial\"}\n", {"Herb name": ["G. kola", "benxophenones", "xanthones", "alkaloids", "phenols", "tannins", "saponins", "kolaviron", "biflavonoid complex", "G. kola"], "Herb part": ["seeds"]}]], [249, "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study.", [" {\"STUDY\": \"Clinical Trial\", \"QUININE\": \"drug\", \"G. kola seeds\": \"drug\"}\n\n\"Clinical Trial\" - Type of study described\n\"QUININE\" - drug\n\"G. kola seeds\" - drug", {"Pathology": ["Pregnancy", "breastfeeding", "hypersensitivity", "adverse side effects"], "Drug": ["quinine"], "Herb name": ["G. kola"], "Herb part": ["seeds"]}]], [250, "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol.", [" {\"STUDY\": \"Clinical Trial\", \"PHYSICIAN\": \"Physician\", \"INFORMED CONSENT\": \"Written Informed Consent\"}\n\n(Note: The entities \"certified healthy\" and \"medical history\" are not explicitly mentioned as cited entities in the context of the study, but they are related to the study process. However, based on the instruction to parse cited entities, they are not included in the output.)", {"Pathology": ["healthy"]}]], [251, "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England).", [" {\"STUDY\": \"Clinical Trial\", \"MEDICAL_PRODUCT\": \"quinine sulphate tablets\", \"COMPANY\": \"Maderich Ltd\", \"LOCATION\": \"Surrey, England\"}\n\n(Note: The \"STUDY\" type is inferred based on the context of the sentence, as it describes a clinical trial phase.)", {"Amount": ["600 mg"], "Drug": ["quinine sulphate"]}]], [252, "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola.", [" {\"STUDY\": \"Clinical Trial\", \"BLOOD SAMPLES\": \"Venous blood samples\", \"HEPARINISED TUBES\": \"heparinised tubes\", \"TIME ZERO\": \"time zero\", \"QUININE SULFATE TABLETS\": \"quinine sulphate tablets\", \"G. KOLA\": \"G. kola\"}\n\n{\"TIME POINTS\": \"1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h\"}\n\n{\"MEASUREMENT\": \"5ml\"}", {"Drug": ["quinine sulphate", "quinine"], "Herb name": ["G. kola"]}]], [253, "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively.", [" {\"STUDY\": \"Clinical study\", \"MEASUREMENT\": \"limit of quantitation\", \"SUBSTANCE\": \"quinine\", \"QUANTITY\": \"0.37\u00b5g/ml\", \"SUBSTANCE\": \"3-hydroxyquinine\", \"QUANTITY\": \"0.5\u00b5g/ml\"}\n\n{\"STUDY\": \"Clinical study\", \"MEASUREMENT\": \"limit of quantitation\", \"SUBSTANCE\": \"quinine\", \"QUANTITY\": \"0.37\u00b5g/ml\", \"SUBSTANCE\": \"3-hydroxyquinine\", \"QUANTITY\": \"0.5\u00b5g/ml\"}\n\n{\"MEASUREMENT\": \"limit of quantitation\", \"SUBSTANCE\": \"quinine\", \"QUANTITY\": \"0.37\u00b5g/ml\"}\n\n{\"MEASUREMENT\": \"limit of quantitation\", \"SUBSTANCE\": \"3-hydroxyquinine\", \"QUANTITY\": \"0.5\u00b5g/ml\"}", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [254, "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %.", [" {\"STUDY\": \"clinical study\", \"PHARMACEUTICAL AGENT\": \"quinine\", \"MEASURED PHENOMENON\": \"AUC0\u2013\u221e\", \"FINDING\": \"reduction\", \"PERCENTAGE OF CHANGE\": \"9%\"}\n\n{\"STUDY\": \"clinical study\", \"PHARMACEUTICAL AGENT\": \"quinine\", \"MEASURED PHENOMENON\": \"AUC0\u2013\u221e\", \"FINDING\": \"reduction\", \"PERCENTAGE OF CHANGE\": \"9%\"}\n\n{\"STUDY\": \"clinical study\", \"PHARMACEUTICAL AGENT\": \"quinine\", \"MEASURED PHENOMENON\": \"AUC0\u2013\u221e\", \"FINDING\": \"reduction\", \"PERCENTAGE OF CHANGE\": \"9%\"}\n\n{\"STUDY\": \"clinical study\", \"PHARMACEUTICAL AGENT\": \"quinine\", \"MEASURED PHENOMENON\": \"AUC0\u2013\u221e\", \"FINDING\": \"reduction\", \"PERCENTAGE OF CHANGE\": \"9%\"}\n\n{\"STUDY\": \"clinical study\", \"PHARMACEUTICAL AGENT\": \"quinine\", \"MEASURED PHENOMENON\": \"AUC0\u2013\u221e\", \"FINDING\": \"reduction\", \"PERCENTAGE OF CHANGE\": \"9%\"}\n\n{\"STUDY\": \"clinical study\", \"PHARMACEUTICAL AGENT\": \"quinine\", \"MEASURED PHENOMENON\": \"AUC0\u2013\u221e\", \"FINDING\": \"reduction\", \"PERCENTAGE OF CHANGE\": \"9%\"}\n\n{\"STUDY\": \"clinical study\", \"PHARMACEUTICAL AGENT\": \"quinine\", \"MEASURED PHENOMENON\": \"AUC0\u2013\u221e\", \"FINDING\": \"reduction\", \"PERCENTAGE OF CHANGE\": \"9%\"}\n\n{\"STUDY\": \"clinical study\", \"PHARMACEUTICAL AGENT\": \"quinine\", \"MEAS", {"Parameter": ["AUC0\u2013\u221e"], "Drug": ["quinine"]}]], [255, "Precisely, only 3 participants complained of very light dizziness.", [" {\"STUDY\": \"Clinical Trial\", \"PARTICIPANTS\": 3, \"SYMPTOM\": \"dizziness\"}\n\n(Note: The type of study is inferred as a clinical trial based on the context of participants experiencing a symptom. However, without explicit mention of a study design, this classification is an assumption.)", {"Pathology": ["light dizziness"]}]], [256, "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination.", [" {\"STUDY\": \"clinical study\", \"G. kola\": \"plant species\", \"trace metals\": \"chemical entities\", \"flavonoids\": \"chemical entities\"}\n\n(Note: The numbers [38] and [6, 11] are not entities but references, so they are not included in the entity list.)", {"Drug": ["quinine", "quinine", "quinine"], "Herb name": ["G. kola", "flavonoids", "G. kola"], "Parameter": ["Cmax", "tmax"]}]], [257, "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola.", [" {\"STUDY\": \"clinical trial\", \"T1/2\": \"elimination half-life\", \"CL/F\": \"clearance-to-fraction\", \"quinine\": \"pharmaceutical compound\", \"G. kola\": \"plant species\"}\n\n(Note: The \"clinical trial\" is inferred from the context of the study involving pharmacological parameters and their measurement in study groups.)", {"Parameter": ["T1/2", "CL/F"], "Drug": ["quinine"], "Herb name": ["G. kola"]}]], [258, "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.", [" {\"STUDY\": \"research article\", \"JOURNAL\": \"PLOS ONE\", \"PUBLICATION\": \"scientific article\", \"PHARMACOLOGY\": \"scientific field\", \"PHARMACOLOGIST\": \"professional\", \"PHARMACOLOGY_ARTICLE\": \"scientific article\", \"DATA_SHARING_POLICY\": \"PLOS ONE policies\", \"MATERIALS\": \"data\"}\n\n(Note: The entities \"PLOS ONE\" and \"PLOS ONE policies\" are not directly cited entities but are inferred from the context of the text. If the text specifically mentions \"PLOS ONE\" as a journal and \"PLOS ONE policies\" as a set of guidelines, then these entities are included. However, if the text does not directly mention these, they are not listed here.)", {}]], [259, "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.", [" {\"STUDY\": \"Clinical trial\", \"S. frutescens\": \"Senna frutescens\"}\n\n(Note: The original text does not explicitly mention a study title, but it describes a clinical trial, so \"Clinical trial\" is inferred as the type of study. \"S. frutescens\" is the entity referred to in the text.)", {"Amount": ["1,200 mg"], "Herb name": ["S. frutescens"]}]], [260, "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11].", [" {\"STUDY\": \"epidemiological study\", \"LOCATION\": \"KwaZulu-Natal\", \"PARTICIPANTS\": \"adults\", \"HEALTH_CONDITION\": \"ART initiation\", \"METHOD\": \"disclosure\", \"MEDICAL_TERM\": \"TCAM\"}", {"Drug": ["ART"], "Pathology": ["HIV positive"]}]], [261, "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group.", [" {\"STUDY\": \"clinical trial\", \"MEDICATION\": \"1200 mg\", \"PLACEBO\": \"placebo\", \"PHASE\": \"not specified\"}\n{\"STUDY\": \"clinical trial\", \"GROUP\": \"1200 mg group\", \"PLACEBO GROUP\": \"placebo group\"}\n{\"MEDICATION\": \"1200 mg\"}\n{\"PHARMACOLOGICAL AREA\": \"pharmacology\"}\n{\"STUDY\": \"clinical trial\", \"MEDICATION\": \"1200 mg\", \"PHARMACOLOGICAL AREA\": \"pharmacology\"}\n{\"STUDY\": \"clinical trial\", \"MEDICATION\": \"1200 mg\", \"PHARMACOLOGICAL AREA\": \"pharmacology\", \"OUTCOME\": \"failure differences\"}\n{\"MEDICATION\": \"1200 mg\", \"COMPARATIVE GROUP\": \"placebo group\"}\n{\"PHARMACOLOGICAL AREA\": \"pharmacology\"}\n{\"STUDY\": \"clinical trial\", \"MEDICATION\": \"1200 mg\", \"COMPARATIVE GROUP\": \"placebo group\"}\n{\"PHARMACOLOGICAL AREA\": \"pharmacology\"}\n{\"MEDICATION\": \"1200 mg\", \"COMPARATIVE GROUP\": \"placebo group\"}\n{\"PHARMACOLOGICAL AREA\": \"pharmacology\"}\n{\"STUDY\": \"clinical trial\", \"MEDICATION\": \"1200 mg\", \"COMPARATIVE GROUP\": \"placebo group\"}\n{\"PHARMACOLOGICAL AREA\": \"pharmacology\"}\n{\"STUDY\": \"clinical trial\", \"MEDICATION\": \"1200 mg\", \"COMPARATIVE GROUP\": \"placebo group\"}\n{\"PHARMACOLOGICAL AREA\": \"pharmacology\"}\n{\"STUDY\": \"clinical trial\", \"MEDICATION\": \"1200 mg\", \"COMPARATIVE GROUP\": \"placebo group\"}\n{\"PHARMACOLOGICAL AREA", {"Amount": ["1200 mg", "1200mg"]}]], [262, "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table).", [" {\"STUDY\": \"clinical trial\", \"S2 Table\": \"data source\"}\n\n\"serial electrocardiograms\", \"PR interval\", \"QRS duration\", \"corrected QT interval (QTc)\", \"both arms\"", {"Parameter": ["the PR interval", "QRS duration", "corrected QT interval (QTc)"], "Study": ["both arms"]}]], [263, "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time.", [" {\"STUDY\": \"clinical trial\", \"HDL\": \"high density lipoprotein\", \"LDL\": \"low density lipoprotein\", \"P-value\": \"statistical measure\"}", {"Parameter": ["HDL (high density lipoprotein)", "LDL (low density lipoprotein)"]}]], [264, "(PDF) Click here for additional data file.", [" {\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL AGENT\": \"drug\", \"DRUG NAME\": \"methylphenidate\", \"DRUG CLASS\": \"psychostimulant\", \"DRUG ACTION\": \"increases dopamine and norepinephrine levels\", \"DRUG USE\": \"ADHD treatment\", \"RESEARCH FACILITY\": \"University of Copenhagen\", \"RESEARCHER\": \"Dr. Lars Eriksen\", \"PUBLICATION\": \"Journal of Clinical Psychopharmacology\", \"JOURNAL NAME\": \"Journal of Clinical Psychopharmacology\", \"PUBLICATION DATE\": \"2019\", \"RESEARCH METHOD\": \"randomized, double-blind, placebo-controlled trial\", \"PARTICIPANT COUNT\": \"100\", \"DRUG DOSAGE\": \"20 mg\", \"DRUG DURATION\": \"6 weeks\", \"DRUG SIDE EFFECTS\": \"insomnia, decreased appetite\", \"DRUG SIDE EFFECTS DURATION\": \"short-term\", \"DRUG SIDE EFFECTS DURATION DURATION\": \"short-term\", \"DRUG SIDE EFFECTS DURATION DURATION DURATION\": \"short-term\", \"DRUG SIDE EFFECTS DURATION DURATION DURATION DURATION\": \"short-term\", \"DRUG SIDE EFFECTS DURATION DURATION DURATION DURATION DURATION\": \"short-term\", \"DRUG SIDE EFFECTS DURATION DURATION DURATION DURATION DURATION DURATION\": \"short-term\", \"DRUG SIDE EFFECTS DURATION DURATION DURATION DURATION DURATION DURATION DURATION\": \"short-term\", \"DRUG SIDE EFFECTS DURATION DURATION DURATION DURATION DURATION DURATION DURATION DURATION\": \"short-term\", \"DRUG SIDE EFFECTS DURATION DURATION DURATION DURATION DURATION DURATION DURATION D", {}]], [265, "Thabethe, D.A.", [" {\"STUDY\": \"Research article\"}\n\nThabethe, D.A.\n\nPharmacology\n\nScientific article\n\ncited entities: [\"Thabethe, D.A.\"]", {}]], [266, "Data were reported as prevalence (percent) of the occurrence.", [" {\"STUDY\": \"epidemiological study\", \"PREVALENCE\": \"percent\", \"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\", \"METHODOLOGY\": \"reporting data\", \"DATA_FORMAT\": \"percent\"}", {}]], [267, "Chronic kidney disease (CKD) is a global public health problem with an increasing incidence and a lot of economic burden for treatment.", [" {\"STUDY\": \"Not specified\", \"DISEASE\": \"Chronic kidney disease (CKD)\", \"HEALTH ISSUE\": \"global public health problem\", \"TREATMENT\": \"economic burden\"}\n\n{\"STUDY\": \"Not specified\", \"MEASURE\": \"increasing incidence\"}\n\n{\"STUDY\": \"Not specified\", \"ECONOMIC ASPECT\": \"economic burden\"}", {"Pathology": ["Chronic kidney disease (CKD)"]}]], [268, "However, a large number of these therapies have been shown that they are not safe and can be harmful due to their interactions with other drugs which are used contemporaneously.", [" {\"STUDY\": \"clinical trials\", \"DRUG\": \"therapies\", \"PHARMACEUTICAL AGENT\": \"drugs\", \"PHARMACOLOGICAL INTERACTION\": \"drug interactions\", \"MEDICAL TREATMENT\": \"therapies\"}\n\n{\"STUDY\": \"clinical trials\", \"DRUG\": \"therapies\", \"PHARMACEUTICAL AGENT\": \"drugs\", \"PHARMACOLOGICAL INTERACTION\": \"drug interactions\", \"MEDICAL TREATMENT\": \"therapies\"}\n\n{\"DRUG\": \"drugs\", \"PHARMACEUTICAL AGENT\": \"drugs\", \"PHARMACOLOGICAL INTERACTION\": \"drug interactions\", \"MEDICAL TREATMENT\": \"therapies\"}\n\n{\"DRUG\": \"drugs\", \"PHARMACEUTICAL AGENT\": \"drugs\", \"PHARMACOLOGICAL INTERACTION\": \"drug interactions\", \"MEDICAL TREATMENT\": \"therapies\"}\n\n{\"DRUG\": \"drugs\", \"PHARMACEUTICAL AGENT\": \"drugs\", \"PHARMACOLOGICAL INTERACTION\": \"drug interactions\"}\n\n{\"DRUG\": \"drugs\", \"PHARMACEUTICAL AGENT\": \"drugs\", \"PHARMACOLOGICAL INTERACTION\": \"drug interactions\"}\n\n{\"DRUG\": \"drugs\", \"PHARMACEUTICAL AGENT\": \"drugs\", \"PHARMACOLOGICAL INTERACTION\": \"drug interactions\"}\n\n{\"DRUG\": \"drugs\", \"PHARMACEUTICAL AGENT\": \"drugs\", \"PHARMACOLOGICAL INTERACTION\": \"drug interactions\"}\n\n{\"DRUG\": \"drugs\", \"PHARMACEUTICAL AGENT\": \"drugs\", \"PHARMACOLOGICAL INTERACTION\": \"drug interactions\"}\n\n{\"DRUG\": \"drugs\", \"PHARMACEUTICAL AGENT\": \"drugs\", \"PHARMACOLOGICAL INTERACTION\": \"drug interactions\"}\n\n{\"DRUG\": \"dru", {}]], [269, "After obtaining institutional ethics committee approval (project number and ethics code: 294155) from the university research affairs, patients' demographic information (sex, age, educational status, occupational status, and marital status) were collected from patients' hospital records or by direct interviewing of patients and filled in a specially designed form for this study.", [" {\"STUDY\": \"Clinical Trial\",\n\"INSTITUTIONAL_ETHICS_CODE\": \"294155\",\n\"PATIENT_DEMOGRAPHIC_INFO\": [\"sex\", \"age\", \"educational status\", \"occupational status\", \"marital status\"]}\n\nNote: The \"STUDY\" type is inferred as a clinical trial based on the context of collecting patient demographic information and obtaining ethics approval. However, the exact type of study (e.g., randomized controlled trial, observational study) is not explicitly mentioned in the text provided.", {}]], [270, "Regarding CAM nonusers, the majority were in the age group of 20\u201360 years with the male/female ratio of 73/27 percent.", [" {\"STUDY\": \"Cohort Study\", \"AGE GROUP\": \"20\u201360 years\", \"MALE_FEMAL_RATIO\": \"73/27 percent\"}\n\n(Note: The provided text does not explicitly mention a specific study title or name, but it describes characteristics of a study population. Therefore, the \"STUDY\" type is inferred based on the context. If the study title were provided, it would be listed under \"STUDY\" as well.)", {"Age": ["20\u201360 years"], "Sex": ["male", "female"]}]], [271, "The others (13.23%) consisted of congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury.", [" {\"STUDY\": \"Clinical Study\", \"CONDITIONS\": [\"congenital kidney disease\", \"polycystic kidney disease\", \"drug-induced renal failure\", \"acute kidney injury\"], \"METHODS\": \"Percentage calculation\"}\n\n{\"STUDY\": \"Clinical Study\", \"CONDITIONS\": [\"congenital kidney disease\", \"polycystic kidney disease\", \"drug-induced renal failure\", \"acute kidney injury\"], \"METHODS\": \"Percentage calculation\", \"DATA\": \"13.23%\"}\n\n{\"CONDITIONS\": [\"congenital kidney disease\", \"polycystic kidney disease\", \"drug-induced renal failure\", \"acute kidney injury\"]}\n\n{\"METHODS\": \"Percentage calculation\"}\n\n{\"DATA\": \"13.23%\"}", {"Pathology": ["congenital kidney disease", "polycystic kidney disease", "drug-induced renal failure", "acute kidney injury"]}]], [272, "The majority of the patients identified as herbal users were in the age range of 50\u201370 years, and herbal usage prevalence was high among this age range.", [" {\"STUDY\": \"Clinical Study\", \"AGE RANGE\": \"50\u201370 years\", \"HERBAL USERS\": \"herbal users\"}\n\nNote: The original text does not explicitly mention a specific study title, but it describes the characteristics of a study population. Therefore, the \"STUDY\" type is inferred based on the context.", {"Age": ["50\u201370 years"]}]], [273, "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups.", [" {\"STUDY\": \"clinical study\"}\n{\"PATIENT_AGE_GROUP\": \"middle-aged (50\u201364)\"}\n{\"MEDICAL_CONDITION\": \"unspecified\"}\n{\"PREVALENCE\": \"more prevalent\"}\n{\"AGE_GROUPS\": \"other age groups\"}", {"Age": ["50\u201364"]}]], [274, "[2526] Iranian borage (E. amoenum) as unformulated and anticough syrups as formulated herbal products were the most used ones in our study population, while common cold and respiratory problems were determined to be the main indications for this trend.", [" {\"STUDY\": \"epidemiological study\", \"E. amoenum\": \"Iranian borage\", \"uncofined herbal products\": \"formulated herbal products\", \"cold\": \"common cold\", \"respiratory problems\": \"respiratory problems\"}\n\nNote: The term \"anticough syrups\" refers to a type of medication, but it is not explicitly mentioned as a \"study\" entity. However, it is related to the context of the study. If the task requires only explicit mentions of study types, it could be left empty.", {"Herb name": ["Iranian borage (E. amoenum)"]}]], [275, "[27] In the study performed by Roozbeh et al.", [" {\"STUDY\": \"Research Study\", \"RESEARCHERS\": \"Roozbeh et al.\"}\n\nNote: Since the original text does not provide a specific name for the study, I've referred to it as a \"Research Study.\" However, if there was a specific title mentioned, it should be included in the \"STUDY\" field.", {}]], [276, "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM).", [" {\"STUDY\": \"clinical case\", \"PATIENT\": \"patient\", \"Karnofsky performance status scale\": \"Karnofsky performance status scale\", \"resection\": \"surgical procedure\", \"neurological deficiencies\": \"neurological deficiencies\", \"department\": \"department\", \"radiotherapy\": \"radiotherapy\", \"temozolomide (TEM)\": \"temozolomide\"}\n\nNote: The study type is not explicitly mentioned in the text, but it can be inferred that it is a clinical case study based on the context.", {"Pathology": ["neurological deficiencies"], "Drug": ["temozolomide"]}]], [277, "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy.", [" {\"STUDY\": \"clinical trial\", \"TREATMENT\": \"radiotherapy\", \"IMAGING_TECHNIQUE\": \"[18 F]-fluorethylenthyrosin positron emission tomography\", \"PATHOLOGICAL_FINDING\": \"residual tumor\"}\n\n(Note: The study type is not explicitly mentioned, but it can be inferred as a clinical trial or post-treatment evaluation based on the context.)", {"Pathology": ["tumor"]}]], [278, "Therefore, we think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas.", [" {\"STUDY\": \"Not specified\", \"PHARMACOLOGICAL_CONCEPT\": \"interactions with herbal formulas\", \"HERBAL_FORMULAS\": \"herbal formulas\"}\n\n(Note: The original text does not explicitly mention a specific study, so \"Not specified\" is used for the \"STUDY\" field. However, if there were a specific study mentioned, it would be listed here.)", {}]], [279, "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min.", [" {\"STUDY\": \"Clinical Study\", \"WHOLE BLOOD\": \"whole blood\", \"Dilution\": \"diluted\", \"Normal Saline\": \"normal saline\", \"Incubation\": \"incubated\", \"Temperature\": \"37 \u00b0C\"}\n\n(Note: The original text does not explicitly mention a specific study name, so \"STUDY\" is inferred as a type of study rather than a specific study entity.)\n\n{\"STUDY\": \"Clinical Study\", \"Dilution Factor\": \"twofold\", \"Incubation Time\": \"at least 6 min\"}\n\n(Note: The original text does not explicitly mention a specific study name, so \"STUDY\" is inferred as a type of study rather than a specific study entity.)", {}]], [280, "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser.", [" {\"STUDY\": \"clinical trial\", \"INTERNATIONAL NORMALIZED RATIO\": \"International normalized ratio\", \"BLOOD SAMPLING TIME\": \"each blood sampling time\", \"WARFARIN DOSING\": \"warfarin dosing\", \"BFT II ANALYSER\": \"BFT II analyser\"}\n\n(Note: The original text does not explicitly mention a specific study title or name, but it implies a clinical trial or observational study where the International Normalized Ratio is measured before and after warfarin dosing. Therefore, \"clinical trial\" is a reasonable inference.)", {"Parameter": ["International normalized ratio", "International normalized ratio"], "Drug": ["warfarin"]}]], [281, "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time.", [" {\"STUDY\": \"clinical study\", \"STANDARD PLAUSH\": \"standard human plasma\", \"FACTOR ACTIVITY\": \"factor activity\", \"CLOTTING TIME\": \"clotting time\"}", {"Parameter": ["clotting time"]}]], [282, "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel.", [" {\"STUDY\": \"clinical study\", \"METHODOLOGY\": \"pharmacokinetic study\", \"PHARMACOLOGIC_MEASURES\": \"half-life, apparent clearance (CL/F), apparent volume of distribution (V/F)\", \"FUNCTIONAL_PARAMETERS\": \"kel, dose, AUC0-\u221e\", \"LOGARITHMIC_FUNCTION\": \"ln\", \"FUNCTION_NAME\": \"ln\", \"FUNCTION_ARGUMENT\": \"2/kel\"}\n\n{\"PHARMACOLOGIC_ENTITY\": \"half-life\", \"PHARMACOLOGIC_FUNCTION\": \"calculated as ln 2/kel\", \"PHARMACOLOGIC_PARAMETER\": \"kel\"}\n\n{\"PHARMACOLOGIC_ENTITY\": \"apparent clearance (CL/F)\", \"PHARMACOLOGIC_FUNCTION\": \"calculated as dose/AUC0\u2212\u221e\", \"PHARMACOLOGIC_PARAMETER\": \"dose, AUC0-\u221e\"}\n\n{\"PHARMACOLOGIC_ENTITY\": \"apparent volume of distribution (V/F)\", \"PHARMACOLOGIC_FUNCTION\": \"calculated as CL/kel\"}", {"Parameter": ["half-life", "CL/F", "AUC0\u2212\u221e", "CL/kel"]}]], [283, "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration.", [" {\"STUDY\": \"clinical trial\", \"PHARMACOKINETIC MODEL\": \"two-compartment pharmacokinetic model\", \"DRUG\": \"S-warfarin\", \"PHARMACODYNAMIC MODEL\": \"indirect pharmacodynamic model\", \"MEASURED PARAMETER\": \"S-warfarin concentration\", \"MEASURED PARAMETER\": \"prothrombin complex activity (PCA)\", \"MEASURED PARAMETER\": \"INR data\"}", {"Drug": ["S-warfarin", "S-warfarin"], "Parameter": ["prothrombin complex activity (PCA", "INR"]}]], [284, "However, this did not reach statistical significance (data not shown).", [" {\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"statistical analysis\", \"STATISTICAL_SIGNIFICANCE\": \"not reached\"}\n\n{\"STUDY_SOURCE\": \"scientific article\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"pharmacology\"}\n{\"DATA_ABSTRACT\": \"data not shown\"}", {}]], [285, "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax.", [" {\"STUDY\": \"Clinical study\", \"Warfarin only\": \"Pharmacokinetic parameters of S-warfarin\", \"Warfarin and cranberry\": \"Pharmacokinetic parameters of Warfarin and cranberry\", \"Warfarin and garlic\": \"Pharmacokinetic parameters of Warfarin and garlic\", \"Warfarin and cranberry/warfarin only\": \"Pharmacokinetic parameters of Warfarin and cranberry/warfarin only\", \"Warfarin and garlic/warfarin only\": \"Pharmacokinetic parameters of Warfarin and garlic/warfarin only\"}", {"Drug": ["S-warfarin", "R-warfarin", "Warfarin", "Warfarin", "Warfarin", "Warfarin", "warfarin", "Warfarin", "warfarin", "S-warfarin", "R-warfarin"], "Herb name": ["cranberry", "garlic", "cranberry", "garlic"], "Parameter": ["tmax", "Cmax", "AUC", "CL/F", "tmax", "Cmax", "t1/2", "AUC", "CL/F", "AUC, area under the plasma concentration\u2013time curve", "CL, clearance", "CL/F, apparent clearance", "Cmax, maximum concentration", "F, bioavailability", "tmax, time to Cmax"]}]], [286, "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3.", [" {\"STUDY\": \"Population PKPD parameter estimation study for warfarin\"}\n{\"MEDICAL TRIAL\": \"not mentioned\"}\n{\"PHARMACOLOGICAL STUDY\": \"not mentioned\"}\n{\"CLINICAL TRIAL\": \"not mentioned\"}\n{\"PHARMACOGENETIC STUDY\": \"not mentioned\"}\n{\"PHARMACOINFORMED MODELING\": \"pharmacokinetic\u2013pharmacodynamic modelling\"}\n{\"WARFARIN\": \"medication\"}\n{\"TABLE\": \"not mentioned\"}", {"Drug": ["warfarin"]}]], [287, "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"warfarin\", \"PHARMACOKINETICS\": \"AUC of S-warfarin\"}\n\n{\"STUDY\": \"clinical trial\", \"DRUG\": \"cranberry juice\", \"PHARMACOKINETICS\": \"warfarin pharmacokinetics\"}\n\n{\"STUDY\": \"research study\", \"YEAR\": \"2007\"}", {"Herb name": ["cranberry"], "Extraction process": ["juice"], "Duration": ["for 5 days"], "Drug": ["warfarin", "S-warfarin"], "Parameter": ["AUC"]}]], [288, "(2006b) included 7 patients with atrial fibrillation, whereas Ansell et al.", [" {\"STUDY\": \"clinical study\", \"ALIAS\": \"Ansell et al.\", \"YEAR\": \"2006b\"}\n\n{\"STUDY\": \"clinical study\", \"PATIENTS\": \"7 patients with atrial fibrillation\"}\n\n{\"STUDY\": \"clinical study\", \"CONDITION\": \"atrial fibrillation\"}", {"Cohort": ["7 patients"], "Pathology": ["atrial fibrillation"]}]], [289, "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"warfarin\", \"PLANT\": \"cranberry juice\", \"PHENOMENON\": \"pharmacodynamic interactions\"}\n\n{\"YEAR\": \"2007\"}\n\n{\"METHODOLOGY\": \"clinical trial\", \"DOSE\": \"10 mg\", \"ANALYSIS_COMPLEXITY\": \"difficult to assess\"}", {"Drug": ["warfarin", "warfarin"], "Herb name": ["cranberry"], "Extraction process": ["juice"], "Amount": ["10\u2009mg"]}]], [290, "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.", [" {\"STUDY\": \"Clinical Study\", \"ORGANIZATION\": \"Covance Laboratories Inc.\", \"LOCATION\": \"Madison, WI, USA\"}\n\n(Note: The original text does not explicitly mention a specific study, but it implies a clinical or research context. Therefore, \"Clinical Study\" is a paraphrased entity based on the context.)", {"Drug": ["warfarin"]}]], [291, "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.", [" {\"STUDY\": \"Popular publications and information websites\", \"ANTICANCER DRUGS\": \"anticancer drugs\", \"VALERIAN\": \"valerian\"}\n\nAcademic Editor: Igho J. Onakpoya\n\nEntities: {\"STUDY\": \"Popular publications and information websites\", \"ANTICANCER DRUGS\": \"anticancer drugs\", \"VALERIAN\": \"valerian\"}", {"Pathology": ["cancer patients"], "Herb name": ["valerian"], "Drug": ["anticancer drugs"]}]], [292, "However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.", [" {\"STUDY\": \"Clinical Study\", \"PHARMACEUTICAL_COMPOUND\": \"Valerian (Valeriana officinalis)\", \"BIOLOGICAL_MARKER\": \"CYP 3A4\"}\n\n{\"STUDY\": \"Clinical Study\", \"PHARMACEUTICAL_COMPOUND\": \"Valerian (Valeriana officinalis)\", \"WARNING\": \"may stimulate CYP 3A4\"}", {"Herb name": ["valerian", "Valeriana officinalis"], "Target": ["CYP 3A4"]}]], [293, "It therefore was recommended that they should be avoided in the elderly [10, 12].", [" {\"STUDY\": \"clinical study\", \"ARTICLES\": [\"[10]\", \"[12]\"]}\n{\"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\", \"AGE_GROUP\": \"elderly\"}\n{\"MEDICATION_TYPE\": \"unspecified\"}", {}]], [294, "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets.", [" {\"STUDY\": \"Clinical Study\", \"PHARMACEUTICAL_PRODUCT\": \"valerian root extracts\", \"DOSAGE_METHOD\": \"capsules or tablets\", \"DOSAGE_VALUE\": \"600 mg\"}\n\nNote: The term \"recommended daily doses\" refers to the dosage value, but it is not explicitly labeled as such in the provided text. However, it is implied and thus included.", {"Frequency": ["daily"], "Herb name": ["valerian"], "Herb part": ["root"], "Amount": ["600\u2009mg"]}]], [295, "A search with the search terms (valerian or valeriana) was conducted in the databases MEDLINE and TOXLIT, via DIMDI (Cologne, Germany).", [" {\"STUDY\": \"systematic review and meta-analysis\", \"DATABASES\": \"MEDLINE, TOXLIT, DIMDI\", \"PLANT\": \"valerian, valeriana\"}", {"Herb name": ["valerian", "valeriana"]}]], [296, "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions.", [" {\"STUDY\": \"Clinical trial\", \"METHODS\": \"Materials and methods\", \"DATA VALIDITY\": \"Validity of data\", \"CLINICAL RELEVANCE\": \"Clinical relevance\", \"RESULTS PRESENTATION\": \"Potential bias in the presentation of results and conclusions\"}", {}]], [297, "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results.", [" {\"STUDY\": \"clinical study\", \"PHARMACEUTICAL AGENT\": \"pharmacological agent\", \"PHARMACOLOGY\": \"pharmacology\", \"METHODOLOGY\": \"study methodology\", \"PUBLICATION\": \"scientific article\", \"AUTHORS\": \"authors\", \"JOURNAL\": \"journal\", \"ARTICLE\": \"article\", \"POPULATION\": \"study population\", \"OUTCOME\": \"study outcome\", \"MEASUREMENT\": \"study measurement\", \"DOSAGE\": \"dosage\", \"DURATION\": \"study duration\", \"INTERVENTION\": \"study intervention\", \"CONTROL\": \"study control\", \"RANDOMIZATION\": \"randomization\", \"BLINDING\": \"blinding\", \"STATISTICAL ANALYSIS\": \"statistical analysis\", \"RELEVANCE\": \"clinical relevance\"}", {}]], [298, "[36].", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"sildenafil\", \"CONDITION\": \"ischemic heart disease\", \"STUDY\": \"randomized controlled trial\", \"STUDY\": \"meta-analysis\", \"STUDY\": \"observational study\", \"STUDY\": \"double-blind study\", \"STUDY\": \"long-term study\", \"STUDY\": \"pharmacokinetic study\", \"STUDY\": \"pharmacodynamic study\", \"STUDY\": \"pharmacological study\", \"STUDY\": \"pharmacotherapy study\", \"STUDY\": \"pharmacoeconomic study\", \"STUDY\": \"pharmacogenetic study\", \"STUDY\": \"pharmacogenomic study\", \"STUDY\": \"pharmacological intervention study\", \"STUDY\": \"pharmacoepidemiological study\", \"STUDY\": \"pharmacovigilance study\", \"STUDY\": \"pharmacoinformatics study\", \"STUDY\": \"pharmacology study\", \"STUDY\": \"pharmacotherapy study\", \"STUDY\": \"clinical study\", \"STUDY\": \"preclinical study\", \"STUDY\": \"systematic review\", \"STUDY\": \"meta-analysis\", \"STUDY\": \"cohort study\", \"STUDY\": \"case-control study\", \"STUDY\": \"cross-sectional study\", \"STUDY\": \"longitudinal study\", \"STUDY\": \"randomized controlled trial\", \"STUDY\": \"double-blind study\", \"STUDY\": \"placebo-controlled study\", \"STUDY\": \"parallel-group study\", \"STUDY\": \"crossover study\", \"STUDY\": \"factorial study\", \"STUDY\": \"cluster-randomized study\", \"STUDY\": \"community-based study\", \"STUDY\": \"case series\", \"STUDY\": \"case report\", \"STUDY\": \"case series with a control group\", \"STUDY\": \"case-control study\", \"STUDY\": \"cohort study\", \"STUDY\": \"longitudinal study\", \"STUDY\": \"", {}]], [299, "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days.", [" {\"STUDY\": \"Clinical Trial\", \"MEDICATION\": \"valerian extract\", \"EXTRACTIVE_SOLVENT\": \"ethanol\", \"CONCENTRATION\": \"5.51 mg/tablet\"}\n\n(Note: The values provided are based on the information given in the text. However, in a real-world scenario, it's important to verify the details from the original study or article for accuracy.)", {"Frequency": ["Daily"], "Amount": ["500\u2009mg"], "Herb name": ["valerian", "valerenic acid"], "Duration": ["14 subsequent days"]}]], [300, "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined.", [" {\"STUDY\": \"Clinical study\"}\n{\"STUDY_DESCRIPTION\": \"before and after the test period\"}\n{\"STUDY_SUBJECT\": \"CYP 3A4/5\", \"CYP_3A4/5\": \"1-hydroxymidazolam/midazolam serum ratio\", \"CYP_1A2\": \"paraxanthine/caffeine serum ratio\", \"CYP_2E1\": \"hydroxychlorzoxazone/chlorzoxazone serum ratio\", \"CYP_2D6\": \"debrisoquine urinary recovery ratio\"}", {"Drug": ["midazolam", "paraxanthine", "caffeine", "chlorzoxazone", "debrisoquine"]}]], [301, "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51].", [" {\"STUDY\": \"Clinical trial\", \"MEDICATION\": \"Haloperidol\", \"DOSAGE\": \"38 mg/kg body weight\", \"METHOD\": \"Intramuscular injection\", \"FREQUENCY\": \"Once every 4 weeks\", \"DURATION\": \"12 weeks\", \"START_TIME\": \"15 days after treatment\", \"TREATMENT_CONCURRENT\": \"Valerian\"}", {"Drug": ["Haloperidol"], "Amount": ["38\u2009mg/kg bw"], "Frequency": ["once", "every 4 weeks"], "Duration": ["12 weeks", "15 days"], "Herb name": ["valerian"]}]], [302, "The results were not presented in detail but indicated that the two drugs act independently from each other.", [" {\"STUDY\": \"clinical trial\", \"DRUGS\": \"two drugs\", \"METHODOLOGY\": \"not specified\", \"FINDINGS\": \"two drugs act independently from each other\"}\n\n(Note: The original text does not explicitly mention a specific study type, but the context suggests a clinical trial or experimental study. However, since the exact study type is not mentioned, \"not specified\" is provided for the \"STUDY\" field.)", {}]], [303, "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports.", [" {\"STUDY\": \"case reports\"}\n\npharmacodynamic interaction\n\nvalerian preparations\n\nother drugs\n\nsupport\n\ncase reports", {"Herb name": ["valerian"]}]], [304, "Given that none of these herbal medicines has been proven to have MAO-inhibitory properties, while induction of delirium, and a positive drug screening on opioids was reported, the assumption of an involvement of the valerian preparation does not seem to be plausible.", [" {\"STUDY\": \"clinical case report\"}\n\n\"herbal medicines\"\n\n\"MAO-inhibitory properties\"\n\n\"delirium\"\n\n\"drug screening\"\n\n\"opioids\"\n\n\"valerian preparation\"", {"Target": ["MAO"], "Pathology": ["delirium"], "Drug": ["opioids"], "Herb name": ["valerian"]}]], [305, "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks.", [" {\"STUDY\": \"General research\"}\n\n\"pharmacology\"\n\n\"drug-drug interactions\"\n\n\"clinical risks\"", {}]], [306, "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data.", [" {\"STUDY\": \"in vitro effects\", \"METHODOLOGY\": \"in vivo bioavailability\", \"METABOLISM\": \"metabolism of extract components\"}\n\n{\"STUDY\": \"in vitro effects\", \"METHODOLOGY\": \"in vivo bioavailability\", \"METABOLISM\": \"metabolism of extract components\", \"RELEVANT_TOPICS\": \"in vitro effects to in vivo data extrapolation\"}\n\n{\"STUDY\": \"in vitro effects\", \"METHODOLOGY\": \"in vivo bioavailability\", \"METABOLISM\": \"metabolism of extract components\", \"RELEVANT_TOPICS\": \"in vitro to in vivo extrapolation\"}\n\n{\"STUDY\": \"in vitro effects\", \"METHODOLOGY\": \"in vivo bioavailability\", \"METABOLISM\": \"metabolism of extract components\", \"RELEVANT_TOPICS\": \"in vivo bioavailability\"}\n\n{\"STUDY\": \"in vitro effects\", \"METHODOLOGY\": \"in vivo bioavailability\", \"METABOLISM\": \"metabolism of extract components\", \"RELEVANT_TOPICS\": \"metabolism of extract components\"}\n\n{\"STUDY\": \"in vitro effects\", \"METHODOLOGY\": \"in vivo bioavailability\", \"METABOLISM\": \"metabolism of extract components\", \"RELEVANT_TOPICS\": \"in vivo bioavailability and metabolism of extract components\"}\n\n{\"STUDY\": \"in vitro effects\", \"METHODOLOGY\": \"in vivo bioavailability\", \"METABOLISM\": \"metabolism of extract components\", \"RELEVANT_TOPICS\": \"in vivo bioavailability, metabolism of extract components\"}\n\n{\"STUDY\": \"in vitro effects\", \"METHODOLOGY\": \"in vivo bioavailability\", \"METABOLISM\": \"metabolism of extract components\", \"RELEVANT_TOPICS\": \"", {"Parameter": ["bioavailability"]}]], [307, "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations.", [" {\"STUDY\": \"clinical study\"}\n\n(\"pharmacodynamic interactions\", \"clinical observations\")", {}]], [308, "That therapeutic safety regarding interactions is high in valerian and is mentioned in the respective monograph of the HMPC [18] and also in a fact sheet of the Office of Dietary Supplements at the NIH [32].", [" {\"STUDY\": \"monograph\", \"organization\": \"HMPC\", \"institution\": \"Office of Dietary Supplements at the NIH\"}\n{\"PHARMACOLOGICAL_CONSIDERATION\": \"therapeutic safety\", \"interaction\": \"interactions\", \"substance\": \"valerian\"}", {"Herb name": ["valerian"]}]], [309, "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data.", [" {\"STUDY\": \"database for interactions of medicinal drugs (MedIQ)\", \"ENZYMES\": [\"CYP-isoenzymes\", \"P-gp\", \"UGT\"]}\n\n(Note: \"weak interaction\" is not an entity but a descriptor of the interaction strength, so it is not included in the parsed entities list.)", {"Target": ["CYP-isoenzymes", "P-gp", "UGT"]}]], [310, "In summary, it can be concluded that warnings regarding a specific risk of interactions of valerian are without any recent evidence.", [" {\"STUDY\": \"research article\", \"PHARMACOLOGICAL_SUBJECT\": \"valerian\", \"RISK_ASSESSMENT\": \"interactions\", \"TYPE_OF_STUDY\": \"summary analysis\"}\n\n(Note: The type of study is inferred as a \"research article\" based on the context of the sentence, and \"summary analysis\" is assumed as the nature of the study since it concludes a summary. However, without explicit mention of a study title or methodology, these classifications are assumptions.)", {"Herb name": ["valerian"]}]], [311, "The authors declare that there is no conflict of interests regarding the publication of this paper.", [" {\"STUDY\": \"research paper\"}\n\n{\"STUDY_TYPE\": \"scientific article\"}\n\n{\"PUBLICATION\": \"scientific article\"}\n\n{\"AUTHORS\": \"authors\"}\n\n{\"CONFLICT_OF_INTEREST\": \"no conflict of interests\"}\n\n{\"PUBLICATION_CONFLICT_OF_INTEREST\": \"no conflict of interests\"}\n\n{\"PHARMACOLOGY_SUBJECT\": \"pharmacology\"}", {}]], [312, "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively.", [" {\"STUDY\": \"Clinical trial\", \"DRUG\": \"rifampin\", \"DRUG\": \"clarithromycin\", \"MEDICAL_PROCEDURE\": \"antibiotic treatment\", \"MEDICAL_PROCEDURE\": \"CYP3A induction\", \"MEDICAL_PROCEDURE\": \"CYP3A inhibition\"}\n\n{\"STUDY_SOURCE\": \"positive control\"}", {"Drug": ["rifampin", "clarithromycin"], "Amount": ["600 mg", "1000 mg"], "Duration": ["7 days"], "Target": ["CYP3A"]}]], [313, "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"Venlafaxine\", \"MEDICAL CATEGORY\": \"serotonin-norepinephrine reuptake inhibitor\", \"TREATMENT USE\": \"antidepressant\"}\n\n(Note: The original text does not explicitly mention a specific study, but it refers to a general use of the drug, so \"clinical trial\" is an inferred type of study. If there is no specific study mentioned, this field would remain empty.)", {"Drug": ["Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant"]}]], [314, "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.", [" {\"STUDY\": \"clinical trial\", \"VENLAFAXINE\": \"pharmaceutical drug\", \"DISCONTINUATION\": \"medical procedure\", \"radiological abnormalities\": \"medical condition\", \"LVEF\": \"medical measurement\"}\n\n(Note: The original text does not explicitly mention a specific study title or authors, so the \"STUDY\" type is inferred based on the context of the clinical findings.)", {"Drug": ["venlafaxine"], "Pathology": ["the radiological abnormalities"], "Parameter": ["LVEF"]}]], [315, "This was an important case of drug-induced cardiopulmonary toxicity.", [" {\"STUDY\": \"case study\"}\n\n\"drug-induced cardiopulmonary toxicity\"\n{\"CONDITION\": \"cardiopulmonary toxicity\"}\n{\"DRUG\": \"drug\"}\n{\"REACTION\": \"toxicity\"}", {"Pathology": ["drug-induced cardiopulmonary toxicity"]}]], [316, "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation.", [" {\"STUDY\": \"Clinical Observation\", \"DIP\": \"Drug-Induced Polyarthritis\", \"treatment\": \"Drug Therapy\"}\n{\"STUDY\": \"Observational Study\", \"reversibility\": \"Drug-Induced Polyarthritis\", \"drug discontinuation\": \"Drug Therapy\"}", {"Pathology": ["DIP", "DIP"], "Duration": ["hours to months"]}]], [317, "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine.", [" {\"STUDY\": \"clinical case\", \"DRUG\": \"venlafaxine\"}", {"Pathology": ["cardiopulmonary toxicity"], "Drug": ["venlafaxine"]}]], [318, "Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo LBA, estudos de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito e bi\u00f3psia mioc\u00e1rdica.", [" {\"STUDY\": \"Clinical study\", \"METHODOLOGY\": \"Laboratory, Imaging, Autoimmune disease detection, Cardiac catheterization, Myocardial biopsy\"}\n\n{\"STUDY_DESIGN\": \"Comprehensive study\", \"STUDY_SETTING\": \"Not specified\"}\n\n{\"STUDY_SUBJECTS\": \"Not specified\"}\n\n{\"STUDY_OUTCOMES\": \"Not specified\"}\n\n{\"STUDY_LOCATION\": \"Not specified\"}\n\n{\"STUDY_RESOURCES\": \"Not specified\"}\n\n{\"STUDY_TIMELINE\": \"Not specified\"}\n\n{\"STUDY_REVIEW\": \"Not specified\"}\n\n{\"STUDY_RECOMMENDATIONS\": \"Not specified\"}\n\n{\"STUDY_FUNDING\": \"Not specified\"}\n\n{\"STUDY_CONFLICTS_OF_INTEREST\": \"Not specified\"}\n\n{\"STUDY_REVIEWER\": \"Not specified\"}\n\n{\"STUDY_CONSENT\": \"Not specified\"}\n\n{\"STUDY_REGISTRATION\": \"Not specified\"}\n\n{\"STUDY_DESIGN_TYPE\": \"Not specified\"}\n\n{\"METHODOLOGY_TYPE\": \"Not specified\"}\n\n{\"METHODOLOGY_APPLICATION\": \"Not specified\"}\n\n{\"METHODOLOGY_APPLICATION_TYPE\": \"Not specified\"}\n\n{\"METHODOLOGY_APPLICATION_SUBJECT\": \"Not specified\"}\n\n{\"METHODOLOGY_APPLICATION_SUBJECT_TYPE\": \"Not specified\"}\n\n{\"METHODOLOGY_APPLICATION_SUBJECT_LOCATION\": \"Not specified\"}\n\n{\"METHODOLOGY_APPLICATION_SUBJECT_RESOURCES\": \"Not specified\"}\n\n{\"METHODOLOGY_APPLICATION_SUBJECT_TIMELINE\": \"Not specified\"}\n\n{\"METHODOLOGY_APPLICATION_SUBJECT_REVIEW\": \"Not specified\"}\n\n{\"METHODOLOGY_APPLICATION_SUBJECT_RECOMMENDATIONS\": \"", {}]], [319, "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente.", [" {\"STUDY\": \"Clinical study\", \"MEDICAL TREATMENT\": \"administra\u00e7\u00e3o circunstancial\", \"DRUG\": \"inibidores da isoenzima CYP2D6\", \"DRUG METABOLISM\": \"fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6\", \"DRUG NAME\": \"venlafaxina\"}\n\n{\"STUDY\": \"Clinical study\", \"DRUG\": \"venlafaxina\"}\n\n{\"STUDY\": \"Clinical study\", \"DRUG METABOLISM\": \"fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6\", \"DRUG NAME\": \"venlafaxina\"}\n\n{\"STUDY\": \"Clinical study\", \"DRUG\": \"venlafaxina\", \"DRUG METABOLISM\": \"fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6\"}\n\n{\"DRUG\": \"venlafaxina\", \"DRUG METABOLISM\": \"fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6\"}", {}]], [320, "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais.", [" {\"STUDY\": \"Clinical study\", \"PARTICIPANTS\": \"Os par\u00e2metros renais e hep\u00e1ticos\", \"MEASUREMENTS\": \"as prote\u00ednas do complemento e o sedimento urin\u00e1rio\", \"FINDINGS\": \"estavam todos normais\"}\n\n{\"STUDY\": \"Clinical study\", \"ORGANS\": \"par\u00e2metros renais e hep\u00e1ticos\", \"PROTEINS\": \"prote\u00ednas do complemento\", \"SPECIES\": \"humano\"}\n\n{\"STUDY\": \"Clinical study\", \"MEASUREMENTS\": \"prote\u00ednas do complemento e o sedimento urin\u00e1rio\", \"RESULTS\": \"estavam todos normais\"}\n\n{\"STUDY\": \"Clinical study\", \"BIOLOGICAL_PARAMETERS\": \"par\u00e2metros renais e hep\u00e1ticos\", \"URINARY_PARAMETERS\": \"sedimento urin\u00e1rio\"}\n\n{\"STUDY\": \"Clinical study\", \"ORGANS\": \"renais e hep\u00e1ticos\", \"BIOLOGICAL_PARAMETERS\": \"par\u00e2metros renais e hep\u00e1ticos\"}\n\n{\"STUDY\": \"Clinical study\", \"BIOLOGICAL_PARAMETERS\": \"par\u00e2metros renais e hep\u00e1ticos\", \"ORGANS\": \"renais e hep\u00e1ticos\"}\n\n{\"STUDY\": \"Clinical study\", \"MEASUREMENTS\": \"sedimento urin\u00e1rio\", \"URINARY_PARAMETERS\": \"sedimento urin\u00e1rio\"}\n\n{\"STUDY\": \"Clinical study\", \"MEASUREMENTS\": \"sedimento urin\u00e1rio\", \"URINARY_PARAMETERS\": \"sedimento urin\u00e1rio\"}\n\n{\"STUDY\": \"Clinical study\", \"BIOLOGICAL_PARAMETERS\": \"par\u00e2metros renais e hep\u00e1ticos\", \"URINARY_PARAMETERS\": \"sedimento urin\u00e1rio\"}\n\n{\"STUDY\": \"Clinical study\", \"BIOLOGICAL_PARAMETERS\": \"par\u00e2metros renais e hep\u00e1ticos\", \"ORGANS\":", {}]], [321, "A maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.", [" {\"STUDY\": \"Unspecified study\"}\n\n\"medicamentos card\u00edacos\": \"Cardiovascular drugs\"\n\n\"descontinuada\": \"Discontinued drugs\"", {}]], [322, "O caso ocorreu em uma paciente previamente h\u00edgida de 35 anos de idade que foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas.", [" {\"STUDY\": \"clinical case study\", \"PATIENT\": \"35-year-old woman\", \"HEALTH_STATUS\": \"previously healthy\", \"AGE\": \"35 years old\", \"MEDICAL_CONDITION\": \"unknown\", \"STUDY_TYPE\": \"investigation\", \"STUDY_DESIGN\": \"exhaustive\", \"STUDY_OUTCOME\": \"exclusion of other causes\"}\n\n(Note: The original text does not explicitly mention a specific study title or authors, so those fields are left empty.)", {}]], [323, "Apoio financeiro: Nenhum.", [" {\"STUDY\": \"Not specified\"}\n\nNote: The provided text does not describe a specific study, so there is no information to extract regarding the type of study. The mention of \"Apoio financeiro\" (financial support) does not directly refer to a study entity.", {}]], [324, "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms.", [" {\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL AGENT\": \"red ginseng and herb extract complex (RHC)\"}\n\n(Note: The original text does not explicitly mention a specific study type, but it implies a clinical trial or safety evaluation. Therefore, \"clinical trial\" is a reasonable inference based on the context.)", {"Herb name": ["red ginseng", "herb extract complex (RHC)"], "Pathology": ["menopausal symptoms"]}]], [325, "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.", [" {\"EXCLUSION CRITERIA\": [\"women who became menopausal from surgery or chemotherapy\", \"women who underwent hysterectomy\", \"women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers\", \"women with uncontrolled hypertension\", \"women with uncontrolled diabetes mellitus\", \"uncontrolled thyroid patients\", \"women who have had severe migraines within the last year\", \"women with atypical uterine bleeding after 1 year of menopause\", \"women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs, bisphosphonates, or calcitonin within 4 weeks\", \"women who have taken plant hormones in the form of supplements or medicines within 4 weeks\", \"women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids, and blood circulation within 4 weeks\", \"women who were administered female hormone formulations within 6 months\", \"women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit\", \"women with creatinine levels exceeding 2 times the laboratory's normal upper limit\", \"women with hypersensitivity to the test drug or its ingredients\", \"women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS))\", \"women who have participated in other clinical trials within 1 month of the start of the current study\", \"women who are planning to participate in another clinical trial during the study period\"]}", {"Sex": ["women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "female", "women", "women", "women", "women", "women", "women"], "Pathology": ["menopausal", "surgery", "hysterectomy", "endometrial hyperplasia", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "uncontrolled diabetes mellitus", "diabetes", "uncontrolled thyroid", "severe migraines", "thromboembolism", "cerebrovascular disease", "cardiovascular disease", "uterine bleeding", "menopause", "drug or alcohol abuse", "hypersensitivity"], "Drug": ["chemotherapy", "sleep inducers", "antidepressants", "selective estrogen receptor modulators", "antihyperlipidemic drugs", "antithrombotic drugs", "Aspirin", "Warfarin", "Clopidogrel", "bisphosphonates", "calcitonin"], "Amount": ["160/100\u00a0mmHg", "180\u00a0mg/dL"], "Parameter": ["fasting blood sugar", "triglyceride", "cholesterol", "alanine aminotransferase (ALT)", "aspartate aminotransferase (AST)", "creatinine"], "Duration": ["within 3\u00a0mo", "within the last year", "after 1\u00a0yr", "within 4\u00a0wk", "within 4\u00a0wk", "within 4\u00a0wk", "within 6\u00a0mo", "more than 10\u00a0h", "within 3\u00a0mo", "women", "within 1\u00a0mo"], "Herb name": ["isoflavone", "flaxseed", "pomegranate", "horseradish", "white sorghum", "red shamrock", "red ginseng"], "Study": ["clinical trials", "clinical trial"]}]], [326, "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included.", [" {\"STUDY\": \"Clinical study\", \"ADVERSE REACTION\": \"adverse reaction\", \"TEST SUBSTANCE\": \"test substance\", \"Drug\": \"name of the drug other than the test substance\", \"TREATMENT\": \"treatment of adverse reactions\"}\n\n(Note: The provided text does not explicitly mention specific study names, so \"Type of study described\" is generalized as \"Clinical study\". If specific study names were mentioned, they would be listed here following the same format.)", {"Pathology": ["adverse reactions", "adverse reaction", "adverse reactions"]}]], [327, "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups.", [" {\"STUDY\": \"Clinical study\", \"DEMOGRAPHIC INFORMATION\": \"demographic information and characteristics\", \"CONSUMPTION GROUPS\": \"intake groups\"}\n\n(Note: The original text does not explicitly mention a specific study title or authors, so the \"STUDY\" type is inferred based on the context of the examination of demographic information and consumption groups.)", {}]], [328, "p-value by Fisher's exact test.", [" {\"STUDY\": \"Clinical trial\", \"METHODOLOGY\": \"Fisher's exact test\", \"PUBLICATION\": \"Scientific article\", \"PHARMACOLOGY\": \"Pharmacology\"}\n\n{\"PHARM_DRUG\": \"Not specified\", \"PHARM_SIDE_EFFECT\": \"Not specified\", \"PHARM_DOSAGE\": \"Not specified\", \"PHARM_EXAMPLE\": \"Not specified\"}\n\n{\"STUDY_SOURCE\": \"Scientific article\"}", {}]], [329, "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group.", [" {\"STUDY\": \"clinical trial\", \"SUBJECTS\": \"subject with pruritus and hot flash, subject with headache\", \"PLACEBO GROUP\": \"placebo group\"}\n\n{\"STUDY\": \"clinical trial\", \"TREATMENT\": \"administration\", \"RESPONSE\": \"fully recovered\"}\n\n{\"STUDY\": \"clinical trial\", \"GROUP\": \"placebo group\"}", {"Pathology": ["pruritus", "hot flash", "headache"]}]], [330, "It is noteworthy that no severe adverse reactions were observed in this study.", [" {\"STUDY\": \"clinical trial\", \"ADVERSE REACTIONS\": \"severe adverse reactions\", \"REACTION\": \"severe adverse reactions\"}", {"Pathology": ["adverse reactions"]}]], [331, "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects.", [" {\"STUDY\": \"longitudinal cohort study\", \"SUBJECT\": \"menopausal subjects\", \"MEDICAL_CONDITION\": \"long-term safety of RHC intake\", \"MEDICAL_SUBSTANCE\": \"RHC\"}\n\n(Note: The original text does not explicitly mention a specific study title, but it describes a type of study, which is a longitudinal cohort study. The subjects are menopausal subjects, and the medical condition is the long-term safety of RHC intake. RHC refers to a medical substance, which is not specified in the text but is implied to be the subject of the study.)", {"Herb name": ["RHC"], "Pathology": ["menopausal"]}]], [332, "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation.", [" {\"STUDY\": \"inhibition kinetic study\", \"PLOT\": \"Dixon plot\", \"PLOT\": \"Lineweaver-Burk plot\", \"INHIBITOR\": \"celastrol\", \"MEDIATED_GLUCOROONIDATION\": \"UGT1A1-mediated 4-MU glucuronidation\", \"COMPETITIVE_INHIBITOR\": \"UGT2B7-catalyzed 4-MU glucuronidation\"}", {"Study": ["inhibition kinetic study"], "Herb name": ["celastrol"], "Target": ["UGT1A1-mediated 4-MU glucuronidation", "UGT2B7-catalyzed 4-MU glucuronidation"]}]], [333, "Therefore, evaluation of inhibition of compounds towards UGT isoforms was always carried out using recombinant UGTs and nonspecific substrates [19,20,21].", [" {\"STUDY\": \"Research studies\", \"RECOMDIBLE UGTs\": \"recombinant UGTs\", \"NONSPECIFIC SUBSTRATES\": \"nonspecific substrates\"}\n\n{\"SOURCE\": \"scientific articles\"}\n{\"JOURNAL\": \"Journal of Pharmacology and Experimental Therapeutics\", \"ARTICLE_REFERENCE\": \"[19,20,21]\"}\n{\"PUBLICATION_YEAR\": \"Not specified\"}\n{\"PUBLICATION_SOURCE\": \"Not specified\"}\n{\"PHARMACOLOGIC_SUBJECT\": \"UGT isoforms\"}\n{\"PHARMACOLOGIC_OBJECT\": \"compounds\"}\n{\"PHARMACOLOGIC_SUBSTRATE\": \"nonspecific substrates\"}\n{\"PHARMACOLOGIC_REACTANT\": \"compounds\"}\n{\"PHARMACOLOGIC_REACTION\": \"inhibition\"}\n{\"PHARMACOLOGIC_OUTCOME\": \"not specified\"}\n{\"PHARMACOLOGIC_STUDY_TYPE\": \"not specified\"}", {"Target": ["UGT isoforms", "UGTs"]}]], [334, "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive.", [" {\"STUDY\": \"research study\", \"authors\": \"Dixon, Lineweaver\", \"study type\": \"Dixon and Lineweaver-Burk plots\", \"inhibition type\": \"competitive\"}\n\n{\"MEDICAL TERM\": \"inhibition type\"}\n\n{\"METHODOLOGY\": \"Dixon and Lineweaver-Burk plots\"}\n\n{\"METHODOLOGY\": \"vertical axis\"}\n\n{\"METHODOLOGY\": \"second quadrant\"}\n\n{\"PHARMACOLOGICAL CONCEPT\": \"competitive inhibition\"}", {}]], [335, "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM.", [" {\"STUDY\": \"Clinical study\", \"METHODOLOGY\": \"Slope vs. celastrol concentration\", \"PHARMACOLOGICAL_MEASURE\": \"inhibition kinetic parameter (Ki)\", \"MEASUREMENT_CONCENTRATION\": \"0.49 \u03bcM\"}", {"Herb name": ["celastrol"]}]], [336, "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24].", [" {\"STUDY\": \"Research article\", \"JOURNAL\": \"unknown\", \"ARTICLE_NUMBER\": \"24\", \"GENES\": \"UGT1A6\", \"PROTEINS\": \"UGT1A6\", \"LIVER\": \"human liver\", \"MEASUREMENT\": \"120-fold variability\", \"ENZYME\": \"UGT1A6\", \"REACTANT\": \"serotonin\", \"PRODUCT\": \"glucuronidation\"}\n\n{\"STUDY\": \"Research article\", \"JOURNAL\": \"unknown\", \"ARTICLE_NUMBER\": \"24\", \"GENES\": \"unknown\", \"PROTEINS\": \"unknown\", \"LIVER\": \"human liver\", \"MEASUREMENT\": \"13-fold variability\", \"ENZYME\": \"unknown\", \"REACTANT\": \"serotonin\", \"PRODUCT\": \"glucuronidation\"}", {"Target": ["UGT1A6"]}]], [337, "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25].", [" {\"STUDY\": \"clinical study\", \"DRUG\": \"clofibric acid, valproic acid\", \"PUBLICATION\": \"25\"}", {"Drug": ["valproic acid"]}]], [338, "The previous study performed by Du et al.", [" {\"STUDY\": \"previous study\"}\n\nDu et al.", {}]], [339, "Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation.", [" {\"STUDY\": \"inhibition kinetic analysis\", \"TARGET ENZYME\": \"UGT2B7\", \"SUBSTANCE\": \"celastrol (Cela)\", \"METHOD\": \"4-MU glucuronidation\"}\n\n{\"STUDY\": \"inhibition kinetic analysis\", \"SUBSTANCE\": \"celastrol (Cela)\", \"ANALOGY\": \"4-MU glucuronidation\"}", {"Herb name": ["celastrol (Cela)"], "Target": ["UGT2B7-catalyzed 4-MU glucuronidation"]}]], [340, "The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8].", [" {\"STUDY\": \"Research studies\", \"Paper References\": [\"[3]\", \"[4]\", \"[5]\", \"[6]\", \"[7]\", \"[8]\"]}\n\n\"ginseng\"\n\n\"anti-diabetic\"\n\n\"anti-inflammatory effect\"\n\n\"anti-oxidative response\"\n\n\"chronic liver disease\"\n\n\"[3]\", \"[4]\", \"[5]\", \"[6]\", \"[7]\", \"[8]\" (representing the cited references)\n\n{\"PHARMACOLOGICAL AGENT\": \"ginseng\"}", {"Herb name": ["ginseng"], "Pathology": ["chronic liver disease"]}]], [341, "In case of ginseng interactions, it was reported that no herb\u2013drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5\u20132.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].", [" {\"STUDY\": \"clinical study\", \"HERB\": \"Korean red ginseng extract\", \"DRUG\": \"probe substrates for five cytochrome P450 (CYP) enzymes\", \"ANIMAL\": \"mouse\"}", {"Herb name": ["ginseng", "red ginseng extract (RGE)"], "Ethnic group": ["Korean"], "Amount": ["0.5\u20132.0 g/kg"], "Target": ["cytochrome P450 (CYP) enzymes", "CYP1A2, 2C9, 2C19, 2D6, 3A"]}]], [342, "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides.", [" {\"STUDY\": \"clinical study\", \"DRUG\": \"valsartan\", \"DRUG_INTERACTION\": \"herb-drug interaction\", \"HERB\": \"ginsenosides\", \"DRUG_TRANSPORTER\": \"OATP (human) or Oatp (rat)\"}\n\n\nNote: The term \"model drug\" implies a type of study, but since the format requested is to find specific entities, I've identified the primary entities related to the study. If you need a specific type of study identified, please let me know.", {"Drug": ["valsartan", "valsartan"], "Target": ["OATP", "Oatp"], "Herb name": ["RGE", "ginsenosides"]}]], [343, "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8).", [" {\"STUDY\": \"clinical study\", \"RGE\": \"Rosmarinus Glauca Extract\", \"Rc\": \"Rosmarinus Glauca\", \"valsartan\": \"medication\"}\n\n{\"STUDY_DESCRIPTION\": \"clinical study\", \"RGE\": \"Rosmarinus Glauca Extract\", \"Rc\": \"Rosmarinus Glauca\", \"valsartan\": \"medication\"}\n\n{\"INTERACTION_ENTITY\": \"herb-drug interactions\"}\n\n{\"MEDICATION\": \"valsartan\"}\n\n{\"FIGURE\": \"Figure\"}", {"Herb name": ["RGE", "Rc"], "Drug": ["valsartan"]}]], [344, "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B).", [" {\"STUDY\": \"Clinical study\", \"TARGET_COMPOUND\": \"tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc)\", \"MEASURED_COMPONENT\": \"unbound fraction\", \"ORGANS_EXAMINED\": \"rat plasma, rat liver\", \"MEASUREMENT_RANGE\": \"0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver\", \"MEASUREMENT_TYPE\": \"concentration\", \"MEASUREMENT_UNIT\": \"\u03bcM\", \"FIGURE\": \"Figure 9B\"}\n\nNote: The \"STUDY\" field is inferred as a clinical study due to the context of plasma concentration and unbound fraction measurements in biological samples. However, the text does not explicitly mention a study design or methodology, so this is an assumption based on the context.", {"Herb name": ["tri-glycosylated PPD-type ginsenosides", "Rb1", "Rb2", "Rc"]}]], [345, "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan.", [" {\"STUDY\": \"Clinical Study\", \"Blood Samples\": \"blood samples\", \"Plasma Samples\": \"plasma samples\", \"Analysis\": \"analysis of ginsenosides and valsartan\"}\n\n{\"SUBSTANCE\": \"ginsenosides\", \"Drug\": \"valsartan\"}\n\n{\"TECHNIQUE\": \"centrifugation\", \"Speed\": \"16,000\u00d7 g\", \"Duration\": \"10 min\", \"Storage Condition\": \"\u221280 \u00b0C\", \"Storage Volume\": \"50 \u03bcL\"}", {"Herb name": ["ginsenosides"], "Drug": ["valsartan"]}]], [346, "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing.", [" {\"STUDY\": \"Clinical Study\", \"VALSARTAN\": \"Drug\", \"RETRO-ORBITAL VEIN\": \"Anatomical Location\", \"TIME POINTS\": \"Time Intervals\"}\n\n{\"VALSARTAN\": \"Drug\", \"BLOOD SAMPLES\": \"Biological Samples\", \"RETRO-ORBITAL VEIN\": \"Anatomical Location\", \"TIME POINTS\": \"Time Intervals\"}\n\n{\"VALSARTAN\": \"Drug\", \"DOSING\": \"Administration Method\", \"TIME POINTS\": \"Time Intervals\"}\n\n{\"VALSARTAN\": \"Drug\", \"BLOOD SAMPLES\": \"Biological Samples\", \"TIME POINTS\": \"Time Intervals\"}\n\n{\"VALSARTAN\": \"Drug\", \"BLOOD SAMPLES\": \"Biological Samples\", \"TIME POINTS\": \"Time Intervals\"}\n\n{\"VALSARTAN\": \"Drug\", \"BLOOD SAMPLES\": \"Biological Samples\", \"TIME POINTS\": \"Time Intervals\"}\n\n{\"VALSARTAN\": \"Drug\", \"BLOOD SAMPLES\": \"Biological Samples\", \"TIME POINTS\": \"Time Intervals\"}\n\n{\"VALSARTAN\": \"Drug\", \"BLOOD SAMPLES\": \"Biological Samples\", \"TIME POINTS\": \"Time Intervals\"}\n\n{\"VALSARTAN\": \"Drug\", \"BLOOD SAMPLES\": \"Biological Samples\", \"TIME POINTS\": \"Time Intervals\"}\n\n{\"VALSARTAN\": \"Drug\", \"BLOOD SAMPLES\": \"Biological Samples\", \"TIME POINTS\": \"Time Intervals\"}\n\n{\"VALSARTAN\": \"Drug\", \"BLOOD SAMPLES\": \"Biological Samples\", \"TIME POINTS\": \"Time Intervals\"}\n\n{\"VALSARTAN\": \"Drug\", \"BLOOD SAMPLES\": \"Biological Samples\", \"TIME POINTS\": \"Time Intervals\"}\n\n{\"VALSARTAN\": \"Drug\", \"BLOOD SAMPLES\": \"Biological Samples\", \"TIME P", {"Drug": ["valsartan"]}]], [347, "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).", [" {\"STUDY\": \"clinical trial\", \"SUBJECT\": \"rat plasma\", \"COMPOSED_OF\": [\"Rb1\", \"Rb2\", \"Rc\", \"Rd\", \"PPD\", \"PPT\"], \"TREATMENT\": \"red ginseng extract (RGE)\", \"DURATION\": \"1-week repeated administration\"}", {"Herb name": ["ginsenosides", "Rb1", "Rb2", "Rc", "Rd", "PPD", "PPT", "red ginseng extract (RGE)"], "Duration": ["1-week"]}]], [348, "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats.", [" {\"STUDY\": \"clinical pharmacokinetic study\", \"SUBJECT\": \"rats\", \"MEDICAL TREATMENT\": \"valsartan\", \"DOSAGE\": \"1 mg/kg\", \"METHOD\": \"intravenous injection\", \"TIME PERIOD\": \"0 to 48 h\", \"PHARMACOKINETIC PARAMETER\": \"AUC\", \"PHARMACOKINETIC PARAMETER\": \"C\", \"PHARMACOKINETIC PARAMETER\": \"Pharmacokinetic parameters\"}\n\n{\"STUDY\": \"clinical pharmacokinetic study\", \"MEDICAL TREATMENT\": \"valsartan\", \"DOSAGE\": \"1 mg/kg\", \"METHOD\": \"intravenous injection\", \"TIME PERIOD\": \"0 to 48 h\", \"PHARMACOKINETIC PARAMETER\": \"AUC\", \"PHARMACOKINETIC PARAMETER\": \"C\", \"PHARMACOKINETIC PARAMETER\": \"Pharmacokinetic parameters\", \"PHARMACOKINETIC PARAMETER\": \"Rc\"}\n\n{\"STUDY\": \"clinical pharmacokinetic study\", \"SUBJECT\": \"rats\", \"MEDICAL TREATMENT\": \"valsartan\", \"DOSAGE\": \"1 mg/kg\", \"METHOD\": \"intravenous injection\", \"TIME PERIOD\": \"0 to 48 h\", \"PHARMACOKINETIC PARAMETER\": \"AUC\", \"PHARMACOKINETIC PARAMETER\": \"C\", \"PHARMACOKINETIC PARAMETER\": \"Pharmacokinetic parameters\", \"PHARMACOKINETIC PARAMETER\": \"Rc\", \"PLACES\": \"intravenous\"}", {"Parameter": ["AUC: area under the plasma"], "Drug": ["valsartan", "valsartan"], "Herb name": ["Rc"], "Amount": ["1 mg/kg"]}]], [349, "Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14].", [" {\"STUDY\": \"research study\", \"HERBAL PRODUCTS\": \"herbal products\", \"EFFICACY\": \"efficacy\", \"SAFETY\": \"safety\", \"DRUG INTERACTIONS\": \"drug interactions\"}\n{\"SOURCE\": \"scientific article\"}\n{\"ARTICLE_REFERENCE\": \"14\"}", {"Herb name": ["herbal products"], "Parameter": ["efficacy and safety"]}]], [350, "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted.", [" {\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"visit duration\", \"TIMEFRAME\": \"\u00b11 day\"}", {"Duration": ["\u00b11\u00a0day"]}]], [351, "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.", [" {\"STUDY\": \"Clinical trial\"}\n{\"PARTICIPANTS\": \"study participants\"}\n{\"TREATMENT PHASES\": \"treatment phases\"}\n{\"RANDOMIZATION\": \"randomisation\"}\n{\"PHASE 1\": \"first treatment phase\"}\n{\"PHASE 2\": \"second treatment phase\"}", {"Cohort": ["a total of 24 subjects"]}]], [352, "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3].", [" {\"STUDY\": \"Clinical Study\", \"Oxidative Stress\": \"Condition\", \"PCOS Patients\": \"Population\", \"Circulating Serum Markers\": \"Biological Measures\", \"Catalase (CAT)\": \"Enzyme\", \"Glutathione Peroxidase (GPx)\": \"Enzyme\", \"Superoxide Dismutase (SOD)\": \"Enzyme\", \"Malondialdehyde (MDA)\": \"Biomarker\"}", {"Pathology": ["Oxidative stress", "PCOS"], "Parameter": ["catalase (CAT)", "glutathione peroxidase (GPx)", "superoxide dismutase (SOD)", "malondialdehyde (MDA)"]}]], [353, "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13].", [" {\"STUDY\": \"Research article\", \"PHARMACOLOGICAL AGENT\": \"herbal agent\", \"ANTIOXIDANT PROPERTIES\": \"antioxidant\", \"POLYPHENOLIC PROPERTIES\": \"polyphenolic\", \"DISEASE\": \"PCOS\", \"DEFICIENCY\": \"antioxidant deficiency\"}\n\n{\"STUDY\": \"Research article\", \"JOURNAL\": \"not specified\", \"ARTICLE NUMBER\": \"13\"}\n\n{\"STUDY\": \"Research article\", \"PHARMACOLOGICAL AGENT\": \"herbal agent\", \"TREATMENT\": \"treat\", \"POLICY\": \"not specified\", \"DISEASE\": \"PCOS\", \"DEFICIENCY\": \"antioxidant deficiency\"}\n\n{\"STUDY\": \"Research article\", \"PHARMACOLOGICAL AGENT\": \"herbal agent\", \"ANTIOXIDANT PROPERTIES\": \"antioxidant\", \"POLYPHENOLIC PROPERTIES\": \"polyphenolic\", \"DISEASE\": \"PCOS\", \"SIDE EFFECTS\": \"not specified\"}\n\n{\"STUDY\": \"Research article\", \"PHARMACOLOGICAL AGENT\": \"herbal agent\", \"ANTIOXIDANT PROPERTIES\": \"antioxidant\", \"POLYPHENOLIC PROPERTIES\": \"polyphenolic\", \"DISEASE\": \"PCOS\", \"TREATMENT\": \"treat\"}\n\n{\"STUDY\": \"Research article\", \"PHARMACOLOGICAL AGENT\": \"herbal agent\", \"ANTIOXIDANT PROPERTIES\": \"antioxidant\", \"POLYPHENOLIC PROPERTIES\": \"polyphenolic\", \"DISEASE\": \"PCOS\", \"TREATMENT\": \"treat\", \"SIDE EFFECTS\": \"not significant\"}\n\n{\"STUDY\": \"Research article\", \"PHARMACOLOGICAL AGENT\": \"herbal agent\", \"ANTIOXIDANT PROPERTIES\": \"antiox", {"Herb name": ["polyphenolic"], "Pathology": ["side effects", "PCOS"]}]], [354, "Furthermore, it decreases insulin and blood glucose markedly [17].", [" {\"STUDY\": \"Clinical trial\", \"MEDICATION\": \"metformin\", \"EFFECT\": \"decreases insulin and blood glucose\", \"SOURCE\": \"reference [17]\"}\n{\"STUDY\": \"Research article\"}\n{\"STUDY\": \"Scientific article\"}\n{\"STUDY\": \"Pharmacological study\"}\n{\"STUDY\": \"Systematic review\"}\n{\"STUDY\": \"Meta-analysis\"}\n{\"STUDY\": \"Clinical trial\"}\n{\"MEDICATION\": \"metformin\"}\n{\"EFFECT\": \"decreases insulin and blood glucose\"}\n{\"SOURCE\": \"reference [17]\"}", {"Parameter": ["insulin", "blood glucose"]}]], [355, "Citrus Sinensis (L.) Osbeck from Rutaceae family mainly contains hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool), and these phenolic bioactive compounds indicate considerable cytoprotective effects against OS [18].", [" {\"STUDY\": \"Research article\", \"ORGANISM\": \"Citrus Sinensis (L.)\", \"FAMILY\": \"Rutaceae\", \"COMPOUNDS\": \"hesperidin, polymethoxylated flavonoids (PMF), terpenoids (limonene, linalool)\", \"PHENOLIC_COMPOUNDS\": \"hesperidin, polymethoxylated flavonoids (PMF), terpenoids (limonene, linalool)\", \"BIOACTIVE_COMPOUNDS\": \"hesperidin, polymethoxylated flavonoids (PMF), terpenoids (limonene, linalool)\", \"EFFECTS\": \"cytoprotective effects against oxidative stress (OS)\"}\n\n{\"STUDY\": \"Research article\", \"SOURCE\": \"Rutaceae family\", \"COMPOUNDS\": \"hesperidin, polymethoxylated flavonoids (PMF), terpenoids (limonene, linalool)\"}\n\n{\"STUDY\": \"Research article\", \"ORGANISM\": \"Citrus Sinensis (L.)\", \"FAMILY\": \"Rutaceae\", \"COMPOUNDS\": \"hesperidin, polymethoxylated flavonoids (PMF), terpenoids (limonene, linalool)\"}\n\n{\"STUDY\": \"Research article\", \"EFFECTS\": \"cytoprotective effects against oxidative stress (OS)\"}\n\n{\"STUDY\": \"Research article\", \"COMPOUNDS\": \"hesperidin, polymethoxylated flavonoids (PMF), terpenoids (limonene, linalool)\"}\n\n{\"STUDY\": \"Research article\", \"PHENOLIC_COMPOUNDS\": \"hesperidin, polymethoxylated flavonoids (PMF), terpenoids (limonene, linalool)\"}\n\n{\"STUDY\": \"Research article\", \"ORGANISM\": \"Citrus Sinensis (L.)\", \"FAMILY\": \"Rutaceae\", \"COMPOUNDS\": \"hesperidin, polymeth", {"Herb name": ["Citrus Sinensis (L.) Osbeck from Rutaceae family", "hesperidin", "polymethoxylated flavonoids (PMF)", "terpenoids", "limonene", "linalool", "phenolic"], "Pathology": ["OS"]}]], [356, "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19].", [" {\"STUDY\": \"Research Study\", \"PUBLICATION\": \"Journal Article\", \"JOURNAL\": \"Not Specified\", \"ARTICLE_REFERENCE\": \"19\", \"PHARMACOGENETIC_COMPONENT\": \"Hesperidin\", \"SOURCE_PLANT\": \"C. sinensis (Chinese hawthorn)\", \"ANTIOXIDANT_METRICS\": \"SOD (Superoxide Dismutase), CAT (Catalase)\", \"MAO_METRIC\": \"MDA (Malondialdehyde)\"}\n\nNote: The \"JOURNAL\" field is left empty as the specific journal name was not provided in the text.", {"Herb name": ["hesperidin", "C. sinensis"], "Parameter": ["SOD", "CAT", "MDA"]}]], [357, "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses.", [" {\"STUDY\": \"experimental study\", \"EXTRACT\": \"methanolic extract\", \"REAGENT\": \"Folin-Ciocalteau reagent\", \"ANALYSIS\": \"Total flavonoids\", \"APPARATUS\": \"Clevenger type apparatus\", \"SUBSTANCE\": \"herbal mixture\", \"METHOD\": \"hydrodistillation\"}", {"Extraction process": ["methanolic extract"], "Herb name": ["flavonoids"]}]], [358, "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL).", [" {\"STUDY\": \"analytical study\", \"METHODOLOGY\": \"calibration curve construction\", \"STANDARD\": \"1,1\u2032,3,3\u2032-tetramethoxypropane\", \"MEASUREMENT\": \"concentration (pg/mL)\", \"REFERENCE\": \"1.32 pg/mL\"}\n\nNote: The \"reference value\" is not explicitly mentioned as a cited entity in the text, but it is implied as part of the context. However, since the instruction asks for explicit mentions, it is not included in the output. If the format allows for implied entities, it could be included as follows:\n\n{\"REFERENCE\": \"1.32 pg/mL\"}\n\n{\"STUDY\": \"analytical study\", \"METHODOLOGY\": \"calibration curve construction\", \"STANDARD\": \"1,1\u2032,3,3\u2032-tetramethoxypropane\", \"MEASUREMENT\": \"concentration (pg/mL)\", \"CONCENTRATION_RANGE\": \"0.54\u20131.32 pg/mL\"}", {}]], [359, "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable.", [" {\"STUDY\": \"Clinical study\", \"MEASURES\": \"Descriptive statistics, frequency and percentage, measures of central tendency and dispersion, mean and standard deviation (SD)\"}\n\n{\"MEASURES\": \"Descriptive statistics, frequency and percentage, measures of central tendency and dispersion, mean and standard deviation (SD)\"}\n\n{\"MEASURES\": \"Descriptive statistics, frequency and percentage, measures of central tendency and dispersion, mean and standard deviation (SD)\"}\n\n{\"MEASURES\": \"Descriptive statistics, frequency and percentage, measures of central tendency and dispersion, mean and standard deviation (SD)\"}\n\n{\"MEASURES\": \"Descriptive statistics, frequency and percentage, measures of central tendency and dispersion, mean and standard deviation (SD)\"}\n\n{\"MEASURES\": \"Descriptive statistics, frequency and percentage, measures of central tendency and dispersion, mean and standard deviation (SD)\"}\n\n{\"MEASURES\": \"Descriptive statistics, frequency and percentage, measures of central tendency and dispersion, mean and standard deviation (SD)\"}\n\n{\"MEASURES\": \"Descriptive statistics, frequency and percentage, measures of central tendency and dispersion, mean and standard deviation (SD)\"}\n\n{\"MEASURES\": \"Descriptive statistics, frequency and percentage, measures of central tendency and dispersion, mean and standard deviation (SD)\"}\n\n{\"MEASURES\": \"Descriptive statistics, frequency and percentage, measures of central tendency and dispersion, mean and standard deviation (SD)\"}\n\n{\"MEASURES\": \"Descriptive statistics, frequency and percentage, measures of central tendency and dispersion, mean and standard deviation (SD)\"}\n\n{\"MEASURES\": \"Descriptive statistics, frequency and percentage, measures of central tendency and dispersion, mean and standard deviation (SD)\"}\n\n{\"MEASURES\": \"Descriptive statistics, frequency and percentage, measures of central tendency and dispersion, mean and standard deviation (SD)\"}\n\n{\"MEASURES\": \"Descriptive statistics, frequency and percentage, measures of central tendency and dispersion, mean and standard deviation (SD)\"}\n\n{\"MEASURES\": \"Descriptive statistics", {}]], [360, "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25).", [" {\"STUDY\": \"Clinical Trial\", \"GROUPS\": [\"group 1: CC\", \"group 2: herbal mixture\", \"group 3: CC with herbal mixture\"], \"PARTICIPANTS\": \"75\", \"GROUP SIZE\": {\"group 1\": \"25\", \"group 2\": \"25\", \"group 3\": \"25\"}}\n\n(\"CC\" refers to Control Condition)\n\n{\"STUDY\": \"Clinical Trial\", \"CONDITIONS\": [\"CC\"], \"TREATMENTS\": [\"herbal mixture\"], \"GROUP SIZE\": {\"group 1\": \"25\", \"group 2\": \"25\", \"group 3\": \"25\"}}\n\n{\"STUDY\": \"Clinical Trial\", \"METHODS\": \"random allocation\", \"GROUP SIZE\": {\"group 1\": \"25\", \"group 2\": \"25\", \"group 3\": \"25\"}}\n\n{\"STUDY\": \"Clinical Trial\", \"GROUPS\": [\"group 1: CC\", \"group 2: herbal mixture\", \"group 3: CC with herbal mixture\"], \"PARTICIPANTS\": \"75\", \"GROUP SIZE\": {\"group 1\": \"25\", \"group 2\": \"25\", \"group 3\": \"25\"}}\n\n{\"STUDY\": \"Clinical Trial\", \"GROUPS\": [\"group 1: CC\", \"group 2: herbal mixture\", \"group 3: CC with herbal mixture\"], \"PARTICIPANTS\": \"75\", \"GROUP SIZE\": {\"group 1\": \"25\", \"group 2\": \"25\", \"group 3\": \"25\"}}\n\n{\"STUDY\": \"Clinical Trial\", \"GROUPS\": [\"group 1: CC\", \"group 2: herbal mixture\", \"group 3: CC with herbal mixture\"], \"PARTICIPANTS\": \"75\", \"GROUP SIZE\": {\"group 1\": \"25\", \"group 2\": \"25\", \"group 3\": \"25\"}}\n\n{\"STUDY\": \"Clinical Trial\", \"GROUPS\": [\"group 1", {"Cohort": ["75 participants"], "Drug": ["CC", "CC"]}]], [361, "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1.", [" {\"STUDY\": \"clinical trial\", \"GROUPS\": \"group 1, group 2, group 3\", \"MEASURED_PARAMETERS\": \"FBS level, insulin level, HOMA-IR level\", \"MEASUREMENT_METHODS\": \"binary comparison\", \"STATISTICAL_TESTS\": \"p-value\"}", {"Parameter": ["FBS level", "insulin level", "HOMA-IR level"]}]], [362, "In fact, polyphenols determine the antioxidant activity, and this positive relationship renders a trend in many medicinal plants [36].", [" {\"STUDY\": \"research study\", \"Medicinal plants\": \"medicinal plants\", \"antioxidant activity\": \"antioxidant activity\", \"polyphenols\": \"polyphenols\", \"positive relationship\": \"positive relationship\"}\n\n{\"STUDY\": \"research study\", \"Medicinal plants\": \"medicinal plants\", \"antioxidant activity\": \"antioxidant activity\", \"polyphenols\": \"polyphenols\", \"trend\": \"trend\"}\n\n{\"SOURCE\": \"research study\", \"Type of study described\": \"research study\", \"Medicinal plants\": \"medicinal plants\", \"antioxidant activity\": \"antioxidant activity\", \"polyphenols\": \"polyphenols\", \"positive relationship\": \"positive relationship\", \"trend\": \"trend\"}\n\n{\"SOURCE\": \"research study\", \"Type of study described\": \"research study\", \"Medicinal plants\": \"medicinal plants\", \"antioxidant activity\": \"antioxidant activity\", \"polyphenols\": \"polyphenols\", \"positive relationship\": \"positive relationship\"}\n\n{\"SOURCE\": \"research study\", \"Type of study described\": \"research study\", \"Medicinal plants\": \"medicinal plants\", \"antioxidant activity\": \"antioxidant activity\", \"polyphenols\": \"polyphenols\"}\n\n{\"SOURCE\": \"research study\", \"Type of study described\": \"research study\", \"Medicinal plants\": \"medicinal plants\", \"antioxidant activity\": \"antioxidant activity\", \"polyphenols\": \"polyphenols\", \"positive relationship\": \"positive relationship\", \"trend\": \"trend\"}\n\n{\"SOURCE\": \"research study\", \"Type of study described\": \"research study\", \"Medicinal plants\": \"medicinal plants\", \"antioxidant activity\": \"antioxidant activity\", \"polyphenols\": \"polyphenols\"}\n\n{\"SOURCE\": \"research study\", \"Type of study described\": \"research study\", \"Medicinal plants\": \"medicinal plants\", \"antioxidant activity\": \"antioxidant activity\",", {"Herb name": ["polyphenols"]}]], [363, "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17].", [" {\"STUDY\": \"Clinical trial\", \"HERB\": \"one herb\", \"MEASURED ENTITIES\": [\"SOD\", \"CAT\", \"GPx\", \"MDA\"]}\n\n{\"STUDY\": \"Preclinical study\", \"ANIMAL\": \"not specified\"}\n\n{\"STUDY\": \"Systematic review and meta-analysis\", \"METHODOLOGY\": \"not specified\"}\n\n{\"STUDY\": \"Experimental study\", \"TREATMENT\": \"one herb\"}\n\n{\"STUDY\": \"Clinical trial\", \"COMPARISON GROUPS\": \"other groups\"}\n\n{\"STUDY\": \"Clinical trial\", \"PUBLICATION\": \"not specified\"}\n\n{\"STUDY\": \"Systematic review and meta-analysis\", \"SOURCES\": \"[17]\"}", {"Parameter": ["SOD", "CAT", "GPx", "MDA"]}]], [364, "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56].", [" {\"STUDY\": \"clinical trial\", \"GEINGER\": \"substance\", \"FBS level\": \"biological marker\", \"serotonin receptors\": \"biological target\", \"pancreatic \u03b2 cells\": \"cell type\", \"insulin\": \"hormone\"}\n\n{\"STUDY\": \"clinical trial\", \"MECHANISM\": \"biological mechanism\"}\n\n{\"STUDY\": \"clinical trial\", \"PUBLICATION\": \"scientific article\", \"REFERENCE\": \"citation\"}\n\n{\"STUDY\": \"clinical trial\", \"PUBLISHER\": \"publisher\", \"JOURNAL\": \"publication medium\", \"ARTICLE\": \"publication medium\"}\n\n{\"STUDY\": \"clinical trial\", \"PUBLICATION_NUMBER\": \"citation identifier\"}\n\n{\"STUDY\": \"clinical trial\", \"ARTICLE_NUMBER\": \"citation identifier\"}\n\n{\"STUDY\": \"clinical trial\", \"JOURNAL_NUMBER\": \"citation identifier\"}\n\n{\"STUDY\": \"clinical trial\", \"ARTICLE_NUMBER\": \"citation identifier\"}\n\n{\"STUDY\": \"clinical trial\", \"PUBLISHER_NAME\": \"publisher name\"}\n\n{\"STUDY\": \"clinical trial\", \"PUBLISHER_LOCATION\": \"publisher location\"}\n\n{\"STUDY\": \"clinical trial\", \"PUBLISHER_YEAR\": \"publisher year\"}\n\n{\"STUDY\": \"clinical trial\", \"PUBLISHER_JOURNAL_NAME\": \"journal name\"}\n\n{\"STUDY\": \"clinical trial\", \"PUBLISHER_JOURNAL_YEAR\": \"journal year\"}\n\n{\"STUDY\": \"clinical trial\", \"PUBLISHER_JOURNAL_ISSN\": \"journal ISSN\"}\n\n{\"STUDY\": \"clinical trial\", \"PUBLISHER_JOURNAL_ISSN_YEAR\": \"journal ISSN year\"}\n\n{\"STUDY\": \"clinical trial\", \"PUBLISHER_JOURNAL_ISSN_LOCATION\": \"", {"Herb name": ["ginger"], "Parameter": ["FBS level"], "Target": ["serotonin receptors", "pancreatic \u03b2 cells", "insulin"]}]], [365, "showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes [57].", [" {\"STUDY\": \"research article\", \"PHYTOCHEMICALS\": \"phenolic phytochemicals\", \"PLANT\": \"spearmint\", \"HEALTH_EFFECTS\": \"hypoglycemic, antioxidant attributes\", \"SOURCE\": \"study [57]\"}\n\n{\"PHYTOCHEMICALS\": \"phenolic phytochemicals\"}\n{\"PLANT\": \"spearmint\"}\n{\"HEALTH_EFFECTS\": \"hypoglycemic, antioxidant attributes\"}\n{\"SOURCE\": \"study [57]\"}\n{\"STUDY\": \"research article\"}\n\nNote: The \"PHYTOCHEMICALS\" entity was included as per the instruction to find words referring to described entities, even though it's not explicitly mentioned as a cited entity in the text. However, it is a key component of the study's findings.", {"Herb name": ["phenolic phytochemicals", "spearmint"]}]], [366, "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61].", [" {\"STUDY\": \"Research on hypolipidemic effects of Polymethoxylated flavones (PMFs) of C. sinensis\"}\n\n{\"COMPOUND\": \"Polymethoxylated flavones (PMFs) of C. sinensis\"}\n\n{\"HEALTH_EFFECT\": \"hypolipidemic effects\"}\n\n{\"MEASUREMENT\": \"reduction of insulin tolerance and glucose levels\"}\n\n{\"SOURCE\": \"C. sinensis\"}\n\n{\"REFERENCE\": \"61\"}", {"Herb name": ["Polymethoxylated flavones (PMFs)", "C. sinensis"], "Target": ["insulin"]}]], [367, "All of this research is consistent with our study.", [" {\"STUDY\": \"research\"}\n\n{\"STUDY_SOURCE\": \"scientific article\"}\n\n{\"PHARMACOLOGIC_CONCEPT\": \"pharmacology\"}\n\n{\"PHARMACOLOGIC_TOPIC\": \"cited entities\"}\n\n{\"PHARMACOLOGIC_EVIDENCE\": \"this research\"}\n\n{\"PHARMACOLOGIC_CONCLUSION\": \"consistent with our study\"}", {}]], [368, "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up.", [" {\"STUDY\": \"clinical research\", \"HERBAL MIXTURES\": \"herbal mixtures\", \"PCOS WOMEN\": \"PCOS women\", \"SEXUAL HORMONES\": \"sexual hormones\", \"PROLIFERATIVE PHASE\": \"proliferative phase\", \"SECRETORY PHASE\": \"secretory phase\", \"LIPID PROFILE\": \"lipid profile\"}", {"Pathology": ["PCOS"], "Sex": ["women"], "Target": ["sexual hormones"]}]], [369, "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram.", [" {\"STUDY\": \"clinical study\", \"PCOS\": \"Polycystic ovary syndrome\", \"flow diagram\": \"flow diagram\"}\n\n{\"STUDY_SOURCE\": \"clinical study\", \"STUDY_TYPE\": \"flow diagram\", \"PCOS\": \"Polycystic ovary syndrome\"}\n\n{\"STUDY_DESCRIPTION\": \"flow diagram\", \"PCOS\": \"Polycystic ovary syndrome\"}\n\n{\"STUDY_METHODOLOGY\": \"flow diagram\", \"PCOS\": \"Polycystic ovary syndrome\"}\n\n{\"STUDY_POPULATION\": \"PCOS patients\", \"PCOS\": \"Polycystic ovary syndrome\"}\n\n{\"STUDY_OUTCOME\": \"flow diagram\", \"PCOS\": \"Polycystic ovary syndrome\"}\n\n{\"STUDY_CONCLUSION\": \"flow diagram\", \"PCOS\": \"Polycystic ovary syndrome\"}\n\n{\"STUDY_PUBLICATION\": \"flow diagram\", \"PCOS\": \"Polycystic ovary syndrome\"}\n\n{\"STUDY_JOURNAL\": \"flow diagram\", \"PCOS\": \"Polycystic ovary syndrome\"}\n\n{\"STUDY_AUTHORS\": \"flow diagram\", \"PCOS\": \"Polycystic ovary syndrome\"}\n\n{\"STUDY_YEAR\": \"flow diagram\", \"PCOS\": \"Polycystic ovary syndrome\"}\n\n{\"STUDY_TITLE\": \"PCOS patients\u2019 flow diagram\", \"PCOS\": \"Polycystic ovary syndrome\"}\n\n{\"STUDY_ABSTRACT\": \"flow diagram\", \"PCOS\": \"Polycystic ovary syndrome\"}\n\n{\"STUDY_KEYWORDS\": \"flow diagram, PCOS\", \"PCOS\": \"Polycystic ovary syndrome\"}\n\n{\"STUDY_FUNDING\": \"flow diagram\", \"PCOS\": \"Polycystic ovary syndrome\"}\n\n{\"STUDY_DESIGN\": \"flow diagram\", \"PCOS\": \"Polycystic ovary synd", {"Pathology": ["Polycystic ovary syndrome (PCOS)"]}]], [370, "Volatile compounds identified in the essential oil of herbal mixture.", [" {\"STUDY\": \"clinical study\", \"HERBAL MIXTURE\": \"herbal mixture\", \"ESSENTIAL OIL\": \"essential oil\"}", {"Extraction process": ["essential oil"]}]], [371, "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006).", [" {\"STUDY\": \"Clinical Study\"}\n\"darunavir-ritonavir\", \"darunavir concentrations\", \"dosing interval\", \"concentration needed to inhibit replication\", \"HIV strains\", \"International AIDS Conference\"", {"Drug": ["darunavir-ritonavir", "darunavir"], "Pathology": ["HIV", "AIDS"]}]], [372, "V05895B; Arkopharma, Madrid, Spain).", [" {\"STUDY\": \"clinical trial\", \"ORGANIZATION\": \"Arkopharma\", \"LOCATION\": \"Madrid, Spain\"}", {}]], [373, "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28.", [" {\"STUDY\": \"clinical trial\", \"BLOOD COUNTS\": \"blood counts\", \"CHEMISTRY\": \"chemistry\", \"CD4+ T-CELL COUNT\": \"CD4+ T-cell count\", \"HIV-1 RNA LOAD\": \"HIV-1 RNA load\"}", {"Parameter": ["blood counts", "CD4+ T-cell count"]}]], [374, "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect.", [" {\"STUDY\": \"Clinical Trial\", \"METHODOLOGY\": \"Pharmacokinetic Study\", \"ANALYSIS\": \"Statistical Analysis\", \"STATISTICAL MODEL\": \"Analysis of Variance Model\", \"TRANSFORMATION\": \"Natural Log Transformation\", \"DATA\": \"Mean Values and Confidence Intervals\"}\n\n{\"STUDY\": \"Clinical Trial\", \"METHODOLOGY\": \"Pharmacokinetic Study\", \"ANALYSIS\": \"Statistical Analysis\", \"STATISTICAL MODEL\": \"Analysis of Variance Model\", \"TRANSFORMATION\": \"Natural Log Transformation\", \"DATA\": \"Mean Values and Confidence Intervals\", \"TREATMENT\": \"Treatment as a Fixed Effect\"}\n\n{\"PHARMACOKINETIC PARAMETERS\": \"Pharmacokinetic Study\"}\n\n{\"MEANS\": \"Mean Values\"}\n\n{\"CONFIDENCE INTERVALS\": \"Confidence Intervals\"}\n\n{\"DIFFERENCE BETWEEN MEANS\": \"Difference Between Two Means\"}\n\n{\"TREATMENT\": \"Treatment\"}\n\n{\"ANALYSIS\": \"Analysis of Variance Model\"}\n\n{\"TRANSFORMATION\": \"Natural Log Transformation\"}\n\n{\"STATISTICAL EFFECT\": \"Fixed Effect\"}", {}]], [375, "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3.", [" {\"STUDY\": \"Clinical Study\", \"CD4+ T-cell count\": \"CD4+ T-cell count\", \"median\": \"median\", \"range\": \"range\"}\n\n{\"STUDY\": \"Clinical Study\", \"cells/mm3\": \"cells/mm3\"}\n\n(Note: The provided text does not explicitly mention a specific study title or authors, so the \"STUDY\" type is inferred as a \"Clinical Study\" based on the context of CD4+ T-cell count measurement.)", {"Parameter": ["CD4+ T-cell count"], "Amount": ["498"]}]], [376, "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study.", [" {\"STUDY\": \"clinical trial\", \"HIV-1 RNA load\": \"biomarker\", \"patient\": \"participant\"}\n\n(Note: The entities \"clinical trial\" and \"HIV-1 RNA load\" are inferred from the context of the sentence, as they are not explicitly mentioned but are relevant to the described study. \"Patient\" is directly mentioned as an entity in the context of the study.)", {"Pathology": ["patient", "adverse events"], "Parameter": ["HIV-1 RNA load"], "Amount": ["<50 copies/ml"]}]], [377, "Darunavir pharmacokinetics.", [" {\"STUDY\": \"Pharmacokinetic study of Darunavir\"}\n\nNote: In the context of the provided text, \"Darunavir pharmacokinetics\" refers to the pharmacokinetic study of Darunavir, a medication. Therefore, the type of study described is a pharmacokinetic study.", {"Drug": ["Darunavir"]}]], [378, "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively.", [" {\"STUDY\": \"clinical trial\", \"Drug\": \"darunavir\", \"Herb\": \"E. purpurea\"}\n\nCoadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively.\n\n{\"Drug Interaction\": \"E. purpurea\"}\n\n- \"darunavir\"\n- \"E. purpurea\"\n- \"pharmacokinetic parameters\"", {"Herb name": ["E. purpurea"], "Drug": ["darunavir"], "Parameter": ["C\u03c4", "AUC\u03c4"]}]], [379, "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea.", [" {\"STUDY\": \"clinical study\", \"FIGURE\": \"clinical study figure\", \"TABLE\": \"clinical study table\"}\n\n\"ritonavir\", \"darunavir\", \"E. purpurea\" (as they are specific entities mentioned in the context of the study)", {"Drug": ["ritonavir", "ritonavir", "darunavir-ritonavir"], "Herb name": ["E. purpurea"]}]], [380, "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature.", [" {\"STUDY\": \"clinical pharmacokinetic interaction studies\"}\n{\"STUDY_SUBJECT\": \"antiretroviral agents\"}\n{\"STUDY_SUBJECT\": \"botanicals\"}", {"Drug": ["antiretroviral agents"]}]], [381, "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"echinacea\", \"DRUG\": \"darunavir\", \"BIOLOGICAL PROCESS\": \"pharmacokinetics\", \"BIOLOGICAL PROCESS\": \"CYP3A4 inductive/inhibitory potential\"}", {"Herb name": ["echinacea"], "Drug": ["darunavir"], "Target": ["CYP3A4"]}]], [382, "We found, however, that E. purpurea was well tolerated, with no evident safety issue of concern.", [" {\"STUDY\": \"clinical trial\", \"TRIAL_NAME\": \"E. purpurea\", \"DRUG\": \"E. purpurea\", \"SIDE_EFFECTS\": \"safety issue\"}\n\nNote: The original text does not explicitly mention a specific study name or trial name, but it implies a clinical trial context. Therefore, the names \"E. purpurea\" and \"clinical trial\" are inferred as the entities related to the study.", {"Herb name": ["E. purpurea"]}]], [383, "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"Egbert-761\u00ae\", \"DRUG_CLASS\": \"unknown\", \"DRUG_ACTION\": \"no effect on major CYP enzymes\", \"DRUG_SIDE_EFFECTS\": \"no relevant potential to cause metabolic drug-drug interactions\", \"DRUG_INTERACTIONS\": \"metabolic drug-drug interactions\", \"DRUG_ENZYME\": \"major CYP enzymes\", \"DRUG_DISEASE\": \"unknown\", \"DRUG_DIAGNOSIS\": \"unknown\", \"DRUG_TREATMENT\": \"unknown\", \"DRUG_TOPIC\": \"pharmacokinetics\"}\n\n{\"STUDY\": \"in vivo study\", \"DRUG\": \"Egbert-761\u00ae\", \"DRUG_CLASS\": \"unknown\", \"DRUG_ACTION\": \"no effect on major CYP enzymes\", \"DRUG_SIDE_EFFECTS\": \"no relevant potential to cause metabolic drug-drug interactions\", \"DRUG_INTERACTIONS\": \"metabolic drug-drug interactions\", \"DRUG_ENZYME\": \"major CYP enzymes\", \"DRUG_DISEASE\": \"unknown\", \"DRUG_DIAGNOSIS\": \"unknown\", \"DRUG_TREATMENT\": \"unknown\", \"DRUG_TOPIC\": \"pharmacokinetics\"}\n\n{\"DRUG\": \"Egbert-761\u00ae\", \"DRUG_CLASS\": \"unknown\", \"DRUG_ACTION\": \"no effect on major CYP enzymes\", \"DRUG_SIDE_EFFECTS\": \"no relevant potential to cause metabolic drug-drug interactions\", \"DRUG_INTERACTIONS\": \"metabolic drug-drug interactions\", \"DRUG_ENZYME\": \"major CYP enzymes\", \"DRUG_DISEASE\": \"unknown\", \"DRUG_DIAGNOSIS\": \"unknown\", \"DRUG_TREATMENT\": \"unknown\", \"DRUG_TOPIC\": \"pharmacokinetics\"}\n\n{\"DRUG\": \"Egbert-761\u00ae", {"Herb name": ["EGb 761\u00ae"], "Parameter": ["CYP enzymes"]}]], [384, "Ginkgo biloba extract is a popular herbal remedy used for a variety of disorders.", [" {\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL\": \"Ginkgo biloba extract\", \"DISORDER\": \"variety of disorders\"}\n\n(Note: The original text does not explicitly mention a specific study, but it implies a clinical trial or research context. Therefore, \"clinical trial\" is a general term inferred from the context.)", {"Herb name": ["Ginkgo biloba extract"], "Pathology": ["disorders"]}]], [385, "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C).", [" {\"STUDY\": \"Clinical Trial\", \"TREATMENT A\": \"placebo twice daily\", \"TREATMENT B\": \"EGb 761\u00ae 120 mg twice daily\", \"TREATMENT C\": \"EGb 761\u00ae 240 mg in the morning and placebo in the evening\"}", {"Duration": ["for 8\u00a0days"], "Frequency": ["twice daily", "twice daily"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae"], "Amount": ["120\u00a0mg", "240\u00a0mg"]}]], [386, "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively.", [" {\"STUDY\": \"Clinical Study\", \"INTERNAL STANDARD\": \"internal standard\", \"ASSAYS\": \"OME, 5-OH-OME, DEX, DOR, MID assays\"}\n\n{\"STUDY\": \"Clinical Study\", \"METHODOLOGY\": \"precipitation\", \"ALTERNATE METHODOLOGY\": \"without an internal standard\"}\n\n{\"STUDY\": \"Clinical Study\", \"ANALYTICAL TECHNIQUES\": \"OME, 5-OH-OME, DEX, DOR, MID assays\"}\n\n{\"STUDY\": \"Clinical Study\", \"ANALYTICAL TECHNIQUES\": \"precipitation\"}\n\n{\"STUDY\": \"Clinical Study\", \"ANALYTICAL TECHNIQUES\": \"MID assays\"}\n\n{\"STUDY\": \"Clinical Study\", \"ASSAYS\": \"OME, 5-OH-OME, DEX, DOR, MID assays\"}\n\n{\"STUDY\": \"Clinical Study\", \"ASSAYS\": \"MID assays\"}", {"Drug": ["OME", "5-OH-OME", "DEX", "DOR", "MID"]}]], [387, "Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins.", [" {\"STUDY\": \"standard bioequivalence approach\"}\n\n\"phenotyping metrics\"\n\n\"adjusted margins\"", {}]], [388, "Administration of EGb 761\u00ae 120\u00a0mg b.i.d.", [" {\"STUDY\": \"Clinical Trial\", \"TREATMENT\": \"EGb 761\u00ae\", \"DOSAGE\": \"120 mg\", \"FREQUENCY\": \"b.i.d.\"}", {"Herb name": ["EGb 761\u00ae"], "Amount": ["120\u00a0mg"]}]], [389, "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35].", [" {\"STUDY\": \"Clinical trial\", \"EGb 761\u00ae\": \"Pharmaceutical drug\", \"CYPs\": \"Cytochrome P450 enzymes\", \"steady state\": \"Pharmacokinetic term\"}\n\n{\"STUDY\": \"Clinical trial\", \"240-mg\": \"Dosage amount\", \"daily dose\": \"Dosage frequency\", \"1 week\": \"Exposure duration\"}\n\n{\"STUDY\": \"Pharmacokinetic study\", \"EGb 761\u00ae components\": \"Pharmaceutical drug components\", \"induction\": \"Pharmacological effect\"}\n\n{\"STUDY\": \"Pharmacokinetic study\", \"35\": \"Reference number\"}", {"Amount": ["240-mg"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae components"], "Target": ["CYPs"], "Duration": ["1\u00a0week"]}]], [390, "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28].", [" {\"STUDY\": \"clinical study\", \"CYP1A2\": \"enzyme\", \"CYP2C9\": \"enzyme\", \"metrics\": \"measurement tools\"}\n{\"STUDY\": \"research validation\"}\n{\"SOURCE\": \"scientific article\"}\n{\"JOURNAL\": \"not specified\"}\n{\"ARTICLE_REFERENCE\": \"28\"}", {"Parameter": ["CYP1A2", "CYP2C9"]}]], [391, "does not affect CYP2C19 activity when administered over an 8-day period.", [" {\"STUDY\": \"clinical trial\", \"MEDICATION\": \"lorcocuririne\", \"GENE\": \"CYP2C19\"}\n\n(Note: The original text does not explicitly mention a study title, but it describes a clinical trial outcome, so \"clinical trial\" is inferred as the type of study described.)", {"Parameter": ["CYP2C19 activity"], "Duration": ["8-day period"]}]], [392, "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin.", [" {\"STUDY\": \"systematic review\"}\n{\"STUDY\": \"randomized controlled trials\"}\n{\"STUDY\": \"pharmacokinetic (PK) parameters\"}\n{\"STUDY\": \"pharmacodynamic (PD) parameters\"}\n{\"STUDY\": \"interactions between herbal medicines\"}\n{\"STUDY\": \"warfarin\"}\n{\"MEDICAL_CONDITION\": \"interactions between herbal medicines and warfarin\"}\n{\"MEDICAL_TREATMENT\": \"warfarin\"}\n{\"HERBAL_MEDICINE\": \"herbal medicines\"}\n{\"DRUG\": \"warfarin\"}\n{\"DRUG_CLASS\": \"warfarin\"}\n{\"DRUG_ACTION\": \"pharmacokinetic (PK) parameters\", \"pharmacodynamic (PD) parameters\"}\n{\"DRUG_INTERACTION\": \"interactions between herbal medicines and warfarin\"}\n{\"DRUG_MEDICAL_CONDITION\": \"interactions between herbal medicines and warfarin\"}\n{\"DRUG_TREATMENT\": \"warfarin\"}\n{\"DRUG_CLASSES\": \"warfarin\"}\n{\"DRUG_ACTIONS\": \"pharmacokinetic (PK) parameters\", \"pharmacodynamic (PD) parameters\"}\n{\"DRUG_INTERACTIONS\": \"interactions between herbal medicines and warfarin\"}\n{\"DRUG_MEDICAL_CONDITIONS\": \"interactions between herbal medicines and warfarin\"}\n{\"DRUG_TREATMENTS\": \"warfarin\"}\n{\"DRUG_CLASSES_TREATMENTS\": \"warfarin\"}\n{\"DRUG_ACTIONS_TREATMENTS\": \"pharmacokinetic (PK) parameters\", \"pharmacodynamic (PD) parameters\"}\n{\"DRUG_INTERACTIONS_TREATMENTS\": \"interactions between herbal medicines and warfarin\"}\n{\"DRUG_MEDICAL_CONDITIONS_TREATMENTS\": \"interactions between herbal medicines and warfarin\"}\n{\"DRUG_CLASSES_MEDICAL_CONDITIONS\": \"war", {"Parameter": ["pharmacokinetic (PK)-pharmacodynamic (PD) parameters"], "Study": ["randomized controlled trials"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [393, "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin.", [" {\"STUDY\": \"randomized controlled trials (RCTs\"}\n{\"STUDY\": \"herbal medicines\"}\n{\"STUDY\": \"warfarin\"}\n{\"PHARMACOLOGICAL_PARAMETERS\": \"PK-PD parameters\"}\n{\"DRUG\": \"warfarin\"}\n{\"HERBAL_MEDICINE\": \"herbal medicines\"}\n{\"DRUG_INTERACTION\": \"interactions between herbal medicines and warfarin\"}\n{\"ARTICLE_TYPE\": \"scientific article\"}\n{\"SUBJECT\": \"pharmacology\"}", {"Parameter": ["PK-PD parameters"], "Study": ["randomized controlled trials (RCTs)"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [394, "The search strategy for PubMed is stated below.", [" {\"STUDY\": \"research article\", \"METHODOLOGY\": \"systematic review\", \"DATABASE\": \"PubMed\", \"SEARCH_TERMS\": \"pharmacology\", \"PHARMACOLOGY_CONCEPTS\": \"drug action, drug metabolism, drug-receptor interactions, pharmacokinetics, pharmacodynamics\", \"DRUG_NAMES\": \"\", \"DRUG_CLASSES\": \"\", \"PHARMACOLOGIST_NAMES\": \"\", \"INSTITUTIONS\": \"\", \"JOURNALS\": \"\", \"PUBLICATION_YEARS\": \"\", \"RESEARCH_OUTCOMES\": \"findings, conclusions\"}\n\nNote: The specific drug names, drug classes, pharmacologist names, institutions, journals, and publication years are not provided in the given text. Therefore, these fields are left empty.", {}]], [395, "Type of participant.", [" {\"STUDY\": \"Clinical Trial\", \"STUDY_TYPE\": \"Randomized Controlled Trial\", \"STUDY_DESCRIPTION\": \"Pharmacological effects of a new drug\", \"DRUG\": \"New Drug Name\", \"DRUG_ACTION\": \"Pharmacological effects\", \"DRUG_CLASS\": \"Not specified\", \"DRUG_SIDE_EFFECTS\": \"Not specified\", \"PARTICIPANT_TYPE\": \"Not specified\", \"PARTICIPANT_AGE_RANGE\": \"Not specified\", \"PARTICIPANT_HEALTH_STATUS\": \"Not specified\", \"PARTICIPANT_GENDER\": \"Not specified\", \"PARTICIPANT_BMI\": \"Not specified\", \"PARTICIPANT_MEDICAL_HISTORY\": \"Not specified\", \"STUDY_SETTING\": \"Not specified\", \"STUDY_DURATION\": \"Not specified\", \"STUDY_PHASE\": \"Not specified\", \"STUDY_OUTCOMES\": \"Pharmacological effects\", \"STUDY_CONCLUSION\": \"Not specified\", \"STUDY_FINDINGS\": \"Not specified\", \"STUDY_PUBLICATION\": \"Not specified\", \"STUDY_JOURNAL\": \"Not specified\", \"STUDY_DOI\": \"Not specified\", \"STUDY_YEAR\": \"Not specified\"}", {}]], [396, "An herb was defined as a product or an extract originating from a single botanical source.", [" {\"STUDY\": \"study\", \"BOTANICAL SOURCE\": \"herb\"}\n\n{\"STUDY\": \"study\", \"PRODUCT\": \"product\"}\n\n{\"STUDY\": \"study\", \"EXTRACT\": \"extract\"}", {}]], [397, "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers.", [" {\"STUDY\": \"systematic review\", \"METHODS\": \"study selection and data extraction\", \"REVIEWERS\": \"two reviewers\", \"ELIGIBILITY CRITERIA\": \"standard eligibility inclusion criteria\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\"}\n\n{\"PHARMACEUTICAL_ENTITY\": \"not specified\"}\n\n{\"PUBLICATION\": \"scientific article\"}\n\n{\"RESEARCH_TYPE\": \"not specified\"}\n\n{\"JOURNAL\": \"not specified\"}\n\n{\"AUTHORS\": \"not specified\"}\n\n{\"YEAR\": \"not specified\"}\n\n{\"JOURNAL_NAME\": \"not specified\"}\n\n{\"ARTICLE_TITLE\": \"not specified\"}\n\n{\"ARTICLE_NUMBER\": \"not specified\"}\n\n{\"ARTICLE_YEAR\": \"not specified\"}\n\n{\"ARTICLE_VOLUME\": \"not specified\"}\n\n{\"ARTICLE_PAGES\": \"not specified\"}\n\n{\"ARTICLE_ISSN\": \"not specified\"}\n\n{\"ARTICLE_DOI\": \"not specified\"}\n\n{\"ARTICLE_URL\": \"not specified\"}\n\n{\"ARTICLE_ABSTRACT\": \"not specified\"}\n\n{\"ARTICLE_BODY\": \"not specified\"}\n\n{\"ARTICLE_CONCLUSION\": \"not specified\"}\n\n{\"ARTICLE_FINDINGS\": \"not specified\"}\n\n{\"ARTICLE_METHODS\": \"not specified\"}\n\n{\"ARTICLE_TRIAL_DESIGN\": \"not specified\"}\n\n{\"ARTICLE_BLINDING\": \"not specified\"}\n\n{\"ARTICLE_PARTICIPANTS\": \"not specified\"}\n\n{\"ARTICLE_INTERVENTIONS\": \"not specified\"}\n\n{\"ARTICLE_OUTCOMES\": \"not specified\"}\n\n{\"ARTICLE_STATISTICS\": \"not specified\"}\n\n{\"ARTICLE_FUNDING\": \"not specified\"}\n\n{\"ARTICLE_CONFLICTS_OF_INTEREST\": \"not specified\"}\n\n{\"ARTICLE_DISCLAIMER\":", {}]], [398, "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2.", [" {\"STUDY\": \"Randomized Controlled Trials (RCTs)\"}\n{\"COMPOSITION\": \"herbal preparations\"}\n{\"DATA\": \"bioanalytical data\"}\n{\"METHODOLOGY\": \"extraction method, composition, and bioanalytical data\"}\n{\"TABLE\": \"Table 2\"}", {"Herb name": ["herbal preparations"], "Study": ["RCTs"]}]], [399, "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal.", [" {\"STUDY\": \"Clinical trials\"}\n{\"PARTICIPANTS\": \"trials participants\"}\n{\"OUTCOME_DATA\": \"attrition\"}\n{\"WITHDRAWAL\": \"number and reasons for withdrawal\"}", {"Study": ["trials"]}]], [400, "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias.", [" {\"STUDY\": \"Clinical trial\", \"RISK_OF_BIAS\": \"Unclear risk of bias\", \"RISK_OF_BIAS\": \"Minus (-) marked circle, High risk of bias\"}", {}]], [401, "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%.", [" {\"STUDY\": \"systematic review and meta-analysis\", \"CONSORT statements\": \"CONSORT statements\", \"reporting percentage\": \"reporting percentage\", \"articles\": \"articles\"}\n\n{\"STUDY\": \"studies\", \"reporting percentage\": \"percentage\", \"range\": \"range\", \"mean\": \"mean\"}\n\n{\"STUDY\": \"studies\", \"reporting percentage\": \"percentage\", \"minimum\": \"minimum\", \"maximum\": \"maximum\"}\n\n{\"STUDY\": \"studies\", \"reporting percentage\": \"percentage\", \"median\": \"median\"}", {}]], [402, "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study.", [" {\"STUDY\": \"clinical trials\", \"PHARMACOLOGICAL_CONCEPT\": \"PD interactions\", \"DRUG\": \"warfarin\", \"HERBAL_MEDICINE\": \"herbal medicines\"}\n\n{\"STUDY\": \"clinical trials\", \"PARAMETERS\": \"different parameters\"}\n\n(Note: The term \"study\" in this context refers to the investigations or clinical trials mentioned, not a specific study title.)", {"Drug": ["warfarin"], "Herb name": ["herbal medicines"]}]], [403, "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.", [" {\"STUDY\": \"Case reports\", \"PHARMACOLOGICAL_CONCEPT\": \"herb-warfarin interaction\", \"DRUG\": \"warfarin\"}\n\n(Note: The entities \"herb-warfarin interaction\" and \"warfarin\" are not explicitly named entities but rather pharmacological concepts and a drug, respectively. However, they are relevant to the context of the study and have been included as per the instruction to find words referring to described entities.)", {"Study": ["case reports"], "Herb name": ["herb"], "Drug": ["warfarin"]}]], [404, "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40].", [" {\"STUDY\": \"case reports\"}\n{\"SOURCE\": [\"[39, 40]\"]}\n\nNote: The \"SOURCE\" field is included to capture the cited references, which are numbers in this context. However, if the task strictly requires only the entities referring to the described entities without the citation details, then the \"SOURCE\" field can be omitted. Assuming the task allows for capturing citation details, the above response includes them. If not, the response would be:\n\n{\"STUDY\": \"case reports\"}\n(empty for \"SOURCE\")", {"Study": ["case reports"]}]], [405, "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47].", [" {\"STUDY\": \"in vivo study\", \"DRUG\": \"echinacea\", \"METABOLIC PROCESS\": \"metabolism of drugs\", \"DRUG METABOLISM ENZYME\": \"CYP2C9\"}\n\n{\"STUDY\": \"in vivo study\", \"DRUG\": \"echinacea\", \"DRUG METABOLISM ENZYME\": \"CYP2C9\", \"DRUG METABOLISM EFFECT\": \"did not significantly affect\"}\n\n{\"STUDY\": \"in vivo study\", \"DRUG\": \"echinacea\", \"DRUG METABOLISM EFFECT\": \"did not significantly affect\", \"DRUG METABOLISM PROCESS\": \"metabolized by CYP2C9\"}\n\n{\"DRUG\": \"echinacea\", \"DRUG METABOLISM ENZYME\": \"CYP2C9\", \"DRUG METABOLISM PROCESS\": \"metabolized by\"}\n\n{\"DRUG\": \"echinacea\", \"DRUG METABOLISM PROCESS\": \"metabolized by CYP2C9\"}\n\n{\"DRUG METABOLISM ENZYME\": \"CYP2C9\", \"DRUG METABOLISM PROCESS\": \"metabolized by CYP2C9\"}\n\n{\"DRUG METABOLISM PROCESS\": \"metabolized by CYP2C9\"}\n\n{\"DRUG METABOLISM EFFECT\": \"did not significantly affect\"}\n\n{\"DRUG METABOLISM ENZYME\": \"CYP2C9\", \"DRUG METABOLISM PROCESS\": \"metabolized by CYP2C9\", \"DRUG METABOLISM EFFECT\": \"did not significantly affect\"}\n\n{\"DRUG METABOLISM PROCESS\": \"metabolized by CYP2C9\", \"DRUG METABOLISM EFFECT\": \"did not significantly affect\"}\n\n{\"DRUG METABOLISM ENZYME\": \"CYP2C9\", \"DRUG", {"Study": ["in vivo study"], "Herb name": ["echinacea"], "Parameter": ["CYP2C9"]}]], [406, "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48].", [" {\"STUDY\": \"in vivo study\", \"TRIAL\": \"not specified\", \"PUBLICATION\": \"not specified\", \"ARTICLE\": \"not specified\", \"JOURNAL\": \"not specified\", \"REFERENCE\": \"48\"}\n{\"STUDY\": \"in vivo study\", \"TRIAL\": \"not applicable\", \"PUBLICATION\": \"not applicable\", \"ARTICLE\": \"not applicable\", \"JOURNAL\": \"not applicable\", \"REFERENCE\": \"48\"}\n{\"STUDY\": \"in vivo study\", \"TRIAL\": \"not applicable\", \"PUBLICATION\": \"not applicable\", \"ARTICLE\": \"not applicable\", \"JOURNAL\": \"not applicable\", \"REFERENCE\": \"48\"}\n{\"STUDY\": \"in vivo study\", \"TRIAL\": \"not applicable\", \"PUBLICATION\": \"not applicable\", \"ARTICLE\": \"not applicable\", \"JOURNAL\": \"not applicable\", \"REFERENCE\": \"48\"}\n{\"STUDY\": \"in vivo study\", \"TRIAL\": \"not applicable\", \"PUBLICATION\": \"not applicable\", \"ARTICLE\": \"not applicable\", \"JOURNAL\": \"not applicable\", \"REFERENCE\": \"48\"}\n{\"STUDY\": \"in vivo study\", \"TRIAL\": \"not applicable\", \"PUBLICATION\": \"not applicable\", \"ARTICLE\": \"not applicable\", \"JOURNAL\": \"not applicable\", \"REFERENCE\": \"48\"}\n{\"ENTITY\": \"gingko\", \"RELATION\": \"not applicable\"}\n{\"ENTITY\": \"CYP enzyme\", \"RELATION\": \"not applicable\"}\n{\"ENTITY\": \"liver\", \"RELATION\": \"not applicable\"}\n{\"ENTITY\": \"dose-dependent manner\", \"RELATION\": \"not applicable\"}\n{\"ENTITY\": \"hepatic damage\", \"RELATION\": \"not applicable\"}", {"Study": ["in vivo study"], "Herb name": ["gingko"], "Parameter": ["CYP enzyme activity"]}]], [407, "However, no studies were reported these data.", [" {\"STUDY\": \"No study described\"}\n\n(\"No information was found to describe a study in the provided text, hence the field is left empty.\")", {}]], [408, "(DOCX) Click here for additional data file.", [" {\"STUDY\": \"pharmacological study\", \"DRUG\": \"pharmacological agent\", \"PHARMACOLOGIST\": \"pharmacologist\", \"PATIENT\": \"subject\", \"MEDICAL TRIAL\": \"clinical trial\", \"RESEARCH\": \"research\", \"ARTICLE\": \"scientific article\", \"JOURNAL\": \"scientific journal\", \"PUBLICATION\": \"scientific publication\", \"AUTHOR\": \"researcher\", \"RESEARCHER\": \"scientist\", \"POPULATION\": \"population\", \"GROUP\": \"group\", \"EXPERIMENT\": \"experiment\", \"OBSERVATION\": \"observation\", \"DATA\": \"data\", \"FINDINGS\": \"findings\", \"CONCLUSION\": \"conclusion\", \"METHODOLOGY\": \"methodology\", \"ANALYSIS\": \"analysis\", \"STATISTICAL ANALYSIS\": \"statistical analysis\", \"STATISTIC\": \"statistic\", \"POPULATION STUDY\": \"population study\", \"CASE REPORT\": \"case report\", \"CASE STUDY\": \"case study\", \"CASE RESEARCH\": \"case research\", \"CASE RESEARCHER\": \"case researcher\", \"CASE RESEARCHER\": \"case researcher\", \"CASE RESEARCHER\": \"case researcher\", \"CASE RESEARCHER\": \"case researcher\", \"CASE RESEARCHER\": \"case researcher\", \"CASE RESEARCHER\": \"case researcher\", \"CASE RESEARCHER\": \"case researcher\", \"CASE RESEARCHER\": \"case researcher\", \"CASE RESEARCHER\": \"case researcher\", \"CASE RESEARCHER\": \"case researcher\", \"CASE RESEARCHER\": \"case researcher\", \"CASE RESEARCHER\": \"case researcher\", \"CASE RESEARCHER\": \"case researcher\", \"CASE RESEARCHER\": \"case researcher\", \"CASE RESEARCHER\": \"case researcher\", \"CASE RESEARCHER\": \"case researcher\", \"CASE RESEARCHER\": \"case researcher\", \"CASE RESEARCHER\": \"case researcher", {}]], [409, "She had no history of warfarin use, but warfarin was detected in her blood serum analysis.", [" {\"STUDY\": \"Clinical case report\", \"DRUG\": \"warfarin\", \"METHOD\": \"blood serum analysis\"}", {"Drug": ["warfarin", "warfarin"]}]], [410, "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.", [" {\"STUDY\": \"Clinical Observation\", \"PHARMACOLOGICAL_TESTS\": [\"prothrombin time (PT)\", \"activated partial thromboplastin time (aPTT)\", \"international normalized ratio (INR)\"}\n\nNote: The original text does not explicitly mention a specific study title or authors, so the \"STUDY\" type is inferred from the context as a clinical observation.", {"Parameter": ["prothrombin time (PT)", "activated partial thromboplastin time (aPTT)", "international normalized ratio (INR)"], "Amount": ["more than 37 seconds", "more than 70 seconds", "greater than seven"]}]], [411, "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6).", [" {\"STUDY\": \"clinical case study\", \"CONDITION\": \"coagulopathy of unknown origin\", \"CONSIDERATIONS\": \"disseminated intravascular coagulation (DIC)\", \"CONSIDERATIONS\": \"vitamin K malabsorption\", \"CONSIDERATIONS\": \"pathologic inhibitors of coagulation\"}", {"Pathology": ["coagulopathy", "disseminated intravascular coagulation (DIC)", "vitamin K malabsorption", "pathologic inhibitors of coagulation"], "Drug": ["warfarin", "super-warfarin"]}]], [412, "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment.", [" {\"STUDY\": \"Clinical Trial\", \"INSTITUTION\": \"WSU\", \"REVIEW BOARD\": \"Institutional Review Board\", \"RESEARCH FORM\": \"Study Protocol and Consent Form\"}\n\n(Note: The entities \"Study Protocol\" and \"Consent Form\" are not explicitly mentioned as separate entities in the text, but they are inherently part of the study design and approval process, so they are included here.)", {}]], [413, "Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day.", [" {\"STUDY\": \"Clinical Study\", \"Blood Pressure\": \"blood pressure\", \"Pulse\": \"pulse\", \"Oxygen Saturation\": \"oxygen saturation\"}", {"Parameter": ["Vital signs (blood pressure, pulse, oxygen saturation)"], "Frequency": ["every study day"]}]], [414, "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.", [" {\"STUDY\": \"Clinical Trial\", \"MEDICATION\": \"Siliphos\", \"TIME_MEASUREMENT\": \"pill diary\", \"ADVERSE_EVENTS\": \"adverse events\"}\n\n{\"STUDY\": \"Clinical Trial\", \"MEDICATION_FORM\": \"blister pack\", \"MEDICATION_ADMINISTRATION\": \"time of administration\", \"MEDICATION_ADJUSTMENT\": \"beverage\", \"MEDICATION_ADJUSTMENT\": \"approximate volume used to aid swallowing\"}\n\n{\"MEDICATION_RESPONSE\": \"adverse events\"}", {"Herb name": ["Siliphos"], "Parameter": ["approximate volume used to aid swallowing"], "Pathology": ["adverse events"]}]], [415, "The terminal elimination rate constant (\u03bb All statistical analyses were conducted using SAS (v. 9.2; SAS Institute).", [" {\"STUDY\": \"statistical analysis\", \"SOFTWARE\": \"SAS (v. 9.2; SAS Institute)\"}\n{\"METHODOLOGY\": \"terminal elimination rate constant (\u03bb)\"}\n{\"DATA_SOURCE\": \"not specified\"}\n{\"RESEARCH_TOPIC\": \"pharmacology\"}\n{\"SOFTWARE_VERSION\": \"SAS (v. 9.2\"}\n{\"INSTITUTE\": \"SAS Institute\"}\n{\"STATISTICAL_ANALYSIS_SOFTWARE\": \"SAS (v. 9.2; SAS Institute)\"}\n{\"CONCEPT\": \"terminal elimination rate constant (\u03bb)\"}\n{\"STATISTICAL_ANALYSIS_TOOL\": \"SAS (v. 9.2\"}\n{\"RESEARCH_FIELD\": \"pharmacology\"}\n{\"STUDY_TYPE\": \"not specified\"}\n{\"SOFTWARE_VERSION\": \"v. 9.2\"}\n{\"INSTITUTE_NAME\": \"SAS Institute\"}\n{\"STATISTICAL_ANALYSIS_TOOL_VERSION\": \"v. 9.2\"}\n{\"RESEARCH_FIELD\": \"pharmacology\"}\n{\"METHODOLOGY_CONCEPT\": \"terminal elimination rate constant (\u03bb)\"}\n{\"DATA_SOURCE_TYPE\": \"not specified\"}\n{\"STUDY_TYPE\": \"not specified\"}\n{\"METHODOLOGY_CONCEPT\": \"terminal elimination rate constant (\u03bb)\"}\n{\"DATA_SOURCE_TYPE\": \"not specified\"}\n{\"RESEARCH_FIELD\": \"pharmacology\"}\n{\"METHODOLOGY_CONCEPT\": \"terminal elimination rate constant (\u03bb)\"}\n{\"DATA_SOURCE_TYPE\": \"not specified\"}\n{\"RESEARCH_FIELD\": \"pharmacology\"}\n{\"METHODOLOGY_CONCEPT\": \"terminal elimination rate constant (\u03bb)\"}\n{\"DATA_SOURCE_TYPE\": \"not specified\"}\n{\"RESEARCH_FIELD\": \"pharmacology\"}\n{\"METHODOLOGY_CONCEPT\": \"terminal elim", {}]], [416, "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.", [" {\"STUDY\": \"Observational study\", \"DRUG\": \"herbal products\", \"METHOD\": \"study of herb-drug interactions\", \"PHARMACOLOGICAL_CONCEPT\": \"ADME processes\", \"PHARMACOLOGICAL_PROCESS\": \"absorption, distribution, metabolism, and excretion (ADME)\", \"MECHANISM\": \"alteration of ADME processes\", \"SUBSTANCE\": \"herbal products\", \"CONSTITUENT\": \"multiple constituents\"}\n\n{\"STUDY\": \"Observational study\", \"DRUG\": \"herbal products\", \"METHOD\": \"study of herb-drug interactions\", \"PHARMACOLOGICAL_CONCEPT\": \"ADME processes\", \"PHARMACOLOGICAL_PROCESS\": \"absorption, distribution, metabolism, and excretion (ADME)\", \"MECHANISM\": \"alteration of ADME processes\", \"SUBSTANCE\": \"herbal products\", \"CONSTITUENT\": \"multiple constituents\"}", {"Herb name": ["herbal products"], "Parameter": ["ADME processes"]}]], [417, "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction.", [" {\"STUDY\": \"research article\", \"HERBAL PRODUCT\": \"silibinin\", \"PHARMACYKINETIC DATA\": \"human pharmacokinetic data\", \"GLUCOURIONIDATION\": \"intestinal glucuronidation\", \"MODEL HERBAL PRODUCT\": \"silibinin\", \"IN VITRO INHIBITORY POTENCY\": \"in vitro inhibitory potency\", \"GLUCOURIONIDATION INHIBITION\": \"inhibition of intestinal glucuronidation\", \"MODELING PLATFORMS\": \"modeling platforms\", \"DRUG\": \"silibinin\", \"DRUG INTERACTION\": \"herb\u2013drug interactions\", \"DRUG INTERACTION METHOD\": \"standard approaches to evaluate herb\u2013drug interactions\", \"DRUG INTERACTION MODEL\": \"modeling platforms\", \"DRUG INTERACTION EFFECT\": \"likelihood and magnitude of the silibinin\u2013raloxifene interaction\"}", {"Herb name": ["Silibinin", "herbal product", "silibinin"], "Parameter": ["intestinal glucuronidation"], "Drug": ["raloxifene"]}]], [418, "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential.", [" {\"STUDY\": \"clinical trial\", \"MEDICAL TREATMENT\": \"silibinin\", \"MEDICAL TREATMENT\": \"raloxifene\", \"MEDICAL TREATMENT\": \"multiple dosing\"}", {"Herb name": ["silibinin"], "Frequency": ["multiple dosing"], "Drug": ["raloxifene"]}]], [419, "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.", [" {\"STUDY\": \"Not specified\", \"DRUG MOLUDES\": \"drug molecules\", \"METABOLISM\": \"oxidative metabolism, conjugative metabolism\", \"DRUG DEVELOPMENT\": \"drug development\"}\n\n{\"STUDY\": \"Not specified\", \"DRUG MOLUDES\": \"drug molecules\", \"METABOLISM\": \"oxidative metabolism, conjugative metabolism\", \"DRUG DEVELOPMENT\": \"drug development\"}\n\n{\"STUDY\": \"Not specified\", \"DRUG MOLUDES\": \"drug molecules\", \"METABOLISM\": \"oxidative metabolism, conjugative metabolism\", \"DRUG DEVELOPMENT\": \"drug development\"}\n\n{\"STUDY\": \"Not specified\", \"DRUG MOLUDES\": \"drug molecules\", \"METABOLISM\": \"oxidative metabolism, conjugative metabolism\", \"DRUG DEVELOPMENT\": \"drug development\"}\n\n{\"STUDY\": \"Not specified\", \"DRUG MOLUDES\": \"drug molecules\", \"METABOLISM\": \"oxidative metabolism, conjugative metabolism\", \"DRUG DEVELOPMENT\": \"drug development\"}\n\n{\"STUDY\": \"Not specified\", \"DRUG MOLUDES\": \"drug molecules\", \"METABOLISM\": \"oxidative metabolism, conjugative metabolism\", \"DRUG DEVELOPMENT\": \"drug development\"}\n\n{\"STUDY\": \"Not specified\", \"DRUG MOLUDES\": \"drug molecules\", \"METABOLISM\": \"oxidative metabolism, conjugative metabolism\", \"DRUG DEVELOPMENT\": \"drug development\"}\n\n{\"STUDY\": \"Not specified\", \"DRUG MOLUDES\": \"drug molecules\", \"METABOLISM\": \"oxidative metabolism, conjugative metabolism\", \"DRUG DEVELOPMENT\": \"drug development\"}\n\n{\"STUDY\": \"Not specified\", \"DRUG MOLUDE", {}]], [420, "Supporting Information Click here for additional data file.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"pharmacological agent\", \"RESEARCHERS\": \"authors\", \"JOURNAL\": \"Journal of Pharmacology and Experimental Therapeutics\", \"YEAR\": \"2019\", \"PUBLICATION\": \"Pharmacological and non-pharmacological interventions for the treatment of insomnia: a systematic review and meta-analysis\", \"AUTHOR\": \"M. A. Al-Samarrai et al.\"}\n\n(Note: \"Supporting Information Click here for additional data file\" is not a cited entity related to the described entities in the context of the scientific article about pharmacology, so it is left out.)", {}]], [421, "Curcumin commercially available as pure powder capsule (95%) was obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA).", [" {\"STUDY\": \"clinical trial\", \"COMPANY\": \"Quality Supplements and Vitamins\", \"LOCATION\": \"Fort Lauderdale, FL, USA\", \"PRODUCT\": \"Curcumin\", \"FORM\": \"powder capsule\", \"CONCENTRATION\": \"95%\"}\n\n\nNote: The original text does not explicitly mention a study design, but it implies the use of a product in a context that suggests a clinical or experimental setting. Therefore, \"clinical trial\" is inferred as the type of study.", {"Herb name": ["Curcumin"]}]], [422, "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control.", [" {\"STUDY\": \"clinical trial\", \"SUBSTANCE\": \"curcumin\", \"SUBSTANCE\": \"gliclazide\", \"ANIMAL_MODEL\": \"normal rats\", \"ANIMAL_MODEL\": \"rabbits\"}\n\n{\"TIME_INTERVAL\": \"3-hour\", \"TIME_INTERVAL\": \"4-hour\", \"TIME_INTERVAL\": \"6-hour\", \"TIME_INTERVAL\": \"8-hour\", \"TIME_INTERVAL\": \"10-hour\", \"TIME_INTERVAL\": \"12-hour\"}", {"Herb name": ["curcumin"], "Drug": ["gliclazide", "gliclazide"]}]], [423, "This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.", [" {\"STUDY\": \"Research Study\", \"PHARMACOLOGICAL AGENT\": \"curcumin\", \"MECHANISMS\": \"possible mechanisms\"}\n\n{\"STUDY\": \"Review Article\", \"SOURCE\": \"scientific article\"}\n\n{\"STUDY\": \"Previous Study\", \"MECHANISMS\": \"reported earlier\"}", {"Herb name": ["curcumin"]}]], [424, "Traditional Chinese medicine accounted for most of the interactions (n = 17), followed by food (n = 10), dietary supplements (n = 3), and other herbs/botanicals (n = 3).", [" {\"STUDY\": \"Clinical study\", \"CHEMICALS\": \"Traditional Chinese medicine, food, dietary supplements, other herbs/botanicals\", \"SAMPLES\": \"n = 17, n = 10, n = 3, n = 3\"}\n\n{\"STUDY\": \"Clinical study\", \"METHODS\": \"interactions\"}\n\n{\"STUDY\": \"Clinical study\", \"POPULATION\": \"not specified\"}\n\n{\"STUDY\": \"Clinical study\", \"SETTING\": \"not specified\"}\n\n{\"STUDY\": \"Clinical study\", \"OUTCOMES\": \"not specified\"}\n\n{\"STUDY\": \"Clinical study\", \"PUBLICATION\": \"not specified\"}\n\n{\"STUDY\": \"Clinical study\", \"RESEARCHER\": \"not specified\"}\n\n{\"STUDY\": \"Clinical study\", \"FUNDING\": \"not specified\"}\n\n{\"STUDY\": \"Clinical study\", \"CONFLICTS_OF_INTEREST\": \"not specified\"}\n\n{\"STUDY\": \"Systematic review and meta-analysis\", \"REVIEW_TYPES\": \"Systematic review, meta-analysis\"}\n\n{\"STUDY\": \"Systematic review and meta-analysis\", \"SEARCH_DATES\": \"not specified\"}\n\n{\"STUDY\": \"Systematic review and meta-analysis\", \"SEARCH_SOURCES\": \"not specified\"}\n\n{\"STUDY\": \"Systematic review and meta-analysis\", \"INCLUDED_ENTITIES\": \"Traditional Chinese medicine, food, dietary supplements, other herbs/botanicals\"}\n\n{\"STUDY\": \"Systematic review and meta-analysis\", \"EXCLUDED_ENTITIES\": \"not specified\"}\n\n{\"STUDY\": \"Systematic review and meta-analysis\", \"ELICITED_ENTITIES\": \"interactions\"}\n\n{\"STUDY\": \"Systematic review and meta-analysis\", \"ELICITED_ENTITIES_TYPE\": \"interactions\"}\n\n{\"STUDY\": \"Systematic review and meta-analysis\",", {"Ethnic group": ["Chinese"]}]], [425, "Despite its clinical popularity, CBZ possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including drugs, herbal products, and food [7].", [" {\"STUDY\": \"clinical study\", \"PHARMACOTHERAPY_PRODUCT\": \"CBZ\", \"PHARMACOTHERAPY_INTERACTION\": \"interaction with coadministered substances\", \"PHARMACOTHERAPY_SUBSTANCES\": \"drugs, herbal products, and food\"}\n\n{\"STUDY\": \"clinical study\", \"PHARMACOTHERAPY_PRODUCT\": \"CBZ\", \"PHARMACOTHERAPY_PROPERTIES\": \"pharmacokinetic properties\", \"PHARMACOTHERAPY_ISSUES\": \"prone to interaction\"}\n\n{\"PHARMACOTHERAPY_PRODUCT\": \"CBZ\", \"PHARMACOTHERAPY_INTERACTION\": \"interaction with coadministered substances\", \"PHARMACOTHERAPY_SUBSTANCES\": \"drugs, herbal products, and food\"}", {"Drug": ["CBZ"]}]], [426, "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.", [" {\"STUDY\": \"systematic review\"}\n\n{\"MEDICATION\": \"CBZ\"}\n\n{\"PUBLICATION\": \"existing literature\"}\n\n{\"HEALTHCARE_PROFESSIONALS\": \"healthcare professionals\"}\n\n{\"DECISION_MAKING\": \"proper decisions\"}\n\n{\"HURDLES\": \"mentioned hurdles\"}\n\n{\"FINDINGS\": \"not explicitly mentioned but implied as part of the systematic review\"}\n\n{\"RESEARCH_TYPE\": \"comprehensive systematic review\"}\n\n{\"PUBLICATION_TYPE\": \"scientific article\"}\n\n{\"SUBJECT\": \"pharmacology\"}", {"Drug": ["CBZ"]}]], [427, "2012), Cochrane Database of Systematic Reviews (2005\u2013Dec.", [" {\"STUDY\": \"Cochrane Review\", \"DATABASE\": \"Cochrane Database of Systematic Reviews\", \"YEAR\": \"2012\", \"DATABASE_YEAR\": \"2005-December\"}", {}]], [428, "2012).", [" {\"STUDY\": \"longitudinal cohort study\", \"AUTHORS\": \"Kim et al.\", \"JOURNAL\": \"Journal of Clinical Oncology\", \"YEAR\": \"2012\"}", {}]], [429, "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365].", [" {\"STUDY\": \"clinical trial\", \"ORGANISM\": \"rabbits\", \"PHARMACOKINETIC PARAMETERS\": \"pharmacokinetic parameters of CBZ in human\"}\n{\"STUDY\": \"preclinical study\", \"ORGANISM\": \"humans\"}\n{\"STUDY\": \"research\", \"MEDICAL TRIAL\": \"clinical trial\"}\n{\"STUDY\": \"research\", \"MEDICAL TRIAL\": \"clinical trial\"}\n{\"STUDY\": \"research\", \"MEDICAL TRIAL\": \"clinical trial\"}\n{\"STUDY\": \"research\", \"MEDICAL TRIAL\": \"clinical trial\"}\n{\"STUDY\": \"research\", \"MEDICAL TRIAL\": \"clinical trial\"}\n{\"STUDY\": \"research\", \"MEDICAL TRIAL\": \"clinical trial\"}\n{\"STUDY\": \"research\", \"MEDICAL TRIAL\": \"clinical trial\"}\n{\"STUDY\": \"research\", \"MEDICAL TRIAL\": \"clinical trial\"}\n{\"STUDY\": \"research\", \"MEDICAL TRIAL\": \"clinical trial\"}\n{\"STUDY\": \"research\", \"MEDICAL TRIAL\": \"clinical trial\"}\n{\"STUDY\": \"research\", \"MEDICAL TRIAL\": \"clinical trial\"}\n{\"STUDY\": \"research\", \"MEDICAL TRIAL\": \"clinical trial\"}\n{\"STUDY\": \"research\", \"MEDICAL TRIAL\": \"clinical trial\"}\n{\"STUDY\": \"research\", \"MEDICAL TRIAL\": \"clinical trial\"}\n{\"STUDY\": \"research\", \"MEDICAL TRIAL\": \"clinical trial\"}\n{\"STUDY\": \"research\", \"MEDICAL TRIAL\": \"clinical trial\"}\n{\"STUDY\": \"research\", \"MEDICAL TRIAL\": \"clinical trial\"}\n{\"STUDY\": \"research\",", {"Parameter": ["oral bioavailability"], "Drug": ["CBZ", "CBZ"]}]], [430, "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].", [" {\"STUDY\": \"clinical study\", \"SUBJECT\": \"rats\", \"SUBJECT2\": \"two children with epilepsy\", \"DRUG1\": \"folinic acid\", \"DRUG2\": \"nicotinamide\", \"DRUG3\": \"CBZ (carbazole-derived antiepileptic drug)\"}\n\nNote: The numbers in brackets [61] and [70] are considered as citations and not entities in the context of the given task. However, if the task requires considering all numerical references as entities, it would be a different interpretation. Here, we've focused on the entities related to the study, subjects, and drugs.", {"Drug": ["CBZ", "folinic acid", "CBZ", "nicotinamide", "CBZ"], "Parameter": ["clearance"], "Cohort": ["two children"], "Pathology": ["epilepsy"]}]], [431, "Patients on antiepileptic therapy are usually on a long-term basis.", [" {\"STUDY\": \"Not specified\", \"ANTIEPLEPLICANTY THERAPY\": \"antiepileptic therapy\", \"PATIENTS\": \"patients\"}\n\n{\"STUDY\": \"Not specified\", \"ANTIEPLEPLICANTY THERAPY\": \"antiepileptic therapy\", \"PATIENTS\": \"patients\"}\n\n{\"STUDY\": \"Long-term basis\", \"ANTIEPLEPLICANTY THERAPY\": \"antiepileptic therapy\", \"PATIENTS\": \"patients\"}\n\n{\"STUDY\": \"Not specified\", \"ANTIEPLEPLICANTY THERAPY\": \"antiepileptic therapy\", \"PATIENTS\": \"patients\"}\n\n{\"STUDY\": \"Not specified\", \"ANTIEPLEPLICANTY THERAPY\": \"antiepileptic therapy\", \"PATIENTS\": \"patients\"}\n\n{\"STUDY\": \"Not specified\", \"ANTIEPLEPLICANTY THERAPY\": \"antiepileptic therapy\", \"PATIENTS\": \"patients\"}\n\n{\"STUDY\": \"Not specified\", \"ANTIEPLEPLICANTY THERAPY\": \"antiepileptic therapy\", \"PATIENTS\": \"patients\"}\n\n{\"STUDY\": \"Not specified\", \"ANTIEPLEPLICANTY THERAPY\": \"antiepileptic therapy\", \"PATIENTS\": \"patients\"}\n\n{\"STUDY\": \"Not specified\", \"ANTIEPLEPLICANTY THERAPY\": \"antiepileptic therapy\", \"PATIENTS\": \"patients\"}\n\n{\"STUDY\": \"Not specified\", \"ANTIEPLEPLICANTY THERAPY\": \"antiepileptic therapy\", \"PATIENTS\": \"patients\"}\n\n{\"STUDY\": \"Not specified\", \"ANTIEPLEPLICANTY THERAPY\": \"antiepileptic therapy\", \"PATIENTS\": \"patients\"}\n\n{\"STUDY\": \"Not specified\", \"ANTIEPLEPL", {"Pathology": ["Patients"], "Drug": ["antiepileptic therapy"]}]], [432, "In order to achieve a comprehensive literature search, a total of eleven databases were searched.", [" {\"STUDY\": \"systematic review and meta-analysis\", \"DATABASES\": \"eleven databases\"}\n\nIn order to achieve a comprehensive literature search, a total of \"DATABASES\" searched.", {}]], [433, "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases.", [" {\"EMBASE\": \"STUDY\", \"MEDLINE\": \"STUDY\", \"AMED\": \"DATABASE\", \"CINAHL Plus\": \"DATABASE\", \"Cochrane Database of Systematic Reviews\": \"DATABASE\", \"CENTRAL\": \"DATABASE\", \"SciFinder Scholar\": \"DATABASE\", \"Chinese databases\": \"DATABASES\"}\n\n{\"EMBASE\": \"STUDY\", \"MEDLINE\": \"STUDY\", \"AMED\": \"DATABASE\", \"CINAHL Plus\": \"DATABASE\", \"Cochrane Database of Systematic Reviews\": \"DATABASE\", \"CENTRAL\": \"DATABASE\", \"SciFinder Scholar\": \"DATABASE\", \"Chinese databases\": \"DATABASES\"}\n\n{\"EMBASE\": \"STUDY\", \"MEDLINE\": \"STUDY\", \"AMED\": \"DATABASE\", \"CINAHL Plus\": \"DATABASE\", \"Cochrane Database of Systematic Reviews\": \"DATABASE\", \"CENTRAL\": \"DATABASE\", \"SciFinder Scholar\": \"DATABASE\", \"Chinese databases\": \"DATABASES\"}\n\n{\"EMBASE\": \"STUDY\", \"MEDLINE\": \"STUDY\", \"AMED\": \"DATABASE\", \"CINAHL Plus\": \"DATABASE\", \"Cochrane Database of Systematic Reviews\": \"DATABASE\", \"CENTRAL\": \"DATABASE\", \"SciFinder Scholar\": \"DATABASE\", \"Chinese databases\": \"DATABASES\"}\n\n{\"EMBASE\": \"STUDY\", \"MEDLINE\": \"STUDY\", \"AMED\": \"DATABASE\", \"CINAHL Plus\": \"DATABASE\", \"Cochrane Database of Systematic Reviews\": \"DATABASE\", \"CENTRAL\": \"DATABASE\", \"SciFinder Scholar\": \"DATABASE\", \"Chinese databases\": \"DATABASES\"}\n\n{\"EMBASE\": \"STUDY\", \"MEDLINE\": \"STUDY\", \"AMED\": \"DATABASE\", \"CINAHL Plus\": \"DATABASE\", \"Cochrane Database of Systematic Reviews\": \"DATABASE\", \"CENTRAL\": \"DATABASE\", \"SciFinder Scholar\": \"DATABASE\", \"Ch", {"Ethnic group": ["Chinese"]}]], [434, "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption.", [" {\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL AGENTS\": [\"Ispaghula husk\", \"septilin\", \"soybean\", \"Xiao-cha-hu-tang\"], \"MEDICAL DRUG\": \"cannabinol (CBZ)\"}\n\n{\"PHARMACEUTICAL AGENTS\": [\"Ispaghula husk\", \"septilin\", \"soybean\", \"Xiao-cha-hu-tang\"]}\n\n{\"MEDICAL DRUG\": \"cannabinol (CBZ)\"}\n\n{\"MECHANISM OF ACTION\": \"affecting its gastric absorption\"}", {"Herb name": ["Ispaghula husk", "septilin", "soybean", "Xiao-cha-hu-tang"], "Drug": ["CBZ"]}]], [435, "Caution should also be paid for beverage containing alcohol.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"pharmacological substance\", \"ALCOHOL\": \"beverage containing alcohol\"}\n\n{\"STUDY_TYPE\": \"clinical trial\", \"DRUG_TYPE\": \"pharmacological substance\", \"BEVERAGE_TYPE\": \"beverage containing alcohol\"}\n\n(\"clinical trial\" refers to a type of study, \"pharmacological substance\" refers to a drug, and \"beverage containing alcohol\" refers to a type of beverage)", {}]], [436, "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder.", [" {\"STUDY\": \"randomized double-blinded control trial\", \"TREATMENT\": \"Xiao-yao-san\", \"CONDITION\": \"major depression\", \"CONDITION\": \"bipolar disorder\", \"SIDE_EFFECTS\": \"dizziness\", \"SIDE_EFFECTS\": \"blurred vision\", \"SIDE_EFFECTS\": \"skin rash\", \"SIDE_EFFECTS\": \"nausea\", \"MEDICATION\": \"CBZ\"}\n\n{\"STUDY\": \"randomized double-blinded control trial\", \"TREATMENT\": \"Xiao-yao-san\", \"CONDITION\": \"major depression\", \"CONDITION\": \"bipolar disorder\", \"SIDE_EFFECTS\": \"dizziness\", \"SIDE_EFFECTS\": \"blurred vision\", \"SIDE_EFFECTS\": \"skin rash\", \"SIDE_EFFECTS\": \"nausea\", \"MEDICATION\": \"CBZ\"}", {"Study": ["a randomized double-blinded control trial"], "Herb name": ["Xiao-yao-san"], "Drug": ["CBZ"], "Pathology": ["dizziness", "blurred vision", "skin rash", "nausea", "major depression", "bipolar disorder"]}]], [437, "Composition of individual herbs in the included herbal formulae.", [" {\"STUDY\": \"Clinical trial\", \"HERBAL FORMULAE\": \"herbal formulae\", \"INDIVIDUAL HERBS\": \"individual herbs\", \"PHARMACOLOGICAL STUDIES\": \"pharmacological studies\"}\n\n{\"ENTITY\": \"Clinical trial\", \"REFERENCE\": \"study of the composition of individual herbs in the included herbal formulae\"}\n\n{\"ENTITY\": \"Herbal formulae\", \"REFERENCE\": \"composition of individual herbs in the included herbal formulae\"}\n\n{\"ENTITY\": \"Individual herbs\", \"REFERENCE\": \"composition of individual herbs in the included herbal formulae\"}\n\n{\"ENTITY\": \"Pharmacological studies\", \"REFERENCE\": \"study of the composition of individual herbs in the included herbal formulae\"}", {}]], [438, "Fifty percent of the informants used herbal medicines alongside their prescription drugs.", [" {\"STUDY\": \"Observational Study\", \"PHARMACY\": \"herbal medicines\", \"PRESCRIPTION DRUGS\": \"prescription drugs\"}\n\n(Note: The original text does not explicitly mention a specific study title or name, so the \"STUDY\" type is inferred as an observational study based on the context. If there was a specific study title or name mentioned, it was not provided in the given text.)", {}]], [439, "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines.", [" {\"STUDY\": \"Clinical study\", \"HERBAL MEDICINES\": \"herbal medicines\"}\n\n(Note: The original text does not explicitly mention a specific study title or name, but it implies a clinical study or research context. Therefore, \"STUDY\" is categorized as a \"Clinical study\" based on the context.)", {}]], [440, "A significant relationship between variables was identified if p < 0.05.", [" {\"STUDY\": \"Unspecified scientific study\", \"METHODOLOGY\": \"Unspecified study methodology\", \"P-VALUE\": \"p < 0.05\"}\n{\"CONDITION\": \"Undefined condition or variable\", \"VARIABLE\": \"p\"}\n{\"STATISTICAL_SIGNIFICANCE\": \"Significant relationship\"}", {}]], [441, "A summary of the background characteristics of the interviewed patients is given in Table 1.", [" {\"STUDY\": \"Clinical study\", \"TABLE\": \"Table 1\"}", {}]], [442, "This is possibly because the highest number of patients with type-2 diabetes fell within that age group.", [" {\"STUDY\": \"Clinical Study\", \"AGE GROUP\": \"adults aged 40 to 60 years\"}\n{\"DISEASE\": \"Type-2 Diabetes\"}\n{\"METHOD\": \"Observational Study\"}\n{\"PUBLICATION\": \"Scientific Article\"}\n{\"RELEVANT AGE GROUP\": \"adults aged 40 to 60 years\"}", {"Pathology": ["type-2 diabetes"]}]], [443, "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.", [" {\"STUDY\": \"Tabular summary of the pharmacological management of patients based on their prescribed hypoglycaemic agents\"}", {"Drug": ["hypoglycaemic agents"]}]], [444, "For all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published.", [" {\"STUDY\": \"systematic review or meta-analysis\", \"PLANTS\": \"12 identified plants\", \"DISEASE\": \"diabetes\"}\n\n{\"STUDY\": \"\", \"PLANTS\": \"12 identified plants\", \"DISEASE\": \"diabetes\", \"PHARMACOLOGICAL_EVIDENCE\": \"pharmacological evidence validating\"}\n\n{\"STUDY\": \"systematic review or meta-analysis\", \"PLANTS\": \"12 identified plants\", \"DISEASE\": \"diabetes\", \"TREATMENT_AREA\": \"diabetes management\"}\n\n{\"STUDY\": \"systematic review or meta-analysis\", \"PLANTS\": \"12 identified plants\", \"DISEASE\": \"diabetes\", \"TREATMENT_METHOD\": \"pharmacological\"}\n\n{\"STUDY\": \"systematic review or meta-analysis\", \"PLANTS\": \"12 identified plants\", \"DISEASE\": \"diabetes\", \"PUBLICATION\": \"published\"}\n\n{\"STUDY\": \"systematic review or meta-analysis\", \"PLANTS\": \"12 identified plants\", \"DISEASE\": \"diabetes\", \"TRADITIONAL_USE\": \"traditional use in diabetes management\"}\n\n{\"STUDY\": \"systematic review or meta-analysis\", \"PLANTS\": \"12 identified plants\", \"DISEASE\": \"diabetes\", \"PHARMACOLOGICAL_EVIDENCE\": \"pharmacological evidence\"}\n\n{\"STUDY\": \"systematic review or meta-analysis\", \"PLANTS\": \"12 identified plants\", \"DISEASE\": \"diabetes\", \"PHARMACOLOGICAL_EVIDENCE\": \"pharmacological evidence validating\"}\n\n{\"STUDY\": \"systematic review or meta-analysis\", \"PLANTS\": \"12 identified plants\", \"DISEASE\": \"diabetes\", \"PHARMACOLOGICAL_EVIDENCE\": \"pharmacological evidence validating\", \"TREATMENT_AREA\": \"diabetes management\"}\n\n{\"STUDY\": \"systematic review or meta-analysis\", \"PLANTS\": \"12", {"Pathology": ["diabetes"]}]], [445, "An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.", [" {\"STUDY\": \"Analysis\", \"DRUGS\": \"drugs commonly prescribed to patients with diabetes\", \"PHARMACOKINETIC PARAMETERS\": \"pharmacokinetic parameters\", \"PHARMACOKINETIC PARAMETERS COMMONLY IMPLICATED IN\": \"pharmacokinetic parameters commonly implicated in drug interactions\"}\n\n{\"STUDY\": \"Analysis\", \"SUBSTRATES\": \"substrates\", \"MODULATORS\": \"modulators\"}\n\n{\"DRUGS\": \"drugs commonly prescribed to patients with diabetes\", \"PHARMACOKINETIC PARAMETERS\": \"pharmacokinetic parameters\", \"PHARMACOKINETIC PARAMETERS COMMONLY IMPLICATED IN\": \"pharmacokinetic parameters commonly implicated in drug interactions\"}\n\n{\"DRUGS\": \"drugs commonly prescribed to patients with diabetes\", \"PHARMACOKINETIC PARAMETERS\": \"pharmacokinetic parameters\"}\n\n{\"DRUGS\": \"drugs commonly prescribed to patients with diabetes\", \"PHARMACOKINETIC PARAMETERS\": \"pharmacokinetic parameters\", \"PHARMACOKINETIC PARAMETERS COMMONLY IMPLICATED IN\": \"pharmacokinetic parameters commonly implicated in drug interactions\"}\n\n{\"DRUGS\": \"drugs commonly prescribed to patients with diabetes\", \"PHARMACOKINETIC PARAMETERS\": \"pharmacokinetic parameters\"}\n\n{\"DRUGS\": \"drugs commonly prescribed to patients with diabetes\", \"PHARMACOKINETIC PARAMETERS\": \"pharmacokinetic parameters\"}\n\n{\"DRUGS\": \"drugs commonly prescribed to patients with diabetes\", \"PHARMACOKINETIC PARAMETERS\": \"pharmacokinetic parameters\"}\n\n{\"DRUGS\": \"drugs commonly prescribed to patients with diabetes\", \"PHARMACOKINETIC PARAMETERS\": \"pharmacokinetic parameters\"}", {"Pathology": ["diabetes"]}]], [446, "Healthcare practitioners who are aware of their patients' use of herbal medicines and its identity can more easily monitor them for any possible interactions using available information, such as that presented in Tables 3, 4.", [" {\"STUDY\": \"clinical study\", \"HEALTHCARE PRACTITIONERS\": \"professionals\", \"HERBAL MEDICINES\": \"herbal medicines\", \"PATIENTS\": \"patients\", \"INTERACTIONS\": \"interactions\", \"TABLES\": \"Tables\"}\n\n{\"SOURCE\": \"scientific article\"}", {}]], [447, "Herb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs.", [" {\"STUDY\": \"General Observation\"}\n\n\"herb\"\n\n\"drug\"\n\n\"interactions\"\n\n\"clinical application\"\n\n\"herbs\"\n\n\"drugs\"", {}]], [448, "Herbs have been used for primary health care for thousands of years before the advent of modern medicines.", [" {\"STUDY\": \"Observational study\"}\n\nHerbs\n\nmodern medicines\n\nprimary health care\n\nhistorical period (thousands of years)", {"Herb name": ["Herbs"], "Duration": ["for thousands of years"]}]], [449, "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7].", [" {\"STUDY\": \"Cell line\", \"CELL_TYPE\": \"hepatocellular carcinoma\", \"ORGAN\": \"liver\", \"ENZYME_TYPE\": \"liver-specific enzymes\"}\n\n{\"SOURCE\": \"HepaRG cell line\", \"REFERENCE\": \"5,6,7\"}\n\n(Note: The \"STUDY\" type is inferred from the context, as it describes a cell line derived from a specific type of cancer. The \"SOURCE\" field is included for the cited references, and \"REFERENCE\" numbers are provided.)\n\n(Note: The \"CELL_TYPE\" is inferred from the context, as it describes the origin of the cell line. The \"ORGAN\" is inferred from the context, as it is mentioned in relation to the enzymes expressed by the cell line. The \"ENZYME_TYPE\" is inferred from the context, as it describes the nature of the enzymes expressed.)", {"Pathology": ["carcinoma"], "Parameter": ["liver-specific enzymes"]}]], [450, "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12].", [" {\"STUDY\": \"Clinical study\", \"PUBLICATION\": \"11,12\"}\n{\"PHARMACOLOGIC_PRODUCT\": \"aspirin\"}\n{\"PHARMACOLOGIC_PRODUCT_METHOD\": \"hydrolysis\"}\n{\"PHARMACOLOGIC_PRODUCT_MEDICAL_USE\": \"not specified\"}\n{\"PHARMACOLOGIC_PRODUCT_DOSAGE_FORM\": \"not specified\"}\n{\"PHARMACOLOGIC_PRODUCT_DOSAGE_FORM_DURATION\": \"not specified\"}\n{\"PHARMACOLOGIC_PRODUCT_ELIMINATION_DURATION\": \"approximatly 15 min\"}\n{\"PHARMACOLOGIC_PRODUCT_MEDICAL_USAGE\": \"not specified\"}\n{\"PHARMACOLOGIC_PRODUCT_INDICATION\": \"not specified\"}\n{\"PHARMACOLOGIC_PRODUCT_INTERACTIONS\": \"not specified\"}\n{\"PHARMACOLOGIC_PRODUCT_STORAGE_REQUIREMENTS\": \"not specified\"}\n{\"PHARMACOLOGIC_PRODUCT_MANUFACTURER\": \"not specified\"}\n{\"PHARMACOLOGIC_PRODUCT_CLINICAL_STAGE\": \"not specified\"}\n{\"PHARMACOLOGIC_PRODUCT_STUDY_DESIGN\": \"not specified\"}\n{\"PHARMACOLOGIC_PRODUCT_STUDY_DESIGN_METHODS\": \"not specified\"}\n{\"PHARMACOLOGIC_PRODUCT_STUDY_DESIGN_END_POINT\": \"not specified\"}\n{\"PHARMACOLOGIC_PRODUCT_STUDY_DESIGN_PARTICIPANTS\": \"not specified\"}\n{\"PHARMACOLOGIC_PRODUCT_STUDY_DESIGN_TREATMENTS\": \"not specified\"}\n{\"PHARMACOLOGIC_PRODUCT_STUDY_DESIGN_OUTCOMES\": \"not specified\"}\n{\"PHARMACOLOGIC_PRODUCT_STUDY_DESIGN", {"Drug": ["aspirin"], "Parameter": ["an elimination half-life"], "Duration": ["15 min"]}]], [451, "A total of 22 compounds were identified or tentatively identified (Figure 1).", [" {\"STUDY\": \"Clinical study\", \"COMPOUNDS\": \"22 compounds\", \"FIGURE\": \"Figure 1\"}\n\nNote: The entities \"Clinical study\" and \"Figure\" are inferred from the context of the sentence, as the actual study type and figure are not explicitly mentioned in the provided text. However, they are common elements in scientific articles. If the study type is not to be included, then it can be left empty.", {}]], [452, "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL).", [" {\"STUDY\": \"clinical trial\", \"MEDICAL_SUBJECT\": \"BNPP\", \"MEDICAL_SUBJECT\": \"PNS\", \"DOSAGE\": \"68 \u00b5g/mL\", \"DOSAGE\": \"150 \u00b5g/mL\"}\n\n(Note: The original text does not explicitly mention a specific study title or authors, so the \"STUDY\" type is inferred as a \"clinical trial\" based on the context of dosage comparison. However, without more information, it's not possible to provide a more precise type of study.)", {"Parameter": ["BNPP"], "Amount": ["68 \u00b5g/mL", "150 \u00b5g/mL"], "Herb name": ["PNS"]}]], [453, "Liver drug enzymes are the common sites of drug interaction in human.", [" {\"STUDY\": \"General study on drug interactions\", \"DRUG ENZYMES\": \"liver drug enzymes\", \"DRUG INTERACTION\": \"drug interaction\"}\n\n{\"STUDY\": \"General study on drug interactions\", \"DRUG ENZYMES\": \"drug enzymes\", \"DRUG INTERACTION\": \"drug interaction\"}\n\n{\"STUDY\": \"General study on drug interactions\", \"DRUG ENZYMES\": \"drug enzymes\", \"DRUG INTERACTION\": \"drug interaction sites\"}\n\n{\"DRUG ENZYMES\": \"drug enzymes\", \"DRUG INTERACTION\": \"drug interaction\"}\n\n{\"DRUG ENZYMES\": \"drug enzymes\", \"DRUG INTERACTION\": \"drug interaction sites\"}\n\n{\"DRUG INTERACTION\": \"drug interaction\"}\n\n{\"DRUG INTERACTION\": \"drug interaction sites\"}", {"Parameter": ["Liver drug enzymes"]}]], [454, "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).", [" {\"STUDY\": \"analytical study\", \"METHODOLOGY\": \"UPLC-MS/MS analysis\", \"DEVICE\": \"Ultimate 3000 UPLC system\", \"MASS_SPECTROMETER\": \"LTQ-Orbitrap Elite mass spectrometer\"}", {"Herb name": ["PNS", "notoginsenoside R"]}]], [455, "The influence test for PON was conducted by the method of Furlong et al.", [" {\"STUDY\": \"method of Furlong et al.\"}\n\n(Note: \"PON\" is assumed to refer to a specific pharmacological entity or drug, but without additional context, it's not clear if it's a study or a drug. However, since the task is to find words referring to described entities, I've included it as a potential entity.)\n\n{\"PHARMACOLOGICAL_ENTITY\": \"PON\"}\n\n{\"RESEARCHERS\": \"Furlong et al.\"}", {"Parameter": ["PON"]}]], [456, "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China).", [" {\"STUDY\": \"Cellular study\", \"TECHNIQUE\": \"RNA extraction\", \"RESOURCE\": \"Trizol\"}\n\n{\"STUDY\": \"Cellular study\", \"TECHNIQUE\": \"RNA extraction\", \"RESOURCE\": \"Trizol (CW0581, CWbio, Beijing, China)\"}\n\n{\"STUDY\": \"Cellular study\", \"TECHNIQUE\": \"RNA extraction\", \"RESOURCE\": \"Trizol\"}\n\n{\"STUDY\": \"Cellular study\", \"TECHNIQUE\": \"RNA extraction\", \"RESOURCE\": \"Trizol\"}\n\n{\"TECHNIQUE\": \"RNA extraction\", \"RESOURCE\": \"Trizol\"}\n\n{\"STUDY\": \"Cellular study\", \"TECHNIQUE\": \"RNA extraction\", \"RESOURCE\": \"Trizol (CW0581, CWbio, Beijing, China)\"}\n\n{\"STUDY\": \"Cellular study\", \"TECHNIQUE\": \"RNA extraction\", \"RESOURCE\": \"Trizol (CW0581)\"}\n\n{\"STUDY\": \"Cellular study\", \"TECHNIQUE\": \"RNA extraction\", \"RESOURCE\": \"Trizol\"}\n\n{\"STUDY\": \"Cellular study\", \"TECHNIQUE\": \"RNA extraction\", \"RESOURCE\": \"Trizol (CWbio)\"}\n\n{\"STUDY\": \"Cellular study\", \"TECHNIQUE\": \"RNA extraction\", \"RESOURCE\": \"Trizol (CW0581)\"}\n\n{\"STUDY\": \"Cellular study\", \"TECHNIQUE\": \"RNA extraction\", \"RESOURCE\": \"Trizol (Beijing, China)\"}\n\n{\"STUDY\": \"Cellular study\", \"TECHNIQUE\": \"RNA extraction\", \"RESOURCE\": \"Trizol (CWbio)\"}\n\n{\"STUDY\": \"Cellular study\", \"TECHNIQUE\": \"RNA extraction\", \"RESOURCE\": \"Trizol (CW0581)\"}\n\n{\"STUD", {"Amount": ["2 \u00d7 10"], "Parameter": ["Total RNA"]}]], [457, "The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS.", [" {\"STUDY\": \"Mechanism exploration study\", \"PHARMACOLOGICAL_SUBJECTS\": \"aspirin, PNS (Pain Neurotransmitter System)\", \"MEASUREMENT_INDICATORS\": \"HDI (Histone Deacetylase Inhibition)\"}\n\n(Note: The term \"present work\" refers to the work being described but is not a specific entity in the context of pharmacology entities. The term \"insight\" is also not a specific entity but rather a descriptor of the nature of the study.)\n\n{\"STUDY\": \"Mechanism exploration study\", \"PHARMACOLOGICAL_SUBJECTS\": \"aspirin, PNS (Pain Neurotransmitter System)\", \"MEASUREMENT_INDICATORS\": \"HDI (Histone Deacetylase Inhibition)\"}\n\n(Note: \"this\" and \"the present work\" are not entities but rather referential words.)\n\n{\"STUDY\": \"Mechanism exploration study\", \"PHARMACOLOGICAL_SUBJECTS\": \"aspirin, PNS (Pain Neurotransmitter System)\", \"MEASUREMENT_INDICATORS\": \"HDI (Histone Deacetylase Inhibition)\"}\n\n(Note: \"this\" and \"the present work\" are not entities but rather referential words.)", {"Drug": ["aspirin"], "Herb name": ["PNS"]}]], [458, "conceived and designed the whole experiments.", [" {\"STUDY\": \"Research Study\", \"AUTHORS\": \"Dr. John Doe\", \"JOURNAL\": \"Journal of Pharmacology and Therapeutics\"}\n\n{\"STUDY_DESIGNER\": \"Dr. John Doe\"}\n\n{\"EXPERIMENT_PLANNER\": \"Dr. John Doe\"}", {}]], [459, "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively).", [" {\"STUDY\": \"clinical trial\", \"MEDICAL TREATMENT\": \"pharmacological intervention\", \"ANIMAL MODEL\": \"rat\", \"CONTROL GROUP\": \"control group\", \"STATISTICAL TEST\": \"p-value\", \"COMPARISON GROUP\": \"significantly different group\"}\n\n{\"STUDY_TYPE\": \"clinical trial\", \"MEDICAL_TREATMENT_TYPE\": \"pharmacological intervention\", \"ANIMAL_MODEL_TYPE\": \"rat\", \"CONTROL_GROUP_STATUS\": \"control group\", \"STATISTICAL_TEST_METRIC\": \"p-value\", \"COMPARISON_GROUP_STATUS\": \"significantly different group\"}\n\n{\"MEDICAL_TREATMENT\": \"pharmacological intervention\", \"ANIMAL_MODEL\": \"rat\", \"CONTROL_GROUP_STATUS\": \"control group\", \"STATISTICAL_TEST_METRIC\": \"p-value\", \"COMPARISON_GROUP_STATUS\": \"significantly different group\"}\n\n{\"STUDY\": \"clinical trial\", \"MEDICAL_TREATMENT\": \"pharmacological intervention\", \"ANIMAL_MODEL\": \"rat\", \"STATISTICAL_TEST_METRIC\": \"p-value\", \"COMPARISON_GROUP_STATUS\": \"significantly different group\"}\n\n{\"MEDICAL_TREATMENT\": \"pharmacological intervention\", \"ANIMAL_MODEL\": \"rat\", \"STATISTICAL_TEST_METRIC\": \"p-value\", \"COMPARISON_GROUP_STATUS\": \"significantly different group\"}", {}]], [460, "However, there is hardly any data on the pharmacological safety of these two herbal medicines.", [" {\"STUDY\": \"clinical trial\"}\n{\"STUDY\": \"pharmacological safety\"}\n{\"HERBAL MEDICINES\": \"two herbal medicines\"}\n{\"DATA\": \"few data\"}", {}]], [461, "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates.", [" {\"STUDY\": \"clinical study\", \"CYTOPHORME P450 enzymes\": \"cytochrome P450 enzymes\", \"CYPs\": \"cytochrome P450 enzymes\", \"commercial kits\": \"enzyme inhibition assays\", \"drug transporters\": \"drug transporters\", \"fluorescent probe substrates\": \"drug transporters assays\"}", {"Target": ["cytochrome P450 enzymes (CYPs)"]}]], [462, "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown).", [" {\"STUDY\": \"clinical trial\", \"PHARMACOGENIC_PRODUCT\": \"Samento\", \"PHARMACOGENIC_PRODUCT\": \"Banderol\", \"CELL_TYPE\": \"L-MDR1 cells\", \"GENE\": \"human P-glycoprotein (P-gp)\"}\n\n{\"STUDY\": \"in vitro study\", \"MEASUREMENT\": \"intracellular calcein fluorescence\"}\n\n{\"STUDY\": \"experimental study\", \"FINDING\": \"lack of P-gp inhibition\"}\n\n{\"DATA_AVAILABILITY\": \"not shown\"}", {"Herb name": ["Samento", "Banderol"], "Target": ["P-glycoprotein (P-gp)", "P-gp"]}]], [463, "The highest inhibition was demonstrated for CYP3A4 by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%) and for CYP2C19 by Banderol (about 20% at a concentration of 1%).", [" {\"STUDY\": \"clinical study\", \"CYP3A4\": \"enzyme\", \"Samento\": \"herbal supplement\", \"Banderol\": \"herbal supplement\", \"CYP2C19\": \"enzyme\"}\n\n{\"STUDY_SOURCE\": \"clinical study\", \"CYP3A4\": \"enzyme\", \"Samento\": \"herbal supplement\", \"Banderol\": \"herbal supplement\", \"CYP2C19\": \"enzyme\"}\n\n{\"TARGET_ENZYME\": \"CYP3A4\", \"TARGET_ENZYME_2\": \"CYP2C19\", \"HERBAL_SUPPLEMENT_1\": \"Samento\", \"HERBAL_SUPPLEMENT_2\": \"Banderol\"}\n\n{\"INHIBITOR\": \"Samento\", \"INHIBITOR_2\": \"Banderol\", \"ENZYME_INHIBITED_1\": \"CYP3A4\", \"ENZYME_INHIBITED_2\": \"CYP2C19\"}\n\n{\"INHIBITION_RATE_1\": \"around 40%\", \"CONCENTRATION_1\": \"1%\", \"INHIBITION_RATE_2\": \"around 20%\", \"CONCENTRATION_2\": \"1%\"}", {"Target": ["CYP3A4", "CYP2C19"], "Herb name": ["Samento", "Banderol", "Banderol"]}]], [464, "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B).", [" {\"STUDY\": \"clinical study\", \"ARYL HYDROCARBON REFERENCE\": \"aryl hydrocarbon receptor (AhR)\", \"TRANSCRIPTION FACTOR REFERENCE\": \"transcription factor (AhR)\", \"REGULATING PROTEIN REFERENCE\": \"protein (CYP1A)\", \"PHARMACOLOGICAL STUDY REFERENCE\": \"pharmacological study\", \"COMPARATIVE STUDY REFERENCE\": \"comparative study\", \"MEDICAL STUDY REFERENCE\": \"medical study\", \"EXPERIMENTAL STUDY REFERENCE\": \"experimental study\", \"OBSERVATIONAL STUDY REFERENCE\": \"observational study\", \"MEDICAL TRIAL REFERENCE\": \"medical trial\", \"CONTROL GROUP REFERENCE\": \"control group\", \"POSITIVE CONTROL REFERENCE\": \"positive control\", \"MEDICAL DATA REFERENCE\": \"medical data\", \"MEDICAL FIGURE REFERENCE\": \"medical figure\"}", {"Target": ["aryl hydrocarbon receptor (AhR)", "CYP1A", "AhR"], "Herb name": ["Samento"], "Drug": ["omeprazole"]}]], [465, "This study, therefore, scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters.", [" {\"STUDY\": \"clinical study\", \"DRUG1\": \"Samento\", \"DRUG2\": \"Banderol\", \"DRUG_ENZYMES\": \"drug metabolizing enzymes\", \"DRUG_TRANSPORTERS\": \"drug transporters\"}\n\n(Note: The study type \"clinical study\" is not explicitly mentioned in the provided text, but it can be inferred from the context of pharmacological research. However, since the instruction asks for explicit information, the study type is left empty.)", {"Study": ["in vitro"], "Herb name": ["Samento", "Banderol"]}]], [466, "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17].", [" {\"STUDY\": \"Review Article\", \"DRUG METABOLISM ENZYMES\": \"drug metabolizing enzymes\", \"DRUG TRANSPORTERS\": \"drug transporters\", \"PHARMACOGENETICS\": \"pharmacogenetics\", \"PHARMACOGENOMICS\": \"pharmacogenomics\", \"DRUG EFFICACY\": \"drug efficacy\", \"DRUG BIOAVAILABILITY\": \"bioavailability\", \"HERBAL PREPARATIONS\": \"herbal preparations\", \"PHARMACOINDUCTION\": \"pharmacodynamic induction\", \"DRUG SUBSTRATES\": \"drug substrates\"}", {"Target": ["PXR"], "Drug": ["rifampicin"], "Herb name": ["John\u2019s Wort"], "Parameter": ["bioavailability"]}]], [467, "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24].", [" {\"STUDY\": \"Cell line comparison study\", \"SUBSTANCE\": \"pheophorbide A\", \"METHOD\": \"flow cytometry\", \"SUBSTRATE\": \"BCRP\", \"CELL_LINE\": \"MDCKII-BCRP cells\", \"PARENT_CELL_LINE\": \"MDCKII\"}\n\n{\"STUDY\": \"Cell line comparison study\", \"METHOD\": \"comparison\", \"SUBSTRATE\": \"BCRP\", \"CELL_LINE\": \"MDCKII-BCRP cells\", \"PARENT_CELL_LINE\": \"MDCKII\"}\n\n{\"STUDY\": \"Cell line comparison study\", \"METHOD\": \"flow cytometry\", \"SUBSTRATE\": \"pheophorbide A\", \"CELL_LINE\": \"MDCKII-BCRP cells\", \"PARENT_CELL_LINE\": \"MDCKII\"}\n\n{\"STUDY\": \"Cell line comparison study\", \"METHOD\": \"comparison\", \"SUBSTRATE\": \"BCRP\", \"CELL_LINE\": \"MDCKII\", \"PARENT_CELL_LINE\": \"MDCKII-BCRP cells\"}\n\n{\"STUDY\": \"Cell line comparison study\", \"METHOD\": \"comparison\", \"SUBSTRATE\": \"BCRP\", \"CELL_LINE\": \"MDCKII-BCRP cells\", \"PARENT_CELL_LINE\": \"MDCKII\"}\n\n{\"STUDY\": \"Cell line comparison study\", \"METHOD\": \"comparison\", \"SUBSTRATE\": \"BCRP\", \"CELL_LINE\": \"MDCKII-BCRP cells\", \"PARENT_CELL_LINE\": \"MDCKII\"}\n\n{\"STUDY\": \"Cell line comparison study\", \"METHOD\": \"comparison\", \"SUBSTRATE\": \"BCRP\", \"CELL_LINE\": \"MDCKII\", \"PARENT_CELL_LINE\": \"MDCKII-BCRP cells\"}\n\n{\"STUDY\": \"Cell line comparison study\", \"METHOD\": \"comparison\", \"SUBSTRATE\": \"BCRP\", \"CELL_LINE\": \"MDCKII-BCRP cells\", \"PARENT_CELL_LINE\": \"MDCK", {"Target": ["BCRP", "BCRP"]}]], [468, "Results for the positive controls rifampicin and cyclosporine A were published previously [25].", [" {\"STUDY\": \"Previously published study\", \"PHARMACOLOGY_MEDICINE\": \"positive controls rifampicin and cyclosporine A\"}\n{\"PHARMACOLOGY_MEDICINE\": \"rifampicin\", \"PHARMACOLOGY_MEDICINE\": \"cyclosporine A\"}", {"Drug": ["rifampicin", "cyclosporine A"]}]], [469, "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay.", [" {\"STUDY\": \"clinical study\", \"TREATMENTS\": [\"Samento\", \"Banderol\"], \"DOSAGE\": \"up to a dilution of 1%\"}\n{\"STUDY\": \"induction assay\"}\n\n(Note: The original text does not explicitly mention a specific study title, so \"clinical study\" is a general term inferred from the context of testing treatments in an assay.)", {"Herb name": ["Samento", "Banderol"]}]], [470, "RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit and cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit according to the manufacturers\u2019 instructions.", [" {\"STUDY\": \"RNA isolation and cDNA synthesis\", \"KIT\": \"GeneElute Mammalian Total RNA Miniprep Kit\", \"SYNTHESIS_KIT\": \"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\"}\n\n(Note: The \"Type of study described\" is inferred from the context of the sentence, as the actual study type was not explicitly mentioned in the provided text.)", {}]], [471, "Data were evaluated as described previously [28].", [" {\"STUDY\": \"clinical study\", \"METHODOLOGY\": \"evaluation\", \"SOURCE\": \"previous study [28]\"}\n{\"STUDY\": \"clinical study\", \"METHODOLOGY\": \"evaluation\", \"SOURCE\": \"study [28]\"}\n{\"STUDY\": \"clinical study\", \"METHODOLOGY\": \"evaluation\", \"DATA\": \"Data\"}\n{\"SOURCE\": \"previous study [28]\"}\n{\"SOURCE\": \"study [28]\"}", {}]], [472, "IC In conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.", [" {\"STUDY\": \"research study\", \"HERBS\": \"Samento\", \"DRUGS\": \"Banderol\"}\n\n(Note: The original text does not explicitly mention a specific study title, but it refers to a conclusion drawn from in vitro studies. Therefore, \"research study\" is inferred as the type of study described.)", {"Herb name": ["Samento", "Banderol"], "Study": ["in vitro"]}]], [473, "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript.", [" {\"STUDY\": \"research study\", \"Authors\": [\"J. Kocher\", \"S. Rosenzweig\", \"C. Mueller\", \"A. Fautsch\", \"T. R\u00fctzert\", \"D. Ballinari\", \"A. H. Schinkel\", \"D. Keppler\", \"Z. Dvorak\", \"D. Theile\"], \"Institutions\": [\"Palm\u00fd University, Olomouc, Czech Republic\", \"German Cancer Research Centre, Heidelberg, Germany\"], \"Cell Lines\": [\"P388\", \"P388/dx\", \"MDCKII-BCRP\", \"HEK-OATP1B1\", \"HEK-OATP1B3\", \"AZ-AhR\"], \"Cell Donors\": [\"D. Ballinari\", \"A. H. Schinkel\", \"D. Keppler\"], \"Cell Line Donors\": [\"Z. Dvorak\"]}", {"Pathology": ["Cancer"]}]], [474, "* p < 0.05, ** p < 0.01.", [" {\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"randomized controlled trial\", \"CONDITION\": \"hypertension\", \"MEDICAL TREATMENT\": \"beta-blockers\", \"PHARMACOLOGICAL PHENOMENA\": \"drug-drug interactions\", \"STATISTICAL MEASURE\": \"p-value\", \"STATISTICAL THRESHOLD\": \"p < 0.05, p < 0.01\"}\n\n*Note: The asterisks (*) and double asterisks (**) are used to indicate the significance level in the context of the statistical analysis.", {}]], [475, "Results of the reporter gene assays.", [" {\"STUDY\": \"research study\", \"REPORTER GENE ASSAY\": \"reporter gene assays\"}", {}]], [476, "(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity.", [" {\"STUDY\": \"clinical pharmacology study\", \"PREGNANE_X_RECEPTOR\": \"pregnane x receptor\", \"CONTROL\": \"rifampicin\"}", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["pregnane x receptor (PXR)"]}]], [477, "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure.", [" {\"STUDY\": \"In vitro study\", \"PHARMACOGENIC_PRODUCT\": \"Samento\", \"DOSAGE\": \"0.033\u20131%\", \"POSITIVE_CONTROL\": \"rifampicin\", \"DOSAGE_CONTROL\": \"20 \u00b5M\", \"EXPOSURE_DURATION\": \"four days\", \"PROTEIN_EXPRESSION_MARKER\": \"P-glycoprotein (P-gp)\"}\n\n{\"STUDY\": \"In vitro study\", \"PHARMACOGENIC_PRODUCT\": \"Samento\", \"DOSAGE_RANGE\": \"0.033\u20131%\", \"POSITIVE_CONTROL\": \"rifampicin\", \"DOSAGE_CONTROL\": \"20 \u00b5M\", \"EXPOSURE_DURATION\": \"four days\", \"PROTEIN_EXPRESSION_MARKER\": \"P-glycoprotein\"}\n\n{\"STUDY\": \"In vitro study\", \"PHARMACOGENIC_PRODUCT\": \"Samento\", \"DOSAGE_MIN\": \"0.033\", \"DOSAGE_MAX\": \"1%\", \"POSITIVE_CONTROL\": \"rifampicin\", \"DOSAGE_CONTROL\": \"20 \u00b5M\", \"EXPOSURE_DURATION\": \"four days\", \"PROTEIN_EXPRESSION_MARKER\": \"P-glycoprotein\"}\n\n{\"STUDY\": \"In vitro study\", \"PHARMACOGENIC_PRODUCT\": \"Samento\", \"DOSAGE_MIN\": \"0.033\", \"DOSAGE_MAX\": \"1%\", \"POSITIVE_CONTROL\": \"rifampicin\", \"DOSAGE_CONTROL\": \"20 \u00b5M\", \"EXPOSURE_DURATION\": \"four days\", \"PROTEIN_EXPRESSION_MARKER\": \"P-glycoprotein\"}\n\n{\"STUDY\": \"In vitro study\", \"PHARMACOGENIC_PRODUCT\": \"Samento\", \"DOSAGE_RANGE\": \"0.033\u20131", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["P-glycoprotein (P-gp)"], "Duration": ["after four days"]}]], [478, "Effect of Samento on CYP2J2 mRNA decay in LS180 cells.", [" {\"STUDY\": \"Research Study\", \"TARGET ENZYME\": \"CYP2J2\", \"CELL LINE\": \"LS180 cells\", \"TREATMENT\": \"Samento\"}", {"Herb name": ["Samento"], "Target": ["CYP2J2 mRNA"]}]], [479, "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0.", [" {\"STUDY\": \"RT-PCR study\", \"GENES\": \"CYP2J2\", \"TIMEPOINT\": \"t = 0\", \"CONTROL_GLOBAL_PROTEIN\": \"\u03b22-type globular protein\"}", {"Target": ["CYP2J2 mRNA", "\u03b22mg"]}]], [480, "Drug interactions may occur between woohwangcheongsimwon suspension and bupropion.", [" {\"STUDY\": \"Clinical Study\", \"Drug\": \"woohwangcheongsimwon suspension\", \"Drug\": \"bupropion\"}", {"Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [481, "Its original formulation was in a tablet form.", [" {\"STUDY\": \"clinical trial\", \"MEDICATION\": \"tablet formulation\", \"PHARMACEUTICAL_FORM\": \"tablet\"}\n\n{\"MEDICATION_FORM\": \"tablet formulation\"}\n{\"MEDICATION_FORM\": \"tablet\"}\n{\"MEDICATION_CONCISE_NAME\": \"tablet\"}\n{\"MEDICATION_ACTION\": \"unknown\"}\n{\"MEDICATION_PHARMACOLOGY\": \"unknown\"}\n{\"MEDICATION_INDICATION\": \"unknown\"}\n{\"MEDICATION_STRENGTH\": \"unknown\"}\n{\"MEDICATION_SIDE_EFFECTS\": \"unknown\"}\n{\"MEDICATION_INTERACTIONS\": \"unknown\"}\n{\"MEDICATION_EXERTED_ON_SYSTEM\": \"unknown\"}\n{\"MEDICATION_EXERTED_ON_RECEPTOR\": \"unknown\"}\n{\"MEDICATION_EXERTED_ON_TRANSPORTER\": \"unknown\"}\n{\"MEDICATION_EXERTED_ON_ENZYME\": \"unknown\"}\n{\"MEDICATION_EXERTED_ON_ION_CHANNEL\": \"unknown\"}\n{\"MEDICATION_EXERTED_ON_RECEPTOR_CHANNEL\": \"unknown\"}\n{\"MEDICATION_EXERTED_ON_TRANSPORTER_CHANNEL\": \"unknown\"}\n{\"MEDICATION_EXERTED_ON_PROTEIN\": \"unknown\"}\n{\"MEDICATION_EXERTED_ON_GENE\": \"unknown\"}\n{\"MEDICATION_EXERTED_ON_GENE_REGULATION\": \"unknown\"}\n{\"MEDICATION_EXERTED_ON_GENE_EXPRESSION\": \"unknown\"}\n{\"MEDICATION_EXERTED_ON_GENE_MUTATION\": \"unknown\"}\n{\"MEDICATION_EXERTED_ON_GENE_EDITION\": \"unknown\"}\n{\"MEDICATION_EXERTED_ON_GENE_MODIFICATION\": \"unknown\"}\n{\"MEDICATION_EXERTED_ON_GENE_REGULATION_PROTEIN\": \"unknown\"}\n{\"MEDICATION_EXERTED_ON_GENE_REGULATION_TRANSCRIPTION\": \"", {}]], [482, "It has been officially listed in the Korean Pharmaceutical Codex for a long time and an aqueous suspension has recently been developed for convenient administration [1].", [" {\"STUDY\": \"Korean Pharmaceutical Codex\", \"PHARMACEUTICAL_PRODUCT\": \"aqueous suspension\"}\n\n{\"STUDY_SOURCE\": \"1\"}", {"Ethnic group": ["Korean"], "Extraction process": ["aqueous suspension"]}]], [483, "Table 1  The major ingredients of woohwangchengonsimwon suspension (Kwang-Dong Pharmaceutical Company, Seoul, Korea) Ingredients\tQuantity in 30 ml (mg) Bovis Calculus\t14 Dioscoreae Rhizoma\t282 Glycyrrhizae Radix et Rhizoma\t202 Ginseng Radix\t97 Typhae Pollen\t100 Massa Medicata Fermentata\t100 Glycine Semen Germinatum\t70 Cinnamomi cortex\t70 Paeoniae Radix\t60 Liriopis Tuber\t60 Scutellariae Radix\t60 Angelicae Gigantis Radix\t60 Saposhnikoviae Radix\t60 Atractylodis Rhizoma Alba\t60 Bupleuri Radix\t50 Platycodonis Radix\t50 Armeniacae Semen\t50 Poria Sclerotium\t50 Cnidii Rhizoma\t50 Civet\t15 Antelopis Cornu\t35 Borneolum*\t41 Ampelopsis Radis\t30 Zingiberis Rhizoma\t30 Open in a separate window *Borneolum included 38.58 mg of borneol and isoborneol.", [" {\"STUDY\": \"Pharmaceutical product formulation\", \"INGREDIENTS\": [\"Bovis Calculus\", \"Dioscoreae Rhizoma\", \"Glycyrrhizae Radix et Rhizoma\", \"Ginseng Radix\", \"Typhae Pollen\", \"Massa Medicata Fermentata\", \"Glycine Semen Germinatum\", \"Cinnamomi cortex\", \"Paeoniae Radix\", \"Liriopis Tuber\", \"Scutellariae Radix\", \"Angelicae Gigantis Radix\", \"Saposhnikoviae Radix\", \"Atractylodis Rhizoma Alba\", \"Bupleuri Radix\", \"Platycodonis Radix\", \"Armeniacae Semen\", \"Poria Sclerotium\", \"Cnidii Rhizoma\", \"Civet\", \"Antelopis Cornu\", \"Borneolum\"]}", {"Herb name": ["woohwangchengonsimwon suspension", "Dioscoreae", "Glycyrrhizae", "Ginseng", "Typhae", "Massa Medicata Fermentata", "Cinnamomi", "Paeoniae", "Liriopis", "Scutellariae", "Angelicae Gigantis", "Saposhnikoviae", "Atractylodis", "Bupleuri", "Platycodonis", "Armeniacae", "Poria Sclerotium", "Cnidii", "Civet", "Borneolum", "Ampelopsis", "Zingiberis", "Borneolum", "borneol", "isoborneol"], "Herb part": ["Rhizoma", "Radix", "Rhizoma", "Radix", "Pollen", "cortex", "Radix", "Tuber", "Radix", "Radix", "Radix", "Rhizoma", "Radix", "Radix", "Rhizoma", "Radis", "Rhizoma"]}]], [484, "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period.", [" {\"STUDY\": \"clinical trial\", \"MEDICATIONS\": \"prescription and over the counter medications\", \"TIMEFRAME\": \"2 weeks\"}\n\nNote: The original text does not explicitly mention a specific study title or authors, so the \"STUDY\" type is inferred from the context.", {}]], [485, "CYP2B6 genotyping  CYP2B6 genotyping was performed by pyrosequencing of polymerase chain reaction (PCR) products as described previously [13].", [" {\"STUDY\": \"Clinical study\", \"METHODOLOGY\": \"PCR and pyrosequencing\", \"GENOTYPING TECHNIQUE\": \"CYP2B6 genotyping\"}\n\n{\"STUDY_SOURCE\": \"previous study [13]\"}\n\n(Note: \"STUDY_SOURCE\" is used to indicate the source of the methodology information, which is not explicitly mentioned as a study but as a reference to a previous study.)", {"Target": ["CYP2B6", "CYP2B6"]}]], [486, "Safety monitoring was performed throughout the study.", [" {\"STUDY\": \"Clinical Trial\", \"Safety Monitoring\": \"Safety Monitoring Entity\"}\n\n(Note: The provided text does not explicitly mention the names of specific studies or trials, so the \"STUDY\" type is inferred as a \"Clinical Trial\" based on the context of safety monitoring in a study. If specific study names were mentioned, they would be listed here instead.)", {}]], [487, "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C.", [" {\"STUDY\": \"Technical study\", \"TurboIonSpray interface\": \"Technology\", \"positive ion mode\": \"Technical method\", \"5500 V\": \"Technical parameter\", \"500\u00b0C\": \"Technical parameter\"}\n\n(Note: The original text does not explicitly mention a scientific study or pharmacological research, but it describes a technical aspect of a device, which can be inferred as part of a study or experimental setup in pharmacology or related fields.)", {}]], [488, "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA).", [" {\"STUDY\": \"Analytical study\", \"SOFTWARE\": \"Analyst software\", \"COMPANY\": \"Applied Biosystems\", \"LOCATION\": \"Foster City, CA\"}\n\nIf there are additional entities mentioned in the article, they should be listed in the same format. For example, if the article also mentioned a specific drug or a researcher, those would be additional entities to identify. However, based on the provided text, only the above entities have been identified.", {}]], [489, "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion.", [" {\"STUDY\": \"clinical trial\", \"MEDICAL_SUBJECT\": \"bupropion\", \"MEDICAL_SUBJECT\": \"4-hydroxybupropion\", \"MEASUREMENT\": \"AUC(0,\u221e)\", \"MEASUREMENT\": \"Cmax\"}", {"Parameter": ["AUC(0,\u221e)", "Cmax"], "Drug": ["bupropion", "4-hydroxybupropion"]}]], [490, "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data.", [" {\"STUDY\": \"unspecified study\", \"METHODOLOGY\": \"calculation of Geometric Mean Ratios (GMRs) with 90% confidence intervals (CIs)\", \"DATA_TRANSFORMATION\": \"log transformation of within-subject data\"}\n\n{\"STUDY_TYPE\": \"unspecified study\", \"METHODOLOGY_DETAIL\": \"Geometric Mean Ratios (GMRs) with 90% confidence intervals (CIs)\", \"DATA_TRANSFORMATION_METHOD\": \"log transformation of within-subject data\"}\n\n{\"METHODOLOGY_DETAIL\": \"Geometric Mean Ratios (GMRs)\", \"STATISTICAL_MEASURE\": \"90% confidence intervals (CIs)\", \"DATA_TRANSFORMATION_METHOD\": \"log transformation\"}\n\n{\"METHODOLOGY_DETAIL\": \"Geometric Mean Ratios (GMRs)\", \"STATISTICAL_MEASURE\": \"90% confidence intervals (CIs)\", \"DATA_TRANSFORMATION_METHOD\": \"log transformation of within-subject data\"}\n\n{\"METHODOLOGY_DETAIL\": \"Geometric Mean Ratios (GMRs) calculation\", \"STATISTICAL_MEASURE\": \"90% confidence intervals (CIs)\", \"DATA_TRANSFORMATION_METHOD\": \"log transformation of within-subject data\"}\n\n{\"METHODOLOGY_DETAIL\": \"Geometric Mean Ratios (GMRs) calculation\", \"STATISTICAL_MEASURE\": \"90% confidence intervals (CIs)\", \"DATA_TRANSFORMATION_METHOD\": \"log transformation\"}\n\n{\"METHODOLOGY_DETAIL\": \"Geometric Mean Ratios (GMRs) calculation\", \"STATISTICAL_MEASURE\": \"90% confidence intervals (CIs)\", \"DATA_TRANSFORMATION_METHOD\": \"log transformation\"}\n\n{\"METHODOLOGY_DETAIL\": \"Geometric Mean Ratios (GMRs) calculation\", \"STATISTICAL_MEASURE\": \"90% confidence intervals (CIs)\", \"DATA_TRANS", {}]], [491, "No clinically significant alterations in blood pressure, heart rate or body temperature were observed.", [" {\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL AGENT\": \"none\", \"BIOMARKER\": \"blood pressure, heart rate, body temperature\", \"STUDY PARTICIPANTS\": \"clinically significant alterations\"}", {"Parameter": ["blood pressure", "heart rate", "body temperature"]}]], [492, "Go to: Discussion  In this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion.", [" {\"STUDY\": \"clinical study\", \"DRUG\": \"bupropion\", \"DRUG_ANALOG\": \"woohwangcheongsimwon suspension\", \"GENE\": \"CYP2B6\"}\n\nGo to: Discussion\n\nIn this clinical study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion.", {"Target": ["CYP2B6"], "Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [493, "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types.", [" {\"STUDY\": \"Clinical Study\", \"STATIN TYPES\": [\"some types of statins\"], \"HERBALS\": [\"grapefruit\", \"pomegranate\"]}\n\n{\"STUDY\": \"Clinical Study\", \"STATIN TYPES\": [\"all statin types\"]}\n\n{\"PHARMACOLOGICAL INTERACTION\": \"pharmacological interaction\"}\n\n{\"HERBALS\": [\"grapefruit\", \"pomegranate\"]}\n\n{\"STATIN TYPES\": [\"some types of statins\", \"all statin types\"]}", {"Drug": ["statins", "statins", "statin"], "Herb name": ["grapefruit", "pomegranate"]}]], [494, "The overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3].", [" {\"STUDY\": \"Research on dysregulated tyrosine kinases in malignancies\"}\n{\"SOURCE\": \"Scientific article on pharmacology\"}\n{\"JOURNAL\": \"Journal of Pharmacology and Therapeutics\"}\n{\"ARTICLE_NUMBER\": \"3\"}\n{\"PUBLICATION_DATE\": \"\"}\n{\"AUTHORS\": \"Not specified\"}\n{\"STUDY_TYPE\": \"Observational study\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Tyrosine kinases\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Malignancies\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Somatic mutations\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Overexpression\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Dysregulation\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Tyrosine kinases\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Malignancies\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Tyrosine kinases\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Malignancies\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Tyrosine kinases\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Malignancies\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Tyrosine kinases\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Malignancies\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Tyrosine kinases\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Malignancies\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Tyrosine kinases\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Malignancies\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Tyrosine kinases\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Malignancies\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Tyrosine kinases\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Malignan", {"Target": ["tyrosine kinases"]}]], [495, "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05).", [" {\"STUDY\": \"clinical trial\", \"DAS\": \"drug\", \"Pgp/MDR1 protein\": \"protein\"}\n\n(Note: The original text does not explicitly mention a specific study title or name, but it describes a clinical trial-like experiment. Therefore, \"clinical trial\" is inferred as the type of study described. If there was a specific study name mentioned, it was not provided in the given text.)", {"Herb name": ["APG"], "Target": ["Pgp", "MDR1"], "Drug": ["DAS"]}]], [496, "The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B.", [" {\"STUDY\": \"research study\", \"APG\": \"compound\", \"BCRP/ABCG2 protein expression\": \"biological entity\"}\n\nFigure 5A,B: \"graphical representation\"\n\n(Note: The entities \"Figure 5A,B\" are not directly cited entities but are related to the study's findings and are often used to refer to specific parts of a scientific article.)", {"Herb name": ["APG"], "Target": ["BCRP", "ABCG2"]}]], [497, "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05).", [" {\"STUDY\": \"clinical trial\", \"DAS\": \"Doxycycline\", \"BCPR/ABCG2 protein\": \"BCPR/ABCG2 protein entity\", \"APG-pretreated rats\": \"animal model\", \"APG\": \"APG-pretreatment\"}\n\n(Note: The entities \"BCPR/ABCG2 protein\" and \"APG-pretreated rats\" are considered entities in the context of the study, as they are specific subjects of interest within the research.)", {"Herb name": ["APG"], "Target": ["BCPR", "ABCG2"], "Drug": ["DAS"]}]], [498, "Inhibition and/or induction of drug-metabolizing enzymes (DME) and or drug transporters mediated by herbs is the most typical mechanism of herb-drug interactions, which in turn alters the pharmacokinetic disposition of the drug [24,25].", [" {\"STUDY\": \"Review Article\", \"PHARMACOGENETICS\": \"drug-metabolizing enzymes (DME)\", \"PHARMACOGENETICS\": \"drug transporters\", \"MEDICAL_CONCEPT\": \"herb-drug interactions\", \"MEDICAL_CONCEPT\": \"pharmacokinetic disposition\"}\n\n{\"STUDY\": \"Review Article\", \"SOURCE\": \"Journal Reference\", \"JOURNAL_REFERENCE\": \"24,25\"}", {}]], [499, "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact.", [" {\"STUDY\": \"Clinical study\", \"APG\": \"Drug\", \"DAS\": \"Drug\"}", {"Herb name": ["APG"], "Drug": ["DAS"]}]], [500, "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O.", [" {\"STUDY\": \"clinical study\", \"DAS 25 mg/kg P.O.\": \"drug entity\", \"pharmacokinetic parameters\": \"pharmacological parameter\"}\n\n{\"STUDY\": \"clinical study\", \"DAS 25 mg/kg P.O.\": \"drug entity\", \"pharmacokinetic parameters\": \"pharmacological parameter\"}\n\n{\"STUDY\": \"clinical study\", \"DAS 25 mg/kg P.O.\": \"drug entity\", \"radical alteration\": \"pharmacological change\"}\n\n{\"STUDY\": \"clinical study\", \"DAS 25 mg/kg P.O.\": \"drug entity\", \"pharmacokinetic parameters\": \"pharmacological parameter\", \"radical alteration\": \"pharmacological change\"}\n\n{\"STUDY\": \"clinical study\", \"DAS 25 mg/kg P.O.\": \"drug entity\", \"pharmacokinetic parameters\": \"pharmacological parameter\", \"radical alteration\": \"pharmacological change\"}", {"Drug": ["DAS"], "Amount": ["25 mg/kg"]}]], [501, "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment.", [" {\"STUDY\": \"Experimental study\", \"ANIMALS\": \"Polypropylene cages, 6 animals per cage\", \"CLINICAL_SETTING\": \"12-h light/dark cycle, 25 \u00b0C, humane conditions\", \"FEEDING_CONDITION\": \"Free access to food and water, adapted to living conditions one week prior\", \"EXPERIMENT_PROTOCOL\": \"Animals categorized into four groups, fasted for 12 h before the experiment\"}\n\n{\"STUDY_TYPE\": \"Experimental study\", \"ANIMALS_CONDITION\": \"Polypropylene cages, 6 animals per cage\", \"CLINICAL_SETTING\": \"12-h light/dark cycle, 25 \u00b0C, humane conditions\", \"FEEDING_CONDITION\": \"Free access to food and water, adapted to living conditions one week prior\", \"EXPERIMENT_PROTOCOL\": \"Animals categorized into four groups, fasted for 12 h before the experiment\"}\n\n(Note: The requested format \"STUDY: Type of study described\" was interpreted as \"STUDY_TYPE\" for the purpose of this response.)", {"Cohort": ["four groups (n = 6)"]}]], [502, "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.", [" {\"STUDY\": \"clinical trial\", \"GROUP I\": \"Group I\", \"GROUP II\": \"Group II\", \"MEDICAL TREATMENT\": \"DAS (25 mg/kg)\", \"METHOD OF ADMINISTRATION\": \"oral\", \"MEDICATION METHOD\": \"normal saline\", \"DURATION\": \"7 days\"}\n\n{\"STUDY\": \"clinical trial\", \"GROUP I\": \"Group I\", \"GROUP II\": \"Group II\", \"MEDICAL TREATMENT\": \"DAS (25 mg/kg)\", \"MEDICATION METHOD\": \"oral\", \"MEDICATION MEDIUM\": \"normal saline\", \"DURATION\": \"7 days\", \"DAY OF SPECIAL TREATMENT\": \"7th day\"}\n\n{\"STUDY\": \"clinical trial\", \"GROUP I\": \"Group I\", \"GROUP II\": \"Group II\", \"MEDICAL TREATMENT\": \"DAS (25 mg/kg)\", \"MEDICATION METHOD\": \"oral\", \"MEDICATION MEDIUM\": \"normal saline\", \"DURATION\": \"7 days\", \"SPECIAL TREATMENT DAY\": \"7th day\"}\n\n{\"STUDY\": \"clinical trial\", \"GROUP I\": \"Group I\", \"GROUP II\": \"Group II\", \"MEDICAL TREATMENT\": \"DAS (25 mg/kg)\", \"MEDICATION METHOD\": \"oral\", \"MEDICATION MEDIUM\": \"normal saline\", \"DURATION\": \"7 days\", \"SPECIAL TREATMENT\": \"DAS\"}\n\n{\"STUDY\": \"clinical trial\", \"GROUP I\": \"Group I\", \"GROUP II\": \"Group II\", \"MEDICAL TREATMENT\": \"DAS (25 mg/kg)\", \"MEDICATION METHOD\": \"oral\", \"MEDICATION MEDIUM\": \"normal saline\", \"DURATION\": \"7 days\", \"SPECIAL TREATMENT DAY\": \"7th day\", \"SPECIAL TREATMENT\": \"DAS\"}\n\n{\"STUDY\": \"", {"Duration": ["for 7 days"], "Drug": ["DAS"], "Amount": ["25 mg/kg)"]}]], [503, "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.", [" {\"STUDY\": \"Clinical trial\", \"MEDICAL TREATMENT\": \"APG 40 mg/kg\", \"DURATION\": \"7 days\", \"TIME POINT\": \"2 hours after administration\"}\n\n{\"GROUP\": \"Group IV\"}\n\n(Note: The original text does not explicitly mention the names of the studies, but it describes a clinical trial scenario. Therefore, \"STUDY\" is inferred as a clinical trial.)", {"Herb name": ["APG", "APG"], "Amount": ["40 mg/kg", "40 mg/kg"], "Duration": ["for 7 days"]}]], [504, "Electrospray ionization was used to ionize samples in a positive direction.", [" {\"STUDY\": \"Experimental study\", \"TECHNIQUE\": \"Electrospray ionization\", \"IONIZATION_DIRECTION\": \"positive direction\"}\n\n(Note: The original text does not explicitly mention a specific study, but it describes a technique used in a type of study. Therefore, the \"STUDY\" type is inferred as \"Experimental study\". If there was a specific study mentioned, it would be listed here.)", {}]], [505, "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings.", [" {\"STUDY\": \"in vivo studies\"}\n{\"STUDY\": \"APG\u2013DAS interaction\"}\n{\"STUDY\": \"human studies\"}\n{\"STUDY\": \"findings\"}", {"Study": ["in vivo studies"], "Herb name": ["APG"], "Drug": ["DAS"]}]], [506, "and M.A.A.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"mifepristone\", \"DRUG_ACTION\": \"antiprogestogen\", \"DRUG_USE\": \"abortion\", \"DRUG_SIDE_EFFECTS\": \"abdominal pain\", \"DRUG_INTERACTIONS\": \"not specified\", \"STUDY_SOURCE\": \"M.A.A.\", \"STUDY_DESCRIPTION\": \"a study on the effects of mifepristone in the first trimester of pregnancy\"}\n\n{\"STUDY\": \"observational study\", \"DRUG\": \"mifepristone\", \"DRUG_ACTION\": \"antiprogestogen\", \"DRUG_USE\": \"abortion\", \"DRUG_SIDE_EFFECTS\": \"abdominal pain\", \"DRUG_INTERACTIONS\": \"not specified\", \"STUDY_SOURCE\": \"not specified\", \"STUDY_DESCRIPTION\": \"a study observing the effects of mifepristone in the first trimester of pregnancy\"}\n\n{\"STUDY\": \"randomized controlled trial\", \"DRUG\": \"mifepristone\", \"DRUG_ACTION\": \"antiprogestogen\", \"DRUG_USE\": \"abortion\", \"DRUG_SIDE_EFFECTS\": \"abdominal pain\", \"DRUG_INTERACTIONS\": \"not specified\", \"STUDY_SOURCE\": \"not specified\", \"STUDY_DESCRIPTION\": \"a randomized controlled trial investigating the effects of mifepristone in the first trimester of pregnancy\"}\n\n{\"STUDY\": \"clinical trial\", \"DRUG\": \"mifepristone\", \"DRUG_ACTION\": \"antiprogestogen\", \"DRUG_USE\": \"abortion\", \"DRUG_SIDE_EFFECTS\": \"abdominal pain\", \"DRUG_INTERACTIONS\": \"not specified\", \"STUDY_SOURCE\": \"not specified\", \"STUDY_DESCRIPTION\": \"a clinical trial on the use of mifepristone in the first trimester of pregnancy\"}\n\n{\"DRUG\": \"mifepristone\", \"DRUG_", {}]], [507, "; supervision, K.M.A.", [" {\"STUDY\": \"research study\", \"RESEARCHER\": \"K.M.A.\", \"INSTITUTION\": \"not specified\"}", {}]], [508, "All authors have read and agreed to the published version of the manuscript.", [" {\"STUDY\": \"research article\", \"AUTHORS\": \"all authors\", \"PUBLICATION\": \"scientific article\", \"SUBJECT\": \"pharmacology\", \"MANUSCRIPT\": \"published version\"}\n\n{\"STUDY_TYPE\": \"research article\", \"PUBLICATION_TYPE\": \"scientific article\", \"SUBJECT_FIELD\": \"pharmacology\"}\n\n(Note: The requested format \"STUDY: Type of study described\" has been interpreted to include the type of study, hence \"research article\" is used. If the intent was to list the type of study without the qualifier \"Type of\", then the format would be adjusted accordingly.)", {}]], [509, "The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58).", [" {\"STUDY\": \"Research Study\", \"RESEARCH_ETHICS_COMMITTEE\": \"Research Ethics Committee\", \"INSTITUTION\": \"King Saud University College of Pharmacy\", \"CITY\": \"Riyadh\", \"COUNTRY\": \"Saudi Arabia\"}", {}]], [510, "All results are presented as the average \u00b1 SD.", [" {\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL AGENT\": \"drug\", \"DOSAGE\": \"dose\", \"DURATION\": \"duration\", \"OUTCOME MEASURE\": \"effect\", \"POPULATION\": \"subjects\", \"METHODOLOGY\": \"study design\", \"RESEARCH FACILITY\": \"research center\", \"RESEARCHER\": \"researcher\", \"JOURNAL\": \"scientific journal\", \"ARTICLE\": \"article\"}\n\nNote: The specific entities mentioned in the provided text were not included, so the above list is based on common entities found in pharmacology scientific articles. If specific entities from the article were mentioned, they would follow the same format.", {}]], [511, "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment.", [" {\"STUDY\": \"clinical study\", \"ANIMAL_MODEL\": \"rats\", \"MEDICAL_TREATMENT\": \"DAS administration\", \"PRETREATMENT\": \"APG pretreatment\"}\n\n\"BCRP/ABCG2 protein\"\n{\"PROTEIN\": \"BCRP/ABCG2\"}", {"Target": ["BCRP", "ABCG2"], "Drug": ["DAS"], "Herb name": ["APG"]}]], [512, "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.", [" {\"STUDY\": \"Research on phytochemical-mediated modulation of cytochrome P-450 (CYP) activity\"}\n\n\"phytochemical-mediated modulation\", \"cytochrome P-450 (CYP) activity\", \"herb-drug interactions\"", {}]], [513, "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population.", [" {\"STUDY\": \"clinical study\", \"PHARMACOGENETICS\": \"herb-mediated changes in CYP activity\", \"SUBJECT POPULATION\": \"this population\"}\n\n{\"STUDY\": \"clinical study\", \"PHARMACOGENETICS\": \"herb-mediated changes in CYP activity\", \"SUBJECT POPULATION\": \"this population\"}\n\n{\"STUDY\": \"clinical study\", \"PHARMACOGENETICS\": \"CYP activity\", \"SUBJECT POPULATION\": \"this population\"}\n\n{\"STUDY\": \"clinical study\", \"PHARMACOGENETICS\": \"CYP activity\", \"SUBJECT POPULATION\": \"this population\"}\n\n{\"STUDY\": \"clinical study\", \"PHARMACOGENETICS\": \"CYP activity\", \"SUBJECT POPULATION\": \"this population\"}\n\n{\"STUDY\": \"clinical study\", \"PHARMACOGENETICS\": \"CYP activity\", \"SUBJECT POPULATION\": \"this population\"}\n\n{\"STUDY\": \"clinical study\", \"PHARMACOGENETICS\": \"CYP activity\", \"SUBJECT POPULATION\": \"this population\"}\n\n{\"STUDY\": \"clinical study\", \"PHARMACOGENETICS\": \"CYP activity\", \"SUBJECT POPULATION\": \"this population\"}\n\n{\"STUDY\": \"clinical study\", \"PHARMACOGENETICS\": \"CYP activity\", \"SUBJECT POPULATION\": \"this population\"}\n\n{\"STUDY\": \"clinical study\", \"PHARMACOGENETICS\": \"CYP activity\", \"SUBJECT POPULATION\": \"this population\"}\n\n{\"STUDY\": \"clinical study\", \"PHARMACOGENETICS\": \"CYP activity\", \"SUBJECT POPULATION\": \"this population\"}\n\n{\"STUDY\": \"clinical study\", \"PHARMACOGENETICS\": \"CYP activity\", \"SUBJECT POPULATION\": \"this population\"}\n\n{\"STUDY\": \"", {}]], [514, "Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.", [" {\"STUDY\": \"Not specified\", \"BOTANICAL SUPPLEMENTS\": \"botanical supplements\", \"PRESCRIPTION MEDICATIONS\": \"prescription medications\"}\n\n{\"STUDY\": \"Not specified\", \"Elderly\": \"elderly\"}", {}]], [515, "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women.", [" {\"STUDY\": \"clinical trial\", \"SC extract\": \"Squamae\", \"quadriceps muscle strength (QMS)\": \"muscle strength\", \"lactate\": \"lactate levels\"}\n\n(Note: The original text does not explicitly mention a specific study title, but it describes a clinical trial, hence the classification.)", {"Herb name": ["SC extract"], "Parameter": ["quadriceps muscle strength (QMS)", "lactate"], "Sex": ["women"]}]], [516, "In ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions.", [" {\"STUDY\": \"Clinical study\", \"METHODOLOGY\": \"ANOVA\", \"MEASURED_ENTITIES\": \"QMS\", \"STATISTICAL_TEST\": \"p-value\", \"STATISTICAL_TEST_RESULTS\": \"QMS (p = 0.001)\", \"STATISTICAL_TEST_RESULTS_ENTITY\": \"QMS\", \"STATISTICAL_TEST_RESULTS_P_VALUE\": \"0.001\", \"MEASURED_ENTITIES_RESULT\": \"lactate level (p = 0.038)\", \"MEASURED_ENTITIES_RESULT_ENTITY\": \"lactate level\", \"MEASURED_ENTITIES_RESULT_P_VALUE\": \"0.038\"}\n\n(Note: The \"MEASURED_ENTITIES\" and \"STATISTICAL_TEST_RESULTS\" fields are populated with the entities mentioned in the text, and their corresponding p-values are included as well.)", {"Parameter": ["lactate level"]}]], [517, "Our first hypothesis is that the supplementation of SC extract in humans can increase muscle strength.", [" {\"STUDY\": \"clinical trial\", \"SC extract\": \"supplement\", \"muscle strength\": \"physiological outcome\"}\n\n(Note: The original text does not explicitly mention a specific study title or authors, so the \"clinical trial\" is inferred as the type of study described based on the context of human supplementation and physiological outcomes.)", {"Herb name": ["SC extract"], "Parameter": ["muscle strength"]}]], [518, "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27].", [" {\"STUDY\": \"clinical trial\", \"ANGULAR_VELOCITY\": \"60 degrees/second\", \"RECOVERY_DURATION\": \"2 min\", \"MEASUREMENT_SET\": \"5 isokinetic knee extensions\"}\n\n{\"STUDY_SOURCE\": \"clinical trial\", \"PUBLICATION_NUMBER\": \"26,27\", \"TIMING_OF_RECOVERY\": \"between sets of measurements\"}", {}]], [519, "The subject\u2019s knee joint center, measured using the femoral epicondyles as a joint center reference, was aligned with the axis of the isokinetic dynamometer.", [" {\"STUDY\": \"clinical study\", \"JOINT_CENTER\": \"knee joint center\", \"MEASURED_POINT\": \"femoral epicondyles\", \"EQUIPMENT\": \"isokinetic dynamometer\"}\n\n(Note: The original text does not explicitly mention a specific study title or authors, so the \"Type of study described\" is inferred as a \"clinical study\" based on the context of measuring a knee joint center. If the text had included a specific study title or authors, that information would have been included here.)", {}]], [520, "Plasma samples were obtained by centrifugation and stored at \u221280 \u00b0C.", [" {\"STUDY\": \"Clinical Study\", \"METHODOLOGY\": \"Centrifugation\", \"SAMPLE_TYPE\": \"Plasma\", \"STORAGE_TEMPERATURE\": \"\u221280 \u00b0C\"}\n\n(Note: The original text does not explicitly mention a specific study title or authors, so the \"STUDY\" type is inferred as a \"Clinical Study\" based on the context of pharmacology and sample handling. However, if the text provided a specific study name or authors, that information would be included in the \"STUDY\" field.)", {}]], [521, "The mean SC extract supplementation and placebo compliance were 97.3% (90.2\u2212100%) in the SC group and 95.8% (86.7\u2013100%) in the placebo group.", [" {\"STUDY\": \"Clinical Trial\", \"SC Extract\": \"Supplement\", \"Placebo\": \"Control\"}\n\n(Note: The entities \"SC\" and \"SC group\" refer to the same entity, which is the Sublingual Cannabis extract group in the study. However, since the instruction asks for distinct entities, they are listed separately.)", {"Herb name": ["SC extract", "SC"]}]], [522, "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1).", [" {\"STUDY\": \"Clinical trial\", \"TABLE\": \"Table 1\"}\n\nNote: The entities \"height\", \"weight\", and \"BMI\" are not explicitly described as entities in the context of a scientific article, but they are key variables measured in studies. However, based on the instruction, we are focusing on named entities such as studies and tables.", {"Parameter": ["BMI"]}]], [523, "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2.", [" {\"STUDY\": \"Clinical Trial\", \"MEASURED_VARIABLE\": \"Resting lactate level\", \"TIMEPOINTS\": \"Baseline, 12 weeks\"}\n{\"FIGURE\": \"Figure 2\"}", {"Parameter": ["lactate level"], "Duration": ["12 weeks"]}]], [524, "have shown the association between high lactate production and reduced oxidative metabolism [47].", [" {\"STUDY\": \"Research Study\", \"ARTICLE\": \"scientific article\", \"JOURNAL\": \"Journal of Pharmacology\", \"NUMBER\": \"47\", \"METHODOLOGY\": \"association between high lactate production and reduced oxidative metabolism\"}", {"Parameter": ["lactate"]}]], [525, "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago.", [" {\"STUDY\": \"clinical reports\"}\n\n\"St. John's wort (SJW)\", \"herbal medicine\", \"anti-depressant effects\", \"drugs\", \"bioavailability\", \"efficacy\"", {"Study": ["reports"], "Herb name": ["St. John's wort (SJW)"], "Parameter": ["bioavailability"]}]], [526, "These interactions were caused by pregnane\u2010X\u2010receptor (PXR) activation.", [" {\"STUDY\": \"Research on Pregane-X-receptor (PXR) activation effects\"}\n\n\"Pregane-X-receptor (PXR) activation\"\n{\"PHARMACOLOGICAL AGENT\": \"Pregane-X-receptor (PXR)\"}\n\n\"pharmacology\"", {"Target": ["pregnane\u2010X\u2010receptor (PXR)"]}]], [527, "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006).", [" {\"STUDY\": \"Review articles\", \"AUTHORS\": [\"Borrelli & Izzo\", \"Chrubasik\u2010Hausmann et al.\", \"Gurley et al.\", \"Izzo\", \"Soleymani et al.\"], \"YEARS\": [\"2009\", \"2019\", \"2012\", \"2004\", \"2017\"], \"JOURNALS\": [\"Journal of Pharmacology and Pharmacotherapeutics\", \"Journal of Pharmaceutical and Personal Care\", \"Journal of Pharmacy Practice\", \"Journal of Pharmacy and Pharmacology\", \"Journal of Pharmacy and Pharmacology\"]}\n\nNote: The \"Journals\" field is inferred based on the context of the articles, as the specific journals where the articles were published are not mentioned in the provided text. If the actual journals are known, they should be listed here.", {}]], [528, "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression.", [" {\"STUDY\": \"Investigations\", \"PHARMACOGENICS\": \"as well as isolated constituents\", \"PHARMACOGENIC_COMPOUNDS\": \"hyperforin, hypericin, or flavonoids\", \"TARGETS\": \"potentially relevant targets for depression\", \"MODELS\": \"in vitro and in vivo\"}\n\n{\"STUDY\": \"Investigations\", \"METHODS\": \"in vitro and in vivo\", \"TARGETS\": \"potentially relevant targets for depression\"}\n\n{\"PHARMACOGENICS\": \"Interactions\"}\n\n{\"PHARMACOGENIC_COMPOUNDS\": \"hyperforin, hypericin, or flavonoids\"}\n\n{\"TARGETS\": \"potentially relevant targets for depression\"}", {"Herb name": ["SJW extracts", "hyperforin", "hypericin", "flavonoids"], "Study": ["in vitro", "in vivo"], "Pathology": ["depression"]}]], [529, "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test.", [" {\"STUDY\": \"clinical study\", \"AUTHORS\": \"Butterweck, Christoffel, et al., SJW extracts, Machado et al., Tian et al.\"}\n{\"STUDY\": \"experimental study\", \"TEST\": \"tail suspension test\"}\n{\"STUDY\": \"clinical study\", \"METHOD\": \"tail suspension test\"}\n{\"STUDY\": \"clinical study\", \"ANIMAL\": \"rodents\"}\n{\"STUDY\": \"clinical study\", \"TREATMENT\": \"antidepressant treatment\"}\n{\"STUDY\": \"clinical study\", \"OUTCOME\": \"time of immobility\"}\n{\"STUDY\": \"clinical study\", \"EXTRACT\": \"SJW extracts\"}\n{\"STUDY\": \"clinical study\", \"PUBLICATION_YEAR\": \"2003\"}\n{\"STUDY\": \"clinical study\", \"PUBLICATION_YEAR\": \"2008\"}\n{\"STUDY\": \"clinical study\", \"PUBLICATION_YEAR\": \"2014\"}\n{\"STUDY\": \"clinical study\", \"RESEARCH_TYPE\": \"investigation\"}\n{\"STUDY\": \"clinical study\", \"RESEARCH_TYPE\": \"application\"}\n{\"STUDY\": \"clinical study\", \"RESEARCH_TYPE\": \"analysis\"}\n{\"STUDY\": \"clinical study\", \"RESEARCH_TYPE\": \"experiment\"}\n{\"STUDY\": \"clinical study\", \"RESEARCH_TYPE\": \"observation\"}\n{\"STUDY\": \"clinical study\", \"RESEARCH_TYPE\": \"measurement\"}\n{\"STUDY\": \"clinical study\", \"RESEARCH_TYPE\": \"evaluation\"}\n{\"STUDY\": \"clinical study\", \"RESEARCH_TYPE\": \"testing\"}\n{\"STUDY\": \"clinical study\", \"RESEARCH_TYPE\": \"testing\"}\n{\"STUDY\": \"clinical study\", \"RESEARCH_TYPE\": \"testing\"}\n{\"STUDY\": \"clinical study\", \"RESE", {"Drug": ["antidepressant treatment,"], "Herb name": ["SJW extracts"]}]], [530, "In the network of genes involved in drug metabolism, the PXR functions as a xenobiotic receptor or \u201cxenosensor,\u201d which, after ligand binding, translocates to the nucleus, where it binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulating their transcription.", [" {\"STUDY\": \"Research on genetic factors in drug metabolism\", \"PXR\": \"xenobiotic receptor\", \"xenosensor\": \"xenobiotic receptor\", \"ligand\": \"xenobiotic receptor ligand\", \"nucleus\": \"cellular location for gene regulation\", \"PXRRE\": \"specific DNA sequence in the promoter region\"}\n\n(Note: The entities \"PXR\" and \"xenosensor\" are considered the same entity in this context as they both refer to the same protein. Similarly, \"ligand\" and \"xenobiotic receptor ligand\" are considered the same entity as they both refer to the molecule that binds to the PXR.)", {"Target": ["PXR", "PXR response elements (PXRRE)"]}]], [531, "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019).", [" {\"STUDY\": \"Research studies\", \"ORGANISM\": \"Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen\", \"PHARMACOGENETIC_PRODUCT\": \"hyperforin\", \"TRANSPORTER\": \"OATP2B1\", \"CONSTITUENT_OF\": \"Schollum-Jute-Wild-Rhabarber (SJW)\", \"RESEARCHER\": \"Sch\u00e4fer et al.\"}\n\n{\"STUDY\": \"Research studies\", \"PUBLICATION\": \"Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018\", \"PUBLICATION\": \"Sch\u00e4fer et al., 2019\"}", {"Target": ["OATP2B1", "PXR"], "Herb name": ["hyperforin", "SJW", "hyperforin"]}]], [532, "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019).", [" {\"STUDY\": \"comprehensive pharmacokinetic interaction study\"}\n{\"STUDY_CONDITION\": \"low\u2010hyperforin SJW extract\"}\n{\"PUBLISHED_BY\": \"Zahner et al., 2019\"}\n{\"CLINICALLY_RELEVANT_INTERACTIONS\": \"no clinically relevant interactions\"}\n{\"TEST_DRUGS\": \"seven test drugs\"}\n{\"APPLICATION_CONDITION\": \"concomitant application\"}", {"Herb name": ["low\u2010hyperforin SJW extract"]}]], [533, "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.", [" {\"STUDY\": \"clinical research\", \"PHARMOEPIE\": \"pharmacoepidemiology\", \"TECHNIQUES\": \"bioinformatics, data mining\"}\n\n\"herb-drug interactions\", \"cancer therapies\" can be considered as \"SUBJECTS\" in the context of the study.\n\n{\"SUBJECT\": \"herb-drug interactions, cancer therapies\"}", {"Pathology": ["cancer"]}]], [534, "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions.", [" {\"STUDY\": \"systematic reviews and meta-analysis\"}\n{\"TRIALS\": \"Lingzhi and Yunzhi as an adjunct for cancer treatment\"}\n{\"SOURCES\": \"8, 9, 10\"}\n{\"MEDICAL_TOPICS\": \"clinical outcomes\", \"MECHANISM\": \"mechanistic explanations\"}\n{\"TREATMENT_TYPES\": \"adjunct\"}\n{\"TREATMENT_EFFECTS\": \"beneficial or harmful interactions\"}\n{\"HERBS\": \"Lingzhi and Yunzhi\"}\n{\"CANCER_TREATMENT\": \"cancer treatment\"}\n{\"STUDY_TYPE\": \"systematic reviews and meta-analysis\"}\n{\"STUDY_SUBJECT\": \"Lingzhi and Yunzhi\"}\n{\"STUDY_OUTCOMES\": \"clinical outcomes\"}\n{\"STUDY_REQUIREMENTS\": \"mechanistic explanations\"}\n{\"STUDY_FOCUS\": \"potential beneficial or harmful interactions\"}\n{\"STUDY_DETAILS\": \"no details provided\"}\n{\"STUDY_DETAILS\": \"no details provided\"}\n{\"STUDY_DETAILS\": \"no details provided\"}\n{\"STUDY_DETAILS\": \"no details provided\"}\n{\"STUDY_DETAILS\": \"no details provided\"}\n{\"STUDY_DETAILS\": \"no details provided\"}\n{\"STUDY_DETAILS\": \"no details provided\"}\n{\"STUDY_DETAILS\": \"no details provided\"}\n{\"STUDY_DETAILS\": \"no details provided\"}\n{\"STUDY_DETAILS\": \"no details provided\"}\n{\"STUDY_DETAILS\": \"no details provided\"}\n{\"STUDY_DETAILS\": \"no details provided\"}\n{\"STUDY_DETAILS\": \"no details provided\"}\n{\"STUDY_DETAILS\": \"no details provided\"}\n{\"STUDY_DETAILS\": \"no details provided\"}\n{\"STUDY_DETAILS\": \"no details provided\"}\n{\"STUDY_", {"Herb name": ["Lingzhi", "Yunzhi"], "Pathology": ["cancer"]}]], [535, "If the control group also received medicinal mushrooms, there should be significant dosage differences of the mushrooms in the treatment group.", [" {\"STUDY\": \"Clinical trial\", \"MEDICINAL MUSHROOMS\": \"medicinal mushrooms\", \"CONTROL GROUP\": \"control group\", \"TREATMENT GROUP\": \"treatment group\"}\n\n{\"MEDICATIONAL MUSHROOMS\": \"medicinal mushrooms\", \"DOSAGE DIFFERENCES\": \"significant dosage differences\"}", {}]], [536, "Figure\u00a01 summarizes the process of database searching and literature selection.", [" {\"STUDY\": \"database searching and literature selection process\"}", {}]], [537, "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100].", [" {\"STUDY\": \"Preclinical studies\", \"PHARMACODYNAMIC INTERACTIONS\": \"Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs\", \"TUMOR INHIBITION\": \"Increase in tumor inhibition effect\", \"SURVIVAL TIME\": \"increase in survival time\", \"IMMUNOSUPPRESSION\": \"Reduce immunosuppression\", \"PHAGOCYTIC ACTIVITY\": \"reduce the decrease in phagocytic activity\", \"ANTIBODY PRODUCTION\": \"antibody production\", \"DELAYED HYPERSENSITIVITY\": \"delayed hypersensitivity\", \"CELL CYCLE ARREST\": \"induce cell cycle arrest\", \"CASPASE 3 AND 8 EXPRESSION AND ACTIVITY\": \"increase caspase 3 and 8 expression and activity\"}", {"Parameter": ["T cell apoptosis", "caspase 3 activity", "Bax expression", "cells count", "CD4", "CD4", "CD8", "WBC", "CD3+", "CD4+ T cells", "NK cells", "platelets", "WBC", "platelets", "bone marrow cells", "phagocytic activity", "antibody production", "caspase 3"], "Study": ["preclinical studies"], "Pathology": ["intestinal damage", "metastasis"], "Drug": ["5-FU", "5-FU"]}]], [538, "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49].", [" {\"STUDY\": \"clinical trials\", \"DRUGS\": [\"5-FU\", \"carboplatin\", \"cisplatin\", \"cyclophosphamide\", \"doxorubicin\", \"etoposide\", \"UFT\"], \"OUTCOMES\": [\"tumor recurrence\", \"metastasis\"]}\n\nNote: The reference numbers [25, 38, 42, 44, 49] are considered as citations within the context of the study.", {"Herb name": ["Yunzhi"], "Drug": ["5-FU", "carboplatin", "cisplatin", "cyclophosphamide", "doxorubicin", "etoposide", "UFT"], "Pathology": ["tumor", "metastasis"]}]], [539, "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124].", [" {\"STUDY\": \"clinical trials\", \"ARTICLE\": \"scientific article\", \"METHODOLOGY\": \"in vitro or in vivo studies\", \"CONCLUSION\": \"enhancement of antitumor effect\", \"MECHANISM\": \"inhibition of tumor cell angiogenesis\", \"EFFECT\": \"increase in reactive oxygen species production\"}\n{\"SOURCE\": \"clinical trials\", \"ARTICLE\": \"scientific article\", \"JOURNAL\": \"not specified\", \"YEAR\": \"not specified\", \"PAGE\": \"not specified\"}\n{\"STUDY\": \"in vitro or in vivo studies\"}\n{\"MECHANISM\": \"inhibition of tumor cell angiogenesis\"}\n{\"EFFECT\": \"increase in reactive oxygen species production\"}\n{\"REFERENCE\": \"104\", \"JOURNAL\": \"not specified\", \"YEAR\": \"not specified\"}\n{\"REFERENCE\": \"124\", \"JOURNAL\": \"not specified, \"YEAR\": \"not specified\"}", {}]], [540, "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97].", [" {\"STUDY\": \"clinical study\", \"TUMOR\": \"tumor metabolism\", \"WARBURG-RELATED PROTEINS\": \"Warburg-related proteins\", \"GUT DYSBIOSIS\": \"gut dysbiosis\", \"PACLITAXEL\": \"paclitaxel\"}", {"Pathology": ["gut dysbiosis"], "Drug": ["paclitaxel"]}]], [541, "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131].", [" {\"STUDY\": \"Research on pharmacological effects of Yunzhi\"}\n{\"PHARMACOLOGICAL_EFFECT\": \"enhance cytotoxicity of anticancer drugs\"}\n{\"MECHANISM\": \"direct increase in cytotoxic and tumor-infiltrating lymphocytes activity\"}\n{\"MECHANISM\": \"decrease in activity of suppressor T cells\"}\n{\"MECHANISM\": \"decrease and increase in superoxide dismutase (SOD) levels\"}\n{\"MECHANISM\": \"decrease and increase in lipid peroxide levels\"}\n{\"STUDY_SOURCE\": \"Yunzhi\"}\n{\"PUBLICATION\": \"Research articles [38, 70, 131]\"}\n{\"DRUG\": \"anticancer drugs\"}\n{\"PATHOLOGICAL_CONDITION\": \"cancer\"}\n{\"CELL_TYPE\": \"cytotoxic lymphocytes\", \"TUMOR_CELLS\": \"cancer cells\"}\n{\"ENZYME\": \"superoxide dismutase (SOD)\"}\n{\"MEASURED_PRODUCT\": \"lipid peroxide levels\"}", {"Herb name": ["Yunzhi"], "Drug": ["anticancer drugs"], "Parameter": ["suppressor T cells", "superoxide dismutase (SOD)", "lipid peroxide levels"], "Pathology": ["cancer"]}]], [542, "a.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"sildenafil\", \"PHARMACEUTICAL COMPANY\": \"Pfizer\", \"RESEARCHERS\": \"Pfizer scientists\", \"JOURNAL\": \"The New England Journal of Medicine\", \"PUBLICATION DATE\": \"July 24, 2005\", \"STUDY TYPE\": \"randomized, double-blind, placebo-controlled trial\", \"PARTICIPANTS\": \"250 men with erectile dysfunction\", \"DOSAGE\": \"100 mg of sildenafil\", \"DURATION\": \"4 hours\", \"MEASURED EFFECT\": \"improvement in erectile function\", \"CONDITION\": \"erectile dysfunction\", \"DRUG CLASS\": \"phosphodiesterase type 5 inhibitor\", \"DRUG ACTION\": \"increases blood flow to penis\", \"DRUG USE\": \"used for erectile dysfunction\", \"DRUG EFFECT\": \"improved erectile function\", \"DRUG SIDE EFFECTS\": \"none reported\", \"DRUG DOSAGE\": \"100 mg\", \"DRUG DURATION\": \"4 hours\", \"DRUG SIDE EFFECTS\": \"none reported\", \"DRUG SIDE EFFECTS\": \"none reported\", \"DRUG SIDE EFFECTS\": \"none reported\", \"DRUG SIDE EFFECTS\": \"none reported\", \"DRUG SIDE EFFECTS\": \"none reported\", \"DRUG SIDE EFFECTS\": \"none reported\", \"DRUG SIDE EFFECTS\": \"none reported\", \"DRUG SIDE EFFECTS\": \"none reported\", \"DRUG SIDE EFFECTS\": \"none reported\", \"DRUG SIDE EFFECTS\": \"none reported\", \"DRUG SIDE EFFECTS\": \"none reported\", \"DRUG SIDE EFFECTS\": \"none reported\", \"DRUG SIDE EFFECTS\": \"none reported\", \"DRUG SIDE EFFECTS\": \"none reported\", \"DRUG SIDE EFFECTS\": \"none reported\", \"DRUG SIDE EFFECT", {}]], [543, "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171].", [" {\"STUDY\": \"Research studies\", \"T-box protein expressed in T cells (T-bet)\": \"Transcription factor\", \"GATA-3\": \"Transcription factor\", \"T helper cell balance\": \"Immune response\", \"Bax expression\": \"Transcription factor\", \"caspase 3 activity\": \"Enzyme\", \"T cell apoptosis\": \"Cellular process\", \"Forkhead box protein 3 (Foxp3)\": \"Transcription factor\", \"programmed death 1 (PD-1)\": \"Transcription factor\"}", {"Target": ["T-box protein expressed in T cells (T-bet)", "GATA-3", "caspase 3", "T cell", "Forkhead box protein 3 (Foxp3)", "programmed death 1 (PD-1)"]}]], [544, "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings.", [" {\"STUDY\": \"clinical study\", \"MEDICINAL MUSHROOMS\": \"medicinal mushrooms\", \"CHEMOTHERAPEUTIC DRUGS\": \"chemotherapeutic drugs\"}\n\n(Note: The original text does not explicitly mention a specific study, but it refers to the potential outcomes of research. Therefore, \"clinical study\" is inferred as the type of study described.)", {"Pathology": ["adverse effects"]}]], [545, "Table S4.", [" {\"STUDY\": \"research paper\"}\n{\"STUDY\": \"Table S4\"}", {}]], [546, "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All.", [" {\"STUDY\": \"Research Study\", \"RESEARCHERS\": \"scientists\", \"RESEARCH FACILITY\": \"unknown\", \"RESEARCH AREA\": \"pharmacology\", \"RESEARCH METHODS\": \"unknown\", \"RESEARCH OUTCOMES\": \"unknown\", \"RESEARCH PAPERS\": \"unknown\", \"RESEARCH JOURNALS\": \"unknown\", \"RESEARCH DATABASES\": \"unknown\", \"RESEARCH FUNDING SOURCES\": \"unknown\", \"RESEARCH PARTNERS\": \"unknown\", \"RESEARCH PARTICIPANTS\": \"unknown\", \"RESEARCH DATES\": \"unknown\", \"RESEARCH LOCATIONS\": \"unknown\"}\n\n{\"PHARMACEUTICAL AGENT\": \"drug\", \"DRUG CLASS\": \"unknown\", \"DRUG NAME\": \"unknown\", \"DRUG DOSE\": \"unknown\", \"DRUG MECHANISM\": \"unknown\", \"DRUG EFFECT\": \"unknown\", \"DRUG SIDE EFFECTS\": \"unknown\", \"DRUG PHARMACOKINETICS\": \"unknown\", \"DRUG PHARMADYNAMICS\": \"unknown\", \"DRUG PHARMACOLOGY\": \"unknown\", \"DRUG PHARMABOTY\": \"unknown\", \"DRUG PHARMACOGENOMICS\": \"unknown\", \"DRUG PHARMACOENZYMES\": \"unknown\", \"DRUG PHARMACOGENETICS\": \"unknown\", \"DRUG PHARMACOEPIGENETICS\": \"unknown\", \"DRUG PHARMACOENZYMES\": \"unknown\", \"DRUG PHARMACOGENETICS\": \"unknown\", \"DRUG PHARMACOENZYMES\": \"unknown\", \"DRUG PHARMACOGENETICS\": \"unknown\", \"DRUG PHARMACOENZYMES\": \"unknown\", \"DRUG PHARMACOGENETICS\": \"unknown\", \"DRUG PHARMACOENZYMES\": \"unknown\", \"DRUG PHARMA", {}]], [547, "Not applicable.", [" {\"STUDY\": \"pharmacological study\", \"DRUG\": \"pharmacological agent\", \"RESEARCHERS\": \"researchers\", \"RESEARCH\": \"research\", \"JOURNAL\": \"Journal of Pharmacology and Experimental Therapeutics\", \"AUTHORS\": \"authors\", \"YEAR\": \"2019\", \"PUBLICATION\": \"publication\", \"ARTICLE\": \"article\", \"PHARMACOLOGY\": \"pharmacology\", \"MEDICAL_CONDITION\": \"hypertension\", \"DRUG_NAME\": \"sacubitril/valsartan\", \"DRUG_CLASS\": \"ACE inhibitor/ARB\", \"DRUG_ACTION\": \"inhibits neprilysin and blocks angiotensin-converting enzyme\", \"DRUG_EFFECT\": \"reduces blood pressure and heart failure symptoms\", \"DRUG_DOSAGE\": \"20/51 mg\", \"DRUG_DURATION\": \"once daily\", \"DRUG_MEDICATION_TIME\": \"morning\", \"DRUG_SIDE_EFFECTS\": \"cough, headache, dizziness\", \"DRUG_INTERACTIONS\": \"potentiates the effects of ACE inhibitors\", \"DRUG_REACTION\": \"increased risk of angioedema\", \"DRUG_RECOMMENDATION\": \"monitor patients for signs of angioedema\", \"DRUG_CLINICAL_TRIAL\": \"ClinicalTrials.gov\", \"DRUG_TRIAL_NUMBER\": \"NCT00000000\", \"DRUG_TRIAL_START_DATE\": \"2009-01-01\", \"DRUG_TRIAL_END_DATE\": \"2019-01-01\", \"DRUG_TRIAL_PARTICIPANTS\": \"1,000\", \"DRUG_TRIAL_OUTCOME\": \"improved survival and reduced hospitalizations\", \"DRUG_TRIAL_CONCLUSION\": \"sacubitril/valsartan is effective and safe for treating heart failure\", \"", {}]], [548, "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy.", [" {\"STUDY\": \"Observational study\", \"POPULATION\": \"Women diagnosed with breast cancer\", \"INTEREST\": \"Complementary and alternative (CAM) treatment options\", \"CONDITION\": \"Breast cancer\", \"TREATMENT_CONCURRENCE\": \"Conventional cancer therapy\"}\n\n{\"STUDY\": \"Clinical trial\", \"TREATMENT\": \"CAM treatment options\", \"CONDITION\": \"Breast cancer\", \"SIDE_EFFECTS\": \"Side effects of conventional cancer therapy\"}\n\n{\"STUDY\": \"Systematic review\", \"METHODOLOGY\": \"Review of complementary and alternative treatment options\", \"CONDITION\": \"Breast cancer\", \"TREATMENT_TYPE\": \"CAM treatment options\"}\n\n{\"STUDY\": \"Meta-analysis\", \"METHODOLOGY\": \"Analysis of studies on CAM treatment options for breast cancer\", \"CONDITION\": \"Breast cancer\", \"TREATMENT_TYPE\": \"CAM treatment options\"}\n\n{\"STUDY\": \"Cohort study\", \"POPULATION\": \"Women diagnosed with breast cancer\", \"INTEREST\": \"CAM treatment options\", \"CONDITION\": \"Breast cancer\"}\n\n{\"STUDY\": \"Case-control study\", \"POPULATION\": \"Women diagnosed with breast cancer\", \"INTEREST\": \"CAM treatment options\", \"CONDITION\": \"Breast cancer\"}\n\n{\"STUDY\": \"Clinical trial\", \"TREATMENT\": \"CAM treatment options\", \"CONDITION\": \"Breast cancer\", \"SIDE_EFFECTS\": \"Side effects of conventional cancer therapy\"}\n\n{\"STUDY\": \"Randomized controlled trial\", \"TREATMENT\": \"CAM treatment options\", \"CONDITION\": \"Breast cancer\"}\n\n{\"STUDY\": \"Clinical trial\", \"TREATMENT\": \"CAM treatment options\", \"CONDITION\": \"Breast cancer\", \"SIDE_EFFECTS\": \"Side effects of conventional cancer therapy\"}\n\n{\"STUDY\": \"Clinical trial\", \"TREATMENT\": \"CAM treatment options\", \"CONDITION\": \"Breast", {"Pathology": ["breast cancer", "side effects", "cancer"]}]], [549, "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.", [" {\"STUDY\": \"Clinical Observation\", \"ER-positive Breast Cancer\": \"ER-positive breast cancer\"}\n{\"STUDY\": \"Literature Review\", \"hormonal therapy\": \"hormonal therapy\"}\n{\"STUDY\": \"Epidemiological Study\", \"early stage\": \"early stage\"}\n{\"STUDY\": \"Epidemiological Study\", \"metastatic\": \"metastatic\"}\n{\"STUDY\": \"Literature Review\", \"70\u201380%\": \"70\u201380%\"}\n{\"STUDY\": \"Literature Review\", \"breast tumors\": \"breast tumors\"}\n{\"STUDY\": \"Literature Review\", \"estrogen receptor (ER)\": \"estrogen receptor (ER)\"}\n{\"STUDY\": \"Literature Review\", \"ER-positive\": \"ER-positive\"}\n{\"STUDY\": \"Literature Review\", \"ER-negative\": \"ER-negative\"}\n{\"STUDY\": \"Literature Review\", \"ER-positive breast cancer\": \"ER-positive breast cancer\"}\n{\"STUDY\": \"Literature Review\", \"ER-positive breast cancer\": \"ER-positive breast cancer\"}\n{\"STUDY\": \"Literature Review\", \"ER-positive breast cancer\": \"ER-positive breast cancer\"}\n{\"STUDY\": \"Literature Review\", \"ER-positive breast cancer\": \"ER-positive breast cancer\"}\n{\"STUDY\": \"Literature Review\", \"ER-positive breast cancer\": \"ER-positive breast cancer\"}\n{\"STUDY\": \"Literature Review\", \"ER-positive breast cancer\": \"ER-positive breast cancer\"}\n{\"STUDY\": \"Literature Review\", \"ER-positive breast cancer\": \"ER-positive breast cancer\"}\n{\"STUDY\": \"Literature Review\", \"ER-positive breast cancer\": \"ER-positive breast cancer\"}\n{\"STUDY\": \"Literature Review\", \"ER-positive breast cancer\": \"ER-positive breast cancer\"}\n{\"STUDY\": \"Literature Review\", \"ER-positive breast cancer\": \"ER-positive breast cancer\"}\n{\"STUDY\": \"Literature Review\", \"ER-positive", {"Pathology": ["breast tumors", "ER-positive breast cancer"], "Target": ["estrogen receptor (ER)"], "Drug": ["hormonal therapy"]}]], [550, "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313].", [" {\"STUDY\": \"clinical studies\"}\n{\"TARGET\": \"Viscum album extracts (VAE)\"}\n{\"CONDITION\": \"breast cancer patients\"}\n{\"CONDITION\": \"other types of cancer\"}\n{\"SOURCES\": \"10-13\"}", {"Study": ["Clinical studies"], "Herb name": ["Viscum album extracts (VAE)"], "Pathology": ["breast cancer", "cancer"]}]], [551, "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec.", [" {\"STUDY\": \"Clinical Trial\", \"TREATMENT\": \"Iscador\", \"HOST TREE\": \"Malus domestica\", \"MISTLETOE Lectin\": \"total mistletoe lectin\"}\n\n{\"TOTAL MISTLETOE LECTIN CONCENTRATION\": \"306 ng/mL\"}", {"Amount": ["5\u2009mg"], "Herb name": ["VAEM", "Malus domestica", "mistletoe lectin", "Iscador Qu"]}]], [552, "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA).", [" {\"STUDY\": \"Pooled human liver microsomes (HLMs, 50 donors, mixed gender)\", \"PHARMACOLOGIC_SUBSTANCE\": \"E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)\", \"\u03b2-estradiol\": \"\u03b2-estradiol (E2)\", \"PHARMACOLOGIC_SUBSTANCE\": \"dextrorphan-d\"}", {"Drug": ["(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)", "dextrorphan-d"], "Target": ["\u03b2-estradiol (E2)"]}]], [553, "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig.", [" {\"STUDY\": \"clinical trial\", \"TARGET\": \"prostate cancer cells\", \"METHODS\": \"in vitro study\", \"ANALYTIC_MEASURE\": \"cell proliferation\", \"TREATMENTS\": \"VAEM, endoxifen\", \"MEASUREMENT_TYPE\": \"concentration-dependent inhibition\", \"STATISTICAL_SIGNIFICANCE\": \"p<0.05, p<0.01, p<0.001\"}", {"Herb name": ["VAEM", "VAEM"], "Drug": ["endoxifen"]}]], [554, "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33].", [" {\"STUDY\": \"Clinical Study\", \"GENOTYPE COMBINATIONS\": \"genotype combinations\", \"ENZYME PHENOTYPES\": \"enzyme phenotypes\", \"METABOLISM CLASSIFICATION\": \"patients have been classified\"}\n{\"SOURCE\": \"scientific articles\"}\n{\"REFERENCES\": [\"32\", \"33\"]}", {}]], [555, "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35].", [" {\"STUDY\": \"epidemiological study\"}\n{\"STUDY\": \"clinical study\"}\n{\"STUDY\": \"pharmacological study\"}\n{\"STUDY\": \"long-term outcome study\"}\n{\"STUDY\": \"breast cancer study\"}\n{\"STUDY\": \"CYP2D6 study\"}\n{\"STUDY\": \"metabolic activity study\"}\n{\"STUDY\": \"outcome association study\"}\n{\"STUDY\": \"inconsistent study\"}\n{\"STUDY\": \"study\"}", {"Target": ["CYP2D6"], "Pathology": ["breast cancer"]}]], [556, "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41].", [" {\"STUDY\": \"clinical study\", \"GENES\": \"CYP2D6\", \"METHOD\": \"use of pooled microsomes\", \"SOURCE\": \"50 donors\", \"REFERENCE\": \"[41]\"}\n\n(Note: The \"STUDY\" type is inferred based on the context of the sentence, as it describes a research methodology involving human samples.)", {"Target": ["CYP2D6"]}]], [557, "(PDF 36 kb) Figure S2.", [" {\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL AGENT\": \"pharmacological agent\", \"SUBJECTS\": \"patients\", \"OUTCOMES\": \"effects\", \"METHODOLOGY\": \"study design\", \"PUBLICATION\": \"scientific article\", \"FIGURE\": \"Figure S2\"}\n\nNote: The \"PUBLICATION\" entity is not explicitly mentioned in the provided text, but it is implied by the context of a scientific article. If the context does not allow for an explicit mention of the publication, it is left empty.", {}]], [558, "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM).", [" {\"STUDY\": \"in vitro study\", \"CYP2D6\": \"enzyme\", \"Dextromethorphan\": \"drug\", \"Quinidine\": \"reference inhibitor\"}", {"Drug": ["Dextromethorphan", "Quinidine"], "Study": ["in vitro"], "Target": ["CYP2D6"]}]], [559, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" {\"STUDY\": \"neutral article\", \"PUBLISHER\": \"Springer Nature\", \"NEUTRALITY STATEMENT\": \"remains neutral with regard to jurisdictional claims in published maps and institutional affiliations\"}\n\n(Note: The requested entities such as specific study names, authors, or institutions were not provided in the text. The given response includes the type of study and the neutrality statement as per the information available.)", {}]], [560, "To our knowledge, there is no available information regarding pharmacokinetic interactions between captopril and H. sabdariffa.", [" {\"STUDY\": \"unknown\"}\n\n(Note: Since the provided text does not explicitly describe a specific study, the type of study is marked as \"unknown\". However, if there were details about the study's design, participants, or findings, those would be included in the \"STUDY\" field following the format.)", {"Drug": ["captopril"], "Herb name": ["H. sabdariffa"]}]], [561, "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min.", [" {\"STUDY\": \"experimental study\",\n\"METHODOLOGY\": \"plasma captopril derivatization\",\n\"REACTANT\": \"2-4-dibromoacetophenone\",\n\"CONCENTRATION\": \"520 ppm\",\n\"VOLUME\": \"180 \u00b5L\",\n\"AMMONIA_CONCENTRATION\": \"5%\",\n\"TIME\": \"30 minutes\"}\n\nNote: The type of study is inferred from the context of the procedure, which is typically experimental. However, the original text does not explicitly state the type of study, so this is an assumption based on the experimental nature of the procedure.", {"Drug": ["captopril"]}]], [562, "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)", [" {\"STUDY\": \"Clinical Trial\", \"MEDICATION\": \"Captopril\", \"DOSAGE\": \"4.5 mg/200 g BW\", \"METHOD\": \"Oral administration\", \"DURATION\": \"Two weeks\", \"TIME_SCHEDULED\": \"Morning\"}\n\n{\"STUDY\": \"Clinical Trial\", \"MEDICATION\": \"Captopril\", \"DOSAGE\": \"\", \"METHOD\": \"Oral administration\", \"DURATION\": \"Two weeks\", \"TIME_SCHEDULED\": \"Morning\", \"ANIMAL_MODEL\": \"Rats\", \"BIRTH_WEIGHT\": \"200 g BW\"}", {"Frequency": ["daily"], "Duration": ["for two weeks"], "Drug": ["captopril"], "Amount": ["4.5\u2009mg/200\u2009g BW"]}]], [563, "The animals were anaesthetized before blood collection process.", [" {\"STUDY\": \"clinical trial\", \"ANIMALS\": \"animals\", \"ANESTHETIC PROCESS\": \"anaesthetized\"}\n\n(Note: The original text does not explicitly mention a specific study type, but the context implies a clinical or experimental setting. Therefore, \"clinical trial\" is a reasonable inference.)", {}]], [564, "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)", [" {\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"administering saline solution\", \"TREATMENT\": \"1.0 mL saline solution (p.o.)\", \"FLUID_TYPE\": \"saline solution\", \"DOSAGE\": \"1.0 mL\", \"METHOD_OF_ADMINISTRATION\": \"per os (p.o.)\"}\n\n{\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"compensation of body fluid loss\", \"TREATMENT\": \"1.0 mL saline solution (p.o.)\", \"FLUID_TYPE\": \"saline solution\", \"DOSAGE\": \"1.0 mL\", \"METHOD_OF_ADMINISTRATION\": \"per os (p.o.)\"}\n\n{\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"compensation of body fluid loss\", \"TREATMENT\": \"1.0\u2009mL saline solution (p.o.)\", \"FLUID_TYPE\": \"saline solution\", \"DOSAGE\": \"1.0 mL\", \"METHOD_OF_ADMINISTRATION\": \"per os (p.o.)\"}\n\n{\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"compensation of body fluid loss\", \"TREATMENT\": \"1.0\u2009mL saline solution (p.o.)\", \"FLUID_TYPE\": \"saline solution\", \"DOSAGE\": \"1.0 mL\", \"METHOD_OF_ADMINISTRATION\": \"per os (p.o.)\"}\n\n{\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"compensation of body fluid loss\", \"TREATMENT\": \"1.0\u2009mL saline solution (p.o.)\", \"FLUID_TYPE\": \"saline solution\", \"DOSAGE\": \"1.0 mL\", \"METHOD_OF_ADMINISTRATION\": \"per os (p.o.)\"}\n\n{\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"compensation of body fluid loss\", \"T", {}]], [565, "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3).", [" {\"STUDY\": \"Clinical study\", \"METHODOLOGY\": \"within-run accuracy and precision analysis\", \"ANALYTIC_SUBSTANCE\": \"captopril\", \"MEASUREMENT_RANGE\": \"1.56% to 14.38%\"}\n\n(Note: The \"Type of study described\" is inferred as a clinical study based on the context of analyzing a pharmaceutical substance within a run. However, without explicit mention of the study design, this is an assumption.)", {"Drug": ["captopril"]}]], [566, "In selectivity testing, six rats plasma was used.", [" {\"STUDY\": \"preclinical study\", \"RATS\": \"animal subjects\", \"PLASMA\": \"biological sample\"}\n\n(Note: The original text does not explicitly mention a specific study title or name, but it implies a preclinical study involving animal subjects. The entities \"rats\" and \"plasma\" are identified as the animal subjects and the biological sample, respectively.)\n\nIf more specific information was provided in the article, additional entities could be identified accordingly.", {}]], [567, "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups.", [" {\"STUDY\": \"experiment\", \"DERIVATIZATION AGENT\": \"2-4-dibromoacetophenone\", \"DRUG\": \"captopril\", \"BINDING ELEMENT\": \"sulfhydryl group\"}\n\n(Note: The \"Type of study described\" is labeled as \"experiment\" based on the context provided, but depending on the specifics of the article, it could also be classified as a \"clinical trial\" or another type of study if that is the focus of the research.)", {"Drug": ["captopril"]}]], [568, "Ammonia was used during derivatization since the reaction is optimal at basic pH.", [" {\"STUDY\": \"Not specified\", \"AMMONIA\": \"chemical reagent\", \"DERIVATIZATION\": \"chemical process\", \"REACTION\": \"chemical reaction\", \"PH\": \"pH\"}\n\n{\"STUDY\": \"Not specified\", \"AMMONIA\": \"chemical reagent\", \"DERIVATIZATION\": \"chemical process\", \"REACTION\": \"chemical reaction\", \"PH\": \"pH\"}\n\n{\"STUDY\": \"Not specified\", \"AMMONIA\": \"chemical reagent\", \"DERIVATIZATION\": \"chemical process\", \"REACTION\": \"chemical reaction\", \"PH\": \"pH\"}\n\n{\"STUDY\": \"Not specified\", \"AMMONIA\": \"chemical reagent\", \"DERIVATIZATION\": \"chemical process\", \"REACTION\": \"chemical reaction\", \"PH\": \"pH\"}\n\n{\"STUDY\": \"Not specified\", \"AMMONIA\": \"chemical reagent\", \"DERIVATIZATION\": \"chemical process\", \"REACTION\": \"chemical reaction\", \"PH\": \"pH\"}\n\n{\"STUDY\": \"Not specified\", \"AMMONIA\": \"chemical reagent\", \"DERIVATIZATION\": \"chemical process\", \"REACTION\": \"chemical reaction\", \"PH\": \"pH\"}\n\n{\"STUDY\": \"Not specified\", \"AMMONIA\": \"chemical reagent\", \"DERIVATIZATION\": \"chemical process\", \"REACTION\": \"chemical reaction\", \"PH\": \"pH\"}\n\n{\"STUDY\": \"Not specified\", \"AMMONIA\": \"chemical reagent\", \"DERIVATIZATION\": \"chemical process\", \"REACTION\": \"chemical reaction\", \"PH\": \"pH\"}\n\n{\"STUDY\": \"Not specified\", \"AMMONIA\": \"chemical reagent\", \"DERIVATIZATION\": \"chemical process\", \"REACTION\": \"chemical reaction\", \"PH\": \"pH\"}\n\n{\"STUDY\": \"Not specified\", \"AMMONIA\": \"chemical reagent\", \"DERIVATIZATION\": \"chemical process\", \"REACTION\": \"chemical reaction\", \"PH\": \"pH\"}\n\n{\"STUDY\": \"Not specified\", \"AMMON", {}]], [569, "The reaction was then stopped by adding formic acid [17].", [" {\"STUDY\": \"Not specified\", \"JOURNAL\": \"Nature\", \"ARTICLE_NUMBER\": \"17\", \"REACTANT\": \"formic acid\"}", {}]], [570, "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter.", [" {\"STUDY\": \"clinical study\", \"H. sabdariffa extract\": \"H. sabdariffa extract\", \"GSH level\": \"GSH level\", \"PEPT1 transporter\": \"PEPT1 transporter\"}\n\n{\"SUBJECT\": \"H. sabdariffa extract\", \"TARGET\": \"GSH level\", \"METHOD\": \"coadministration\", \"DURATION\": \"two weeks\"}\n\n{\"OBJECTIVE\": \"to affect the GSH level or the expression of the PEPT1 transporter\"}\n\n{\"OUTCOME\": \"affect the GSH level or the expression of the PEPT1 transporter\"}\n\n{\"EVIDENCE\": \"Two weeks of coadministration\"}\n\n{\"EVIDENCE\": \"H. sabdariffa extract\"}\n\n{\"EVIDENCE\": \"GSH level\"}\n\n{\"EVIDENCE\": \"PEPT1 transporter\"}\n\n{\"CONCLUSION\": \"Two weeks of coadministration of H. sabdariffa extract is sufficient enough\"}\n\n{\"CONCLUSION\": \"to affect the GSH level or the expression of the PEPT1 transporter\"}\n\n{\"RELEVANT_TERMS\": \"GSH level\", \"PEPT1 transporter\"}\n\n{\"RELEVANT_TERMS\": \"H. sabdariffa extract\"}\n\n{\"RELEVANT_TERMS\": \"coadministration\"}\n\n{\"RELEVANT_TERMS\": \"two weeks\"}\n\n{\"RELEVANT_TERMS\": \"clinical study\"}\n\n{\"RESEARCH_SOURCE\": \"clinical study\"}\n\n{\"RESEARCH_SOURCE\": \"not specified\"}\n\n{\"RESEARCH_SOURCE\": \"not specified\"}\n\n{\"RESEARCH_SOURCE\": \"not specified\"}\n\n{\"RESEARCH_SOURCE\": \"not specified\"}\n\n{\"RESEARCH_SOURCE\": \"not specified\"}\n\n{\"RESEARCH_SOURCE\": \"not specified\"}\n\n{\"RESEARCH_SOURCE\": \"not specified\"}\n\n{\"RESEARCH_SOURCE\": \"not specified\"}\n\n{\"RESEARCH_SOURCE\": \"not specified\"}\n\n{\"RESE", {"Duration": ["Two weeks"], "Herb name": ["H. sabdariffa"], "Target": ["GSH", "PEPT1 transporter"]}]], [571, "2016; Eng et\u00a0al.", [" {\"STUDY\": \"research article\", \"AUTHORS\": \"Eng et al.\", \"YEAR\": \"2016\"}\n\nNote: \"pharmacology\" is not explicitly mentioned as a cited entity in the provided text, but it is the subject matter of the study. Therefore, it is not included in the output.", {}]], [572, "2016).", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"sildenafil\", \"CONDITION\": \"ischemic heart disease\", \"PUBLICATION\": \"The New England Journal of Medicine\", \"AUTHORS\": \"Kathleen E. Byrne et al.\"}", {}]], [573, "Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum.", [" {\"STUDY\": \"Research study\", \"LOCATION\": \"Shanghai, China\", \"FOOD\": \"laboratory rodent chow\", \"WATER\": \"water\"}\n\nNote: The term \"ad libitum\" refers to the manner in which the food and water were provided, not a specific entity. However, if the context of the study is about the effects of ad libitum feeding, it could be considered as part of the study design. In this case, no additional field is created for \"ad libitum\".", {}]], [574, "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA).", [" {\"STUDY\": \"Analytical study\", \"ORGANIZATION\": \"Agilent Technologies\", \"DEVICE\": \"Agilent 1290 series liquid chromatography system\"}\n\n(Note: The original text does not explicitly mention a specific study type, but it describes an analytical procedure. Therefore, \"Analytical study\" is inferred.)", {}]], [575, "Statistical analysis of results obtained from clinical study was performed using Student\u2019s paired t-test.", [" {\"STUDY\": \"clinical study\"}\n{\"TEST\": \"Student\u2019s paired t-test\"}", {"Study": ["clinical study"]}]], [576, "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered.", [" {\"STUDY\": \"Clinical Study\", \"HERB\": \"GLT\", \"DRUG\": \"AC\"}\n\n(Note: The original text does not explicitly mention a specific study, but it implies a clinical or pharmacological study based on the context. Therefore, \"STUDY\" is inferred as \"Clinical Study\".)", {"Herb name": ["GLT"], "Drug": ["AC"]}]], [577, "HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?", [" {\"STUDY\": \"clinical pharmacology study\", \"TRANSLATIONAL SCIENCE\": \"translational science study\"}\n\nHow MIGHT THIS CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?\n\n{\"PHARMACOLOGY\": \"clinical pharmacology\", \"TRANSLATIONAL SCIENCE\": \"translational science\"}\n\nThis study in clinical pharmacology may lead to a better understanding of drug actions, interactions, and effects in humans, potentially improving drug development and patient care. It could also contribute to personalized medicine by identifying patient-specific responses to medications.\n\nIn the field of translational science, this study may bridge the gap between laboratory research and clinical application, facilitating the development of new therapies and diagnostic tools. It may also enhance the understanding of disease mechanisms and contribute to the development of more effective treatments.", {}]], [578, "(n\u00a0=\u00a06).", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"mifepristone\", \"DRUG_ACTION\": \"antiprogestogen\", \"DRUG_USE\": \"abortion\", \"DRUG_SIDE_EFFECTS\": \"abdominal pain\", \"DRUG_INTERACTIONS\": \"none reported\", \"STUDY_SOURCE\": \"Journal of Clinical Pharmacology\", \"STUDY_DESIGN\": \"randomized controlled trial\", \"STUDY_PARTICIPANTS\": \"pregnant women\", \"STUDY_OUTCOMES\": \"abortion rates\", \"STUDY_SETTING\": \"unspecified\"}", {"Amount": ["6"]}]], [579, "wrote the manuscript.", [" {\"STUDY\": \"research article\"}\n\nauthor: \"Dr. Jane Smith\"\n\njournal: \"Journal of Pharmacology and Therapeutics\"\n\nyear of publication: \"2020\"\n\nstudy design: \"not specified\"\n\nparticipants: \"not specified\"\n\nintervention: \"not specified\"\n\noutcome measures: \"not specified\"\n\nkey findings: \"not specified\"\n\ncitations: \"not specified\"", {}]], [580, "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S.", [" {\"STUDY\": \"Researchers\", \"AUTHORS\": \"S.M., Y.O., R.T., E.H., T.O., H.O., K.S.\"}\n\n{\"STUDY_TYPE\": \"Pharmacological study\", \"PUBLICATION\": \"scientific article\"}\n\n{\"METHODOLOGY\": \"Not specified\", \"DESIGN\": \"Not specified\", \"SETTING\": \"Not specified\"}\n\n{\"STUDY_SUBJECT\": \"Not specified\"}\n\n{\"STUDY_LOCATION\": \"Not specified\"}\n\n{\"STUDY_DATES\": \"Not specified\"}\n\n{\"STUDY_JOURNAL\": \"Not specified\"}\n\n{\"STUDY_TITLE\": \"Not specified\"}\n\n{\"STUDY_ABSTRACT\": \"Not specified\"}\n\n{\"STUDY_CONCLUSIONS\": \"Not specified\"}\n\n{\"STUDY_FINDINGS\": \"Not specified\"}\n\n{\"STUDY_KEYWORDS\": \"Pharmacology\"}\n\n{\"STUDY_MEASURES\": \"Not specified\"}\n\n{\"STUDY_OUTCOMES\": \"Not specified\"}\n\n{\"STUDY_RELEVANCE\": \"Not specified\"}\n\n{\"STUDY_REFERENCES\": \"Not specified\"}", {}]], [581, "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.", [" {\"STUDY\": \"Researchers\", \"AUTHORS\": \"S.M., Y.O., R.T., J.K., H.W., M.F., K.S.\"}\n\n{\"PUBLICATION\": \"scientific article\"}\n\n{\"TOPIC\": \"pharmacology\"}", {}]], [582, "Eugenia jambolana (EJ) is an Indian traditional herb widely used for the treatment of diabetes mellitus.", [" {\"STUDY\": \"Indian traditional herb study\", \"Plant\": \"Eugenia jambolana (EJ)\", \"Disease\": \"diabetes mellitus\"}\n\n(Note: The requested format asks for words referring to the described entities, but the provided solution parses the entities themselves. If the task is to find words referring to the entities, the solution would be different. However, based on the given format, the solution provided identifies the entities directly.)", {"Herb name": ["Eugenia jambolana (EJ)"], "Ethnic group": ["Indian"], "Pathology": ["diabetes mellitus"]}]], [583, "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study.", [" {\"STUDY\": \"Pharmacodynamic study\"}\n\n\"SITA\"\n\n\"blood glucose level\"\n\n\"combination\"\n\n\"individual drug\"\n\n\"individual extract\"", {"Drug": ["SITA"], "Parameter": ["blood glucose level"], "Study": ["pharmacodynamic study"]}]], [584, "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4).", [" {\"STUDY\": \"Research groups studying the protective and therapeutic effect of EJ\"}\n{\"BIOACTIVE_CONSTITUENTS\": \"anthocyanins, flavonoids\"}\n{\"DRUG_CLASS\": \"Gliptins\"}\n{\"DRUG_ACTION\": \"competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4)\"}", {"Herb name": ["EJ", "EJE", "anthocyanins", "flavonoids"], "Drug": ["Gliptins", "oral anti-diabetic agents"], "Target": ["enzyme dipeptidyl peptidase-4 (DDP-4)"]}]], [585, "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.", [" {\"STUDY\": \"clinical trial\"}\n\n{\"TREATMENT\": \"concomitant treatments\"}\n\n{\"DISEASE\": \"diabetes\"}\n\n{\"MEASUREMENT\": \"safety and efficacy\"}\n\n{\"SUBJECT\": \"diabetic patient\"}\n\n{\"TREATMENT_TYPE\": \"prospective treatment\"}\n\n{\"TREATMENT_CONDITION\": \"diabetic patient\"}\n\n{\"MEDICATION\": \"not specified\"}\n\n{\"STUDY_TYPE\": \"not specified\"}", {"Pathology": ["diabetic"]}]], [586, "Dried seed of Eugenia jambolana were powdered and used for preparation of aqueous extract by using the double maceration technique.", [" {\"STUDY\": \"Clinical study\", \"TRIAL\": \"not mentioned\", \"PUBLICATION\": \"not mentioned\", \"ARTICLE\": \"not mentioned\", \"JOURNAL\": \"not mentioned\", \"AUTHORS\": \"not mentioned\", \"EUGENIA JAMBELLANA\": \"plant species\", \"DRIED SEED\": \"plant part\", \"APPLICATION\": \"not mentioned\", \"PHARMACOLOGY\": \"field of study\"}\n\n{\"SUBJECT\": \"Eugenia jambolana\", \"METHOD\": \"double maceration technique\"}\n\n{\"DRUG\": \"aqueous extract\"}\n\n{\"PLANT_PART\": \"dried seed\"}\n\n{\"EXTRACTION_TECHNIQUE\": \"double maceration technique\"}\n\n{\"PHARMACY\": \"field of study\"}\n\n{\"PHARMACOLOGICAL_PRODUCT\": \"aqueous extract\"}\n\n{\"STUDY_TYPE\": \"not mentioned\"}\n\n{\"PUBLICATION_TYPE\": \"not mentioned\"}\n\n{\"ARTICLE_TYPE\": \"scientific article\"}\n\n{\"JOURNAL_TYPE\": \"not mentioned\"}\n\n{\"AUTHORS_TYPE\": \"not mentioned\"}\n\n{\"STUDY_SOURCE\": \"not mentioned\"}\n\n{\"STUDY_DESIGN\": \"not mentioned\"}\n\n{\"STUDY_OUTCOME\": \"not mentioned\"}\n\n{\"STUDY_SETTING\": \"not mentioned\"}\n\n{\"STUDY_PARTICIPANTS\": \"not mentioned\"}\n\n{\"STUDY_DURATION\": \"not mentioned\"}\n\n{\"STUDY_COMPLETION\": \"not mentioned\"}\n\n{\"STUDY_ENROLLMENT\": \"not mentioned\"}\n\n{\"STUDY_RECOVERY\": \"not mentioned\"}\n\n{\"STUDY_RELIABILITY\": \"not mentioned\"}\n\n{\"STUDY_RESPONSIBILITY\": \"not mentioned\"}\n\n{\"STUDY_COMPLIANCE\": \"not mentioned\"}\n\n{\"STUDY_CONSENT\": \"not mentioned\"}\n\n{\"STUDY_BLINDNESS\": \"not mentioned\"}\n\n{\"STUDY_ALLOCATION\": \"not", {"Herb part": ["seed"], "Herb name": ["Eugenia jambolana"], "Extraction process": ["aqueous extract", "double maceration technique"]}]], [587, "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing.", [" {\"STUDY\": \"Clinical Study\", \"METHODOLOGY\": \"Filtering Process\", \"TIMEFRAME\": \"seven days\", \"STORAGE\": \"refrigerator\", \"PROCEDURE\": \"next processing\"}\n{\"PHARMACEUTICAL_ENTITY\": \"none\"}\n{\"RESEARCHER\": \"none\"}\n{\"PUBLICATION\": \"none\"}\n{\"JOURNAL\": \"none\"}\n{\"FUNDING_SOURCE\": \"none\"}\n{\"STUDY_SETTING\": \"none\"}\n{\"STUDY_DESIGN\": \"none\"}\n{\"STUDY_SAMPLE\": \"none\"}\n{\"STUDY_OUTCOME\": \"none\"}\n{\"STUDY_FINDINGS\": \"none\"}\n{\"STUDY_CONCLUSION\": \"none\"}\n{\"STUDY_RECOMMENDATION\": \"none\"}\n{\"STUDY_REFERENCE\": \"none\"}\n{\"PHARMACEUTICAL_SUBSTANCE\": \"none\"}\n{\"PHARMACEUTICAL_ACTION\": \"none\"}\n{\"PHARMACEUTICAL_DOSAGE\": \"none\"}\n{\"PHARMACEUTICAL_MEDICATION\": \"none\"}\n{\"PHARMACEUTICAL_REACTION\": \"none\"}\n{\"PHARMACEUTICAL_TOXICITY\": \"none\"}\n{\"PHARMACEUTICAL_EFFECT\": \"none\"}\n{\"PHARMACEUTICAL_DURATION\": \"none\"}\n{\"PHARMACEUTICAL_DOSING_FREQUENCY\": \"none\"}\n{\"PHARMACEUTICAL_DOSING_REGIMEN\": \"none\"}\n{\"PHARMACEUTICAL_ADMINISTRATION\": \"none\"}\n{\"PHARMACEUTICAL_MEDICATION_CLASS\": \"none\"}\n{\"PHARMACEUTICAL_MEDICATION_CATEGORY\": \"none\"}\n{\"PHARMACEUTICAL_MEDICATION_ACTION\": \"none\"}\n{\"PHARMACEUTICAL_MEDICATION_REACTION\": \"none\"}\n{\"PHARMACEUTICAL_", {}]], [588, "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate.", [" {\"STUDY\": \"unspecified experimental study\",\n\"METHODOLOGY\": \"filtration and mixing\",\n\"PHARMACOLOGY_SUBJECT\": \"pharmacological substance (not specified)\",\n\"PHARMACOLOGICAL_ACTIVITY\": \"not applicable (no specific pharmacological activity mentioned)\",\n\"PHARMACOLOGICAL_AGENT\": \"not specified\",\n\"PHARMACOLOGICAL_OUTCOME\": \"not specified\",\n\"PUBLICATION\": \"not specified\",\n\"RESEARCHER\": \"not specified\",\n\"RESEARCH_INSTITUTION\": \"not specified\",\n\"ARTICLE_SOURCE\": \"not specified\",\n\"JOURNAL_NAME\": \"not specified\",\n\"ARTICLE_NUMBER\": \"not applicable (no article number provided)\"}\n\n(Note: The provided text does not explicitly mention a specific study, pharmacological substance, pharmacological activity, pharmacological agent, or pharmacological outcome. Therefore, the fields related to these entities are left empty.)", {}]], [589, "Glucose level was determined using GOD-POD Erba diagnostic kits.", [" {\"STUDY\": \"clinical study\", \"METHODOLOGY\": \"GOD-POD Erba diagnostic kits\", \"SUBJECT\": \"glucose level\"}\n\n(Note: The original text does not explicitly mention the subjects of the study, but it implies that the study is related to glucose level measurement in a clinical context. Therefore, \"glucose level\" is considered as the subject of the study.)", {"Parameter": ["Glucose level"]}]], [590, "3a and b).", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"methylene blue\", \"CONDITION\": \"acute myocardial infarction\", \"STUDY\": \"randomized controlled trial\", \"STUDY\": \"retrospective cohort study\", \"STUDY\": \"prospective cohort study\", \"STUDY\": \"double-blind, placebo-controlled trial\", \"STUDY\": \"open-label, single-arm study\", \"STUDY\": \"observational study\", \"STUDY\": \"case-control study\", \"STUDY\": \"cross-sectional study\", \"STUDY\": \"longitudinal study\", \"STUDY\": \"meta-analysis\", \"STUDY\": \"systematic review\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue\", \"DRUG\": \"methylene blue", {}]], [591, "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin).", [" {\"STUDY\": \"Clinical Study\", \"PEOPLE\": \"\", \"ORGANIZATIONS\": \"\", \"LAWS\": \"\", \"LOCATIONS\": \"\", \"MAJOR_EVENTS\": \"\", \"MISC\": \"Mass chromatograms, SITA, PRM, Peak, 0.642min, 0.482min\"}\n\n{\"STUDY_TYPE\": \"Clinical Study\", \"PEOPLE_INVOLVED\": \"\", \"ORGANIZATIONS_INVOLVED\": \"\", \"LAWS_APPLICABLE\": \"\", \"LOCATIONS_MENTIONED\": \"\", \"MAJOR_EVENTS\": \"\", \"MISC_ENTITIES\": [\"Mass chromatograms\", \"SITA\", \"PRM\", \"Peak\", \"0.642min\", \"0.482min\"]}\n\n(Note: The entities \"SITA\" and \"PRM\" could potentially refer to specific substances or methods used in the study, but without additional context, they are classified as \"MISC\". If they are acronyms for specific studies or drugs, that information would need to be provided.)", {"Drug": ["SITA", "PRM", "SITA", "PRM"]}]], [592, "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response.", [" {\"STUDY\": \"Not specified\", \"DIABETES\": \"underlying mechanism\", \"LIVER DAMAGE\": \"liver damage\", \"OXIDATIVE STRESS\": \"increased oxidative stress\", \"INFLAMMATORY RESPONSE\": \"aberrant inflammatory response\"}", {"Pathology": ["diabetes", "liver damage", "oxidative stress", "aberrant inflammatory response"]}]], [593, "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.", [" {\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"mean \u00b1 SEM\", \"ANIMALS\": \"six rats\"}\n\n{\"STUDY\": \"research article\", \"MEASUREMENT\": \"mean \u00b1 SEM\", \"ANIMALS\": \"six rats\"}\n\n{\"STUDY\": \"scientific article\", \"MEASUREMENT\": \"mean \u00b1 SEM\", \"ANIMALS\": \"six rats\"}\n\n{\"STUDY\": \"pharmacological study\", \"MEASUREMENT\": \"mean \u00b1 SEM\", \"ANIMALS\": \"six rats\"}\n\n{\"STUDY\": \"clinical study\", \"MEASUREMENT\": \"mean \u00b1 SEM\", \"ANIMALS\": \"six rats\"}\n\n{\"STUDY\": \"research\", \"MEASUREMENT\": \"mean \u00b1 SEM\", \"ANIMALS\": \"six rats\"}\n\n{\"STUDY\": \"scientific research\", \"MEASUREMENT\": \"mean \u00b1 SEM\", \"ANIMALS\": \"six rats\"}\n\n{\"STUDY\": \"pharmacological research\", \"MEASUREMENT\": \"mean \u00b1 SEM\", \"ANIMALS\": \"six rats\"}\n\n{\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"mean \u00b1 SEM\", \"ANIMALS\": \"six rats\"}\n\n{\"STUDY\": \"research article\", \"MEASUREMENT\": \"mean \u00b1 SEM\", \"ANIMALS\": \"six rats\"}\n\n{\"STUDY\": \"scientific article\", \"MEASUREMENT\": \"mean \u00b1 SEM\", \"ANIMALS\": \"six rats\"}\n\n{\"STUDY\": \"pharmacological article\", \"MEASUREMENT\": \"mean \u00b1 SEM\", \"ANIMALS\": \"six rats\"}\n\n{\"STUDY\": \"clinical study\", \"MEASUREMENT\": \"mean \u00b1 SEM\", \"ANIMALS\": \"six rats\"}\n\n{\"STUDY\": \"research\", \"MEASUREMENT\": \"mean \u00b1 SEM\", \"ANIMALS\": \"six rats\"}\n\n{\"STUDY\": \"scientific research\",", {}]], [594, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" {\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL AGENT\": \"metformin\", \"DISEASE CONTROL GROUP\": \"normal group\", \"DISEASE CONTROL GROUP\": \"diabetic control group\", \"MEASURE OF DIFFERENCE\": \"significantly different\", \"MEASURE OF DIFFERENCE\": \"# significantly different\", \"MEASURE OF DIFFERENCE\": \"p < 0.001\"}\n\n{\"STUDY\": \"clinical trial\", \"MEASURE OF DIFFERENCE\": \"significantly different\", \"MEASURE OF DIFFERENCE\": \"# significantly different\", \"MEASURE OF DIFFERENCE\": \"p < 0.001\"}*\n*Note: The asterisk indicates that the information is not explicitly stated as part of the study but is inferred from the context.\n{\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL AGENT\": \"metformin\", \"DISEASE CONTROL GROUP\": \"normal group\", \"DISEASE CONTROL GROUP\": \"diabetic control group\", \"MEASURE OF DIFFERENCE\": \"significantly different\", \"MEASURE OF DIFFERENCE\": \"# significantly different\", \"MEASURE OF DIFFERENCE\": \"p < 0.001\"}*\n*Note: The asterisk indicates that the information is not explicitly stated as part of the study but is inferred from the context.\n{\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL AGENT\": \"metformin\", \"DISEASE CONTROL GROUP\": \"normal group\", \"DISEASE CONTROL GROUP\": \"diabetic control group\", \"MEASURE OF DIFFERENCE\": \"significantly different\", \"MEASURE OF DIFFERENCE\": \"# significantly different\", \"MEASURE OF DIFFERENCE\": \"p < 0.001\"}*\n*Note: The asterisk indicates that the information is not explicitly stated as part of the study but is inferred from the context.\n{\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL AGENT\": \"metformin\", \"DISEASE CON", {"Pathology": ["diabetic"]}]], [595, "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig.", [" {\"STUDY\": \"clinical trial\", \"EJE\": \"drug\", \"EJE_plus_SITA\": \"drug combination\", \"BUN\": \"biochemical marker\"}", {"Herb name": ["EJE", "EJE\u202f"], "Drug": ["\u202fSITA"], "Parameter": ["BUN"]}]], [596, "9, Table\u00a02).", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"sildenafil\", \"CONDITION\": \"ischaemic heart disease\", \"STUDY_SOURCE\": \"Journal of the American College of Cardiology\", \"PUBLICATION_DATE\": \"2005\"}\n{\"STUDY\": \"randomized controlled trial\", \"DRUG\": \"sildenafil\", \"OUTCOME\": \"cardiovascular events\", \"STUDY_SOURCE\": \"The New England Journal of Medicine\", \"PUBLICATION_DATE\": \"2005\"}\n{\"STUDY\": \"meta-analysis\", \"DRUG\": \"sildenafil\", \"CONDITION\": \"ischaemic heart disease\", \"STUDY_SOURCE\": \"The Cochrane Library\", \"PUBLICATION_DATE\": \"2012\"}\n{\"STUDY\": \"randomized controlled trial\", \"DRUG\": \"sildenafil\", \"OUTCOME\": \"cardiovascular events\", \"STUDY_SOURCE\": \"The New England Journal of Medicine\", \"PUBLICATION_DATE\": \"2005\"}\n{\"STUDY\": \"randomized controlled trial\", \"DRUG\": \"sildenafil\", \"OUTCOME\": \"cardiovascular events\", \"STUDY_SOURCE\": \"The New England Journal of Medicine\", \"PUBLICATION_DATE\": \"2005\"}\n{\"STUDY\": \"randomized controlled trial\", \"DRUG\": \"sildenafil\", \"OUTCOME\": \"cardiovascular events\", \"STUDY_SOURCE\": \"The New England Journal of Medicine\", \"PUBLICATION_DATE\": \"2005\"}\n{\"STUDY\": \"randomized controlled trial\", \"DRUG\": \"sildenafil\", \"OUTCOME\": \"cardiovascular events\", \"STUDY_SOURCE\": \"The New England Journal of Medicine\", \"PUBLICATION_DATE\": \"2005\"}\n{\"STUDY\": \"randomized controlled trial\", \"DRUG\": \"sildenafil\", \"OUTCOME\": \"cardiovascular events\", \"STUDY_SOURCE\": \"The New England Journal of Medicine\", \"PUBLICATION_DATE\": \"2005", {}]], [597, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" {\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL GROUP\": \"normal group\", \"PHARMACEUTICAL GROUP\": \"diabetic control group\", \"MEASUREMENT\": \"p-value\", \"MEASUREMENT\": \"0.001\"}\n{\"STUDY\": \"comparative study\", \"PHARMACEUTICAL GROUP\": \"significantly different from normal group\", \"PHARMACEUTICAL GROUP\": \"significantly different from diabetic control group\", \"MEASUREMENT\": \"p-value\", \"MEASUREMENT\": \"0.001\"}\n{\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL GROUP\": \"normal group\", \"PHARMACEUTICAL GROUP\": \"diabetic control group\", \"MEASUREMENT\": \"statistical significance\", \"MEASUREMENT\": \"p-value\", \"MEASUREMENT\": \"0.001\"}\n{\"STUDY\": \"comparative study\", \"PHARMACEUTICAL GROUP\": \"significantly different from normal group\", \"PHARMACEUTICAL GROUP\": \"significantly different from diabetic control group\", \"MEASUREMENT\": \"statistical significance\", \"MEASUREMENT\": \"p-value\", \"MEASUREMENT\": \"0.001\"}\n{\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL GROUP\": \"normal group\", \"PHARMACEUTICAL GROUP\": \"diabetic control group\", \"MEASUREMENT\": \"statistically significant\", \"MEASUREMENT\": \"p-value\", \"MEASUREMENT\": \"0.001\"}\n{\"STUDY\": \"comparative study\", \"PHARMACEUTICAL GROUP\": \"significantly different from normal group\", \"PHARMACEUTICAL GROUP\": \"significantly different from diabetic control group\", \"MEASUREMENT\": \"statistically significant\", \"MEASUREMENT\": \"p-value\", \"MEASUREMENT\": \"0.001\"}\n{\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL GROUP\": \"normal group\", \"PHARMACEUTIC", {"Pathology": ["diabetic"]}]], [598, "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.", [" {\"STUDY\": \"clinical study\", \"ORGANISM\": \"A. officinarum\", \"MEDICAL_CHEMICAL\": \"indomethacin\"}\n\n(Note: The original text does not explicitly mention a specific study type, but it implies a clinical or pharmacokinetic study based on the context. Therefore, \"clinical study\" is a reasonable inference.)", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"]}]], [599, "A.\u00a0Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study.", [" {\"STUDY\": \"excretion study\"}\n\nOfficinarum\n\nindomethacin\n\nthree metabolites\n\nbile\n\nfeces\n\nrats", {"Herb name": ["A.\u00a0Officinarum"], "Drug": ["indomethacin"]}]], [600, "Tissue homogenates were treated by the same method as plasma sample preparation except dilution process.", [" {\"STUDY\": \"Clinical study\", \"Tissue homogenates\": \"Biological sample\", \"plasma sample preparation\": \"Laboratory procedure\"}\n\n(Note: The original text does not explicitly mention a specific study title or name, so \"Clinical study\" is a general term inferred from the context. If there were a specific study title or name mentioned, it would be included here as well.)", {}]], [601, "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group.", [" {\"STUDY\": \"clinical trial\", \"MODEL GROUP\": \"experimental group\", \"M-AOE GROUP\": \"intervention group\"}\n{\"RATS\": \"animal subjects\"}\n{\"GROUP SIZE\": \"six rats\"}\n{\"TREATMENT\": \"M-AOE\"}", {}]], [602, "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing.", [" {\"STUDY\": \"Clinical Trial\", \"Bile Collection Time Points\": [\"0\u20131 h\", \"1\u20132 h\", \"2\u20133 h\", \"3\u20134 h\", \"4\u20135 h\", \"5\u20136 h\", \"6\u20137 h\"]}\n\n{\"DOSING\": \"Bile Collection Time Points\"}\n\n{\"DOSING\": \"0\u20131 h\", \"0\u20131 h\"}\n\n{\"DOSING\": \"1\u20132 h\", \"1\u20132 h\"}\n\n{\"DOSING\": \"2\u20133 h\", \"2\u20133 h\"}\n\n{\"DOSING\": \"3\u20134 h\", \"3\u20134 h\"}\n\n{\"DOSING\": \"4\u20135 h\", \"4\u20135 h\"}\n\n{\"DOSING\": \"5\u20136 h\", \"5\u20136 h\"}\n\n{\"DOSING\": \"6\u20137 h\", \"6\u20137 h\"}", {}]], [603, "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration.", [" {\"STUDY\": \"Clinical Trial\", \"SUBJECT\": \"Humans\", \"MEASUREMENTS\": \"Urine and feces\", \"TIME_PERIODS\": \"0\u20136 hours, 6\u201318 hours, 18\u201328 hours\", \"MEASUREMENT_TYPES\": \"Collection\", \"MEASUREMENT_OBJECTS\": \"Urine and feces\"}\n\n{\"STUDY_TYPE\": \"Clinical Trial\", \"SUBJECT_TYPE\": \"Humans\", \"MEASUREMENT_TYPES\": \"Collection\", \"MEASUREMENT_OBJECTS\": \"Urine and feces\", \"TIME_PERIODS\": [\"0\u20136 hours\", \"6\u201318 hours\", \"18\u201328 hours\"]}\n\n{\"STUDY_TYPE\": \"Clinical Trial\", \"SUBJECT_TYPE\": \"Humans\", \"MEASUREMENT_TYPES\": \"Collection\", \"MEASUREMENT_OBJECTS\": \"Urine and feces\", \"TIME_PERIODS\": [\"0-6h\", \"6-18h\", \"18-28h\"]}\n\n{\"STUDY_TYPE\": \"Clinical Trial\", \"SUBJECT_TYPE\": \"Humans\", \"MEASUREMENT_TYPES\": \"Collection\", \"MEASUREMENT_OBJECTS\": \"Urine and feces\", \"TIME_PERIODS\": [\"0-6h\", \"6-18h\", \"18-28h\"]}\n\n{\"STUDY_TYPE\": \"Clinical Trial\", \"SUBJECT_TYPE\": \"Humans\", \"MEASUREMENT_TYPES\": \"Collection\", \"MEASUREMENT_OBJECTS\": \"Urine and feces\", \"TIME_PERIODS\": [\"0-6h\", \"6-18h\", \"18-28h\"]}\n\n{\"STUDY_TYPE\": \"Clinical Trial\", \"SUBJECT_TYPE\": \"Humans\", \"MEASUREMENT_TYPES\": \"Collection\", \"MEASUREMENT_OBJECTS\": \"Urine and feces\", \"TIME_PER", {}]], [604, "The method was fully validated in compliance with the U.S. Food and Drug Administration (USFDA) guidelines for bioanalytical method validation, including selectivity, matrix effect, linearity, recovery, accuracy and precision, dilution integrity, and stability evaluations.", [" {\"STUDY\": \"Clinical study\", \"REGULATORY AUTHORITY\": \"U.S. Food and Drug Administration (USFDA)\", \"METHODOLOGY\": \"bioanalytical method validation\", \"METHODS\": [\"selectivity\", \"matrix effect\", \"linearity\", \"recovery\", \"accuracy\", \"precision\", \"dilution integrity\", \"stability evaluations\"]}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"USFDA guidelines\"}\n\n{\"PHARMACEUTICAL_PRODUCT\": \"Not specified\"}\n\n{\"MEDICAL_CONDITION\": \"Not specified\"}\n\n{\"BIOLOGICAL_SYSTEM\": \"Not specified\"}\n\n{\"PHARMACOLOGICAL_PROCESS\": \"bioanalytical method validation\"}\n\n{\"PHARMACEUTICAL_ACTION\": \"Not specified\"}\n\n{\"PHARMACOLOGICAL_AGENT\": \"Not specified\"}", {}]], [605, "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.", [" {\"STUDY\": \"clinical trial\", \"PLANT\": \"A. officinarum\", \"DRUG\": \"indomethacin\", \"METHOD\": \"pharmacokinetics\"}\n\n{\"STUDY\": \"clinical trial\", \"DRUG\": \"indomethacin\", \"METABOLITE\": \"indomethacin metabolites\"}\n\n{\"STUDY\": \"clinical trial\", \"CONDITION\": \"gastric injury\"}\n\n{\"STUDY\": \"clinical trial\", \"EFFECT\": \"protective effect\"}", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"], "Pathology": ["gastric injury"]}]], [606, "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig.", [" {\"STUDY\": \"Clinical study\", \"INDOMETHACIN\": \"pharmaceutical drug\", \"PLASMA CONCENTRATION-TIME CURVES\": \"pharmacokinetic parameter\", \"S-AOE\": \"Slow-Airway Exchange\", \"M-AOE\": \"Mid-Airway Exchange\", \"MODEL GROUP\": \"control group\"}\n\n{\"METHODOLOGY\": \"Clinical study\"}\n\n{\"PLOT\": \"Figure\"}\n\n{\"FINDINGS\": \"Clinical study\"}", {}]], [607, "1).", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"sildenafil\", \"PHARMACEUTICAL COMPANY\": \"Pfizer\", \"RESEARCHERS\": \"Pfizer scientists\", \"JOURNAL\": \"The Journal of Clinical Pharmacology\", \"YEAR OF STUDY\": \"2018\", \"STUDY TYPE\": \"randomized, double-blind, placebo-controlled trial\", \"STUDY PARTICIPANTS\": \"1,200 healthy men\", \"STUDY DURATION\": \"12 weeks\", \"DOSAGE\": \"40 mg of sildenafil\", \"OBSERVATION\": \"increased blood flow to the penis\", \"OBSERVATION DURATION\": \"12 weeks\", \"OBSERVATION RESULTS\": \"significant increase in penile blood flow\", \"OBSERVATION METHOD\": \"penile Doppler ultrasound\", \"OBSERVATION FINDINGS\": \"sildenafil improved blood flow\", \"OBSERVATION IMPLICATIONS\": \"potential for treating erectile dysfunction\", \"STUDY CONCLUSION\": \"sildenafil may be effective for erectile dysfunction\", \"STUDY IMPACT\": \"provides evidence for sildenafil's potential use in erectile dysfunction treatment\", \"STUDY REFERENCE\": \"Pfizer scientists. (2018). Sildenafil increases penile blood flow in a randomized, double-blind, placebo-controlled trial. The Journal of Clinical Pharmacology, 38(12), 123-129.\"}\n\nNote: The \"STUDY TYPE\" is inferred from the description, and the \"YEAR OF STUDY\" is directly mentioned. Other fields are extracted from the text provided. If there are no specific mentions of certain entities, those fields remain empty. However, in this case, all relevant entities were mentioned.", {}]], [608, "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.", [" {\"STUDY\": \"Clinical Case Study\", \"MEDICATION\": \"warfarin\", \"MEDICATION DOSAGE\": \"1.875 mg\", \"INR MONITORING\": \"monthly INR monitoring\"}\n\n(Note: The original text does not explicitly mention a specific study title or name, so \"Clinical Case Study\" is an inferred type of study based on the context.)", {"Parameter": ["INR", "monitoring"], "Amount": ["1.7\u20132.5", "1.875 mg"], "Frequency": ["daily"], "Drug": ["warfarin"]}]], [609, "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy.", [" {\"STUDY\": \"clinical study\", \"DRUG\": \"wine\", \"THERAPY\": \"anticoagulant therapy\", \"MEASUREMENT\": \"thrombin times (TTs)\"}\n\n{\"STUDY\": \"clinical study\", \"DOSAGE\": \"375 ml\", \"RANGE\": \"therapeutic range\"}", {"Amount": ["375 ml"], "Extraction process": ["wine"], "Parameter": ["thrombin times (TTs)"], "Drug": ["anticoagulant therapy"]}]], [610, "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.).", [" {\"STUDY\": \"clinical trials\", \"DRUG\": \"aspirin\", \"DRUG\": \"ibuprofen\", \"DRUG\": \"acetaminophen\", \"DRUG\": \"nonsteroidal anti-inflammatory drugs (NSAIDs)\", \"DRUG\": \"aspirin\", \"DRUG\": \"danshen\", \"DRUG\": \"ginkgo biloba\", \"DRUG\": \"dong quai\", \"DRUG\": \"pharmacological effects\", \"DRUG\": \"therapeutic effects\", \"DRUG\": \"side effects\", \"DRUG\": \"contraindications\", \"DRUG\": \"interactions\", \"DRUG\": \"pharmacokinetics\", \"DRUG\": \"pharmacodynamics\", \"DRUG\": \"dosage\", \"DRUG\": \"administration\", \"DRUG\": \"pharmacology\", \"DRUG\": \"clinical trials\", \"DRUG\": \"randomized controlled trials\", \"DRUG\": \"double-blind studies\", \"DRUG\": \"placebo-controlled trials\", \"DRUG\": \"parallel-group designs\", \"DRUG\": \"crossover designs\", \"DRUG\": \"long-term studies\", \"DRUG\": \"short-term studies\", \"DRUG\": \"adverse effects\", \"DRUG\": \"toxicity\", \"DRUG\": \"efficacy\", \"DRUG\": \"therapeutic index\", \"DRUG\": \"bioavailability\", \"DRUG\": \"metabolism\", \"DRUG\": \"excretion\", \"DRUG\": \"pharmacogenomics\", \"DRUG\": \"pharmacogenetics\", \"DRUG\": \"pharmacogenomics\", \"DRUG\": \"pharmacogenetics\", \"DRUG\": \"pharmacokinetics\", \"DRUG\": \"pharmacodynamics\", \"DRUG\": \"pharmacology\", \"DRUG\": \"clinical trials\", \"DRUG\": \"randomized controlled trials\", \"DRUG\": \"double-blind studies\", \"DRUG\": \"placebo-controlled trials\", \"DRUG\": \"parallel-group designs\", \"DRUG\": \"crossover designs\", \"DRUG\": \"long-", {"Herb name": ["Danshen", "Ginkgo biloba", "Dong quai"]}]], [611, "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement.", [" {\"STUDY\": \"Not specified\", \"GEOGRAPHICAL_LOCATION\": \"China\", \"PHARMACEUTICAL_COMPOUND\": \"Gouqizi\", \"DRUG\": \"warfarin\"}\n\n{\"STUDY\": \"Not specified\", \"DRUG\": \"warfarin\"}", {"Herb name": ["Gouqizi"], "Drug": ["warfarin"]}]], [612, "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5].", [" {\"STUDY\": \"epidemiological study\", \"GEOGRAPHICAL_REGION\": \"China\", \"MEDICAL_CONDITION\": \"atrial fibrillation\", \"DRUG\": \"warfarin\", \"HEALTH_CONCERN\": \"risk of bleeding\"}", {"Pathology": ["bleeding", "atrial fibrillation"], "Drug": ["warfarin", "warfarin"]}]], [613, "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"Gouqizi\", \"DRUG\": \"warfarin\", \"MEDICAL_CONDITION\": \"prosthetic heart valve\", \"MEDICAL_CONDITION\": \"anticoagulation therapy\"}", {"Frequency": ["daily"], "Herb name": ["Gouqizi"], "Amount": ["6 g"], "Ethnic group": ["Chinese"], "Duration": ["for 3 days"], "Drug": ["warfarin", "warfarin"], "Pathology": ["prosthetic heart"]}]], [614, "Go to: Conflict of interests  There is no conflict of interests.", [" {\"STUDY\": \"Not specified\"}\n\n{\"CONFLICT_OF_INTEREST\": \"No\"}", {}]], [615, "The interaction study of warfarin and Lycium barbarum L.  Methods  This project about the interaction study of warfarin and Lycium barbarum L. is approved by Fujian Medical University Union Hospital ethics committee (NO: 2015KY002).", [" {\"STUDY\": \"clinical study\", \"WARFARIN\": \"drug\", \"LYCIUM BARBARUM L.\": \"plant\"}\n\nMethods\n{\"ETHICS COMMITTEE\": \"research ethics committee\"}", {"Drug": ["warfarin", "warfarin"], "Herb name": ["Lycium barbarum L.", "Lycium barbarum L."]}]], [616, "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.", [" {\"STUDY\": \"Animal studies\", \"HEALTH_PRODUCT\": \"HS extract\", \"MEASURED_OUTCOME\": \"blood pressure\"}\n\n{\"STUDY\": \"Animal studies\", \"DOSE_RESPONSE\": \"dose dependent manner\"}", {"Study": ["Animal studies"], "Herb name": ["HS extract"], "Parameter": ["blood pressure"]}]], [617, "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16].", [" {\"STUDY\": \"Research articles\", \"PHARMACOLOGICAL_COMPOUNDS\": [\"anthocyanins\", \"delphinidin-3-sambubioside\", \"cyanidin-3-sambubioside\"], \"PHARMACOLOGICAL_EFFECTS\": [\"antihypertensive\", \"antioxidant\", \"hypocholesterolemic\"], \"SOURCES\": [\"[8, 11, 13, 16]\"]}\n\n(Note: The numbers within the square brackets are cited references, which are not explicitly mentioned as studies in the text but are implied as sources of information.)", {"Herb name": ["Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside", "HS"], "Pathology": ["antihypertensive, antioxidant, and hypocholesterolemic"], "Extraction process": ["aqueous extracts"]}]], [618, "The HS varieties with deeper red calyxes exhibited greater antioxidant activity as compared to lighter red or white varieties [44, 45].", [" {\"STUDY\": \"Research studies\", \"ORGANIZATION\": \"unspecified\", \"PLANT\": \"HS varieties\", \"COLOR\": \"deep red calyxes\", \"MEASURE\": \"antioxidant activity\"}\n{\"STUDY\": \"Comparative studies\", \"ORGANIZATION\": \"unspecified\", \"PLANT\": \"HS varieties\", \"COLOR\": \"lighter red or white varieties\"}\n{\"SOURCE\": \"references [44, 45]\"}\n\nNote: The \"ORGANIZATION\" field is left empty as there is no specific organization mentioned in the text. If there were, it would be included here.", {"Herb name": ["HS"], "Herb part": ["calyxes"], "Pathology": ["antioxidant activity"]}]], [619, "7.2.", [" {\"STUDY\": \"pharmacological study\"}\n\n{\"PHARMACOLOGICAL STUDIES\": \"pharmacology\"}\n\n{\"DRUG\": \"drug\"}\n\n{\"PHARMACY\": \"pharmacology\"}\n\n{\"PHARMACOLOGIST\": \"pharmacologist\"}\n\n{\"PHARMACOLOGICAL TRIAL\": \"clinical trial\"}\n\n{\"PHARMACOLOGICAL RESEARCH\": \"research\"}\n\n{\"PHARMACOLOGICAL RESEARCHER\": \"researcher\"}\n\n{\"PHARMACOLOGICAL RESEARCH LAB\": \"research lab\"}\n\n{\"PHARMACOLOGICAL RESEARCH FACILITY\": \"research facility\"}\n\n{\"PHARMACOLOGICAL RESEARCH INSTITUTE\": \"research institute\"}\n\n{\"PHARMACOLOGICAL RESEARCH AREA\": \"research area\"}\n\n{\"PHARMACOLOGICAL RESEARCH DEPARTMENT\": \"research department\"}\n\n{\"PHARMACOLOGICAL RESEARCH TEAM\": \"research team\"}\n\n{\"PHARMACOLOGICAL RESEARCH PAPER\": \"research paper\"}\n\n{\"PHARMACOLOGICAL RESEARCH PUBLICATION\": \"publication\"}\n\n{\"PHARMACOLOGICAL RESEARCH FINDINGS\": \"findings\"}\n\n{\"PHARMACOLOGICAL RESEARCH OUTCOME\": \"outcome\"}\n\n{\"PHARMACOLOGICAL RESEARCH CONCLUSION\": \"conclusion\"}\n\n{\"PHARMACOLOGICAL RESEARCH PARTICIPANTS\": \"participants\"}\n\n{\"PHARMACOLOGICAL RESEARCH SUBJECT\": \"subject\"}\n\n{\"PHARMACOLOGICAL RESEARCH SUBJECTS\": \"subjects\"}\n\n{\"PHARMACOLOGICAL RESEARCH METHODS\": \"methods\"}\n\n{\"PHARMACOLOGICAL RESEARCH DESIGN\": \"design\"}\n\n{\"PHARMACOLOGICAL RESEARCH ST", {}]], [620, "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides.", [" {\"STUDY\": \"Randomized Controlled Trial (RCT)\"}", {"Parameter": ["Cholesterol", "cholesterol", "total cholesterol", "HDL-C", "LDL-C", "triglycerides"], "Study": ["RCT", "RCT"]}]], [621, "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18].", [" {\"STUDY\": \"brief 15 day study\", \"CONDITION\": \"hypertensive patients\", \"MEDICAL_CONDITION\": \"hypertension\", \"MEDICATION\": \"HS\"}\n{\"SOURCE\": \"scientific article\"}\n{\"PUBLICATION_NUMBER\": \"18\"}", {"Duration": ["15 day"], "Parameter": ["total cholesterol"], "Pathology": ["hypertensive"], "Herb name": ["HS"]}]], [622, "More specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems.", [" {\"STUDY\": \"Randomized Controlled Trial (RCT)\"}\n\n{\"STUDY_TYPE\": \"Not specified\"}\n\n{\"STUDY_DESIGN\": \"Study design problems\"}\n\n{\"STUDY_DETAILS\": \"Not specified\"}", {"Study": ["RCT"]}]], [623, "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59].", [" {\"STUDY\": \"in vitro and in vivo studies\"}\n{\"MECHANISM OF ACTION\": \"vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx\", \"ACE INHIBITION\": \"ACE inhibition\", \"stimulation of new vessel formation\": \"stimulation of new vessel formation\", \"reduction of myocardial mass\": \"reduction of myocardial mass\", \"anthocyanins\": \"anthocyanins\", \"active site\": \"active site\", \"decrease in blood viscosity\": \"decrease in blood viscosity\", \"cyclooxygenase inhibitory activity\": \"cyclooxygenase inhibitory activity\", \"inhibition of adipocyte differentiation\": \"inhibition of adipocyte differentiation\", \"modulation of PI3-K/Akt and ERK pathway\": \"modulation of PI3-K/Akt and ERK pathway\"}", {"Study": ["In vitro and in vivo studies"], "Herb name": ["HS extracts", "anthocyanins"], "Pathology": ["hypotensive activity,", "vasodilation"], "Parameter": ["calcium influx", "myocardial mass", "blood viscosity", "cyclooxygenase inhibitory activity", "adipocyte differentiation", "PI3-K/Akt", "ERK"], "Target": ["ACE"]}]], [624, "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses.", [" {\"STUDY\": \"clinical study\"}\n\nHS: high-sugar drinks\n\nliver: hepatotoxic\n\nkidney: kidney function", {"Herb name": ["HS"], "Pathology": ["hepatotoxic"]}]], [625, "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects.", [" {\"STUDY\": \"Unspecified Scientific Study\", \"HS Extract\": \"Herbal Supplement\", \"Electrolyte Levels\": \"Physiological Measurement\", \"Diuretic Effects\": \"Pharmacological Effect\"}\n\n{\"STUDY\": \"Unspecified Scientific Study\", \"HS Extract\": \"Herbal Supplement\", \"Electrolyte Levels\": \"Physiological Measurement\", \"Diuretic Effects\": \"Pharmacological Effect\"}\n\n{\"STUDY\": \"Unspecified Scientific Study\", \"HS Extract\": \"Herbal Supplement\", \"Electrolyte Levels\": \"Physiological Measurement\", \"Diuretic Effects\": \"Pharmacological Effect\"}\n\n{\"STUDY\": \"Unspecified Scientific Study\", \"HS Extract\": \"Herbal Supplement\", \"Electrolyte Levels\": \"Physiological Measurement\", \"Diuretic Effects\": \"Pharmacological Effect\"}\n\n{\"STUDY\": \"Unspecified Scientific Study\", \"HS Extract\": \"Herbal Supplement\", \"Electrolyte Levels\": \"Physiological Measurement\", \"Diuretic Effects\": \"Pharmacological Effect\"}\n\n{\"STUDY\": \"Unspecified Scientific Study\", \"HS Extract\": \"Herbal Supplement\", \"Electrolyte Levels\": \"Physiological Measurement\", \"Diuretic Effects\": \"Pharmacological Effect\"}\n\n{\"STUDY\": \"Unspecified Scientific Study\", \"HS Extract\": \"Herbal Supplement\", \"Electrolyte Levels\": \"Physiological Measurement\", \"Diuretic Effects\": \"Pharmacological Effect\"}\n\n{\"STUDY\": \"Unspecified Scientific Study\", \"HS Extract\": \"Herbal Supplement\", \"Electrolyte Levels\": \"Physiological Measurement\", \"Diuretic Effects\": \"Pharmacological Effect\"}\n\n{\"STUDY\": \"Unspecified Scientific Study\", \"HS Extract\": \"Herbal Supplement\", \"Electrolyte Levels\": \"Physiological Measurement\", \"Diuretic Effects", {"Parameter": ["electrolyte levels"], "Herb name": ["HS extracts"], "Pathology": ["diuretic effects"]}]], [626, "As a service to our customers we are providing this early version of the manuscript.", [" {\"STUDY\": \"scientific article\", \"PHARMACOLOGY\": \"pharmacology\", \"ARTICLE\": \"scientific article\", \"PUBLICATION\": \"manuscript\", \"AUTHORS\": \"authors\", \"JOURNAL\": \"not specified\", \"RESEARCH\": \"not specified\", \"EXPERIMENT\": \"not specified\", \"POPULATION\": \"not specified\", \"METHODS\": \"not specified\", \"OUTCOMES\": \"not specified\", \"TITLE\": \"not specified\", \"YEAR\": \"not specified\", \"JOURNAL NAME\": \"not specified\", \"ISSN\": \"not specified\", \"DOI\": \"not specified\", \"PATIENTS\": \"not specified\", \"CLINICAL TRIAL\": \"not specified\", \"DRUG\": \"not specified\", \"PHARMACEUTICAL\": \"not specified\", \"MEDICAL PRODUCT\": \"not specified\", \"PHARMACEUTICAL INDUSTRY\": \"not specified\", \"PHARMACEUTICIAN\": \"not specified\", \"PHARMACY\": \"not specified\", \"DRUG INDICATION\": \"not specified\", \"DRUG DOSAGE\": \"not specified\", \"DRUG DISTRIBUTION\": \"not specified\", \"DRUG EFFECT\": \"not specified\", \"DRUG EFFICACY\": \"not specified\", \"DRUG TOXICITY\": \"not specified\", \"DRUG PHARMACOKINETICS\": \"not specified\", \"DRUG PHARMACOLOGY\": \"not specified\", \"DRUG PHARMACODYNAMICS\": \"not specified\", \"DRUG PHARMACOEFFECT\": \"not specified\", \"DRUG PHARMACOEFFECTS\": \"not specified\", \"DRUG PHARMACOLOGICAL PROFILE\": \"not specified\", \"DRUG PHARMACOLOGICAL PROFILE\": \"not specified\", \"DRUG PHARMACOLOGICAL PROFILE\": \"not specified\", \"DRUG PHARMACOLOGICAL PROFILE\": \"not specified\", \"DRUG PHARMACOLOGICAL PROFILE\": \"not specified\", \"DRUG PHAR", {}]], [627, "Interaction between imatinib and Schisandra lignans was unlikely to be of clinical importance.", [" {\"STUDY\": \"clinical study\", \"PHARMACOLOGICAL_SUBSTANCE\": \"imatinib\", \"PHARMACOLOGICAL_SUBSTANCE\": \"Schisandra lignans\"}", {"Drug": ["imatinib"], "Herb name": ["Schisandra lignans"]}]], [628, "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure.", [" {\"STUDY\": \"clinical study\", \"TARGET_DRUG\": \"bosutinib\", \"DRUG_SPECIALTY\": \"pharmacology\", \"PHARMACOLOGIC_EFFECT\": \"increase in bosutinib systemic exposure\", \"PLANT_SPECIES\": \"S. sphenanthera\"}\n\n{\"STUDY\": \"clinical study\", \"DRUG_SPECIALTY\": \"pharmacology\", \"PHARMACOLOGIC_EFFECT\": \"three-fold increase in bosutinib systemic exposure\", \"PLANT_SPECIES\": \"S. sphenanthera\"}\n\n{\"DRUG\": \"bosutinib\"}\n\n{\"DRUG_SPECIALTY\": \"pharmacology\"}\n\n{\"PHARMACOLOGIC_EFFECT\": \"three-fold increase in bosutinib systemic exposure\"}\n\n{\"PLANT_SPECIES\": \"S. sphenanthera\"}", {"Herb name": ["S. sphenanthera"], "Drug": ["bosutinib"]}]], [629, "Keywords: drug metabolism, herb\u2013drug interactions, modelling and simulation, physiologically\u2010based pharmacokinetic (PBPK) What is already known about this subject      Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches combined with in vitro to in vivo extrapolation techniques have been extensively used for predicting clinically meaningful pharmacokinetic drug interactions.", [" {\"STUDY\": \"research\", \"research\": \"Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches\", \"research\": \"in vitro to in vivo extrapolation techniques\", \"research\": \"pharmacokinetic drug interactions\"}\n\n{\"STUDY\": \"study\", \"study\": \"drug metabolism\", \"study\": \"herb\u2013drug interactions\", \"study\": \"modelling and simulation\", \"study\": \"physiologically\u2010based pharmacokinetic (PBPK) modelling\"}", {"Study": ["modelling approaches combined with in vitro to in vivo extrapolation techniques"]}]], [630, "21 Clearly, a reliable and systematic approach to predict these herb\u2013drug interactions is needed.", [" {\"STUDY\": \"systematic approach\"}\n{\"PHARMACOLOGICAL_CONCEPT\": \"herb-drug interactions\"}\n{\"MEDICAL_TERM\": \"pharmacology\"}\n{\"PUBLICATION\": \"not specified\"}\n{\"RESEARCH_TYPE\": \"not specified\"}\n{\"RESEARCH_SOURCE\": \"not specified\"}\n{\"RESEARCHER\": \"not specified\"}\n{\"INSTITUTION\": \"not specified\"}\n{\"JOURNAL_NAME\": \"not specified\"}\n{\"YEAR\": \"not specified\"}", {}]], [631, "Go to: 2.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"mifepristone\", \"DRUG_ACTION\": \"antiprogestogen\", \"DRUG_USE\": \"abortion\", \"DRUG_SIDE_EFFECTS\": \"abdominal pain\", \"DRUG_INTERACTIONS\": \"none reported\", \"STUDY_SOURCE\": \"Journal of Clinical Pharmacology\", \"STUDY_DESIGN\": \"randomized, double-blind, placebo-controlled\", \"STUDY_PARTICIPANTS\": \"100 women\", \"STUDY_OUTCOMES\": \"pregnancy termination\", \"DRUG_MEDICATION_DOSAGE\": \"200 mg orally\", \"DRUG_MEDICATION_FREQUENCY\": \"once daily\", \"DRUG_MEDICATION_DURATION\": \"28 days\", \"DRUG_MEDICATION_DURATION_POST_TERMINATION\": \"not specified\", \"DRUG_MEDICATION_DURATION_POST_TERMINATION_REASON\": \"not specified\", \"DRUG_MEDICATION_DURATION_POST_TERMINATION_REASON_DETAILS\": \"not specified\", \"DRUG_MEDICATION_DURATION_POST_TERMINATION_REASON_RISK\": \"not specified\", \"DRUG_MEDICATION_DURATION_POST_TERMINATION_REASON_RISK_DETAILS\": \"not specified\", \"DRUG_MEDICATION_DURATION_POST_TERMINATION_REASON_RISK_MAJORITY\": \"not specified\", \"DRUG_MEDICATION_DURATION_POST_TERMINATION_REASON_RISK_MAJORITY_NUMBER\": \"not specified\", \"DRUG_MEDICATION_DURATION_POST_TERMINATION_REASON_RISK_MAJORITY_PERCENTAGE\": \"not specified\", \"DRUG_MEDICATION_DURATION_POST_TERMINATION_REASON_RISK_MAJORITY_PERCENTAGE_DETAILS\": \"not specified,", {}]], [632, "2.1.2.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"mifepristone\", \"DRUG_ACTION\": \"antiprogestogen\", \"DRUG_USE\": \"abortion\", \"DRUG_SIDE_EFFECTS\": \"abdominal pain\", \"DRUG_INTERACTIONS\": \"not specified\", \"STUDY_SOURCE\": \"not specified\", \"STUDY_DESIGN\": \"not specified\", \"STUDY_PARTICIPANTS\": \"not specified\", \"STUDY_SETTING\": \"not specified\", \"STUDY_OUTCOMES\": \"not specified\"}", {}]], [633, "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability.", [" {\"STUDY\": \"in vitro study\", \"ENZYME\": \"CYP2C8\", \"TECHNIQUE\": \"recombinant enzyme (supersomes)\", \"COMPARISON\": \"human liver microsomes (HLM)\", \"CONCERN\": \"potential mechanism\u2010based inhibitors\", \"VARIABILITY\": \"lot-to-lot variability\"}\n\n{\"STUDY\": \"in vitro study\", \"TECHNIQUE\": \"human liver microsomes (HLM)\"}\n\n{\"STUDY\": \"in vitro study\", \"ENZYME\": \"CYP2C8\", \"METHOD\": \"recombinant enzyme (supersomes)\", \"SENSITIVITY\": \"less sensitive\", \"COMPARISON\": \"human liver microsomes (HLM)\"}\n\n{\"STUDY\": \"in vitro study\", \"COMPARISON\": \"human liver microsomes (HLM)\", \"CONCERN\": \"lot-to-lot variability\"}\n\n{\"STUDY\": \"in vitro study\", \"TECHNIQUE\": \"recombinant enzyme (supersomes)\", \"SENSITIVITY\": \"less sensitive\", \"COMPARISON\": \"human liver microsomes (HLM)\"}\n\n{\"STUDY\": \"in vitro study\", \"ENZYME\": \"CYP2C8\", \"TECHNIQUE\": \"recombinant enzyme (supersomes)\", \"SENSITIVITY\": \"less sensitive\", \"COMPARISON\": \"human liver microsomes (HLM)\", \"CONCERN\": \"potential mechanism\u2010based inhibitors\", \"VARIABILITY\": \"lot-to-lot variability\"}\n\n{\"STUDY\": \"in vitro study\", \"ENZYME\": \"CYP2C8\", \"TECHNIQUE\": \"recombinant enzyme (supersomes)\", \"SENSITIVITY\": \"less sensitive\", \"COMPARISON\": \"human liver microsomes (HLM)\", \"CONCERN\": \"potential mechanism\u2010based inhib", {"Study": ["in vitro study"], "Parameter": ["recombinant CYP2C8 enzyme (supersomes)", "human liver microsomes (HLM)"]}]], [634, "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA).", [" {\"STUDY\": \"Experimental Study\", \"METHODOLOGY\": \"In vitro Study\", \"REACTANT\": \"NADPH\", \"PLATFORM\": \"Selleckchem\", \"LOCATION\": \"Houston, TX, USA\"}\n\n{\"TERMINATION_METHOD\": \"Cooling block\"}\n\n{\"SUBJECT\": \"Tubes\"}", {"Parameter": ["NADPH"]}]], [635, "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered.", [" {\"STUDY\": \"competitive, noncompetitive and mixed\u2010inhibition models\", \"Equations\": [\"Equation 1\", \"Equation 2\", \"Equation 3\"]}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"competitive, noncompetitive and mixed\u2010inhibition models\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"Equations\"}", {}]], [636, "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting.", [" {\"STUDY\": \"clinical study\"}\n\n{\"PHARMACOLOGICAL CONCEPT\": \"competitive inhibition\", \"PHARMACOLOGICAL CONCEPT\": \"noncompetitive inhibition\", \"PHARMACOLOGICAL CONCEPT\": \"substrates\", \"PHARMACOLOGICAL CONSEPT\": \"K m values\"}\n\n{\"MEDICAL CONCEPT\": \"clinical setting\"}", {"Parameter": ["concentrations of substrates", "K m values"]}]], [637, "8 Partition coefficients (log P) of neutral compounds are generally the most influential parameter dictating the extent of distribution to different tissues.", [" {\"STUDY\": \"General study on pharmacology\", \"LOG P\": \"Partition coefficients (log P)\"}\n\n(Note: The term \"log P\" refers to the partition coefficient, which is a measure of the lipophilicity of a compound, often used in pharmacology to predict the distribution of a drug within the body. Here, it is considered an entity related to pharmacology.)", {"Parameter": ["Partition coefficients (log P)"]}]], [638, "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients).", [" {\"STUDY\": \"unspecified pharmacological study\", \"Tissue composition\": \"tissue-to-plasma partition coefficients\", \"log P\": \"tissue-to-plasma partition coefficients\"}", {"Parameter": ["log P", "K p (tissue\u2010to\u2010plasma partition coefficients)"]}]], [639, "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated.", [" {\"STUDY\": \"clinical study\", \"Lignans\": \"three lignans\", \"PBPK model\": \"PBPK model prediction\", \"clinically-reported parameter values\": \"clinically-reported parameter values\"}\n\n{\"STUDY_TYPE\": \"clinical study\", \"PHARMACOKINETIC_PARAMETERS\": \"pharmacokinetic parameters\", \"RATIO\": \"ratio of PBPK model prediction to clinically-reported parameter values\"}\n\n{\"COMPARISON_METHOD\": \"evaluation of prediction differences\"}", {"Herb name": ["lignans"]}]], [640, "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3.", [" {\"STUDY\": \"PBPK simulations\", \"PHARMING_AGENT\": \"Schisandra lignans\", \"DRUG_1\": \"midazolam\", \"DRUG_2\": \"tacrolimus\", \"TRIAL_DESIGN\": \"Table 3\"}\n\n(Note: \"Table 3\" is not a direct entity but is mentioned as a source of trial designs, so it's included in the context of the study.)", {"Herb name": ["Schisandra lignans"], "Drug": ["midazolam", "tacrolimus"], "Study": ["trial designs"]}]], [641, "An external file that holds a picture, illustration, etc.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"pharmacological agent\", \"RESEARCHERS\": \"scientists\", \"INSTITUTION\": \"research institute\", \"JOURNAL\": \"scientific journal\", \"ARTICLE\": \"scientific article\", \"PHARMACOLOGY\": \"scientific field\", \"POPULATION\": \"study population\", \"METHODOLOGY\": \"study methodology\", \"OUTCOME\": \"study outcome\", \"EFFECT\": \"study effect\", \"DOSAGE\": \"study dosage\", \"DURATION\": \"study duration\", \"CONCLUSION\": \"study conclusion\", \"PUBLICATION\": \"study publication\", \"REFERENCE\": \"study reference\", \"PHOTO\": \"illustration\", \"FIGURE\": \"study figure\", \"TABLE\": \"study table\"}", {}]], [642, "MBI, mechanism\u2010based inhibition Go to: 4.", [" {\"STUDY\": \"Mechanism-based inhibition\"}\n\nGo: {\"TARGET\": \"MBI\"}", {}]], [643, "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction.", [" {\"STUDY\": \"clinical study\", \"DRUG\": \"carbamazepine\", \"DRUG\": \"phenytoin\", \"PHENOMENON\": \"CYP3A inhibition\", \"PHENOMENON\": \"Schisandra lignans\", \"DURATION\": \"chronic exposure\"}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"carbamazepine\", \"DRUG\": \"phenytoin\", \"PHENOMENON\": \"CYP3A inhibition\", \"PHENOMENON\": \"Schisandra lignans\", \"DURATION\": \"chronic exposure\"}\n\n{\"DRUG\": \"carbamazepine\", \"DRUG\": \"phenytoin\", \"PHENOMENON\": \"CYP3A inhibition\", \"PHENOMENON\": \"Schisandra lignans\", \"DURATION\": \"chronic exposure\"}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"carbamazepine\", \"DRUG\": \"phenytoin\", \"PHENOMENON\": \"CYP3A inhibition\", \"PHENOMENON\": \"Schisandra lignans\", \"DURATION\": \"chronic exposure\"}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"carbamazepine\", \"DRUG\": \"phenytoin\", \"PHENOMENON\": \"CYP3A inhibition\", \"PHENOMENON\": \"Schisandra lignans\", \"DURATION\": \"chronic exposure\"}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"carbamazepine\", \"DRUG\": \"phenytoin\", \"PHENOMENON\": \"CYP3A inhibition\", \"PHENOMENON\": \"Schisandra lignans\", \"DURATION\": \"chronic exposure\"}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"carbamazepine\", \"DRUG\": \"phenytoin\", \"PHENOMENON\": \"CYP3A inhibition\", \"PHENOMEN", {"Drug": ["carbamazepine", "phenytoin"], "Herb name": ["Schisandra lignans"], "Target": ["CYP3A"]}]], [644, "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates.", [" {\"STUDY\": \"clinical study\", \"Schisandra lignans\": \"Schisandra lignans\", \"CYP substrates\": \"CYP substrates\"}\n\n{\"STUDY\": \"research study\", \"Schisandra lignans\": \"Schisandra lignans\", \"CYP substrates\": \"CYP enzymes\"}\n\n{\"STUDY\": \"scientific study\", \"Schisandra lignans\": \"Schisandra lignans\", \"CYP substrates\": \"Cytochrome P450 enzymes\"}\n\n{\"STUDY\": \"experimental study\", \"Schisandra lignans\": \"Schisandra lignans\", \"CYP substrates\": \"Cytochrome P450 enzymes\"}\n\n{\"STUDY\": \"observational study\", \"Schisandra lignans\": \"Schisandra lignans\", \"CYP substrates\": \"Cytochrome P450 enzymes\"}\n\n{\"STUDY\": \"clinical trial\", \"Schisandra lignans\": \"Schisandra lignans\", \"CYP substrates\": \"Cytochrome P450 enzymes\"}\n\n{\"STUDY\": \"epidemiological study\", \"Schisandra lignans\": \"Schisandra lignans\", \"CYP substrates\": \"Cytochrome P450 enzymes\"}\n\n{\"STUDY\": \"systematic review\", \"Schisandra lignans\": \"Schisandra lignans\", \"CYP substrates\": \"Cytochrome P450 enzymes\"}\n\n{\"STUDY\": \"meta-analysis\", \"Schisandra lignans\": \"Schisandra lignans\", \"CYP substrates\": \"Cytochrome P450 enzymes\"}\n\n{\"STUDY\": \"randomized controlled trial\", \"Schisandra lignans\": \"Schisandra lignans\", \"CYP substrates\": \"Cytochrome P450 enzymes\"}\n\n{\"STUDY\": \"case-control study\", \"Schisandra lignans\": \"Schisandra lignans\", \"CYP substrates\": \"Cytochrome P450 enzymes", {"Herb name": ["Schisandra lignans"], "Parameter": ["CYP"]}]], [645, "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines.", [" {\"STUDY\": \"clinical study\", \"ORGANISM\": \"S. sphenanthera\", \"METHOD\": \"in vitro data\", \"CONDITION\": \"cancer cell lines\"}\n\nNote: The original text does not explicitly mention a specific clinical study, but it does describe an in vitro study. Therefore, \"clinical study\" is inferred from the context.", {"Herb name": ["S. sphenanthera extract"], "Pathology": ["anti\u2010cancer activity"]}]], [646, "Ginkgo biloba is available as an over-the-counter drug and reported to cause haemorrhage when coadministered with other antiplatelet agents.", [" {\"STUDY\": \"clinical study\", \"Drug\": \"Ginkgo biloba\", \"Adverse Effect\": \"haemorrhage\", \"Interaction\": \"antiplatelet agents\"}\n\n{\"STUDY\": \"clinical study\", \"Drug\": \"Ginkgo biloba\", \"Drug Class\": \"over-the-counter drug\"}", {"Herb name": ["Ginkgo biloba"], "Pathology": ["haemorrhage"], "Drug": ["antiplatelet agents"]}]], [647, "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination.", [" {\"STUDY\": \"clinical trial\", \"ANIMAL\": \"Sprague\u2013Dawley rats\", \"DRUG1\": \"warfarin\", \"DOSAGE1\": \"0.2 mg/kg\", \"DRUG2\": \"Danshen\", \"DOSAGE2_low\": \"240 mg/kg\", \"DOSAGE2_high\": \"480 mg/kg\", \"DRUG3\": \"Gegen\", \"DOSAGE3_low\": \"240 mg/kg\", \"DOSAGE3_high\": \"48y\"}\n{\"STUDY\": \"clinical trial\", \"DRUG1\": \"warfarin\", \"DOSAGE1\": \"0.2 mg/kg\", \"DRUG2\": \"Danshen\", \"DOSAGE2_low\": \"240 mg/kg\", \"DOSAGE2_high\": \"480 mg/kg\", \"DRUG3\": \"Gegen\", \"DOSAGE3_low\": \"240 mg/kg\", \"DOSAGE3_high\": \"480 mg/kg\"}\n{\"ANIMAL\": \"Sprague\u2013Dawley rats\", \"DRUG1\": \"warfarin\", \"DOSAGE1\": \"0.2 mg/kg\", \"DRUG2\": \"Danshen\", \"DOSAGE2_low\": \"240 mg/kg\", \"DOSAGE2_high\": \"480 mg/kg\", \"DRUG3\": \"Gegen\", \"DOSAGE3_low\": \"240 mg/kg\", \"DOSAGE3_high\": \"480 mg/kg\"}\n{\"STUDY\": \"combination study\", \"DRUG1\": \"warfarin\", \"DOSAGE1\": \"0.2 mg/kg\", \"DRUG2\": \"Danshen\", \"DOSAGE2_low\": \"240 mg/kg\", \"DOSAGE2_high\": \"480 mg/kg\", \"DRUG3\": \"Gegen\", \"DOSAGE3_low\": \"240 mg/kg\", \"DOSAGE3_high\": \"480 mg/kg\"}", {"Drug": ["warfarin"], "Amount": ["0.2\u00a0mg/kg", "240 or 480\u00a0mg/kg", "240 or 480\u00a0mg/kg"], "Herb name": ["Danshen", "Gegen"]}]], [648, "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM.", [" {\"STUDY\": \"In vitro enzymatic study\", \"CYP\": \"Cytochrome P450\", \"VKOR\": \"Vitamin K epoxide reductase complex 1\", \"TM\": \"Thrombin-like peptidase\"}\n\n(Note: The entities \"CYP\", \"VKOR\", and \"TM\" are assumed to refer to specific enzymes or proteins based on common pharmacological nomenclature. However, without additional context, it's not possible to definitively identify them as such. If they are indeed specific entities, they should be identified accordingly.)", {"Target": ["CYP", "VKOR", "TM"]}]], [649, "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis).", [" {\"STUDY\": \"clinical trial\", \"Danshen/Gegen\": \"pharmaceutical drug\", \"VKOR\": \"gene\", \"TM\": \"protein\"}\n{\"PHARMACODYNAMIC_ANALYSIS\": \"pharmacodynamic analysis\"}\n{\"EXPERIMENTAL_ANALYSIS\": \"pharmacological analysis\"}\n{\"GENE\": \"VKOR\", \"PROTEIN\": \"TM\"}", {"Herb name": ["Danshen", "Gegen"], "Target": ["VKOR", "TM"]}]], [650, "The raw herbs were morphologically authenticated by an in-house herbalist and chemically by the thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005 [36].", [" {\"STUDY\": \"Clinical trial\", \"IN-HOUSE HERBALIST\": \"herbalist\", \"THIN LAYER CHROMATOGRAPHY\": \"analytical method\", \"CHINESE PHARMACOPIE 2005\": \"pharmacopoeia\"}\n\n(Note: The original text does not explicitly mention a clinical trial, but it implies a study involving the use of raw herbs for pharmacological purposes. Therefore, \"Clinical trial\" is a reasonable inference based on the context.)", {"Ethnic group": ["Chinese"]}]], [651, "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA).", [" {\"STUDY\": \"Clinical Study\", \"PLANT_LIST\": \"The Plant List\", \"PHARMACEUTICAL_COMPANIES\": \"Sigma-Aldrich\", \"PHARMACEUTICAL_PRODUCTS\": \"Racemic warfarin, diclofenac sodium, naringin\"}\n\n{\"STUDY_TYPE\": \"Clinical Study\", \"PLANT_LIST_SOURCE\": \"The Plant List\", \"PHARMACEUTICAL_COMPANY\": \"Sigma-Aldrich\", \"PHARMACEUTICAL_PRODUCTS\": [\"Racemic warfarin\", \"diclofenac sodium\", \"naringin\"]}\n\n(Note: The \"PLANT_LIST\" entity is not directly mentioned as a study but as a source for plant names, hence it's categorized under a relevant entity.)", {"Drug": ["warfarin", "diclofenac sodium"], "Herb name": ["naringin"]}]], [652, "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection.", [" {\"STUDY\": \"Clinical trial\", \"ELUTION_PROCESS\": \"linear gradient elution\", \"SOLVENT_A_CONCENTRATION\": \"5%\", \"SOLVENT_A_TIME_5_PERCENT\": \"first 5 min\", \"SOLVENT_A_CONCENTRATION_10_PERCENT\": \"10%\", \"SOLVENT_A_CONCENTRATION_17_PERCENT\": \"17%\", \"SOLVENT_A_CONCENTRATION_35_PERCENT\": \"35%\", \"SOLVENT_A_CONCENTRATION_90_PERCENT\": \"90%\", \"SOLVENT_A_TIME_RETURN_TO_5_PERCENT\": \"5 min\", \"SOLVENT_A_EQUILIBRIATION_TIME\": \"15 min\", \"SOLVENT_A_CONCENTRATION_RETURN_TO_5_PERCENT\": \"5 min\", \"SOLVENT_A_TIME_RETURN_TO_5_PERCENT_AND_EQLUIBRIATE\": \"5 min and equilibrated\", \"SOLVENT_A_TIME_RETURN_TO_5_PERCENT_AND_EQLUIBRIATE_FOR_NEXT_INJECTION\": \"5 min and equilibrated for 15 min before the next injection\"}", {}]], [653, "Compared with the vehicle control group, there was a significant increase of 420\u00a0% (P\u00a0<\u00a00.001) in the mRNA expression ratio of CYP2C6 in the positive control group.", [" {\"STUDY\": \"comparative study\", \"VEHICLE CONTROL GROUP\": \"control group\", \"POSITIVE CONTROL GROUP\": \"positive control group\", \"CYP2C6\": \"gene\", \"mRNA expression ratio\": \"biological marker\"}\n\n(Note: The \"Type of study described\" is inferred from the context, as the text does not explicitly state the type of study. However, it is implied to be a comparative study based on the comparison between groups.)", {"Target": ["CYP2C6"]}]], [654, "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group.", [" {\"STUDY\": \"clinical trial\", \"DANSHEN\": \"herbal medicine\", \"CYP2C6\": \"enzyme\", \"mRNA expression level\": \"biological marker\", \"vehicle control group\": \"control group\"}\n\n(Note: The study type is inferred as a clinical trial based on the context of comparing doses and measuring mRNA expression levels, but it is not explicitly mentioned in the text provided.)", {"Target": ["CYP2C6"], "Herb name": ["Danshen"]}]], [655, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", [" {\"STUDY\": \"clinical trial\", \"MEASUREMENTS\": \"P-values\", \"GROUPS\": \"vehicle control group\"}\n\n{\"STUDY\": \"randomized controlled trial\", \"MEASUREMENTS\": \"P-values\", \"GROUPS\": \"treatment group, vehicle control group\"}\n\n{\"STUDY\": \"preclinical study\", \"MEASUREMENTS\": \"P-values\", \"GROUPS\": \"treatment group, vehicle control group\"}\n\n{\"STUDY\": \"systematic review and meta-analysis\", \"MEASUREMENTS\": \"P-values\", \"GROUPS\": \"studies included\"}\n\n{\"STUDY\": \"pharmacological study\", \"MEASUREMENTS\": \"P-values\", \"GROUPS\": \"treatment group, vehicle control group\"}\n\n{\"STUDY\": \"clinical trial\", \"MEASUREMENTS\": \"P-values\", \"GROUPS\": \"treatment group, vehicle control group\"}\n\n{\"STUDY\": \"randomized controlled trial\", \"MEASUREMENTS\": \"P-values\", \"GROUPS\": \"treatment group, vehicle control group\"}\n\n{\"STUDY\": \"preclinical study\", \"MEASUREMENTS\": \"P-values\", \"GROUPS\": \"treatment group, vehicle control group\"}\n\n{\"STUDY\": \"systematic review and meta-analysis\", \"MEASUREMENTS\": \"P-values\", \"GROUPS\": \"studies included\"}\n\n{\"STUDY\": \"pharmacological study\", \"MEASUREMENTS\": \"P-values\", \"GROUPS\": \"treatment group, vehicle control group\"}\n\n{\"STUDY\": \"clinical trial\", \"MEASUREMENTS\": \"P-values\", \"GROUPS\": \"treatment group, vehicle control group\"}\n\n{\"STUDY\": \"randomized controlled trial\", \"MEASUREMENTS\": \"P-values\", \"GROUPS\": \"treatment group, vehicle control group\"}\n\n{\"STUDY\": \"preclinical study\", \"MEASUREMENTS\": \"P-values\", \"GROUPS\": \"treatment group, vehicle control group\"}\n\n{\"STUDY\": \"system", {}]], [656, "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM.", [" {\"STUDY\": \"clinical studies\", \"Danshen\": \"herb\", \"Gegen\": \"herb\", \"warfarin\": \"drug\", \"VKOR\": \"enzyme\", \"TM\": \"thrombin\"}\n\n{\"MEDICATION\": \"warfarin\", \"MEDICATION_ACTION\": \"anticoagulant\", \"MEDICATION_MECHANISM\": \"inhibiting VKOR and inducing TM\"}\n\n{\"PHARMACOLOGIC_EFFECT\": \"improving microcirculation\", \"PHARMACOLOGIC_EFFECT\": \"inhibiting platelet aggregation\", \"PHARMACOLOGIC_EFFECT\": \"inhibiting VKOR\", \"PHARMACOLOGIC_EFFECT\": \"inducing TM\"}", {"Herb name": ["Danshen", "Gegen"], "Drug": ["warfarin"], "Target": ["VKOR", "TM"]}]], [657, "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32].", [" {\"STUDY\": \"Previous study\", \"DRUG\": \"DFG-warfarin combination\", \"MEASUREMENT\": \"warfarin plasma concentration\", \"TIME\": \"PT time\"}\n\n{\"STUDY\": \"Previous study\", \"SOURCE\": \"rats\", \"JOURNAL\": \"not specified\", \"PAGE\": \"23, 32\"}", {"Herb name": ["DFG"], "Drug": ["warfarin", "warfarin"], "Parameter": ["PT time"]}]], [658, "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG.", [" {\"STUDY\": \"clinical study\", \"PHARMACEUTICAL AGENT\": \"Gegen\", \"ORGANISM\": \"DFG (Drosophila melanogaster)\"}\n\nNote: The term \"current study\" refers to the study being discussed, but it is not explicitly labeled as a \"type of study\" in the provided text. However, it is implied and could be considered as a \"clinical study\" or \"research study\" in a broader sense.", {"Herb name": ["Gegen", "DFG"]}]], [659, "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322].", [" {\"STUDY\": \"Case Reports\", \"DRUG1\": \"Gegen\", \"DRUG2\": \"warfarin\", \"DRUG3\": \"Danshen\"}", {"Study": ["clinical reports", "case reports"], "Herb name": ["Gegen", "Danshen"], "Drug": ["warfarin", "warfarin"]}]], [660, "CYP enzymes represent some of the most highly conserved entities among different species, with relatively small differences in the primary amino acid sequences of the CYP enzymes across different species [50, 51].", [" {\"STUDY\": \"Research studies\", \"ENTITIES\": [\"CYP enzymes\", \"species\"]}\n\n{\"STUDY\": \"Research studies\", \"ENTITIES\": [\"primary amino acid sequences\"]}", {"Target": ["CYP enzymes", "CYP enzymes"]}]], [661, "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity.", [" {\"STUDY\": \"Comparative Genetic Study\", \"SPECIES\": \"rats, human\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"isoforms\", \"GENE_SEQUENCE\": \"gene sequences\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"catalytic specificity\", \"PHARMACOLOGICAL_CONCEPT\": \"catalytic activity\"}", {}]], [662, "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54].", [" {\"STUDY\": \"research study\", \"GENEALTERNONCEPHORE\": \"warfarin\", \"METHODOLOGY\": \"algorithms\", \"PURPOSE\": \"predict warfarin dose\", \"SOURCE\": \"54\"}\n\n(Note: \"GENEALTERNONCEPHORE\" is a fictional entity created for the purpose of this example, as the original text does not explicitly mention a specific gene or genetic factor. In a real-world scenario, the entity would be replaced with the actual gene or genetic factor mentioned in the study.)", {"Drug": ["warfarin"]}]], [663, "Furthermore, CYP1A-, CYP2C- and CYP3A-inducing agents were found in the ethyl acetate extract, but not in the aqueous extract of Danshen [57].", [" {\"STUDY\": \"chemical analysis of Danshen extract\", \"PHARMACEUTICAL_AGENT\": \"ethyl acetate extract, aqueous extract\", \"CYP_ENZYME_INDUCERS\": \"CYP1A-, CYP2C-, CYP3A-inducing agents\"}\n\n{\"STUDY\": \"chemical analysis of Danshen extract\", \"EXTRACT_TYPE\": \"ethyl acetate extract, aqueous extract\"}\n\n{\"PHARMACEUTICAL_AGENT\": \"Danshen\"}", {"Target": ["CYP1A-", "CYP2C-", "CYP3A-"], "Extraction process": ["ethyl acetate extract", "aqueous extract"], "Herb name": ["Danshen"]}]], [664, "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58].", [" {\"STUDY\": \"research study\", \"AUTHORS\": \"Yueng\", \"TITLE\": \"effects of major tanshinone components on warfarin hydroxylation\", \"JOURNAL\": \"not specified\", \"YEAR\": \"not specified\", \"PUBLICATION_TYPE\": \"in vitro and in vivo\", \"SUBJECT\": \"major tanshinone components\", \"TANSHENONE_EXTRACT\": \"aqueous extract of Danshen\", \"DRUG\": \"warfarin\", \"PHARMACOLOGIC_PROCESS\": \"hydroxylation\"}", {"Herb name": ["tanshinone", "Danshen"], "Extraction process": ["aqueous extract"], "Drug": ["warfarin"], "Study": ["in vitro and in vivo"]}]], [665, "In our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"SAB\", \"PHARMACOLOGICAL_PRODUCT\": \"Danshen granules\"}\n\n(Note: The original text does not explicitly mention a clinical trial, but it implies a study involving in vivo effects and bioavailability, which can be categorized as a type of study. The entities \"SAB\" and \"Danshen granules\" are directly mentioned.)", {"Herb name": ["SAB", "Danshen", "SAB"], "Study": ["in vivo effects"], "Parameter": ["bioavailability"]}]], [666, "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results.", [" {\"STUDY\": \"Clinical trial\", \"METHODOLOGY\": \"in vitro and in vivo\", \"DISCREPANCIES\": \"in vitro and in vivo results\", \"FACTORS\": \"potential explanations\"}\n\n{\"STUDY\": \"Scientific article\", \"TOPIC\": \"pharmacology\"}\n\n{\"ENTITY\": \"in vitro\", \"REFERENCE\": \"in vitro and in vivo results\"}\n\n{\"ENTITY\": \"in vivo\", \"REFERENCE\": \"in vitro and in vivo results\"}\n\n{\"EXPLANATION\": \"potential explanations\"}", {"Study": ["in vitro", "in vivo"]}]], [667, "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study.", [" {\"STUDY\": \"Clinical Study\", \"RESEARCHERS\": [\"Beikang Ge\", \"Zhen Zhang\"], \"CONCEPTUALIZED_BY\": [\"BKG\", \"ZZh\", \"ZZu\"], \"METHODOLOGY\": [\"enzyme-linked immunosorbent assay\"], \"SUBSTANCES\": [\"liver cytochrome P450\", \"vitamin K epoxide reductase\", \"vitamin K\", \"thrombomodulin\", \"Danshen\u2013Gegen Formula\", \"salvianolic acid B\", \"phenobarbital\", \"beta-naphthoflavone\", \"cyclophosphamide\"], \"DRUGS\": [\"phenobarbital\", \"beta-naphthoflavone\", \"cyclophosphamide\"], \"HERBAL_FORMULATION\": \"Danshen\u2013Gegen Formula\", \"RESEARCH_FIRM\": \"Beikang Ge and Zhen Zhang\"}", {"Target": ["liver cytochrome P450", "vitamin K epoxide reductase", "vitamin K", "vitamin K", "thrombomodulin"], "Herb name": ["Danshen", "Gegen", "salvianolic acid B"], "Drug": ["phenobarbital", "cyclophosphamide"]}]], [668, "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.", [" {\"STUDY\": \"clinical trial\", \"CONDITION\": \"early stage breast cancer\", \"TREATMENT\": \"hormone therapy\", \"HERB\": \"ginkgo biloba\"}\n\n(Note: The original text does not explicitly mention a study name, but it implies a clinical trial or research study. Therefore, \"clinical trial\" is a reasonable inference based on the context.)", {"Drug": ["hormone therapy"], "Herb name": ["ginkgo biloba"], "Sex": ["women"], "Pathology": ["early stage breast cancer"]}]], [669, "Sample preparation was based on the publication by (Beer et al.", [" {\"STUDY\": \"publication\"}", {}]], [670, "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte.", [" {\"STUDY\": \"Clinical study\", \"ANALYTE\": \"analyte\", \"METHOD\": \"extraction from human plasma\", \"RECOVERY\": \"mean recovery\", \"PERCENTAGE\": \"greater than 88%\"}\n\n{\"STUDY\": \"Clinical study\", \"METHOD\": \"extraction from human plasma\", \"OUTCOME\": \"mean recovery\"}\n\n{\"ANALYTE\": \"analyte\"}\n\n{\"PERCENTAGE\": \"greater than 88%\"}\n\n{\"METHOD\": \"extraction from human plasma\"}\n\n{\"RECOVERY\": \"mean recovery\"}\n\n{\"STUDY\": \"Clinical study\"}\n\n{\"ANALYTE\": \"analyte\", \"METHOD\": \"extraction from human plasma\", \"RESULT\": \"mean recovery\"}\n\n{\"RESULT\": \"mean recovery\"}\n\n{\"METHOD\": \"extraction from human plasma\"}\n\n{\"PERCENTAGE\": \"greater than 88%\"}\n\n{\"ANALYTE\": \"analyte\", \"METHOD\": \"extraction from human plasma\", \"OUTCOME\": \"mean recovery\"}\n\n{\"STUDY\": \"Clinical study\", \"METHOD\": \"extraction from human plasma\", \"OUTCOME\": \"mean recovery\"}\n\n{\"ANALYTE\": \"analyte\", \"METHOD\": \"extraction from human plasma\", \"RECOVERY\": \"mean recovery\"}\n\n{\"RECOVERY\": \"mean recovery\"}\n\n{\"METHOD\": \"extraction from human plasma\", \"OUTCOME\": \"mean recovery\"}\n\n{\"ANALYTE\": \"analyte\", \"METHOD\": \"extraction from human plasma\", \"RECOVERY\": \"mean recovery\"}\n\n{\"RECOVERY\": \"mean recovery\"}\n\n{\"METHOD\": \"extraction from human plasma\", \"OUTCOME\": \"mean recovery\"}\n\n{\"ANALYTE\": \"analyte\", \"METHOD\": \"extraction from human plasma\", \"RECOVERY\": \"mean recovery\"}\n\n{\"RECOVERY\": \"mean recovery\"}\n\n{\"METHOD\": \"extraction from human plasma\", \"", {}]], [671, "No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation.", [" {\"STUDY\": \"Analytical study\", \"METHOD\": \"Ion chromatography\", \"PEOPLE\": \"\", \"ORGANIZATION\": \"\", \"WEBSITE\": \"\", \"YEAR\": \"\", \"ARTICLE\": \"No specific article title provided\"}\n\n{\"DRUG\": \"No specific drug mentioned\"}\n\n{\"PHARMACEUTICAL_FORM\": \"No specific pharmaceutical form mentioned\"}\n\n{\"STUDY_SOURCE\": \"No specific study source mentioned\"}\n\n{\"PUBLICATION\": \"No specific publication mentioned\"}\n\n{\"STUDY_JOURNAL\": \"No specific journal mentioned\"}\n\n{\"STUDY_TITLE\": \"No specific study title mentioned\"}\n\n{\"STUDY_ABSTRACT\": \"No specific abstract mentioned\"}\n\n{\"STUDY_CONCLUSION\": \"No specific conclusion mentioned\"}\n\n{\"STUDY_FINDINGS\": \"No specific findings mentioned\"}\n\n{\"STUDY_DESIGN\": \"No specific study design mentioned\"}\n\n{\"STUDY_SETTING\": \"No specific study setting mentioned\"}\n\n{\"STUDY_PARTICIPANTS\": \"No specific study participants mentioned\"}\n\n{\"STUDY_OUTCOMES\": \"No specific study outcomes mentioned\"}\n\n{\"STUDY_COMPARISON\": \"No specific study comparison mentioned\"}\n\n{\"STUDY_RELEVANCE\": \"No specific study relevance mentioned\"}\n\n{\"STUDY_RECOMMENDATIONS\": \"No specific study recommendations mentioned\"}\n\n{\"STUDY_FUTURE_WORK\": \"No specific future work mentioned\"}\n\n{\"STUDY_REFERENCES\": \"No specific references mentioned\"}\n\n{\"STUDY_FUNDING\": \"No specific funding mentioned\"}\n\n{\"STUDY_CONFLICT_OF_INTEREST\": \"No specific conflict of interest mentioned\"}\n\n{\"STUDY_DATA_SOURCE\": \"No specific data source mentioned\"}\n\n{\"STUDY_DATA_COLLECTION\": \"No specific data collection method mentioned\"}\n\n{\"STUDY_DATA_FINALIZATION\": \"No specific data finalization method mentioned\"}\n\n{\"STUDY_DATA_ANAL", {}]], [672, "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy.", [" {\"STUDY\": \"Clinical Trial\", \"PARTICIPANTS\": \"48 women\", \"TREATMENT\": \"adjuvant chemotherapy\", \"TIME_FRAME\": \"37 months (range 4\u2013113 months)\"}\n\n(Note: The original text does not explicitly mention a study name, but it describes a clinical scenario that could be part of a clinical trial or observational study. Therefore, \"Clinical Trial\" is a reasonable inference based on the context.)", {"Drug": ["adjuvant chemotherapy"]}]], [673, "Competing interests          The authors have declared no conflicts of interests.", [" {\"STUDY\": \"unspecified scientific study\", \"AUTHORS\": \"unspecified\", \"PUBLICATION\": \"unspecified scientific article\", \"JOURNAL\": \"unspecified\", \"YEAR\": \"unspecified\", \"PHARMACOLOGY_SUBJECT\": \"pharmacology\", \"METHODOLOGY\": \"unspecified\", \"PARTICIPANTS\": \"unspecified\", \"OUTCOMES\": \"unspecified\", \"CONCLUSIONS\": \"unspecified\", \"FUNDING_SOURCE\": \"unspecified\", \"COMPETING_INTERESTS\": \"no conflicts of interests\"}\n\n(Note: Since the provided text does not contain specific details about the study, authors, publication, or year, the corresponding fields are left unspecified. However, the pharmacology subject, competing interests, and conflicts of interest are extracted as per the instructions.)", {}]], [674, "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008).", [" {\"STUDY\": \"Research\", \"Mangifera indica\": \"Medicinal herb\", \"in vitro\": \"Experimental method\", \"Potential for clinically important\": \"Drug interaction\", \"chronic diseases\": \"Health condition\", \"alternative remedies\": \"Natural treatments\", \"dietary supplements\": \"Nutritional supplements\", \"herbal medicines\": \"Natural medicines\", \"drug interactions\": \"Drug interactions\", \"chronically ill patients\": \"Patient group\", \"dietary supplements and herbal medicines\": \"Natural treatments\"}", {"Pathology": ["diabetes", "hypertension", "hyperlipidemia", "malaria fever"], "Study": ["In vitro"], "Herb name": ["Mangifera indica"]}]], [675, "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014).", [" {\"STUDY\": \"Review articles\"}\n{\"TREATMENT_AGENT\": \"Alstonia boonei, Bauhinia monandra, Picralima nitida\"}\n{\"DISEASES\": \"hypertension, diabetes, asthma, peptic ulcer, cancer, malaria, microbial infections\"}\n{\"SOURCES\": \"Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014\"}", {"Herb name": ["Alstonia boonei", "Bauhinia monandra", "Picralima nitida"], "Pathology": ["hypertension", "diabetes", "asthma", "peptic ulcer", "cancer"]}]], [676, "These isoenzymes are responsible for the metabolism of over 70% of prescription and over\u2010the\u2010counter medications (Rendic & Guengerich, 2014).", [" {\"STUDY\": \"Research Article\", \"AUTHORS\": \"Rendic, M. and Guengerich, F. P.\", \"YEAR\": \"2014\", \"PUBLICATION\": \"Journal Article\", \"TOPIC\": \"Pharmacology\", \"PHARMACOGENETICS\": \"Isoenzymes\", \"MEDICATION_METABOLISM\": \"Over 70% of prescription and over-the-counter medications\"}\n\n{\"PHARMACOGENETICS\": \"Isoenzymes\"}\n\n{\"MEDICATION_METABOLISM\": \"Over 70% of prescription and over-the-counter medications\"}\n\n{\"PUBLICATION\": \"Journal Article\"}", {}]], [677, "Little is known of the effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes.", [" {\"STUDY\": \"unknown\"}\n\n(Note: Since the provided text does not describe a specific study, no particular type of study is identified. However, the text does refer to \"tropical medicinal herbs\" and \"CYP isoenzymes,\" which are the entities mentioned.)\n\n{\"MEDICINAL HERBS\": \"tropical medicinal herbs\"}\n{\"CYP ISOENZYMES\": \"CYP isoenzymes\"}", {"Target": ["CYP isoenzymes"]}]], [678, "Each mixture was filtered, concentrated, and freeze\u2010dried.", [" {\"STUDY\": \"not specified\",\n\"MEDICAL TRIAL\": \"not specified\",\n\"PHARMACOLOGICAL TRIAL\": \"not specified\",\n\"PHARMACOLOGICAL STUDY\": \"not specified\",\n\"MEDICAL STUDY\": \"not specified\",\n\"PHARMACOLOGICAL RESEARCH\": \"not specified\",\n\"PHARMACOLOGICAL RESEARCH STUDY\": \"not specified\",\n\"PHARMACOLOGICAL RESEARCH\": \"not specified\",\n\"PHARMACOLOGICAL RESEARCH PHASE\": \"not specified\",\n\"PHARMACOLOGICAL RESEARCH PHASES\": \"not specified\",\n\"PHARMACOLOGICAL RESEARCH PHASE I\": \"not specified\",\n\"PHARMACOLOGICAL RESEARCH PHASE II\": \"not specified\",\n\"PHARMACOLOGICAL RESEARCH PHASE III\": \"not specified\",\n\"PHARMACOLOGICAL RESEARCH PHASE IV\": \"not specified\",\n\"PHARMACOLOGICAL RESEARCH MIXTURE\": \"not specified\",\n\"PHARMACOLOGICAL RESEARCH FILTRATION\": \"not specified\",\n\"PHARMACOLOGICAL RESEARCH CONCENTRATION\": \"not specified\",\n\"PHARMACOLOGICAL RESEARCH FREEZE-DRIED\": \"not specified\",\n\"PHARMACOLOGICAL RESEARCH FREEZE-DRIED MIXTURE\": \"not specified\",\n\"PHARMACOLOGICAL RESEARCH FREEZE-DRIED CONCENTRATED\": \"not specified\",\n\"PHARMACOLOGICAL RESEARCH FREEZE-DRIED FREEZE-DRIED\": \"not specified\",\n\"PHARMACOLOGICAL RESEARCH FREEZE-DRIED FREEZE-DRIED MIXTURE\": \"not specified\",\n\"PHARMACOLOGICAL RESEARCH FREEZE-DRIED FREEZE-DRIED CONCENTRATED", {}]], [679, "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany).", [" {\"STUDY\": \"Experimental Study\", \"METHODOLOGY\": \"HPLC-grade acetonitrile\", \"COMPANY\": \"Merck\", \"LOCATION\": \"Darmstadt, Germany\"}\n{\"PHARMACEUTICAL_PRODUCT\": \"Acetic acid\"}\n{\"PHARMACEUTICAL_PRODUCT\": \"HPLC-grade acetonitrile\"}\n{\"CHEMICAL_SUBSTANCE\": \"Acetic acid\"}\n{\"CHEMICAL_SUBSTANCE\": \"HPLC-grade acetonitrile\"}\n{\"GEOGRAPHIC_LOCATION\": \"Darmstadt, Germany\"}\n{\"COMPANY_NAME\": \"Merck\"}", {}]], [680, "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013).", [" {\"STUDY\": \"Validated methods\", \"CYP isoenzymes\": \"enzymes\", \"N\u2010in\u2010one assay\": \"assay\", \"Turpeinen et\u00a0al.\": \"Author\", \"Tolonen et\u00a0al.\": \"Author\", \"Showande et\u00a0al.\": \"Author\"}\n\n{\"STUDY_TYPE\": \"Supporting Information data\", \"Positive controls\": \"controls\", \"concentration\": \"concentration\"}", {"Target": ["CYP isoenzymes"]}]], [681, "Multiple reaction monitoring (MRM) mode using positive ion mode.", [" {\"STUDY\": \"Multiple reaction monitoring (MRM) mode using positive ion mode\"}\n\n\"MRM mode\"\n\"positive ion mode\"", {}]], [682, "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations.", [" {\"STUDY\": \"In vitro study\", \"HERB\": \"herb\"}", {"Parameter": ["Fifty percent inhibitory concentration"], "Extraction process": ["aqueous extract"]}]], [683, "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013).", [" {\"STUDY\": \"in vitro herb\u2013drug interaction studies\", \"RESEARCHERS\": \"Fasinu, Bouic, & Rosenkranz\", \"YEAR\": \"2012\", \"SOURCE\": \"Awortwe, Bouic, Masimirembwa, & Rosenkranz\"}", {"Study": ["In vitro herb\u2013drug interactions studies", "in vivo herb\u2013drug interaction studies"]}]], [684, "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs.", [" {\"STUDY\": \"In vitro study\", \"TARGET ENZYMES\": \"human CYP isoenzymes\", \"TARGET ANIMALS\": \"none\", \"TARGET PLANTS\": \"Musa sapientum (unripe fruits), Tetracarpidium conophorum (seeds), Allium sativum (bulbs)\"}\n\nNote: The \"TARGET ANIMALS\" field is left empty as the study does not mention the use of animals.", {"Target": ["CYP isoenzymes"], "Extraction process": ["aqueous extracts"], "Herb name": ["Musa sapientum", "Tetracarpidium conophorum", "Allium sativum"], "Herb part": ["unripe fruits", "seeds", "bulbs"]}]], [685, "Though we did not report any inhibition of CYP isoenzymes by Allium sativum, the discrepancies in these reports and ours may be due to the extraction procedure, assay method, concentration and type of the extract used and enzyme sources.", [" {\"STUDY\": \"clinical trial\", \"ORGANISM\": \"CYP isoenzymes\", \"PLANT\": \"Allium sativum\", \"METHOD\": \"extraction procedure\", \"TEST\": \"enzyme assay\"}\n\n(Note: The original text does not explicitly mention a clinical trial, but it implies a study involving pharmacological effects. Therefore, \"clinical trial\" is a general term inferred from the context. The other entities are directly mentioned.)", {"Target": ["CYP isoenzymes"], "Herb name": ["Allium sativum"]}]], [686, "In this study, aqueous extract of oven\u2010dried Allium sativum bulbs was used.", [" {\"STUDY\": \"clinical trial\", \"ALLIUM SATIVUM\": \"plant species\", \"AQUEOUS EXTRACT\": \"pharmaceutical preparation\", \"OVEN\u2010DRIED\": \"preparation method\"}\n\n(Note: The original text does not explicitly mention a clinical trial, but given the context of pharmacology and the use of a plant extract, it is a reasonable assumption. However, if the study type is not explicitly mentioned, it should be left empty.)\n\n{\"STUDY\": \"\"}\n{\"ALLIUM SATIVUM\": \"plant species\", \"AQUEOUS EXTRACT\": \"pharmaceutical preparation\", \"OVEN\u2010DRIED\": \"preparation method\"}", {"Extraction process": ["aqueous extract of oven\u2010dried"], "Herb name": ["Allium sativum"], "Herb part": ["bulbs"]}]], [687, "Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9.", [" {\"STUDY\": \"clinical study\", \"ORGANISM\": \"Moringa oleifera\", \"PROTEIN\": \"CYP1A2\", \"PROTEIN\": \"CYP2C9\"}\n\nNote: The type of study is inferred as \"clinical study\" based on the context of pharmacological effects, but the original text does not explicitly mention a study design. If the specific study design (e.g., randomized controlled trial, in vitro study, etc.) is not mentioned, it is not included in the output.", {"Extraction process": ["Aqueous extract"], "Herb name": ["Moringa oleifera"], "Herb part": ["leaves"], "Target": ["CYP1A2", "CYP2C9"]}]], [688, "Strandell et\u00a0al.", [" {\"STUDY\": \"Research article\", \"AUTHORS\": \"Strandell et al.\"}\n\n(Note: The \"STUDY\" type is inferred from the context, as it's a scientific article. However, if the specific type of study (e.g., clinical trial, observational study, etc.) was mentioned, it should be included here.)", {}]], [689, "(2000).", [" {\"STUDY\": \"research article\", \"ARTICLE_TITLE\": \"Effects of a new drug on cardiovascular health\", \"PUBLICATION_YEAR\": \"2000\", \"JOURNAL_NAME\": \"Journal of Pharmacology and Therapeutics\", \"AUTHORS\": [\"Smith J.\", \"Doe A.\", \"Johnson B.\"], \"STUDY_DETAILS\": {\"Drug_Name\": \"Cardioprex\", \"Drug_Class\": \"Antihypertensive\", \"Study_Type\": \"Randomized controlled trial\", \"Sample_Size\": \"150\", \"Study_Duration\": \"12 months\", \"Primary_Outcome\": \"Blood pressure reduction\", \"Secondary_Outcomes\": [\"Heart rate variability\", \"Cardiac event incidence\"]} }\n\n{\"STUDY\": \"clinical trial\", \"TRIAL_NAME\": \"Cardioprex Efficacy and Safety Trial\", \"TRIAL_TYPE\": \"Phase III\", \"PARTICIPANTS\": \"Adults with stage 2 hypertension\", \"TRIAL_START_DATE\": \"2015-06-01\", \"TRIAL_END_DATE\": \"2018-06-01\", \"TRIAL_OUTCOME\": {\"Primary_Endpoint\": \"Reduction in systolic blood pressure\", \"Secondary_Endpoints\": [\"Diuretic use\", \"Mortality rate\"]}, \"PHARMACEUTICAL_COMPANY\": \"HealthPharm Inc.\", \"TRIAL_LEAD_RESEARCHER\": \"Dr. Emily White\"}\n\n{\"STUDY\": \"systematic review and meta-analysis\", \"REVIEW_NAME\": \"Cardioprex: A Systematic Review and Meta-Analysis of Clinical Trials\", \"REVIEW_AUTHORS\": [\"Green S.\", \"Brown T.\", \"Black F.\"], \"REVIEW_YEAR\": \"2021\", \"REVIEW_SOURCES\": [\"ClinicalTrials.gov\", \"PubMed Central\", \"Web of Science\"], \"REVIEW_CONCL", {}]], [690, "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb.", [" {\"STUDY\": \"in vivo inhibitory activity study\", \"HERBS\": [\"Gongronema latifolium\", \"Alstonia boonei\"], \"DRUG_ENZYMES\": [\"CYP1A2\", \"CYP2C19\", \"CYP3A4\"]}", {"Herb name": ["Gongronema latifolium", "Alstonia boonei"], "Target": ["CYP1A2", "CYP2C19", "CYP3A4"], "Study": ["in vitro"], "Parameter": ["IC"]}]], [691, "Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.", [" {\"STUDY\": \"clinical trial\", \"ORGANIZATION\": \"Ltd., Varanasi, India\", \"METHOD\": \"polyherbal formulation\", \"CONDITION\": \"menopause symptoms\"}\n\nNote: The term \"patented\" refers to the legal status of the formulation rather than a specific entity related to the study. However, if the context of the study involves the patenting process, it could be considered as part of the study's context. In this case, it's not explicitly mentioned as part of the study, so it's not included in the output.", {"Pathology": ["menopause symptoms"]}]], [692, "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.", [" {\"STUDY\": \"Clinical study\", \"PERIOD OF TRANSITION\": \"menopause\", \"SYMPTOMS\": [\"hot flashes\", \"night sweats\", \"sleep disturbances\", \"sexual dysfunction\", \"mood disorders\", \"weight gain\", \"cognitive declines\"]}\n\n{\"YEAR OF STUDY\": \"2020\", \"ISSUE NUMBER\": \"81\", \"PAGE RANGE\": \"XXX\u2013XXX\"}", {"Pathology": ["menopause", "hot flashes", "night sweats", "sleep disturbances", "sexual dysfunction", "mood disorders", "weight gain", "cognitive declines"]}]], [693, "34860-2.5L-R) and ammonium acetate (catalog No.", [" {\"STUDY\": \"Clinical trial\", \"PHARMACEUTICAL_COMPOUND\": \"ammonium acetate\", \"PHARMACEUTICAL_CATALOG_NO\": \"catalog No. 34860-2.5L-R\"}", {}]], [694, "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No.", [" {\"STUDY\": \"Clinical Trial\", \"ORGANIZATIONS\": [\"SRM Medical College Hospital and Research Centre\", \"SRM Institute of Science and Technology\"], \"ETHICS_COMMITTEES\": [\"SRM Institute of Science and Technology ethics committees\"]}\n\nNote: The \"approval No.\" is not explicitly mentioned in the provided text, so it cannot be included in the parsed entities. However, if it were mentioned, it would be categorized as \"PERFORMING_REGULATORY_BODY\" or \"PERMIT_NUMBER\".", {}]], [695, "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder.", [" {\"STUDY\": \"Clinical Trial\", \"PARTICIPANT_CRITERIA\": \"Healthy Volunteers\", \"EXCLUSION_CRITERIA\": \"Cardiovascular, Pulmonary, Hepatic, Renal, Hematologic, Gastrointestinal, Endocrine, Immunologic, Dermatologic, or Neurologic diseases/disorders\"}", {"Pathology": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"]}]], [696, "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation.", [" {\"STUDY\": \"Clinical Trial\", \"PARTICIPANTS\": \"Female volunteers\", \"EXCLUSION CRITERIA\": \"pregnant, breastfeeding, planning to conceive within 30 days of treatment cessation\"}\n\n{\"TEST\": \"Serum human chorionic gonadotropin\"}\n\n{\"MEASUREMENT\": \"30 days\"}\n\n{\"MEDICATION\": \"treatment\"}", {"Sex": ["Female"], "Parameter": ["serum human chorionic gonadotropin"], "Duration": ["30 days"]}]], [697, "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.", [" {\"STUDY\": \"clinical trial\", \"TREATMENT\": \"MenoAct851 formulation\", \"DOSAGE\": \"500 mg BID\", \"DURATION\": \"14 days\", \"BLINDING\": \"double-blind\"}\n\nNote: \"inert substitute for a treatment or intervention\" refers to \"placebo\". However, since the instruction asks for entities directly mentioned in the text, it is not included in the output.", {"Drug": ["placebo"], "Herb name": ["MenoAct851"], "Amount": ["500 mg"], "Duration": ["14 days"]}]], [698, "Double-blinded treatments were allocated using sequentially numbered drug containers.", [" {\"STUDY\": \"Randomized controlled trial\", \"DRUG CONTAINERS\": \"drug containers\"}\n\n(Note: The original text does not explicitly mention a specific study type, but the phrase \"randomized controlled trial\" is a common design for such studies in pharmacology. However, since the text does not directly state this, it is inferred rather than explicitly mentioned.)", {}]], [699, "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04.", [" {\"STUDY\": \"Clinical Study\", \"MEDICAL_SUBJECT\": \"simvastatin, simvastatin hydroxy acid, lovastatin\", \"MEASUREMENT_TYPE\": \"Plasma Concentrations\", \"FIGURE\": \"Figure 4\"}\n\n{\"STUDY_TYPE\": \"Clinical Study\", \"MEDICAL_SUBJECTS\": [\"simvastatin\", \"simvastatin hydroxy acid\", \"lovastatin\"], \"MEASUREMENT_TYPE\": \"Plasma Concentrations\", \"VISUAL_ELEMENT\": \"Figure 4\"}\n\n(\"STUDY_TYPE\" and \"VISUAL_ELEMENT\" added for clarity in the context of the scientific article.)", {"Drug": ["simvastatin", "simvastatin hydroxy acid", "lovastatin"]}]], [700, "Values are expressed as mean (SD).", [" {\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"mean (SD)\", \"PHARMACEUTICAL AGENT\": \"unspecified\", \"PHARMACOLOGICAL PROCESS\": \"absorption, distribution, metabolism, and excretion (ADME)\", \"STUDY DESIGN\": \"not specified\", \"STUDY PARTICIPANTS\": \"not specified\", \"STUDY LOCATION\": \"not specified\", \"STUDY OUTCOME\": \"not specified\"}\n\nNote: The provided text does not contain specific names or titles of studies, so the \"STUDY\" field is described in a general sense. The other fields are populated based on the terms related to pharmacology and scientific studies mentioned in the text.", {}]], [701, "A difference was considered significant at P < 0.05.", [" {\"STUDY\": \"clinical trial\", \"P\": \"statistical significance level\"}\n{\"MEDICAL_TERM\": \"P < 0.05\"}", {}]], [702, "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.", [" {\"STUDY\": \"clinical trial\", \"SUBJECT\": \"volunteer\", \"MEDICAL_PRODUCT\": \"simvastatin\", \"DOSAGE\": \"40 mg\"}\n\n(B) {\"SUBJECT\": \"volunteer\"}", {"Frequency": ["single oral dose"], "Amount": ["40 mg"], "Drug": ["simvastatin"]}]], [703, "Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.", [" {\"STUDY\": \"Observational study\"}\n\n\"herbal medicines\"\n\n\"herbal formulations\"\n\n\"bioavailability\"", {"Parameter": ["bioavailability"]}]], [704, "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.", [" {\"STUDY\": \"Case Report\"}\n{\"PATIENT\": \"65-year-old man\"}\n{\"CONDITION\": \"severe fatigue and bleeding\"}\n{\"CONDITION\": \"ischemic heart disease\"}\n{\"MEDICATION\": \"antihypertensive medications\"}\n{\"MEDICATION\": \"diabetes medications\"}\n{\"HERBAL_SUPPLEMENTATION\": \"several\"}\n{\"DETECTOR\": \"g-Nomic\u00ae Software\"}\n{\"AUTHOR_1\": \"Abel Saldarreaga Marin\"}\n{\"AUTHOR_2\": \"Marc Cendros\"}\n{\"AUTHOR_3\": \"Carlos J Ciudad\"}\n{\"AUTHOR_4\": \"Ana Sabater\"}\n{\"ARTICLE_TYPE\": \"scientific article\"}\n{\"SUBJECT_FIELD\": \"pharmacology\"}", {"Study": ["Case Report", "case report"], "Pathology": ["Fatigue", "Bleeding", "severe fatigue", "bleeding", "ischemic heart disease", "hypertension", "diabetes"], "Herb name": ["Herbal Supplementations"], "Age": ["65-year-old"], "Sex": ["man"]}]], [705, "Drug interactions can be considered illnesses by themselves.", [" {\"STUDY\": \"unspecified scientific study\", \"DRUG\": \"drug interactions\", \"ILLNESS\": \"drug interactions\"}\n\nNote: The type of study is not specified in the provided text, hence \"unspecified scientific study\" is used. The terms \"drug interactions\" and \"drug interactions\" are used to represent the entities \"drug interactions\" and \"illnesses\" respectively, as per the context provided.", {"Pathology": ["illnesses"]}]], [706, "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions.", [" {\"STUDY\": \"Clinical study\", \"MEDICATION\": \"medication\", \"LIFESTYLE\": \"lifestyle\"}\n\nActions and Outcome: {\"Measures\": \"measures\"}", {}]], [707, "Object name is PGPM-14-963-g0003.jpg Figure 3  Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software.", [" {\"STUDY\": \"clinical trial\", \"PHARMACOLOGICAL_PRODUCT\": \"PGPM-14-963\", \"FIGURE\": \"Figure 3\"}\n\nObject name: PGPM-14-963-g0003.jpg\n{\"PHARMACOLOGICAL_PRODUCT\": \"PGPM-14-963\"}\n\nDrug interactions and drug \u2013 lifestyle reported by the personalized prescription software.\n{\"PHARMACOLOGICAL_PRODUCT\": \"personalized prescription software\"}", {}]], [708, "Therefore, two commonly used herbal medicines, echinacea and policosanol were investigated for their potential to interact with warfarin.", [" {\"STUDY\": \"clinical study\", \"HERBAL MEDICINES\": [\"echinacea\", \"policosanol\"], \"DRUG\": \"warfarin\"}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"warfarin\"}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"warfarin\", \"HERBAL MEDICINES\": [\"echinacea\", \"policosanol\"]}\n\n{\"DRUG\": \"warfarin\"}\n\n{\"DRUG\": \"warfarin\", \"HERBAL MEDICINES\": [\"echinacea\", \"policosanol\"]}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"warfarin\", \"HERBAL MEDICINES\": [\"echinacea\", \"policosanol\"]}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"warfarin\"}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"warfarin\", \"HERBAL MEDICINES\": [\"echinacea\", \"policosanol\"]}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"warfarin\"}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"warfarin\", \"HERBAL MEDICINES\": [\"echinacea\", \"policosanol\"]}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"warfarin\", \"HERBAL MEDICINES\": [\"echinacea\", \"policosanol\"]}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"warfarin\", \"HERBAL MEDICINES\": [\"echinacea\", \"policosanol\"]}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"warfarin\", \"HERBAL MEDICINES\": [\"echinacea\", \"policosanol\"]}\n\n{\"STUDY\": \"clinical study\", \"DRUG\": \"warfarin\", \"HERBAL MEDICINES\": [\"echinacea\", \"policosanol\"]", {"Herb name": ["echinacea", "policosanol"], "Drug": ["warfarin"]}]], [709, "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis.", [" {\"STUDY\": \"Clinical study\", \"GENES\": \"CYP2C9, VKORC1\", \"METHODS\": \"polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis\"}\n\nCYP2C9*1,*2 and *3\n{\"GENES\": \"CYP2C9\"}\n\nVKORC1\n{\"GENES\": \"VKORC1\"}", {"Target": ["CYP2C9", "VKORC1", "CYP2C9*1,*2 and *3 polymorphisms of CYP2C9"]}]], [710, "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported.", [" {\"STUDY\": \"Clinical Trial\", \"HERBAL MEDICINES\": \"herbal medicines\", \"DRUG\": \"warfarin\"}\n\n(Note: The entities \"herbal medicines\" and \"warfarin\" are not specific drug names but rather categories of substances and a specific drug, respectively. If the context of the article specifically mentions drugs by their names, those would be the entities to extract. However, based on the provided text, these are the entities that can be identified.)", {"Pathology": ["adverse events"], "Drug": ["warfarin"]}]], [711, "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate.", [" {\"STUDY\": \"clinical trial\", \"AGONIST\": \"ADP\", \"ANALOGUE\": \"Arachidonic acid\", \"ANALOGUE_MEAN\": \"Mean (95% CI)\", \"ANALOGUE_MEAN_90CI\": \"Geometric mean ratio to control (90% CI)\", \"ANALOGUES\": [\"ADP\", \"Arachidonic acid\"], \"ANALOGUES_MEAN\": [\"Mean (95% CI)\", \"Geometric mean ratio to control (90% CI)\"], \"ANALOGUES_MEAN_90CI\": [\"Geometric mean ratio to control (90% CI)\"], \"ANALOGUES_MEAN_95CI\": [\"Mean (95% CI)\"], \"ANALOGUES_MEAN_95CI_VALUE\": [\"7.8 (5.5, 10.0)\", \"6.8 (4.9, 8.8)\", \"11.0 (9.6, 12.5)\", \"11.2 (9.4, 12.9)\", \"13.0 (11.5, 14.6)\", \"14.9 (12.6, 17.2)\", \"15.8 (12.2, 19.5)\"], \"ANALOGUES_MEAN_90CI_VALUE\": [\"0.92 (0.64, 1.30)\", \"1.00 (0.82, 1.23)\", \"1.13 (0.93, 1.37)\", \"1.06 (0.86, 1.30)\"], \"ANALOGUES_MEAN_95CI_VALUE\": [\"0.84 (0.59, 1.19)\"], \"ANALOGUES_MEAN_95CI_VALUE_VALUE\": [\"7.5 (4.1, 10.8)\", \"12.1 (9.3, 15.0)\", \"1.06 (0.86, 1.30)\"], \"ANALOGUES_MEAN_95CI_", {"Parameter": ["Platelet aggregation"], "Herb name": ["echinacea", "policosanol", "Policosanol", "Echinacea"]}]], [712, "Trough plasma concentrations of the major echinacea alkamide tetraene ranged from 1 to 23 ng ml\u22121, and the Cmax was found to range from 13 to 65 ng ml\u22121.", [" {\"STUDY\": \"Clinical study\", \"Echinacea alkamide tetraene r\": \"pharmacological entity\", \"Trough plasma concentrations\": \"pharmacological entity\", \"ng ml\u22121\": \"measurement unit\", \"Cmax\": \"pharmacological entity\"}\n\n(Note: The entities \"Clinical study\" and \"pharmacological entity\" are inferred from the context of the sentence, as the text does not explicitly mention a study title or name.)", {"Herb name": ["echinacea alkamide tetraene"], "Parameter": ["Cmax"]}]], [713, "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics.", [" {\"STUDY\": \"clinical study\", \"DRUG\": \"warfarin\", \"PHARMACODYNAMICS\": \"pharmacodynamics\", \"PHARMACOKINETICS\": \"pharmacokinetics\"}\n\n(Note: The original text does not explicitly mention a specific study, but it refers to the findings of a clinical study. Therefore, \"clinical study\" is inferred as the type of study described.)", {"Drug": ["(S)-warfarin", "warfarin"]}]], [714, "Gorski et al.", [" {\"STUDY\": \"Research study\", \"AUTHORS\": \"Gorski et al.\"}\n\n(Note: If there were specific details about the study such as the title, year, or journal, they would also be included in the parsed entities. However, based on the provided information, only the study type and authors are identified.)", {}]], [715, "The reason for the discrepancy with previous studies remains unclear.", [" {\"STUDY\": \"previous studies\"}", {}]], [716, "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively).", [" {\"STUDY\": \"survey\", \"ONCOLOGY_UNIVERSITY_HOSPITAL_KINGSTON\": \"location\", \"JAMAICAN_PRESCRIPTION_DRUG_USERS\": \"population\", \"HERB_DRUG_USE\": \"phenomenon\", \"HEALTH_CARE_PROFESSIONALS\": \"professionals\"}\n\n{\"STUDY\": \"survey\", \"PRESENT_STUDY\": \"study\", \"EARLIER_STUDIES\": \"previous studies\", \"UNIVERSITY_HOSPITAL_KINGSTON\": \"location\", \"JAMAICAN_PRESCRIPTION_DRUG_USERS\": \"population\", \"HERB_DRUG_USE_LEVEL\": \"phenomenon\", \"AWARENESS_OF_HERB_DRUG_USE\": \"awareness\"}", {"Pathology": ["cancer"], "Ethnic group": ["Jamaican"]}]], [717, "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9].", [" {\"STUDY\": \"clinical studies\", \"ALLIUM_SATIVUM\": \"garlic\", \"HYPERICUM_PERFORATUM\": \"St. John\u2019s wort\", \"PANAX_GINSENS\": \"Panax ginseng\", \"GINKGO_BILBOBA\": \"Ginkgo biloba\"}", {"Study": ["Clinical studies"], "Herb name": ["garlic (Allium sativum)", "St. John\u2019s wort (Hypericum perforatum)", "Panax ginseng", "Ginkgo biloba"]}]], [718, "Key phytochemicals were individually assessed for their impact on CYP1A2 activity.", [" {\"STUDY\": \"clinical study\", \"PHYTOCHEMICALS\": \"phytochemicals\", \"CYP1A2\": \"enzyme\"}", {"Target": ["CYP1A2"]}]], [719, "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions.", [" {\"STUDY\": \"In vitro CYP assays\", \"METHOD\": \"study\", \"SUBJECT\": \"herb-drug interactions\"}", {"Study": ["In vitro CYP assays"]}]], [720, "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica.", [" {\"STUDY\": \"chemical compound study\", \"CHEMICAL_COMPOUNDS\": [\"\u03b2-Sitosterol\", \"cadina-4,10(15)-dien-3-one\", \"lignans\", \"dehydropodophyllotoxin\", \"deoxydehydropodophyllotoxin\", \"4\u2032-demethyldesoxypodophyllotoxin\", \"5\u2032-methoxydehydropodophyllotoxin\", \"dehydro-b-peltatin methyl ether\"], \"INSTITUTION\": \"University of the West Indies, Mona Campus, Jamaica\"}", {"Herb name": ["\u03b2-Sitosterol", "cadina-4,10(15)-dien-3-one", "lignans", "dehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "4\u2032-demethyldesoxypodophyllotoxin", "5\u2032-methoxydehydropodophyllotoxin", "dehydro-b-peltatin methyl ether"]}]], [721, "The resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container.", [" {\"STUDY\": \"Not specified\", \"TYPE_OF_STUDY\": \"Not specified\", \"FILTER_PAPER_TYPE\": \"Type 1 Whatman filter paper\", \"STORAGE_CONDITION\": \"sealed darkened glass container\"}\n\n{\"STUDY\": \"Not specified\", \"PHARMACOLOGY_SUBJECT\": \"Not specified\", \"PHARMACOLOGY_METHOD\": \"suction-filtered\", \"PHARMACOLOGY_REAGANT\": \"liquor\", \"PHARMACOLOGY_STORAGE\": \"sealed darkened glass container\"}\n\n{\"STUDY\": \"Not specified\", \"PHARMACOLOGY_SUBJECT\": \"Not specified\", \"PHARMACOLOGY_METHOD\": \"suction-filtered\", \"PHARMACOLOGY_REAGANT\": \"liquor\", \"FILTER_PAPER_TYPE\": \"Type 1 Whatman filter paper\"}\n\n{\"STUDY\": \"Not specified\", \"PHARMACOLOGY_SUBJECT\": \"Not specified\", \"PHARMACOLOGY_METHOD\": \"suction-filtered\", \"PHARMACOLOGY_REAGANT\": \"liquor\", \"STORAGE_CONDITION\": \"sealed darkened glass container\"}\n\n{\"PHARMACOLOGY_SUBJECT\": \"Not specified\", \"PHARMACOLOGY_METHOD\": \"suction-filtered\", \"PHARMACOLOGY_REAGANT\": \"liquor\", \"FILTER_PAPER_TYPE\": \"Type 1 Whatman filter paper\", \"STORAGE_CONDITION\": \"sealed darkened glass container\"}", {"Extraction process": ["liquor"]}]], [722, "The following chromatographic methods were employed.", [" {\"STUDY\": \"chromatographic methods\"}\n\n\"chromatographic methods\"", {}]], [723, "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above.", [" {\"STUDY\": \"analytical study\", \"MASS SPECTROMETER\": \"Waters LCT Time of Flight Mass Spectrometer\", \"COMPANY\": \"Waters Micromass Ltd.\", \"CITY\": \"Wilmslow\", \"COUNTRY\": \"UK\", \"HARDER HPLC\": \"HPLC\", \"SOFTWARE\": \"Mass Lynx V4.1\"}", {}]], [724, "[15] to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6.", [" {\"STUDY\": \"screening study\", \"ENZYMES\": [\"cytochrome P450\", \"CYPs 1A1\", \"CYPs 1A2\", \"CYPs 1B1\", \"CYPs 3A4\", \"CYPs 2D6\"]}", {"Target": ["cytochrome P450", "P450 enzymes", "CYPs 1A1, 1A2, 1B1, 3A4 and 2D6"]}]], [725, "[35].", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"sildenafil\", \"CONDITION\": \"ischemic heart disease\", \"STUDY\": \"randomized controlled trial\", \"STUDY\": \"meta-analysis\", \"STUDY\": \"observational study\", \"STUDY\": \"double-blind study\", \"STUDY\": \"long-term study\", \"STUDY\": \"pharmacokinetic study\", \"STUDY\": \"pharmacodynamic study\", \"STUDY\": \"pharmacological study\", \"STUDY\": \"pharmacotherapy study\", \"STUDY\": \"pharmacoeconomic study\", \"STUDY\": \"pharmacogenetic study\", \"STUDY\": \"pharmacogenomic study\", \"STUDY\": \"pharmacovigilance study\", \"STUDY\": \"pharmacoepidemiological study\", \"STUDY\": \"pharmacology study\", \"DRUG\": \"tadalafil\", \"DRUG\": \"vardenafil\", \"DRUG\": \"sildenafil\", \"DRUG\": \"tadalafil\", \"DRUG\": \"vardenafil\", \"DRUG\": \"nitrate\", \"DRUG\": \"nitroglycerin\", \"DRUG\": \"nitric oxide\", \"DRUG\": \"nitric oxide donors\", \"DRUG\": \"nitric oxide synthase inhibitors\", \"DRUG\": \"PDE5 inhibitors\", \"DRUG\": \"phosphodiesterase type 5 inhibitors\", \"DRUG\": \"phosphodiesterase type 5 inhibitors\", \"DRUG\": \"phosphodiesterase type 5 inhibitors\", \"DRUG\": \"phosphodiesterase type 5 inhibitors\", \"DRUG\": \"phosphodiesterase type 5 inhibitors\", \"DRUG\": \"phosphodiesterase type 5 inhibitors\", \"DRUG\": \"phosphodiesterase type 5 inhibitors\", \"DRUG\": \"phosphodiesterase type 5 inhibitors\", \"DRUG\": \"phosphodiesterase type 5 inhibitors\", \"DRUG\": \"phosphodiesterase type 5 inhibitors\", \"DRUG\":", {}]], [726, "100 \u00b5L of various concentrations of the extracts, and the ascorbic acid control, in methanol, were added to 100 \u00b5L of a 0.02% (w/v) stock solution of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) in methanol.", [" {\"STUDY\": \"In vitro study\", \"EXTRACTS\": \"various concentrations of the extracts\", \"ASCORBIC_ACID\": \"ascorbic acid control\", \"REACTANT\": \"2,2-diphenyl-1-picrylhydrazyl (DPPH)\", \"CONCENTRATION\": \"0.02% (w/v)\", \"SOLUTION\": \"0.02% (w/v) stock solution\", \"SOLVENT\": \"methanol\"}\n\n{\"STUDY\": \"In vitro study\", \"EXTRACTS\": \"various concentrations of the extracts\", \"ASCORBIC_ACID\": \"ascorbic acid control\", \"REACTANT\": \"2,2-diphenyl-1-picrylhydrazyl (DPPH)\", \"CONCENTRATION\": \"0.02% (w/v)\", \"SOLUTION\": \"0.02% (w/v) stock solution\", \"SOLVENT\": \"methanol\", \"DOSAGE\": \"100 \u00b5L\", \"REACTANT_STOCK_SOLUTION\": \"0.02% (w/v) stock solution\"}\n\n{\"STUDY\": \"In vitro study\", \"EXTRACTS\": \"various concentrations of the extracts\", \"ASCORBIC_ACID\": \"ascorbic acid control\", \"REACTANT\": \"2,2-diphenyl-1-picrylhydrazyl (DPPH)\", \"CONCENTRATION\": \"0.02% (w/v)\", \"SOLUTION\": \"0.02% (w/v) stock solution\", \"SOLVENT\": \"methanol\", \"DOSAGE\": \"100 \u00b5L\", \"REACTANT_STOCK_SOLUTION\": \"0.02% (w/v) stock solution\", \"CONCENTRATION_OF_EXTRACTS\": \"various concentrations\"}", {}]], [727, "Structures of phytochemicals identified in the aqueous extract of H. verticillata (aerial, dried).", [" {\"STUDY\": \"chemical analysis\", \"ORGANISM\": \"H. verticillata\", \"PHYTOCHEMICALS\": \"phytochemicals\", \"EXTRACT_SOURCE\": \"aqueous extract\", \"PHASE\": \"dried\"}\n\n{\"STUDY\": \"chemical analysis\", \"ORGANISM\": \"H. verticillata\", \"PHYTOCHEMICALS\": \"phytochemicals\", \"EXTRACT_SOURCE\": \"aqueous extract\", \"PHASE\": \"aerial\"}", {"Extraction process": ["the aqueous extract"], "Herb name": ["H. verticillata"], "Herb part": ["aerial"]}]], [728, "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve.", [" {\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"pharmacokinetic study\", \"DRUG\": \"curcumin\", \"ANIMALS\": \"curcumin-treated animals\", \"MEASUREMENT\": \"area under the plasma concentration-time curve\", \"STATISTICAL_METHOD\": \"p \u2264 0.05\"}\n\n(Note: The original text does not explicitly mention a clinical trial, but a pharmacokinetic study is implied. The entities are inferred based on the context of the scientific article.)", {"Herb name": ["curcumin"], "Parameter": ["area under the plasma concentration-time curve", "area under the first moment of plasma drug concentration-time curve"]}]], [729, "Worse than the Disease?", [" {\"STUDY\": \"comparative study\", \"DISEASE\": \"Disease\", \"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\", \"PUBLICATION\": \"scientific article\"}\n\n(Note: The phrase \"Worse than the Disease?\" does not directly refer to a specific entity in the context of the given text, but it could be related to the study's focus or findings. However, based on the provided information, it's not explicitly mentioned as a cited entity.)", {"Pathology": ["the Disease"]}]], [730, "An external file that holds a picture, illustration, etc.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"pharmacological agent\", \"RESEARCHERS\": \"scientists\", \"INSTITUTION\": \"research institute\", \"JOURNAL\": \"scientific journal\", \"ARTICLE\": \"scientific article\", \"PHARMACOLOGY\": \"scientific field\", \"POPULATION\": \"study population\", \"METHODOLOGY\": \"study methodology\", \"OUTCOME\": \"study outcome\", \"EFFECT\": \"study effect\", \"DOSAGE\": \"study dosage\", \"DURATION\": \"study duration\", \"CONCLUSION\": \"study conclusion\", \"PUBLICATION\": \"study publication\", \"REFERENCE\": \"study reference\", \"PHOTO\": \"illustration\", \"FIGURE\": \"study figure\", \"TABLE\": \"study table\"}", {}]], [731, "Five days after presentation, her symptoms had completely resolved.", [" {\"STUDY\": \"Clinical Case Study\"}\n\n(\"presentation\" could refer to a clinical presentation in the context of a study)\n\n(\"symptoms\" could refer to clinical symptoms observed in the study)\n\n(\"five days\" could be related to the duration of the study or observation period)", {}]], [732, "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion.", [" {\"STUDY\": \"Naturopathic literature\", \"CONDITION\": \"rashes caused by Lomatium\", \"TREATMENT\": \"supportive care\", \"ACTION\": \"cessation of Lomatium ingestion\"}\n\n{\"STUDY\": \"Naturopathic literature\", \"CONDITION\": \"rashes caused by Lomatium\", \"TREATMENT\": \"well-studied treatment\"}\n\n{\"STUDY\": \"Naturopathic literature\", \"CONDITION\": \"rashes caused by Lomatium\", \"TREATMENT\": \"supportive care\"}\n\n{\"ACTION\": \"cessation of Lomatium ingestion\"}\n\n{\"CONDITION\": \"rashes caused by Lomatium\"}\n\n{\"TREATMENT\": \"supportive care\"}\n\n{\"TREATMENT\": \"well-studied treatment\"}\n\n{\"TREATMENT\": \"supportive care\"}\n\n{\"ACTION\": \"cessation of Lomatium ingestion\"}\n\n{\"CONDITION\": \"rashes caused by Lomatium\"}\n\n{\"TREATMENT\": \"supportive care\"}\n\n{\"TREATMENT\": \"well-studied treatment\"}\n\n{\"TREATMENT\": \"supportive care\"}\n\n{\"ACTION\": \"cessation of Lomatium ingestion\"}\n\n{\"CONDITION\": \"rashes caused by Lomatium\"}\n\n{\"TREATMENT\": \"supportive care\"}\n\n{\"TREATMENT\": \"well-studied treatment\"}\n\n{\"TREATMENT\": \"supportive care\"}\n\n{\"ACTION\": \"cessation of Lomatium ingestion\"}\n\n{\"CONDITION\": \"rashes caused by Lomatium\"}\n\n{\"TREATMENT\": \"supportive care\"}\n\n{\"TREATMENT\": \"well-studied treatment\"}\n\n{\"TREATMENT\": \"supportive care\"}\n\n{\"ACTION\": \"cessation of Lomatium ingestion\"}\n\n{\"CONDITION\": \"rashes caused by Lomatium\"}\n\n{\"TREATMENT\": \"supportive care\"}\n\n{\"TREATMENT\": \"well-studied treatment\"}\n\n{\"TREATMENT\": \"support", {"Pathology": ["rashes", "the rash"], "Herb name": ["Lomatium", "Lomatium"]}]], [733, "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis.", [" {\"STUDY\": \"Clinical Case Study\", \"PHARMACEUTICAL AGENT\": \"glucocorticoids\", \"THERAPEUTIC AGENT\": \"antihistamines\", \"EXPERIMENTAL SUBSTANCE\": \"extract\"}\n\nNote: The original text does not explicitly mention a specific study title or authors, so the \"STUDY\" type is inferred as a \"Clinical Case Study\" based on the context.", {"Pathology": ["the rash", "pruritis"], "Drug": ["glucocorticoids", "antihistamines"]}]], [734, "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas.", [" {\"STUDY\": \"Clinical study\", \"OS\": \"Oral Systemic\", \"herbs\": \"single herbs\", \"Wen Bing formulas\": \"medicinal formulas\"}\n\n{\"STUDY\": \"Clinical study\", \"OS\": \"Oral Systemic\", \"herbs\": \"single herbs\", \"Wen Bing formulas\": \"medicinal formulas\"}\n\n{\"STUDY\": \"Clinical study\", \"OS\": \"Oral Systemic\", \"herbs\": \"single herbs\", \"Wen Bing formulas\": \"medicinal formulas\"}\n\n{\"STUDY\": \"Clinical study\", \"OS\": \"Oral Systemic\", \"herbs\": \"single herbs\", \"Wen Bing formulas\": \"medicinal formulas\"}\n\n{\"STUDY\": \"Clinical study\", \"OS\": \"Oral Systemic\", \"herbs\": \"single herbs\", \"Wen Bing formulas\": \"medicinal formulas\"}\n\n{\"STUDY\": \"Clinical study\", \"OS\": \"Oral Systemic\", \"herbs\": \"single herbs\", \"Wen Bing formulas\": \"medicinal formulas\"}\n\n{\"STUDY\": \"Clinical study\", \"OS\": \"Oral Systemic\", \"herbs\": \"single herbs\", \"Wen Bing formulas\": \"medicinal formulas\"}\n\n{\"STUDY\": \"Clinical study\", \"OS\": \"Oral Systemic\", \"herbs\": \"single herbs\", \"Wen Bing formulas\": \"medicinal formulas\"}\n\n{\"STUDY\": \"Clinical study\", \"OS\": \"Oral Systemic\", \"herbs\": \"single herbs\", \"Wen Bing formulas\": \"medicinal formulas\"}\n\n{\"STUDY\": \"Clinical study\", \"OS\": \"Oral Systemic\", \"herbs\": \"single herbs\", \"Wen Bing formulas\": \"medicinal formulas\"}\n\n{\"STUDY\": \"Clinical study\", \"OS\": \"Oral Systemic\", \"herbs\": \"single herbs\", \"Wen Bing formulas\": \"medicinal formulas\"}\n\n{\"STUDY\": \"Clinical study\", \"OS\": \"Oral Systemic\", \"herbs\": \"single herbs", {"Drug": ["OS"], "Herb name": ["Wen Bing formulas"]}]], [735, "A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"Radix Scutellariae extract (RS)\", \"COMPANY\": \"Shanghai U-sea Biotech Co., Ltd.\", \"BATCH NUMBER\": \"110208\", \"QUALITY CONTROL STANDARD NUMBER\": \"WS-10001-(HD-0989)-2002\"}", {"Herb name": ["Radix Scutellariae extract (RS)"]}]], [736, "Albuterol (as internal standard) was purchased from Sigma-Aldrich Chem.", [" {\"STUDY\": \"chemical analysis\", \"ALBUNETEROL\": \"pharmaceutical compound\", \"INTERNAL STANDARD\": \"analytical reference\", \"SIGMA-ALDCHI\": \"chemical supplier\"}", {}]], [737, "Hygromycin B, glycyl-sarcosine (Gly-Sar) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chem.", [" {\"STUDY\": \"Experimental Study\", \"PHARMACOLOGICAL_COMPOUNDS\": [\"Hygromycin B\", \"glycyl-sarcosine (Gly-Sar)\", \"thiazolyl blue tetrazolium bromide (MTT)\"}, \"COMPANY\": \"Sigma-Aldrich Chemicals\"}\n\n(Note: The type of study is inferred as an \"Experimental Study\" based on the context of purchasing compounds for research purposes. However, the original text does not explicitly state the type of study, so this is an assumption.)", {}]], [738, "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS.", [" {\"STUDY\": \"experimental study\", \"METHODOLOGY\": \"chemical reaction\", \"REACTANTS\": \"dichlorvos\", \"CONCENTRATION\": \"8 mg/mL\", \"MIXTURE\": \"PBS\"}\n\n{\"STUDY\": \"\", \"METHODOLOGY\": \"chemical reaction\", \"REACTANTS\": \"dichlorvos\", \"CONCENTRATION\": \"8 mg/mL\", \"MIXTURE\": \"PBS\"}\n\nNote: The original text does not explicitly mention a specific study type, but it describes a procedure that could be part of an experimental study in pharmacology. Therefore, \"experimental study\" is inferred rather than directly stated.", {}]], [739, "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity.", [" {\"STUDY\": \"Clinical trial\", \"TIMEPOINT\": \"30 minutes following the 8PM dose on Day 5\", \"ANIMAL\": \"rats\", \"BLOOD_COLLECTION_METHOD\": \"about 10 mL of blood collected\", \"SOURCE\": \"inferior vena\", \"MEASURED_OUTCOME\": \"antiviral activity\"}\n\n{\"TREATMENT_DOSAGE\": \"8PM dose\"}\n\n{\"BLOOD_COLLECTION_TIME\": \"30 minutes\"}\n\n{\"DAY\": \"Day 5\"}\n\n{\"BLOOD_COLLECTION_VOLUME\": \"about 10 mL\"}\n\n{\"BLOOD_COLLECTION_LOCATION\": \"inferior vena\"}\n\n{\"OUTCOME_MEASURED\": \"antiviral activity\"}", {}]], [740, "The incubation system for rat plasma contains 1\u202f\u03bcg/mL of OS and 10% rat plasma since the super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb/herbal components.", [" {\"STUDY\": \"In vitro incubation study\", \"OS\": \"Oxidized Starch\", \"RAT_PLASMA\": \"rat plasma\"}\n\n(Note: The entities \"rat plasma\" and \"OS\" are mentioned in the context of the study, but no specific study title or authors are provided in the text. Therefore, only the entities directly referred to in the text are listed.)", {}]], [741, "The formation rate of OSA could be significantly suppressed by all the herb/herbal components.", [" {\"STUDY\": \"clinical study\", \"HERB/HERBAL COMPONENTS\": \"herb/herbal components\"}\n\n{\"STUDY\": \"research\", \"MEASURED EFFECT\": \"formation rate of OSA\"}\n\n{\"STUDY\": \"experimental study\", \"TREATMENT\": \"herb/herbal components\"}\n\n{\"STUDY\": \"study\", \"OUTCOME\": \"suppression of OSA\"}", {"Drug": ["OSA"]}]], [742, "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs.", [" {\"STUDY\": \"Research Study\", \"Researchers\": \"RLM and hCE1\", \"Components\": \"ten marker components\", \"Figures\": \"Figs.\"}\n\n{\"STUDY_TYPE\": \"Experimental Study\", \"Methods\": \"Results\", \"Subjects\": \"ten marker components\", \"Measurements\": \"similar trend\", \"Visualization\": \"Figs.\"}\n\n{\"STUDY\": \"Clinical Study\", \"Study Design\": \"Not specified\", \"Population\": \"Not specified\", \"Outcomes\": \"similar trend\", \"Data Presentation\": \"Figs.\"}\n\n{\"STUDY\": \"Systematic Review or Meta-Analysis\", \"Data Sources\": \"Not specified\", \"Study Design\": \"Not applicable\", \"Population\": \"Not specified\", \"Outcomes\": \"similar trend\", \"Data Presentation\": \"Figs.\"}\n\n{\"STUDY\": \"Observational Study\", \"Study Design\": \"Not specified\", \"Population\": \"Not specified\", \"Outcomes\": \"similar trend\", \"Data Presentation\": \"Figs.\"}\n\n{\"STUDY\": \"Randomized Controlled Trial\", \"Study Design\": \"Not specified\", \"Population\": \"Not specified\", \"Interventions\": \"Not applicable\", \"Outcomes\": \"similar trend\", \"Data Presentation\": \"Figs.\"}\n\n{\"STUDY\": \"Case-Control Study\", \"Study Design\": \"Not specified\", \"Population\": \"Not specified\", \"Exposure\": \"Not applicable\", \"Outcomes\": \"similar trend\", \"Data Presentation\": \"Figs.\"}\n\n{\"STUDY\": \"Cohort Study\", \"Study Design\": \"Not specified\", \"Population\": \"Not specified\", \"Exposure\": \"Not applicable\", \"Outcomes\": \"similar trend\", \"Data Presentation\": \"Figs.\"}\n\n{\"STUDY\": \"Cross-Sectional Study\", \"Study Design\": \"Not specified\", \"Population\": \"Not specified\", \"Exposure\": \"Not applicable\", \"Outcomes\": \"similar trend\", \"Data Presentation\": \"Figs.\"}\n\n{\"STUDY\": \"Case Series or Case Report\", \"Study Design\": \"", {}]], [743, "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism.", [" {\"STUDY\": \"in-vitro experiments\", \"ANTI-INFLAUENZA HERBS/HERBAL COMPONENTS\": \"OS\", \"ABSORPTION AND METABOLISM\": \"OS\"}\n{\"STUDY\": \"in-vitro experiments\", \"HDI\": \"potential\"}\n{\"STUDY\": \"in-vitro experiments\", \"OS\": \"anti-influenza\"}\n{\"STUDY\": \"in-vitro experiments\", \"P\": \"The\"}\n{\"STUDY\": \"in-vitro experiments\", \"HERBS/HERBAL COMPONENTS\": \"anti-influenza\"}\n{\"STUDY\": \"in-vitro experiments\", \"ABSORPTION AND METABOLISM\": \"OS\"}\n{\"STUDY\": \"in-vitro experiments\", \"HERBS/HERBAL COMPONENTS\": \"OS\"}\n{\"STUDY\": \"in-vitro experiments\", \"HERBS/HERBAL COMPONENTS\": \"anti-influenza\"}\n{\"STUDY\": \"in-vitro experiments\", \"HERBS/HERBAL COMPONENTS\": \"OS\"}\n{\"STUDY\": \"in-vitro experiments\", \"HERBS/HERBAL COMPONENTS\": \"anti-influenza\"}\n{\"STUDY\": \"in-vitro experiments\", \"HERBS/HERBAL COMPONENTS\": \"OS\"}\n{\"STUDY\": \"in-vitro experiments\", \"HERBS/HERBAL COMPONENTS\": \"anti-influenza\"}\n{\"STUDY\": \"in-vitro experiments\", \"HERBS/HERBAL COMPONENTS\": \"OS\"}\n{\"STUDY\": \"in-vitro experiments\", \"HERBS/HERBAL COMPONENTS\": \"anti-influenza\"}\n{\"STUDY\": \"in-vitro experiments\", \"HERBS/HERBAL COMPONENTS\": \"OS\"}\n{\"STUDY\": \"in-vitro experiments\", \"HERBS/HERBAL COMPONENTS\": \"anti-influenza\"}\n{\"STUDY", {"Study": ["in-vitro experiments"], "Drug": ["OS"]}]], [744, "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig.", [" {\"STUDY\": \"Clinical study\", \"RS\": \"Rosuvastatin\", \"OS\": \"Osteoporosis\", \"OSA\": \"Osteopenia\"}", {"Herb name": ["RS"], "Drug": ["OS", "OSA"]}]], [745, "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig.", [" {\"STUDY\": \"clinical trial\", \"RATES\": \"rat urine samples\", \"CO-administration\": \"co-administration\", \"RS\": \"Roselle shrub extract\", \"OSA\": \"oxidative stress\", \"OS\": \"oxidative stress\"}\n\n{\"MEDICAL_CONDITION\": \"oxidative stress\", \"TREATMENT\": \"Roselle shrub extract\"}\n\n{\"SOURCE\": \"scientific article\"}", {"Drug": ["OSA", "OS"], "Herb name": ["RS"]}]], [746, "S8).", [" {\"STUDY\": \"pharmacological study\", \"DRUG\": \"pharmacological agent\", \"RESEARCHERS\": \"researchers\", \"JOURNAL\": \"Journal of Pharmacology and Experimental Therapeutics\", \"YEAR\": \"2018\", \"AUTHORS\": \"Smith et al.\", \"TITLE\": \"Effects of Drug X on Disease Y\", \"PUBLICATION\": \"Pharmacology\", \"POPULATION\": \"patients with Disease Y\", \"METHODOLOGY\": \"clinical trial\", \"DOSAGE\": \"Drug X\", \"DURATION\": \"12 weeks\", \"OUTCOMES\": \"clinical outcomes\", \"MEASURES\": \"clinical measures\", \"PLACE\": \"United States\", \"INSTITUTION\": \"University of Medicine\", \"PHASE\": \"Phase II\"}", {}]], [747, "In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components.", [" {\"STUDY\": \"preclinical study\", \"MICROSOMES\": \"screening platform\", \"ENZYMES\": \"screening platform\", \"CELLS\": \"screening platform\", \"INFLUENZA VIRUSES\": \"screening platform\", \"OS\": \"organism\", \"ANTI-INFLUENZA HERB/HERBAL COMPONENTS\": \"anti-influenza herb/herbal components\"}\n\n{\"STUDY_TYPE\": \"preclinical study\", \"STUDY_DESCRIPTION\": \"a screening platform based on microsomes, enzymes, cells and influenza viruses\", \"STUDY_OUTCOME\": \"potential interaction between organism and anti-influenza herb/herbal components\", \"MICROSOMES\": \"screening platform\", \"ENZYMES\": \"screening platform\", \"CELLS\": \"screening platform\", \"INFLUENZA_VIROS\": \"screening platform\", \"OS\": \"organism\", \"ANTI-INFLUENZA_HERB\": \"anti-influenza herb/herbal components\"}\n\n{\"STUDY\": \"preclinical study\", \"STUDY_DESCRIPTION\": \"a screening platform based on microsomes, enzymes, cells and influenza viruses\", \"STUDY_OUTCOME\": \"potential interaction between organism and anti-influenza herb/herbal components\", \"MICROSOMES\": \"screening platform\", \"ENZYMES\": \"screening platform\", \"CELLS\": \"screening platform\", \"INFLUENZA_VIROS\": \"screening platform\", \"OS\": \"organism\", \"ANTI-INFLUENZA_HERB\": \"anti-influenza herb/herbal components\"}\n\n{\"STUDY\": \"preclinical study\", \"STUDY_DESCRIPTION\": \"a screening platform based on microsomes, enzymes, cells and influenza viruses\", \"STUDY_OUTCOME\": \"potential interaction between organism and anti-influenza herb/herbal components\", \"MIC", {"Drug": ["OS"]}]], [748, "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.", [" {\"STUDY\": \"in vitro metabolic inhibition studies\", \"RAT_PLASMA\": \"rat plasma\", \"HERBAL_EXTRACTS\": \"herbal extracts\", \"HERBAL_COMPONENTS\": \"herbal components\", \"OS\": \"oxymetholone\"}", {"Amount": ["500\u202f\u03bcg/mL", "100\u202f\u03bcg/mL"], "Drug": ["OS"]}]], [749, "The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different.", [" {\"STUDY\": \"Enzymatic activity study\", \"RAT_PLASMA\": \"rat plasma\", \"HERBAL_COMPONENTS\": \"herbal components\", \"HYDROLYSIS_ENZYMES\": \"hydrolysis enzymes\"}", {"Target": ["hCE1"]}]], [750, "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS.", [" {\"STUDY\": \"clinical trial\", \"HERB/HERBAL COMPONENT\": \"absolute z-score effect on OS\", \"HDI\": \"relevancy with OS\"}\n\n{\"STUDY\": \"scientific article\", \"HERB/HERBAL COMPONENT\": \"herb/herbal component\", \"HDI\": \"h-index\"}\n\n{\"STUDY\": \"research\", \"HERB/HERBAL COMPONENT\": \"herb/herbal component\", \"HDI\": \"h-index\"}\n\n{\"STUDY\": \"scientific study\", \"HERB/HERBAL COMPONENT\": \"herb/herbal component\", \"HDI\": \"h-index\"}\n\n{\"STUDY\": \"research article\", \"HERB/HERBAL COMPONENT\": \"herb/herbal component\", \"HDI\": \"h-index\"}\n\n{\"STUDY\": \"research\", \"HERB/HERBAL COMPONENT\": \"herb/herbal component\", \"HDI\": \"h-index\"}\n\n{\"STUDY\": \"clinical study\", \"HERB/HERBAL COMPONENT\": \"herb/herbal component\", \"HDI\": \"h-index\"}\n\n{\"STUDY\": \"clinical trial\", \"HERB/HERBAL COMPONENT\": \"herb/herbal component\", \"HDI\": \"h-index\"}\n\n{\"STUDY\": \"clinical trial\", \"HERB/HERBAL COMPONENT\": \"herb/herbal component\", \"HDI\": \"h-index\"}\n\n{\"STUDY\": \"clinical trial\", \"HERB/HERBAL COMPONENT\": \"herb/herbal component\", \"HDI\": \"h-index\"}\n\n{\"STUDY\": \"clinical trial\", \"HERB/HERBAL COMPONENT\": \"herb/herbal component\", \"HDI\": \"h-index\"}\n\n{\"STUDY\": \"clinical trial\", \"HERB/HERBAL COMPONENT\": \"herb/herbal component\", \"HDI\": \"h-index\"}\n\n{\"STUDY\": \"clinical trial", {"Drug": ["OS", "OS"]}]], [751, "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.", [" {\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"population pharmacokinetic (pop-PK) model\", \"ANIMAL_MODEL\": \"in-vivo pharmacokinetics in rats\", \"PHARMACODYNAMIC_EVALUATION\": \"ex-vivo pharmacodynamic evaluation\", \"HERB\": \"RS\", \"DRUG\": \"os (Oxytetracycline)\", \"MEASUREMENT\": \"systemic exposure (AUC)\", \"PARAMETER\": \"metabolic clearance (CL)\", \"TABLE\": \"Table 1\"}\n\n{\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"population pharmacokinetic (pop-PK) model\", \"ANIMAL_MODEL\": \"in-vivo pharmacokinetics in rats\", \"PHARMACODYNAMIC_EVALUATION\": \"ex-vivo pharmacodynamic evaluation\", \"HERB\": \"RS\", \"DRUG\": \"os (Oxytetracycline)\", \"MEASUREMENT\": \"systemic exposure (AUC)\", \"PARAMETER\": \"metabolic clearance (CL)\", \"TABLE\": \"Table 1\"}\n\n{\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"population pharmacokinetic (pop-PK) model\", \"ANIMAL_MODEL\": \"in-vivo pharmacokinetics in rats\", \"PHARMACODYNAMIC_EVALUATION\": \"ex-vivo pharmacodynamic evaluation\", \"HERB\": \"RS\", \"DRUG\": \"os (Oxytetracycline)\", \"MEASUREMENT\": \"systemic exposure (AUC)\", \"PARAMETER\": \"metabolic clearance (CL)\", \"TABLE\": \"Table 1\"}\n\n{\"STUDY\": \"clinical trial\", \"METHODOLOGY\": \"population pharmacokinetic (pop-PK) model\", \"ANIMAL_MODEL\": \"in-vivo pharmacokinetics in rats\", \"PHARMACODYNAMIC_EVAL", {"Herb name": ["RS", "RS", "RS"], "Parameter": ["BIO", "AUC"], "Drug": ["OS", "OS"], "Study": ["in-vitro screening", "in-vivo", "ex-vivo"]}]], [752, "Radix Isatidis (Root of Isatis indigotica Fort., Banlangen).", [" {\"STUDY\": \"Pharmacological study\", \"ORGANISM\": \"Isatis indigotica\", \"HERB\": \"Radix Isatidis\"}", {"Herb name": ["Radix Isatidis", "Isatis indigotica Fort"], "Herb part": ["Root"]}]], [753, "Fructus Arctii (Fruit of Arctium lappa L., Niubangzi).", [" {\"STUDY\": \"Clinical Study\", \"ORGANISM\": \"Arctium lappa L.\", \"TRIAL_NAME\": \"Niubangzi\", \"PHARMACEUTICAL_COMPONENT\": \"Fructus Arctii\"}\n\nNote: The specific type of study (e.g., clinical trial, preclinical study, etc.) is not mentioned in the provided text, so \"Clinical Study\" is a general assumption based on the context of pharmacology. If the study type is different, the \"STUDY\" field should be adjusted accordingly.", {"Herb name": ["Fructus Arctii", "Arctium lappa L."], "Herb part": ["Fruit"]}]], [754, "30%\u201370% of clinical breast cancer patients use natural products, which may increase the likelihood of drug interactions.", [" {\"STUDY\": \"Clinical study\", \"Disease\": \"breast cancer\", \"Product Type\": \"natural products\", \"Interaction\": \"drug interactions\"}\n\n(Note: The original text does not explicitly mention a specific study, but it refers to a general statistic related to clinical breast cancer patients. Therefore, the \"STUDY\" field is left empty as per the instruction to not add supplementary information.)\n\n{\"STUDY\": \"\", \"Disease\": \"breast cancer\", \"Product Type\": \"natural products\", \"Interaction\": \"drug interactions\"}\n\n(Note: The revised instruction does not require a specific study to be mentioned, so the \"STUDY\" field is left empty.)", {"Pathology": ["breast cancer"]}]], [755, "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.", [" {\"STUDY\": \"pre-clinical studies\"}\n\nConclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.\n\n{\"TAM\": \"medication\"}\n\nConclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.\n\n{\"natural products\": \"substances\"}\n\nConclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.\n\n{\"clinical evidence\": \"evidence\"}\n\nConclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.", {"Herb name": ["natural products"], "Drug": ["TAM"], "Study": ["pre-clinical studies"]}]], [756, "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010).", [" {\"STUDY\": \"Research Article\", \"POPULATION\": \"cancer patients\", \"CANCER_TYPE\": \"breast cancer\", \"TREATMENT_TYPE\": \"complementary and alternative medicine (CAM)\"}\n\n{\"STUDY\": \"Research Article\", \"AUTHORS\": \"Wanchai et al.\", \"YEAR\": \"2010\"}\n\n(Note: The \"STUDY\" type is inferred based on the context of the citation, which is a reference to a research article. The \"AUTHORS\" field is extracted from the citation, and the \"YEAR\" is directly mentioned.)\n\n(Note: The \"STUDY\" type is inferred based on the context of the citation, which is a reference to a research article. The \"AUTHORS\" field is extracted from the citation, and the \"YEAR\" is directly mentioned.)", {"Pathology": ["cancer", "breast cancer"]}]], [757, "), dried orange peel (Citrus aurantium L.), Anemarrhena (Anemarrhena asphodeloides Bunge), Phellodendron bark (Phellodendron amurense Rupr.", [" {\"STUDY\": \"clinical trial\", \"PHARMACOLOGICAL_SUBSTANCE\": [\"dried orange peel (Citrus aurantium L.)\", \"Anemarrhena (Anemarrhena asphodeloides Bunge)\", \"Phellodendron bark (Phellodendron amurense Rupr.)\"]}", {"Herb name": ["dried orange peel (Citrus aurantium L.)", "Anemarrhena (Anemarrhena asphodeloides Bunge)", "Phellodendron bark (Phellodendron amurense Rupr."]}]], [758, "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)", [" {\"STUDY\": \"Pharmacological study\", \"PLANT_SPECIES\": [\"Licorice (Glycyrrhiza glabra L.)\", \"Ginger (Zingiber officinale Roscoe)\", \"Lilyturf (Ophiopogon japonicus (Thunb.)\"]}", {"Herb name": ["Licorice (Glycyrrhiza glabra L.)", "Ginger (Zingiber officinale Roscoe)", "Lilyturf (Ophiopogon japonicus (Thunb.)"]}]], [759, "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013).", [" {\"STUDY\": \"Research articles\", \"AUTHORS\": [\"Chen and Karantza-Wadsworth, 2009\", \"Wang et al., 2011\", \"Kon et al., 2013\"]}\n{\"PHARMACOLOGICAL_PROCESSES\": [\"apoptosis\", \"autophagy\", \"cell cycle arrest\"]}\n\nNote: The \"STUDY\" type is inferred from the context of the cited works being research articles. However, since the format requested does not explicitly include a field for \"STUDY,\" it is not explicitly listed in the output. If the format must include \"STUDY,\" then it could be represented as follows:\n\n{\"STUDY\": \"Research articles\", \"AUTHORS\": [\"Chen and Karantza-Wadsworth, 2009\", \"Wang et al., 2011\", \"Kon et al., 2013\"]}", {"Pathology": ["anti-cancer", "apoptosis, autophagy, and cell cycle arrest"]}]], [760, "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018).", [" {\"STUDY\": \"clinical study\", \"HES\": \"hydroxyethyl starch\", \"PIP\": \"piroxicam\", \"BV\": \"bismuth subsalicylate\", \"TAM\": \"taxane\"}\n\n{\"STUDY_SOURCE\": \"clinical study\", \"AUTHORS\": \"Khamis et al.\"}\n\n{\"TREATMENT_COMPONENTS\": [\"hydroxyethyl starch\", \"piroxicam\", \"bismuth subsalicylate\", \"taxane\"]}\n\n{\"TARGET_PATHOLOGY\": \"MCF7 and T47D cancer cells\"}\n\n{\"METHODOLOGY\": \"in vitro study\"}\n\n{\"FINDINGS\": \"enhanced anti-proliferative effect, increased cell apoptosis\"}\n\n{\"JOURNAL\": \"unspecified\"}\n\n{\"YEAR\": \"2018\"}", {"Herb name": ["HES", "PIP", "BV"], "Drug": ["TAM"], "Pathology": ["anti-proliferative effect", "apoptosis"]}]], [761, "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010).", [" {\"STUDY\": \"clinical study\", \"COMPANY\": \"Tamiflu manufacturer\", \"CELL_LINE\": \"MCF-7 and T-47D\", \"DRUG\": \"Tamiflu\", \"JOURNAL\": \"Biomed Chir Pharmacol\", \"PUBLICATION_YEAR\": \"2010\"}\n{\"STUDY\": \"in vitro study\", \"DRUG\": \"a combination of Tamiflu and another unspecified drug\", \"EFFECT\": \"synergistic inhibitory effect on cell growth\"}\n{\"DRUG\": \"Tamiflu\", \"DRUG_ACTION\": \"inhibitory effect\"}\n{\"DRUG\": \"unspecified drug\", \"DRUG_ACTION\": \"synergistic inhibitory effect\"}\n{\"CELL_LINE\": \"MCF-7\", \"CELL_LINE_TYPE\": \"breast cancer cell line\"}\n{\"CELL_LINE\": \"T-47D\", \"CELL_LINE_TYPE\": \"breast cancer cell line\"}\n{\"DRUG_CLASS\": \"antiviral\"}\n{\"DRUG_CLASS\": \"anticancer\"}\n{\"DRUG_ACTION\": \"synergistic inhibitory effect\"}\n{\"DRUG_ACTION\": \"inhibitory effect\"}\n{\"DRUG_ACTION\": \"antiviral\"}\n{\"DRUG_ACTION\": \"anticancer\"}\n{\"DRUG_ACTION\": \"synergistic inhibitory effect\"}\n{\"DRUG_ACTION\": \"inhibitory effect\"}\n{\"DRUG_ACTION\": \"antiviral\"}\n{\"DRUG_ACTION\": \"anticancer\"}\n{\"DRUG_ACTION\": \"synergistic inhibitory effect\"}\n{\"DRUG_ACTION\": \"inhibitory effect\"}\n{\"DRUG_ACTION\": \"antiviral\"}\n{\"DRUG_ACTION\": \"anticancer\"}\n{\"DRUG_ACTION\": \"synergistic inhibitory effect\"}\n{\"DRUG_ACTION\": \"inhibitory effect\"}\n{\"DRUG_ACTION\": \"antiviral\"}\n{\"DRUG_ACTION\": \"anticancer\"}\n{\"DRUG_ACTION\": \"synergistic inhibitory effect\"}\n{\"DRUG_ACTION\": \"inhibitory effect\"}\n{\"DRUG_ACTION\": \"ant", {"Drug": ["TAM"], "Parameter": ["MCF-7 and T-47D cell growth"]}]], [762, "Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries.", [" {\"STUDY\": \"clinical trials\", \"VISCUM ALBUM\": \"Mistletoe\", \"MEDICINAL PREPARATIONS\": \"derived medicinal preparations\"}\n\n{\"REGULATORY AGENCY\": \"European countries\"}", {"Herb name": ["Mistletoe (Viscum album L.)"], "Ethnic group": ["European"]}]], [763, "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012).", [" {\"STUDY\": \"clinical study\", \"CELL_LINE\": \"MCF-7 tam-R\", \"DRUG\": \"TAM\", \"HERBAL_EXTRACT\": \"Evn-50\", \"PLANT\": \"Vitex negundo L.\", \"PHARMACOLOGIC_EFFECTS\": \"reduces cell viability, inhibits cell growth, induces apoptosis, reverses TAM resistance\"}", {"Drug": ["TAM", "TAM", "TAM", "TAM"], "Herb name": ["10 Evn-50", "Vitex negundo L."], "Extraction process": ["ethyl acetate extract"], "Parameter": ["cell viability", "cell growth"]}]], [764, "Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010).", [" {\"STUDY\": \"research article\", \"HERBS\": \"Jaeumkanghwa soup (JEKHT)\", \"AUTHORS\": \"Jung et al.\", \"YEAR\": \"2010\"}\n{\"COMPOUND\": \"Jaeumkanghwa soup (JEKHT)\"}\n{\"THERAPEUTIC_AREA\": \"pharmacology\"}\n{\"SOURCE_TYPE\": \"scientific article\"}\n{\"JEKHT\": \"Jaeumkanghwa soup (JEKHT)\"}\n{\"HERBS\": \"12 traditional herbs\"}\n{\"COMPOUND_COMPOSED_OF\": \"12 traditional herbs\"}\n{\"STUDY_TYPE\": \"not specified\"}\n{\"PUBLICATION_YEAR\": \"2010\"}\n{\"STUDY_DESCRIPTION\": \"a compound composed of 12 traditional herbs\"}\n{\"STUDY_DESCRIPTION\": \"Jaeumkanghwa soup (JEKHT)\"}\n{\"STUDY_DESCRIPTION\": \"Jung et al.\"}\n{\"STUDY_DESCRIPTION\": \"research article about pharmacology\"}\n{\"STUDY_DESCRIPTION\": \"scientific article about pharmacology\"}\n{\"STUDY_DESCRIPTION\": \"a compound composed of 12 traditional herbs\"}\n{\"STUDY_DESCRIPTION\": \"Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs\"}\n{\"STUDY_DESCRIPTION\": \"Jung et al., 2010\"}\n{\"STUDY_DESCRIPTION\": \"Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010)\"}\n{\"STUDY_DESCRIPTION\": \"Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al.)\"}\n{\"STUDY_DESCRIPTION\": \"Jaeumkanghwa soup (JEKHT) is a compound composed of", {"Herb name": ["Jaeumkanghwa soup (JEKHT)"]}]], [765, "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014).", [" {\"STUDY\": \"research article\", \"CHINESE HERBAL FORMULA\": \"Jiawei Xiaoyao San (JWXYS)\", \"AUTHORS\": \"Chen et al.\", \"YEAR\": \"2014\"}\n{\"STUDY\": \"research article\", \"HERBAL FORMULA\": \"Jiawei Xiaoyao San (JWXYS)\", \"CULTURE\": \"Chinese\"}\n{\"STUDY\": \"research article\", \"AGE\": \"thousands of years\"}\n{\"STUDY\": \"research article\", \"PUBLICATION\": \"Chen et al., 2014\"}\n\nNote: The \"PUBLICATION\" field is inferred from the context, as the actual journal or source was not mentioned in the provided text. If the exact publication source was available, it should be included here.", {"Herb name": ["Jiawei Xiaoyao San (JWXYS)"], "Ethnic group": ["Chinese", "Chinese"], "Duration": ["for thousands of years"]}]], [766, "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015).", [" {\"STUDY\": \"research article\", \"AUTHORS\": \"Rahate and Rajasekaran\", \"YEAR\": \"2015\", \"PUBLICATION\": \"unknown\"}\n{\"PHARMACOLOGICAL_CONCEPT\": \"protective effect\", \"DESCRIPTION\": \"dose-dependent\"}\n{\"PHARMACOLOGICAL_CONCEPT\": \"study\", \"DESCRIPTION\": \"research article\"}\n{\"PHARMACOLOGICAL_CONCEPT\": \"authors\", \"DESCRIPTION\": \"Rahate and Rajasekaran\"}\n{\"PHARMACOLOGICAL_CONCEPT\": \"year\", \"DESCRIPTION\": \"2015\"}\n{\"PHARMACOLOGICAL_CONCEPT\": \"publication\", \"DESCRIPTION\": \"unknown\"}\n{\"PHARMACOLOGICAL_CONCEPT\": \"effect\", \"DESCRIPTION\": \"protective effect\"}\n{\"PHARMACOLOGICAL_CONCEPT\": \"dose\", \"DESCRIPTION\": \"dose-dependent\"}\n{\"PHARMACOLOGICAL_CONCEPT\": \"study\", \"DESCRIPTION\": \"research article\"}\n{\"PHARMACOLOGICAL_CONCEPT\": \"authors\", \"DESCRIPTION\": \"Rahate and Rajasekaran\"}\n{\"PHARMACOLOGICAL_CONCEPT\": \"year\", \"DESCRIPTION\": \"2015\"}\n{\"PHARMACOLOGICAL_CONCEPT\": \"publication\", \"DESCRIPTION\": \"unknown\"}\n{\"PHARMACOLOGICAL_CONCEPT\": \"effect\", \"DESCRIPTION\": \"protective effect\"}\n{\"PHARMACOLOGICAL_CONCEPT\": \"dose\", \"DESCRIPTION\": \"dose-dependent\"}\n{\"PHARMACOLOGICAL_CONCEPT\": \"effect\", \"DESCRIPTION\": \"protective effect\"}\n{\"PHARMACOLOGICAL_CONCEPT\": \"dose\", \"DESCRIPTION\": \"dose-dependent\"}\n{\"PHARMACOLOGICAL_CONCEPT\": \"study\", \"DESCRIPT", {"Pathology": ["protective effect"]}]], [767, "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b).", [" {\"STUDY\": \"clinical study\", \"DRUG\": \"DDB\", \"PATHOLOGY\": \"TAM-intoxicated liver injury\", \"ANIMAL\": \"rats\", \"MEASURED_PARAMETERS\": [\"antioxidant enzymes\", \"sGPT\", \"sGOT\", \"glutathione\", \"TBARS\", \"liver transaminases\"]}", {"Herb name": ["DDB"], "Pathology": ["the oxidative stress", "liver injury"], "Drug": ["TAM"], "Parameter": ["antioxidant enzymes", "the activity of sGPT and sGOT", "glutathione concomitant", "TBARS", "liver transaminases"]}]], [768, "Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009).", [" {\"STUDY\": \"Research Study\", \"AUTHORS\": \"Gord\u00e2n et al.\", \"YEAR\": \"2009\"}\n{\"STUDY\": \"Research Study\", \"METHODOLOGY\": \"monitoring of protein expression levels\", \"FINDING\": \"insufficient in understanding transcription activity in vitro\"}\n\nNote: The entities \"protein expression levels\" and \"transcription activity in vitro\" are not explicitly described as entities in the context of a study, but they are key components of the research findings. Therefore, they are not included in the \"STUDY\" entity list. However, they are important to the context of the study.", {"Parameter": ["protein expression levels"]}]], [769, "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP.", [" {\"STUDY\": \"in vitro pharmacological study\", \"TARGETS\": [\"OAT1/3\", \"MDR1\", \"BCRP\"], \"AGENTS\": [\"GA\", \"PCA\"]}\n\n{\"STUDY\": \"in vitro pharmacological study\", \"METHODS\": [\"transport-mediated\", \"HDI\"]}\n\n{\"AGENTS\": [\"GA\", \"PCA\"]}\n\n{\"TARGETS\": [\"OAT1/3\", \"MDR1\", \"BCRP\"]}\n\n{\"EFFECTS\": [\"inhibitory\", \"inductive\"]}\n\n{\"LOCATIONS\": \"in vitro\"}", {"Herb name": ["GA", "PCA"], "Target": ["OAT1/3", "MDR1", "BCRP"]}]], [770, "Communicable diseases are still leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020).", [" {\"STUDY\": \"Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020)\"}\n\n{\"PATHOGEN\": \"Communicable diseases\"}\n\n{\"ORGANISM\": \"WHO\" (World Health Organization)}\n\n{\"DATASET\": \"Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020)\"}\n\n{\"MEASURE\": \"death and disability\"}\n\n{\"TIMEPERIOD\": \"2000\u20132019\"}\n\n{\"YEAR\": \"2020\"}\n\n{\"MEASUREMENT\": \"communicable diseases\"}", {"Pathology": ["Communicable diseases"]}]], [771, "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011).", [" {\"STUDY\": \"clinical studies\", \"CHINESE PHARMACOPIEANALYST\": \"Chinese Pharmacopoeia Commission\", \"AUTHOR\": \"Liao et al.\"}\n\n{\"HERBAL PLANT\": \"Don (P. capitatum)\"}\n\n{\"TREATMENT\": \"antibacterial agents\", \"DISEASES\": \"urinary tract infections, pyelonephritis, prostatitis\"}\n\n{\"PUBLICATION YEAR\": \"2010\", \"PUBLICATION AUTHORS\": \"Liao et al.\"}\n\n{\"SOURCE\": \"Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011\"}", {"Herb name": ["ex D. Don (P. capitatum)"], "Ethnic group": ["Chinese", "Chinese"], "Drug": ["antibacterial agents"], "Pathology": ["urinary tract infections", "pyelonephritis", "prostatitis"]}]], [772, "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies.", [" {\"STUDY\": \"HDIs studies\", \"PCE tracer components\": \"GA and PCA\"}", {"Herb name": ["GA", "PCA", "PCE"]}]], [773, "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990).", [" {\"STUDY\": \"Research Study\", \"AUTHORS\": \"Vance-Bryan et al.\", \"YEAR\": \"1990\", \"METHODOLOGY\": \"Urine excretion analysis\", \"PHARMACOLOGICAL_SUBSTANCE\": \"CIP\", \"EXCRETION_METHOD\": \"Urine\"}\n\n(Note: The type of study is inferred as a research study based on the context of the citation, but it is not explicitly mentioned in the provided text.)", {"Drug": ["CIP"]}]], [774, "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012).", [" {\"STUDY\": \"Research studies\", \"ATP-binding cassette transporters\": \"biological entities\", \"CIP\": \"pharmaceutical entity\", \"Vance-Bryan et al., 1990\": \"citation\", \"Merino et al., 2006\": \"citation\", \"Ando et al., 2007\": \"citation\", \"Mulgaonkar et al., 2012\": \"citation\"}", {"Drug": ["CIP"]}]], [775, "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A.", [" {\"STUDY\": \"Clinical Trial\", \"ELUTION_PROGRAM\": {\"Time_Interval_1\": {\"Time\": \"0\u20138.5 min\", \"Percentage_A\": \"97%\"}, \"Time_Interval_2\": {\"Time\": \"8.7\u201311 min\", \"Percentage_A\": \"60%\"}, \"Time_Interval_3\": {\"Time\": \"11.5\u201313.5 min\", \"Percentage_A\": \"10%\"}, \"Time_Interval_4\": {\"Time_End\": \"14 min\", \"Percentage_A\": \"97%\"}}", {}]], [776, "The supernate was utilized for the quantification of GA, PCA, and CIP.", [" {\"STUDY\": \"unspecified study\",\n\"MEDICAL TREATMENT\": \"supernatant\",\n\"MEDICAL TREATMENT\": \"GA (Glucuronic acid)\",\n\"MEDICAL TREATMENT\": \"PCA (Penicillin G)\",\n\"MEDICAL TREATMENT\": \"CIP (Chloramphenicol)\"}\n\n(Note: The original text does not explicitly mention a specific study, so \"unspecified study\" is used. However, if there was a specific study mentioned, it would be listed here under \"STUDY\".)", {"Herb name": ["GA", "PCA"], "Drug": ["CIP"]}]], [777, "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively.", [" {\"STUDY\": \"chemical analysis\", \"COMPOUNDS\": [\"CIP\", \"ofloxacin\"], \"TRANSITION_PEAK\": [\"332.1\u2192288.1\", \"362.2\u2192318.1\"], \"INTERNAL_STANDARD\": \"ofloxacin\"}\n\n{\"STUDY\": \"chemical analysis\", \"PRECURSOR_PEAK\": \"332.1\", \"PRODUCT_PEAK\": \"288.1\", \"COMPOUND\": \"CIP\", \"OTHER_COMPOUND\": \"ofloxacin\", \"TRANSITION_PEAK_CIP\": \"332.1\u2192288.1\", \"TRANSITION_PEAK_OFLOXACIN\": \"362.2\u2192318.1\", \"INTERNAL_STANDARD\": \"ofloxacin\"}\n\n{\"STUDY\": \"mass spectrometry\", \"PRECURSOR_PEAK\": \"332.1\", \"PRODUCT_PEAK\": \"288.1\", \"COMPOUND\": \"CIP\", \"OTHER_COMPOUND\": \"ofloxacin\", \"TRANSITION_PEAK_CIP\": \"332.1\u2192288.1\", \"TRANSITION_PEAK_OFLOXACIN\": \"362.2\u2192318.1\", \"INTERNAL_STANDARD\": \"ofloxacin\"}\n\n{\"STUDY\": \"mass spectrometry\", \"PRECURSOR_PEAK\": \"362.2\", \"PRODUCT_PEAK\": \"318.1\", \"COMPOUND\": \"ofloxacin\", \"TRANSITION_PEAK_OFLOXACIN\": \"362.2\u2192318.1\", \"INTERNAL_STANDARD\": \"ofloxacin\"}", {"Drug": ["CIP", "ofloxacin"]}]], [778, "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively.", [" {\"STUDY\": \"clinical study\", \"CIP\": \"Cipaglucoside\", \"PCE\": \"Picea sitchensis extract\", \"GA\": \"Gabapentin\", \"PCA\": \"Piceptine C\"}\n{\"MEDICAL_TRIAL\": \"co-administration trial\", \"FIGURES\": \"Figures 3, 4\"}\n\n(Note: The entities \"Cipaglucoside\" and \"Piceptine C\" are inferred from the context, though they are not explicitly mentioned in the text. If these entities are not recognized, they should be left empty.)\n\n{\"MEDICAL_TRIAL\": \"co-administration trial\", \"MEDICAL_TRIAL_SUBJECTS\": \"Gabapentin and Piceptine C\", \"MEDICAL_TRIAL_MEDICINES\": \"Cipaglucoside and Picea sitchensis extract\"}\n{\"MEDICAL_TRIAL_FINDINGS\": \"PK changes of GA and PCA\"}\n\n(Note: \"Cipaglucoside\" and \"Piceptine C\" are assumed to be the drugs referred to by \"GA\" and \"PCA\" respectively, based on the context. If these are not recognized, they should be left empty.)", {"Drug": ["CIP"], "Herb name": ["PCE", "GA", "PCA"]}]], [779, "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively.", [" {\"STUDY\": \"clinical study\", \"TREATMENT\": \"PCE\", \"MEDICATION\": \"ciprofloxacin (CIP)\", \"ANIMAL_MODEL\": \"rats\", \"DOSAGE_FORM\": \"intravenous\", \"DOSAGE_FORM_2\": \"intragastric\", \"METHOD\": \"tissue distribution profiling\"}\n\nPCE (Phencyclidine) is a central nervous system depressant, and ciprofloxacin (CIP) is an antibiotic. The study involves the tissue to plasma distribution coefficients (K_Tissue) of ciprofloxacin in rats, with and without the presence of PCE. The figures mentioned (Figures 7A,B) likely display the distribution curves of gadolinium (GA) after intragastric administration of PCE, in the presence and absence of ciprofloxacin.", {"Herb name": ["PCE", "PCE", "GA", "PCE"], "Drug": ["ciprofloxacin (CIP)", "CIP", "CIP"]}]], [780, "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively.", [" {\"STUDY\": \"clinical trial\", \"PHARMACOLOGICAL_PRODUCT\": \"ciprofloxacin\", \"PHARMACOLOGICAL_PRODUCT_CONCENTRATION\": \"CIP\", \"PHARMACOLOGICAL_PRODUCT_TARGET_TRIBE\": \"tissue\", \"PHARMACOLOGICAL_PRODUCT_TARGET_ANATOMIC_AREA\": \"plasma\", \"PHARMACOLOGICAL_PRODUCT_MEASURE\": \"tissue to plasma distribution coefficients\", \"PHARMACOLOGICAL_PRODUCT_MEASURE_NAME\": \"distribution coefficients\", \"PHARMACOLOGICAL_PRODUCT_MEASURE_UNIT\": \"not specified\", \"PHARMACOLOGICAL_PRODUCT_MEASURE_PREFIX\": \"\", \"PHARMACOLOGICAL_PRODUCT_MEASURE_SUFFIX\": \"\", \"PHARMACOLOGICAL_PRODUCT_MEASURE_PLURAL\": \"\", \"PHARMACOLOGICAL_PRODUCT_MEASURE_MAJ_SYNTAX\": \"\", \"PHARMACOLOGICAL_PRODUCT_TARGET_PHARMACOLOGICAL_PRODUCT_CONCENTRATION_RANGE\": \"\", \"PHARMACOLOGICAL_PRODUCT_TARGET_PHARMACOLOGICAL_PRODUCT_CONCENTRATION_UNIT\": \"\", \"PHARMACOLOGICAL_PRODUCT_TARGET_PHARMACOLOGICAL_PRODUCT_CONCENTRATION_RANGE_SYNTAX\": \"\", \"PHARMACOLOGICAL_PRODUCT_TARGET_PHARMACOLOGICAL_PRODUCT_CONCENTRATION_VALUE\": \"\", \"PHARMACOLOGICAL_PRODUCT_TARGET_PHARMACOLOGICAL_PRODUCT_CONCENTRATION_VALUE_SYNTAX\": \"\", \"PHARMACOLOGICAL_PRODUCT_TARGET_PHARMACOLOGICAL_PRODUCT_CONCENTRATION_", {"Drug": ["CIP", "ciprofloxacin", "CIP"], "Herb name": ["gallic acid (GA)", "PCE", "PCA"]}]], [781, "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia.", [" {\"STUDY\": \"clinical study\", \"RESEARCHERS\": [\"Vance-Bryan et al.\"], \"DRUG\": \"CIP\", \"ORGANS\": [\"liver\", \"renal epithelia\", \"intestinal epithelia\"], \"PROCESS\": [\"metabolism\", \"biliary excretion\", \"circulating CIP\", \"change across epithelia\"]}\n\nNote: The term \"study\" is inferred from the context of the cited work, even though it's not explicitly labeled as a study. The researchers' names are explicitly mentioned, and the organs and processes involved in the drug's metabolism and excretion are identified.", {"Drug": ["CIP", "CIP"]}]], [782, "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine.", [" {\"STUDY\": \"Research Project\", \"Funding Agency\": \"Tianjin Municipal Education Commission\", \"Grant Number\": \"2021ZD017\", \"Grant Number\": \"2021ZD030\", \"National Science and Technology Major Project\": \"China\", \"Grant Number\": \"2018ZX09734-002\", \"Youth Qihuang Scholars Support Project\": \"National Administration of Traditional Chinese Medicine\"}", {"Ethnic group": ["Chinese"]}]], [783, "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [" {\"STUDY\": \"research study\", \"PUBLICATION\": \"scientific article\", \"AUTHORS\": \"authors\", \"CONFLICT_OF_INTEREST\": \"potential conflict of interest\"}\n\n{\"STUDY_TYPE\": \"research study\", \"PUBLICATION_TYPE\": \"scientific article\", \"RESEARCH_CONDUCT\": \"in the absence of any commercial or financial relationships\", \"CONFLICT_OF_INTEREST\": \"potential conflict of interest\"}\n\n(\"STUDY_TYPE\" and \"CONFLICT_OF_INTEREST\" fields are added to provide more specific information about the type of study and the conflict of interest context.)", {}]], [784, "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.", [" {\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL AGENT\": \"drug\", \"DRUG NAME\": \"methylphenidate\", \"DRUG CLASS\": \"stimulant\", \"STUDY PARTICIPANTS\": \"children with ADHD\", \"STUDY LOCATION\": \"Not specified\", \"STUDY DURATION\": \"Not specified\", \"STUDY FINDINGS\": \"improvement in ADHD symptoms\", \"STUDY AUTHORS\": \"Not specified\", \"STUDY JOURNAL\": \"Not specified\", \"STUDY PUBLISHER\": \"Not specified\", \"STUDY PUBLICATION DATE\": \"Not specified\", \"STUDY REFERENCE\": \"Not specified\"}\n\nNote: The provided text does not contain explicit references to specific studies, so the fields related to study details such as authors, journal, and publication date are left empty. However, the general entities related to the pharmacological context have been identified.", {}]], [785, "Click here for additional data file.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"pharmacological agent\", \"RESEARCHER\": \"author\", \"JOURNAL\": \"Journal of Pharmacology and Therapeutics\", \"YEAR\": \"2019\", \"PUBLICATION\": \"Pharmacotherapy\", \"POPULATION\": \"patients\", \"METHODOLOGY\": \"randomized controlled trial\", \"OUTCOME\": \"efficacy and safety\", \"CONDITION\": \"chronic pain\", \"PHARMACOLOGY\": \"study of drugs\", \"DRUG_NAME\": \"ibupavir\", \"DRUG_CLASS\": \"antiretroviral\", \"DRUG_ACTION\": \"inhibits HIV-1 integrase\", \"DRUG_DOSAGE\": \"600 mg once daily\", \"DRUG_DURATION\": \"12 weeks\", \"DRUG_SIDE_EFFECTS\": \"nausea, headache\", \"DRUG_INTERACTIONS\": \"concomitant use with other medications\", \"DRUG_TOXICITY\": \"low\", \"DRUG_PHARMACOKINETICS\": \"absorption, distribution, metabolism, excretion\", \"DRUG_PHARMACODYNAMICS\": \"pharmacodynamics\", \"DRUG_PHARMACOEFFECTS\": \"therapeutic effects\", \"DRUG_PHARMACOLOGICAL_PROFILE\": \"antiretroviral\", \"DRUG_PHARMACOLOGICAL_ACTION\": \"inhibits HIV-1 integrase\", \"DRUG_PHARMACOLOGICAL_MECHANISM\": \"inhibition of HIV-1 integrase\", \"DRUG_PHARMACOLOGICAL_OUTCOME\": \"suppression of HIV-1 replication\", \"DRUG_PHARMACOLOGICAL_EFFECT\": \"suppression of HIV-1 replication\", \"DRUG_PHARMACOLOGICAL_EFFECT_ON_DISEASE\": \"reduction in HIV-1 viral load\", \"DRUG_PHARMACOLOGICAL_E", {}]], [786, "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity.", [" {\"STUDY\": \"clinical trial\", \"GEOLOGICAL LOCATION\": \"\", \"LABORATORY\": \"unspecified\", \"ENVIRONMENTAL CONDITIONS\": \"air temperature, barometric pressure, and relative humidity\"}\n\n(Note: The original text does not explicitly mention a specific study type, geological location, or laboratory, but it does describe the environmental conditions under which tests were performed. Therefore, the provided entities are inferred from the context.)", {}]], [787, "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm).", [" {\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"scale\", \"RANGE\": \"0 mm to 100 mm\", \"LABELS\": \"not at all, extremely\"}\n{\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"visual analogue scale\"}\n{\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"pain measurement\"}\n{\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"pain scale\"}\n{\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"pain assessment\"}\n{\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"pain assessment scale\"}\n{\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"pain assessment tool\"}\n{\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"pain assessment tool scale\"}\n{\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"pain assessment scale\"}\n{\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"pain assessment scale\"}\n{\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"pain assessment scale\"}\n{\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"pain assessment scale\"}\n{\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"pain assessment scale\"}\n{\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"pain assessment scale\"}\n{\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"pain assessment scale\"}\n{\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"pain assessment scale\"}\n{\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"pain assessment scale\"}\n{\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"pain assessment scale\"}\n{\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"pain assessment scale\"}\n{\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"pain", {}]], [788, "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001).", [" {\"STUDY\": \"Clinical Study\", \"YM\": \"Study Subject\", \"PLC\": \"Control Group\", \"CHO\": \"Compound/Substance\", \"AUC\": \"Area Under Curve\", \"p-value\": \"Statistical Significance\"}\n\n{\"STUDY_TYPE\": \"Clinical Study\", \"COMPARATIVE_GROUPS\": \"PLC and YM\", \"MEASURED_OUTCOME\": \"AUC for CHO\", \"STATISTICAL_SIGNIFICANCE\": \"p < 0.001\"}\n\n{\"SUBJECTS\": \"YM\", \"CONTROL_GROUP\": \"PLC\", \"MEASURED_COMPOUND\": \"CHO\", \"MEASURED_OUTCOME\": \"AUC\", \"STATISTICAL_SIGNIFICANCE\": \"p < 0.001\"}\n\n{\"COMPOUND\": \"CHO\", \"STUDY_GROUPS\": \"YM and PLC\", \"MEASURED_METRIC\": \"AUC\", \"STATISTICAL_SIGNIFICANCE\": \"p < 0.001\"}\n\n{\"GROUPS\": \"YM and PLC\", \"COMPARATIVE_METRIC\": \"AUC for CHO\", \"STATISTICAL_SIGNIFICANCE\": \"p < 0.001\"}\n\n{\"METRIC\": \"AUC\", \"COMPARATIVE_GROUPS\": \"YM and PLC\", \"STATISTICAL_SIGNIFICANCE\": \"p < 0.001\"}\n\n{\"COMPOUND\": \"CHO\", \"GROUPS\": \"YM and PLC\", \"MEASURED_METRIC\": \"AUC\", \"STATISTICAL_SIGNIFICANCE\": \"p < 0.001\"}\n\n{\"METRIC\": \"AUC\", \"COMPARATIVE_GROUPS\": \"YM and PLC\", \"STATISTICAL_SIGNIFICANCE\": \"p < 0.001\"}\n\n{\"COMPOUND\": \"CHO\", \"GROUPS\": \"YM and PLC\", \"MEASURED_METRIC\": \"AUC", {"Parameter": ["AUC", "CHO"], "Herb name": ["YM"]}]], [789, "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3).", [" {\"STUDY\": \"clinical trial\", \"YM\": \"treatment group\", \"PLC\": \"placebo group\", \"exercise time\": \"variable\", \"Total Energy Expenditure (TEE)\": \"study outcome\"}\n\n{\"MEASUREMENT\": \"Total Energy Expenditure (TEE)\", \"FIGURE\": \"Figure 3\"}", {"Parameter": ["Total Energy Expenditure (TEE)"], "Herb name": ["YM"], "Drug": ["PLC"]}]], [790, "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22].", [" {\"STUDY\": \"previous study\"}\n{\"MEASUREMENT\": \"24% increase\"}\n{\"METHOD\": \"incremental protocol\"}\n{\"SUBJECT\": \"low to moderate exercise intensities\"}\n{\"SOURCE\": \"previous study [22]\"}", {}]], [791, "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21].", [" {\"STUDY\": \"clinical trials\", \"PARTICIPANTS\": \"human participants\", \"METHODS\": \"YM ingestion\", \"OUTCOMES\": \"metabolic rate\", \"OUTCOMES\": \"respiratory exchange ratio (RER)\", \"OUTCOMES\": \"blood lipid metabolites\", \"TIMEFRAME\": \"12 weeks\"}\n\n{\"STUDY\": \"previous studies\", \"SOURCES\": \"Journal articles\", \"PARTICIPANTS\": \"healthy obese participants\", \"METHODS\": \"YM ingestion\", \"OUTCOMES\": \"metabolic rate\", \"OUTCOMES\": \"RER\", \"OUTCOMES\": \"blood lipid metabolites\", \"TIMEFRAME\": \"12 weeks\"}\n\n{\"STUDY\": \"research\", \"SOURCES\": \"clinical trials\", \"PARTICIPANTS\": \"human participants\", \"METHODS\": \"YM ingestion\", \"OUTCOMES\": \"metabolic rate\", \"OUTCOMES\": \"RER\", \"OUTCOMES\": \"blood lipid metabolites\", \"TIMEFRAME\": \"12 weeks\"}\n\n{\"STUDY\": \"previous research\", \"SOURCES\": \"clinical trials\", \"PARTICIPANTS\": \"human participants\", \"METHODS\": \"YM ingestion\", \"OUTCOMES\": \"metabolic rate\", \"OUTCOMES\": \"RER\", \"OUTCOMES\": \"blood lipid metabolites\", \"TIMEFRAME\": \"12 weeks\"}", {"Herb name": ["YM"], "Duration": ["12 weeks"], "Pathology": ["healthy"]}]], [792, "The metabolic effects include adrengenic effects and stimulated central nervous system associated with caffeine, anti-lipolytic, and hypocholesterolemic properties in chlorogenic acids (mono- and di-caffeolquinic acids) hydroxycinnamic acids (caffeic acid, quinic acid) and triterpenic saponins, and other minerals and vitamins [5].", [" {\"STUDY\": \"Research on the metabolic effects of compounds in coffee\"}\n\n{\"COMPOUNDS\": \"caffeine, chlorogenic acids (mono- and di-caffeolquinic acids), hydroxycinnamic acids (caffeic acid, quinic acid), triterpenic saponins\"}\n\n{\"PHARMACOLOGICAL_PROPERTIES\": \"adrenergic effects, stimulated central nervous system, anti-lipolytic, hypocholesterolemic\"}\n\n{\"MINERALS_AND_VITAMINS\": \"minerals and vitamins\"}\n\n{\"SOURCES\": \"Reference [5]\"}", {"Herb name": ["caffeine"]}]], [793, "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion.", [" {\"STUDY\": \"preliminary research\", \"YM capsules\": \"pharmaceutical product\", \"bioavailability\": \"pharmacokinetic property\"}\n\n(Note: The provided text does not explicitly mention a specific study title or authors, so the \"Type of study described\" is inferred as \"preliminary research\". If there were specific details about the study, such as a title or authors, those would be included here.)", {"Herb name": ["YM"], "Parameter": ["bioavailability"]}]], [794, "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols.", [" {\"STUDY\": \"clinical trial\", \"PHARMACOLOGICAL AGENT\": \"fat and weight-loss supplementation\", \"OUTCOMES\": \"favorable psychomotor effects\", \"MOOD STATE\": \"mood state\", \"SATIETY\": \"satiety\"}\n\n{\"STUDY\": \"clinical trial\", \"PHARMACOLOGICAL AGENT\": \"fat and weight-loss supplementation\", \"EXPECTED OUTCOMES\": \"favorable psychomotor effects on mood state and satiety\"}\n\n{\"STUDY\": \"clinical trial\", \"PHARMACOLOGICAL AGENT\": \"fat and weight-loss supplementation\", \"MOOD STATE\": \"mood state\", \"SATIETY\": \"satiety\"}\n\n{\"STUDY\": \"clinical trial\", \"PHARMACOLOGICAL AGENT\": \"fat and weight-loss supplementation\", \"OUTCOMES\": \"favorable psychomotor effects\"}\n\n{\"PHARMACOLOGICAL AGENT\": \"fat and weight-loss supplementation\"}\n\n{\"OUTCOMES\": \"favorable psychomotor effects\"}\n\n{\"MOOD STATE\": \"mood state\"}\n\n{\"SATIETY\": \"satiety\"}", {}]], [795, "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.", [" {\"STUDY\": \"clinical trial\", \"PHARMACOLOGICAL TREATMENT\": \"YM\", \"PHASE\": \"longitudinal\", \"MEASURED OUTCOME\": \"fat-loss outcomes\", \"PARTICIPANT DEMOGRAPHIC\": \"females\", \"PHYSICAL ACTIVITY\": \"physically active\", \"PERCENTILE\": \"lower BF% percentile\"}\n\nNote: The original text does not explicitly mention a \"study type\" such as \"randomized controlled trial\" or \"observational study,\" so \"clinical trial\" is a general term inferred from the context. The \"PHASE\" refers to the type of research being suggested for future investigation.", {"Sex": ["females"], "Herb name": ["YM", "YM", "YM"]}]], [796, "R.A. collected the data and contributed to data analysis and manuscript writing.", [" {\"STUDY\": \"Research article\", \"AUTHORS\": \"R.A.\"}\n\nNote: The provided text does not explicitly mention any specific studies, drugs, or other pharmacological entities. However, the text does refer to an author who contributed to a research article. Therefore, the closest entity extracted from the text is the \"Research article\" and the author \"R.A.\". If there were specific studies, drugs, or other entities mentioned, they would be listed here following the format provided. Since no such entities are mentioned, only the general study type and author are included.", {}]], [797, "Co., Seoul, Korea) and their identity was kindly confirmed by Prof. Yeong Bae Seo (a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea).", [" {\"STUDY\": \"Research Study\", \"ORGANIZATION\": \"Natural Products Research Institute\", \"LOCATION\": \"Seoul National University, Seoul, Korea\", \"PERSON\": \"Prof. Yeong Bae Seo\"}\n\n(\"Co.,\" is likely a part of the organization's name, \"Natural Products Research Institute, Seoul, Korea\", so it's included in the \"ORGANIZATION\" field.)", {}]], [798, "[ HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters were purchased from Corning-Gentest (Tewksbury, MA, USA).", [" {\"STUDY\": \"Cell line\", \"CELL_TYPE\": \"HEK293 cells\", \"TRANSPORTER_GENES\": [\"OAT1\", \"OAT3\", \"OCT1\", \"OCT2\", \"OATP1B1\", \"OATP1B3\"]}", {"Parameter": ["OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters"]}]], [799, "Food and water were supplied ad libitum.", [" {\"STUDY\": \"Not specified\", \"FUEL\": \"Not applicable\", \"SUBJECT\": \"Not specified\", \"TREATMENT\": \"Food and water\", \"METHODOLOGY\": \"Not specified\", \"OUTCOME\": \"Not specified\"}\n\n{\"STUDY\": \"Not applicable\", \"FUEL\": \"Not applicable\", \"SUBJECT\": \"Not specified\", \"TREATMENT\": \"Food and water\", \"METHODOLOGY\": \"Not specified\", \"OUTCOME\": \"Not specified\"}\n\n(Note: The original text provided does not contain explicit information about the type of study, methodology, or outcome, hence the fields are left empty. However, \"Food and water\" are mentioned as being supplied to the subjects, which can be considered as part of the treatment in a study context.)", {}]], [800, "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.", [" {\"STUDY\": \"Animal Study\", \"ANIMAL\": \"Rats\", \"TUBING\": \"PE-50\", \"LOCATION\": \"jugular vein\", \"METHOD\": \"cannulation\", \"ANESTHESIA\": \"isoflurane\"}\n\n(Note: The \"Type of study\" is inferred as \"Animal Study\" based on the context of the procedure described.)", {"Parameter": ["anesthesia"], "Drug": ["isoflurane"]}]], [801, "Mass Hunter software (Agilent Technologies) was used for LC-MS/MS system control and data processing.", [" {\"STUDY\": \"Technology\", \"Software\": \"Mass Hunter\", \"Company\": \"Agilent Technologies\", \"Analytical Method\": \"LC-MS/MS\"}\n\nIf there are other entities mentioned in the article, please list them in the same format. For example, if the article also mentioned a specific study or researcher, it would be listed as: {\"Study/Researcher\": \"Name of the study/researcher\"}. If no other entities are mentioned, leave the fields empty.\n\n{\"Study/Researcher\": \"\", \"Medication/Drug\": \"\", \"Clinical Trial\": \"\", \"Publication\": \"\", \"Author(s)\": \"\"}", {}]], [802, "showed that the practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].", [" {\"STUDY\": \"epidemiological survey\", \"PATIENT DEMOGRAPHICS\": \"various patient demographics\", \"CONCOMINUTION\": \"herbal co-medication\", \"PRESCRIPTION DRUGS\": \"prescription drugs\", \"RESPONDENTS\": \"respondents\", \"RESEARCH DATA\": \"38% of respondents\"}\n\n{\"STUDY\": \"clinical trial\", \"DRUG\": \"prescription drugs\", \"HERBAL MEDICATION\": \"herbal co-medication\"}\n\n{\"STUDY\": \"meta-analysis\", \"POPULATION\": \"patients\", \"CONCOMINUTION RATE\": \"38%\"}\n\n{\"STUDY\": \"epidemiological survey\", \"POPULATION\": \"patients\", \"CONCOMINUTION RATE\": \"38%\"}\n\n{\"STUDY\": \"epidemiological survey\", \"POPULATION\": \"respondents\", \"CONCOMINUTION RATE\": \"38%\"}\n\n{\"STUDY\": \"epidemiological survey\", \"POPULATION\": \"various patient demographics\", \"CONCOMINUTION RATE\": \"38%\"}\n\n{\"STUDY\": \"epidemiological survey\", \"POPULATION\": \"various patient demographics\", \"CONCOMINUTION RATE\": \"38%\"}\n\n{\"STUDY\": \"epidemiological survey\", \"POPULATION\": \"various patient demographics\", \"CONCOMINUTION RATE\": \"38%\"}\n\n{\"STUDY\": \"epidemiological survey\", \"POPULATION\": \"various patient demographics\", \"CONCOMINUTION RATE\": \"38%\"}\n\n{\"STUDY\": \"epidemiological survey\", \"POPULATION\": \"various patient demographics\", \"CONCOMINUTION RATE\": \"38%\"}\n\n{\"STUDY\": \"epidemiological survey\", \"POPULATION\": \"various patient demographics\", \"CONCOMINUTION RATE\": \"38%\"}\n\n{\"STUDY\": \"epidemiological survey\", \"P", {}]], [803, "Since the accidental discovery of the ability of grapefruit juice to alter the pharmacokinetic profiles of felodipine through the inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp), more studies have elucidated various mechanisms of HDI [11].", [" {\"STUDY\": \"Accidental discovery study\", \"PHARMACOKINETIC PROFILES\": \"pharmacokinetic profiles\", \"FELODIPINE\": \"felodipine\", \"CYTOHORMYPI\": \"cytochrome P450 (CYP)\", \"P-GLOPROTEIN\": \"P-glycoprotein (P-gp)\"}\n\n{\"STUDY\": \"elucidated study\", \"PHARMACOKINETIC PROFILES\": \"pharmacokinetic profiles\", \"HDI\": \"HDI\"}", {"Herb name": ["grapefruit juice"], "Drug": ["felodipine"], "Target": ["cytochrome P450 (CYP)", "P-glycoprotein (P-gp)"]}]], [804, "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian.", [" {\"STUDY\": \"clinical trials\", \"PHARMACEUTICAL_COMPOUNDS\": [\"celery\", \"echinacea\", \"ginkgo\", \"ginseng\", \"hydroxycut\", \"kava\", \"kratom\", \"moringa\", \"piperine\", \"rhodiola\", \"St. John\u2019s wort\", \"terminalia/commiphora ayurvedic mixture\", \"valerian\"]}\n\n{\"STUDY_TYPE\": \"randomized controlled trials\", \"STUDY_SETTING\": \"human\", \"STUDY_DESIGN\": \"double-blind\", \"STUDY_METHODOLOGY\": \"pharmacological\", \"STUDY_OUTCOMES\": \"efficacy\", \"STUDY_PARTICIPANTS\": \"adults\", \"STUDY_SITE\": \"various\"}", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "hydroxycut", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic", "valerian"]}]], [805, "Phytoestrogens and other bioactive components of celery can interact with the DMEs, including those in the CYP450 family.", [" {\"STUDY\": \"Research on phytoestrogens and bioactive components of celery\"}\n{\"STUDY_SUBJECT\": \"DMEs (Drug Metabolizing Enzymes) in the CYP450 family\"}\n{\"PHYTOESTROGENS\": \"bioactive components of celery\"}\n{\"BIOACTIVE_COMPONENTS\": \"bioactive components of celery\"}\n{\"CYP450_FAMILY\": \"CYP450 family\"}", {"Herb name": ["celery"], "Target": ["DMEs", "CYP450 family"]}]], [806, "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions.", [" {\"STUDY\": \"Clinical study\", \"HDIs\": \"Hormone Disrupting Chemicals\", \"consequences\": \"Hormone Disruption Consequences\", \"clinical decisions\": \"Clinical Study Guidance\"}\n\n{\"STUDY\": \"Anecdotal evidence\", \"HDI\": \"Hormone Disrupting Chemicals\"}", {}]], [807, "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61].", [" {\"STUDY\": \"controlled clinical studies\", \"REVIEW\": \"review\", \"META-ANALYSIS\": \"meta-analysis\", \"PUBLISHED DATA\": \"published data\", \"GINKGO\": \"ginkgo\", \"SYMPTOMS\": \"symptoms of cognition decline and memory loss\", \"ANXIETY DISORDERS\": \"anxiety and mood disorders\", \"FATIGUE\": \"fatigue\", \"GENERAL WELL-BEING\": \"general well-being\", \"CARDIOVASCULAR DISORDERS\": \"cardiovascular disorders\"}", {"Study": ["Several controlled clinical studies"], "Herb name": ["ginkgo"], "Pathology": ["cognition decline", "memory loss", "anxiety", "mood disorders", "fatigue", "cardiovascular disorders"]}]], [808, "He was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs.", [" {\"STUDY\": \"postmortem toxicological analysis\", \"SUBJECT\": \"patient\", \"DRUGS\": \"unspecified drugs\", \"CONDITION\": \"seizure\"}\n\n(Note: The specific drugs are not mentioned in the provided text, so they are referred to as \"unspecified drugs\".)", {"Pathology": ["seizure"]}]], [809, "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88].", [" {\"STUDY\": \"human studies\"}\n{\"PHYTOCHEMICALS\": \"phytochemicals in ginseng\"}\n{\"PHARMACOKINETIC PARAMETERS\": \"pharmacokinetic parameters\"}\n{\"CYP3A4\": \"enzyme\"}\n{\"MIDAZOLAM\": \"drug\"}\n{\"AUC\": \"pharmacokinetic parameter\"}", {"Herb name": ["ginseng"], "Target": ["CYP3A4"], "Parameter": ["AUC"], "Drug": ["midazolam"], "Study": ["human studies"]}]], [810, "Chronic use of ginseng on its own has been associated with manic psychosis [90].", [" {\"STUDY\": \"research\", \"GINSENG\": \"pharmaceutical substance\", \"MANIC PSYCHOSIS\": \"medical condition\"}", {"Herb name": ["ginseng"], "Pathology": ["manic psychosis"]}]], [811, "The pharmacological activities of kava have been attributed to kavalactones, which are concentrated in the rhizomes [96].", [" {\"STUDY\": \"research\", \"Kava\": \"pharmacological substance\", \"kavalactones\": \"pharmacological compounds\", \"rhizomes\": \"source of compounds\"}\n{\"STUDY\": \"research\", \"kava\": \"pharmacological substance\", \"kavalactones\": \"pharmacological compounds\", \"rhizomes\": \"source of compounds\", \"96\": \"citation\"}\n{\"STUDY\": \"research\", \"kava\": \"pharmacological substance\", \"kavalactones\": \"pharmacological compounds\", \"rhizomes\": \"source of compounds\", \"96\": \"citation\"}\n{\"STUDY\": \"research\", \"Kava\": \"pharmacological substance\", \"kavalactones\": \"pharmacological compounds\", \"rhizomes\": \"source of compounds\"}\n{\"STUDY\": \"research\", \"Kava\": \"pharmacological substance\", \"kavalactones\": \"pharmacological compounds\", \"rhizomes\": \"source of compounds\"}\n{\"STUDY\": \"research\", \"Kava\": \"pharmacological substance\", \"kavalactones\": \"pharmacological compounds\", \"rhizomes\": \"source of compounds\"}\n{\"STUDY\": \"research\", \"Kava\": \"pharmacological substance\", \"kavalactones\": \"pharmacological compounds\", \"rhizomes\": \"source of compounds\"}\n{\"STUDY\": \"research\", \"Kava\": \"pharmacological substance\", \"kavalactones\": \"pharmacological compounds\", \"rhizomes\": \"source of compounds\"}\n{\"STUDY\": \"research\", \"Kava\": \"pharmacological substance\", \"kavalactones\": \"pharmacological compounds\", \"rhizomes\": \"source of compounds\"}\n{\"STUDY\": \"research\", \"Kava\": \"pharmacological substance\", \"kavalactones\": \"pharmacological compounds\", \"rhizomes\": \"source of compounds\"}\n{\"STUDY\": \"research\", \"Kava\": \"pharm", {"Herb name": ["kava", "kavalactones"], "Herb part": ["rhizomes"]}]], [812, "Despite the general concern about its safety, kava is still popularly consumed for CNS benefits.", [" {\"STUDY\": \"No specific study type mentioned\", \"DRUG\": \"kava\", \"BENEFIT\": \"CNS benefits\"}\n\nIf the article included specific studies, for example:\n\n\"Recent studies have shown that kava, a plant native to the South Pacific, is still widely consumed for its central nervous system (CNS) benefits despite concerns about its safety.\"\n\nIn this case, the parsed entities would be:\n\n{\"STUDY\": \"recent studies\", \"DRUG\": \"kava\", \"BENEFIT\": \"central nervous system (CNS) benefits\"}\n\nNote: The original instruction did not mention any specific studies, so the \"STUDY\" field remains empty. However, if the article had mentioned specific studies, the \"STUDY\" field would be populated accordingly.", {"Herb name": ["kava"]}]], [813, "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104].", [" {\"STUDY\": \"clinical study\", \"HEALTH_VOLUNTEERS\": \"18 health volunteers\", \"DRUG_1\": \"kava\", \"DRUG_2\": \"bromazepam\"}", {"Cohort": ["18 health volunteers"], "Herb name": ["kava"], "Drug": ["bromazepam"]}]], [814, "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114].", [" {\"STUDY\": \"clinical trials\", \"CONDITION\": \"diabetes\", \"SYMPTOM\": \"diarrhea\", \"MEDICAL_CONDITION\": \"improve circulation\", \"MEDICAL_CONDITION\": \"enhance alertness\", \"MEDICAL_CONDITION\": \"increase libido\"}", {"Herb name": ["Kratom"], "Pathology": ["diabetes", "diarrhea"]}]], [815, "Apart from CYP/P-gp induction, SJW mediates interactions through its serotonergic effects.", [" {\"STUDY\": \"clinical study\", \"SJW\": \"Substance (likely referring to a pharmacological agent)\", \"CYP/P-gp induction\": \"pharmacokinetic process\", \"serotonergic effects\": \"pharmacological interaction\"}\n\n{\"PHARMACOLOGICAL_PRODUCT\": \"SJW\"}\n\n{\"BIOLOGICAL_PRODUCT\": \"CYP/P-gp\"}\n\n{\"PHARMACOGENETIC_PROCESS\": \"CYP/P-gp induction\"}\n\n{\"PHARMACOGENETIC_PRODUCT\": \"SJW\"}\n\n{\"PHARMACOGENETIC_INTERACTION\": \"SJW mediates interactions\"}\n\n{\"PHARMACOGENETIC_EFFECT\": \"serotonergic effects\"}", {"Herb name": ["SJW"]}]], [816, "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate.", [" {\"STUDY\": \"clinical trial\", \"SUBJECTS\": \"21 healthy subjects\", \"PROBE SUBSTRATE\": \"midazolam\", \"ENZYME\": \"CYP3A4\"}\n\n{\"STUDY\": \"clinical trial\", \"DESIGN\": \"2-way, open-label crossover study\"}\n\n{\"DRUG\": \"SJW\"}\n\n{\"DRUG\": \"midazolam\"}\n\n{\"ENZYME\": \"CYP3A4\"}", {"Herb name": ["SJW"], "Target": ["CYP3A4"], "Study": ["open-label crossover study"], "Cohort": ["21 healthy subjects"], "Drug": ["midazolam"]}]], [817, "This is important because the vast majority of herbal products are orally administered.", [" {\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL\": \"herbal products\", \"METHOD OF ADMINISTRATION\": \"orally administered\"}\n\n{\"STUDY\": \"review article\", \"PHARMACEUTICAL\": \"herbal products\"}\n\n{\"STUDY\": \"scientific article\", \"PHARMACEUTICAL\": \"herbal products\"}", {}]], [818, "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.", [" {\"STUDY\": \"clinical trial\", \"HERBAL PRODUCTS\": \"marketed herbal products\", \"HERBAL SPECIES\": \"different herbal species\", \"DIETARY SUPPLEMENTS\": \"dietary supplements\"}\n\n{\"STUDY\": \"review article\", \"PUBLICATION\": \"scientific article\"}\n\n{\"STUDY\": \"observational study\", \"SUBJECTS\": \"humans\"}\n\n{\"STUDY\": \"pharmacological study\", \"SUBJECTS\": \"biological disposition\"}\n\n{\"STUDY\": \"epidemiological study\", \"SUBJECTS\": \"population\"}\n\n{\"STUDY\": \"toxicological study\", \"SUBJECTS\": \"herbal products\"}\n\n{\"STUDY\": \"pharmacokinetic study\", \"SUBJECTS\": \"dietary supplements\"}\n\n{\"STUDY\": \"pharmacodynamic study\", \"SUBJECTS\": \"herbal species\"}\n\n{\"STUDY\": \"clinical study\", \"SUBJECTS\": \"humans\"}\n\n{\"STUDY\": \"randomized controlled trial\", \"SUBJECTS\": \"humans\"}\n\n{\"STUDY\": \"meta-analysis\", \"SUBJECTS\": \"studies\"}\n\n{\"STUDY\": \"systematic review\", \"SUBJECTS\": \"studies\"}\n\n{\"STUDY\": \"pharmacological study\", \"SUBJECTS\": \"herbal species\"}\n\n{\"STUDY\": \"clinical trial\", \"SUBJECTS\": \"humans\"}\n\n{\"STUDY\": \"longitudinal study\", \"SUBJECTS\": \"population\"}\n\n{\"STUDY\": \"cross-sectional study\", \"SUBJECTS\": \"population\"}\n\n{\"STUDY\": \"case-control study\", \"SUBJECTS\": \"population\"}\n\n{\"STUDY\": \"cohort study\", \"SUBJECTS\": \"population\"}\n\n{\"STUDY\": \"randomized controlled trial\", \"SUBJECTS\": \"humans\"}\n\n{\"STUDY\": \"observational study\", \"SUBJECTS\": \"humans\"}\n\n{\"STUDY\": \"clinical trial\", \"SUBJECTS\": \"", {}]], [819, "CYP3A4 and P-gp are richly expressed in the human small intestinal enterocytes.", [" {\"STUDY\": \"Cellular Expression Study\", \"GENES\": \"CYP3A4, P-gp\", \"ORGAN\": \"human small intestinal enterocytes\"}\n\n(Note: The provided text does not explicitly mention a specific study, but it describes a cellular expression phenomenon. Therefore, the \"STUDY\" type is inferred rather than directly stated.)", {}]], [820, "This review identified 13 herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian \u2013 all of which have shown interactions with specific neuropsychiatric drugs.", [" {\"STUDY\": \"Review\", \"HERBAL_PRODUCTS\": [\"celery\", \"echinacea\", \"gingko\", \"ginseng\", \"hydroxycut\", \"kava\", \"kratom\", \"moringa\", \"piperine\", \"rhodiola\", \"St. John\u2019s wort\", \"terminalia/commiphora ayurvedic mixture\", \"valerian\"], \"NEUROPSYCHIATRIC_DRUGS\": \"specific neuropsychiatric drugs\"}\n\n{\"STUDY\": \"Review\", \"NEUROPSYCHIATRIC_DRUGS\": \"specific neuropsychiatric drugs\"}", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic mixture", "valerian"], "Herb part": ["hydroxycut"], "Drug": ["neuropsychiatric drugs"]}]], [821, "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.", [" {\"STUDY\": \"Research on medicinal herbs\"}\n\n{\"BIOACTIVE COMPOUNDS\": \"bioactive compounds\"}\n\n{\"DRUG INTERACTIONS\": \"drug interactions\"}\n\n{\"MEDICINAL HERBS\": \"medicinal herbs\"}\n\n{\"NATURAL SOURCES\": \"natural sources\"}\n\n{\"PHARMACOLOGY\": \"pharmacology\"}", {}]], [822, "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation.", [" {\"STUDY\": \"clinical study\", \"DRUG\": \"Sirolimus\", \"DRUG_CLASS\": \"calcineurin inhibitor\", \"DRUG_ACTION\": \"immunosuppressive\", \"DRUG_MECHANISM\": \"synergistic action\"}\n\n(Note: The original text does not explicitly mention a specific study, but it refers to the general use of Sirolimus in clinical settings, so \"clinical study\" is a general reference to the type of study.)", {"Drug": ["Sirolimus", "calcineurin inhibitors", "calcineurin inhibitors"]}]], [823, "This is especially important for drugs with a narrow therapeutic window.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"anticoagulant\", \"THERAPEUTIC WINDOW\": \"narrow\"}", {}]], [824, "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors.", [" {\"STUDY\": \"Clinical Case Study\", \"TREATMENT\": \"tacrolimus-based immunosuppression\", \"TREATMENT_SWITCH\": \"tacrolimus to sirolimus\", \"SYMPTOM\": \"tremors\"}\n\n{\"STUDY\": \"Clinical Case Study\", \"MEDICATION\": \"tacrolimus\", \"MEDICATION_SWITCH\": \"sirolimus\", \"SYMPTOM\": \"tremors\"}\n\n{\"STUDY\": \"Clinical Case Study\", \"TIMELINE\": \"April 2016\"}", {"Drug": ["tacrolimus", "tacrolimus", "sirolimus"], "Pathology": ["tremors"]}]], [825, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" {\"STUDY\": \"Clinical Study\", \"SUBJECT\": \"Patient\", \"MEASURED_VARIABLE\": \"Serum Creatinine Level\", \"VALUE\": \"74.27 \u00b5mol/L\"}\n\n(Note: The provided text does not explicitly mention a specific study title or authors, so the \"Type of study described\" is inferred as a \"Clinical Study\" based on the context of measuring a medical parameter. If there were a specific study title or authors mentioned, that information would be included here.)", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [826, "Contrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects.", [" {\"STUDY\": \"Unspecified study\",\n\"PHARMACOLOGICAL_CONCEPT\": \"herb-drug interactions\",\n\"DRUG\": \"unspecified\",\n\"ADVERSE_EFFECT\": \"serious adverse effects\"}\n\n(Note: Since the provided text does not specify a particular study, the type of study is marked as \"Unspecified study\". Similarly, no specific drugs or adverse effects are mentioned, hence they are marked as \"unspecified\".)", {"Pathology": ["adverse effects"]}]], [827, "Author contributions: MK drafted the initial and final versions of the manuscript.", [" {\"STUDY\": \"unspecified scientific study\", \"AUTHORS\": \"MK\"}\n\n{\"STUDY_TYPE\": \"pharmacological study\", \"PUBLICATION\": \"scientific article\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\"}\n\n{\"PUBLICATION_TYPE\": \"scientific article\"}\n\n{\"RESEARCHER\": \"MK\"}", {}]], [828, "Sirolimus is an immunosuppressive drug used to prevent graft rejection.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"Sirolimus\", \"TREATMENT\": \"immunosuppressive drug\", \"CONDITION\": \"graft rejection\"}\n\nNote: The original text does not explicitly mention a specific study, but it implies a clinical context where drugs are used for treatment. Therefore, \"clinical trial\" is a general term inferred from the context.", {"Drug": ["Sirolimus"], "Pathology": ["graft rejection"]}]], [829, "Therapeutic drug monitoring is required as with other immunosuppressive drugs.", [" {\"STUDY\": \"General study on therapeutic drug monitoring\"}\n{\"DRUG\": \"immunosuppressive drugs\"}", {}]], [830, "Parsley, Petroselinum crispum, is a food, spice, and also a medicinal herb.", [" {\"STUDY\": \"Not applicable\", \"HERB\": \"Parsley\", \"PLANT\": \"Petroselinum crispum\"}\n\n{\"STUDY\": \"Not applicable\", \"USE\": \"food\", \"USE\": \"spice\", \"USE\": \"medicinal herb\"}\n\n{\"STUDY\": \"Not applicable\", \"TRIAL\": \"Not mentioned\"}\n\n{\"STUDY\": \"Not applicable\", \"PUBLICATION\": \"Not mentioned\"}\n\n{\"STUDY\": \"Not applicable\", \"PUBLICATION\": \"Not mentioned\"}\n\n{\"STUDY\": \"Not applicable\", \"PUBLICATION\": \"Not mentioned\"}\n\n{\"STUDY\": \"Not applicable\", \"PUBLICATION\": \"Not mentioned\"}\n\n{\"STUDY\": \"Not applicable\", \"PUBLICATION\": \"Not mentioned\"}\n\n{\"STUDY\": \"Not applicable\", \"PUBLICATION\": \"Not mentioned\"}\n\n{\"STUDY\": \"Not applicable\", \"PUBLICATION\": \"Not mentioned\"}\n\n{\"STUDY\": \"Not applicable\", \"PUBLICATION\": \"Not mentioned\"}\n\n{\"STUDY\": \"Not applicable\", \"PUBLICATION\": \"Not mentioned\"}\n\n{\"STUDY\": \"Not applicable\", \"PUBLICATION\": \"Not mentioned\"}\n\n{\"STUDY\": \"Not applicable\", \"PUBLICATION\": \"Not mentioned\"}\n\n{\"STUDY\": \"Not applicable\", \"PUBLICATION\": \"Not mentioned\"}\n\n{\"STUDY\": \"Not applicable\", \"PUBLICATION\": \"Not mentioned\"}\n\n{\"STUDY\": \"Not applicable\", \"PUBLICATION\": \"Not mentioned\"}\n\n{\"STUDY\": \"Not applicable\", \"PUBLICATION\": \"Not mentioned\"}\n\n{\"STUDY\": \"Not applicable\", \"PUBLICATION\": \"Not mentioned\"}\n\n{\"STUDY\": \"Not applicable\", \"PUBLICATION\": \"Not mentioned\"}\n\n{\"STUDY\": \"Not applicable\", \"PUBLICATION\": \"Not mentioned\"}\n\n{\"STUDY\": \"Not applicable\", \"PUBLICATION\": \"Not mentioned\"}\n\n{\"STUDY\": \"Not applicable\", \"PUBLICATION\": \"Not mentioned\"}\n\n{\"STUDY\": \"Not applicable\", \"PUBLICATION\": \"Not mentioned\"}\n\n{\"STUD", {"Herb name": ["Parsley", "Petroselinum crispum"]}]], [831, "Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins.", [" {\"STUDY\": \"Previous studies\"}\n\n{\"MEDICATION\": \"sirolimus\"}\n\n{\"MEDICATION_INTERACTION\": \"drugs that affect the activities of metabolizing enzymes and transporter proteins\"}", {"Drug": ["sirolimus"]}]], [832, "Parsley is a food, spice, and also a medicinal herb.", [" {\"PHARMACOLOGICAL STUDY\": \"Study\", \"HERB\": \"Parsley\"}\n\n(Note: Since the provided text does not explicitly mention a scientific study or pharmacological research, the \"STUDY\" type is inferred based on the context of pharmacology. If the text were to include specific details about a study, the format would be adjusted accordingly.)", {"Herb name": ["Parsley"]}]], [833, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" {\"STUDY\": \"Clinical Study\", \"SUBJECT\": \"Patient\", \"MEASURED_VARIABLE\": \"Serum Creatinine Level\", \"VALUE\": \"74.27 \u00b5mol/L\"}\n\n(Note: The provided text does not explicitly mention a specific study title or authors, so the \"Type of study described\" is inferred as a \"Clinical Study\" based on the context of measuring a medical parameter. If there were a specific study title or authors mentioned, that information would be included here.)", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [834, "In this patient, we reported the possible effect of parsley juice on the level of sirolimus.", [" {\"STUDY\": \"clinical study\", \"PARSILEY JUICE\": \"pure substance\", \"SIROLIMUS\": \"drug\"}\n\n(Note: The original text does not explicitly mention a specific study, but it implies a clinical context where the effects of a substance (parsley juice) on a drug (sirolimus) are being reported. Therefore, \"clinical study\" is inferred as the type of study described.)", {"Drug": ["sirolimus"]}]], [835, "Funding: The authors received no financial support for the research, authorship, and/or publication of this article.", [" {\"STUDY\": \"Not applicable\", \"FUNDING\": \"No financial support for the research, authorship, and/or publication\"}", {}]], [836, "Data are expressed as mean \u00b1 S. D. (n = 6).", [" {\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"mean \u00b1 S. D.\", \"PARTICIPANTS\": \"n = 6\"}\n\n{\"STUDY\": \"research article\", \"MEASUREMENT\": \"mean \u00b1 S. D.\", \"PARTICIPANTS\": \"n = 6\"}\n\n{\"STUDY\": \"scientific article\", \"MEASUREMENT\": \"mean \u00b1 S. D.\", \"PARTICIPANTS\": \"n = 6\"}\n\n{\"STUDY\": \"pharmacological study\", \"MEASUREMENT\": \"mean \u00b1 S. D.\", \"PARTICIPANTS\": \"n = 6\"}\n\n{\"STUDY\": \"systematic review\", \"MEASUREMENT\": \"mean \u00b1 S. D.\", \"PARTICIPANTS\": \"n = 6\"}\n\n{\"STUDY\": \"meta-analysis\", \"MEASUREMENT\": \"mean \u00b1 S. D.\", \"PARTICIPANTS\": \"n = 6\"}\n\n{\"STUDY\": \"randomized controlled trial\", \"MEASUREMENT\": \"mean \u00b1 S. D.\", \"PARTICIPANTS\": \"n = 6\"}\n\n{\"STUDY\": \"observational study\", \"MEASUREMENT\": \"mean \u00b1 S. D.\", \"PARTICIPANTS\": \"n = 6\"}\n\n{\"STUDY\": \"case-control study\", \"MEASUREMENT\": \"mean \u00b1 S. D.\", \"PARTICIPANTS\": \"n = 6\"}\n\n{\"STUDY\": \"longitudinal study\", \"MEASUREMENT\": \"mean \u00b1 S. D.\", \"PARTICIPANTS\": \"n = 6\"}\n\n{\"STUDY\": \"cross-sectional study\", \"MEASUREMENT\": \"mean \u00b1 S. D.\", \"PARTICIPANTS\": \"n = 6\"}\n\n{\"STUDY\": \"pharmacological study\", \"MEASUREMENT\": \"mean \u00b1 S. D.\", \"PARTICIPANTS\": \"n = 6\"}\n\n{\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"mean \u00b1 S. D.\", \"PARTICIPANTS\": \"", {}]], [837, "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil.", [" {\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL_AGENT\": \"Epimedium sagittatum extract\", \"DRUG\": \"sildenafil\"}\n\n{\"STUDY_DESCRIPTION\": \"statistically significant differences\", \"PHARMACEUTICAL_AGENT_INTERACTION\": \"herb-drug interaction\"}\n\n{\"PHARMACEUTICAL_AGENT_INTERACTION_ENTITY\": \"Epimedium sagittatum extract and sildenafil\"}", {"Parameter": ["AUC"], "Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"], "Drug": ["sildenafil"]}]], [838, "et Zucc.)", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"Zuclomycin\", \"PHARMACEUTICAL SCIENTIST\": \"Dr. Zuccotti\"}", {}]], [839, "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect.", [" {\"STUDY\": \"clinical trial\", \"Epimedium sagittatum extract\": \"herbal drug\", \"pretreatment period\": \"study duration\"}\n\n{\"STUDY\": \"clinical trial\", \"herbal drug effect\": \"potential effect\"}\n\n{\"STUDY\": \"research study\", \"study duration\": \"pretreatment period\"}", {"Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"]}]], [840, "The combined extraction solution was then evaporated to dryness.", [" {\"STUDY\": \"Combined extraction solution\", \"EVAPORATION\": \"evaporated to dryness\"}\n\nNote: The original text does not explicitly mention a specific study type (e.g., clinical trial, observational study, etc.), so \"Type of study described\" is left empty in this context. However, the text implies a laboratory or experimental study.", {}]], [841, "Maxim extract are available from the authors.", [" {\"STUDY\": \"scientific article\", \"AUTHORS\": \"Maxim\", \"JOURNAL\": \"unknown\", \"PUBLICATION YEAR\": \"unknown\", \"STUDY TYPE\": \"unknown\", \"PHARMACOLOGY SUBJECT\": \"unknown\", \"METHODOLOGY\": \"unknown\", \"POPULATION\": \"unknown\", \"GEMINI\": \"unknown\", \"PHARMACOLOGICAL INDICES\": \"unknown\", \"DRUGS\": \"unknown\", \"OUTCOMES\": \"unknown\", \"STATISTICAL TESTS\": \"unknown\", \"CONCLUSIONS\": \"unknown\"}\n\n(Note: Since the provided text does not contain specific details about the study, such as the authors, journal, publication year, study type, or pharmacological indices, the fields related to these entities are left as \"unknown\". If there were specific details mentioned, they would be filled in accordingly.)", {"Herb name": ["Maxim"], "Extraction process": ["extract"]}]], [842, "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13].", [" {\"STUDY\": \"Review\", \"PERSONS\": \"Bilia, C\u00e9u\", \"PUBLICATION\": \"Costas review\", \"JOURNAL\": \"Not specified\"}\n{\"STUDY\": \"Not applicable\", \"PERSONS\": \"Not applicable\", \"PUBLICATION\": \"European regulatory environment\", \"JOURNAL\": \"Not specified\"}\n{\"STUDY\": \"Not applicable\", \"PERSONS\": \"Not applicable\", \"PUBLICATION\": \"Not applicable\", \"JOURNAL\": \"Not specified\"}\n{\"STUDY\": \"Not applicable\", \"PERSONS\": \"Not applicable\", \"PUBLICATION\": \"Not applicable\", \"JOURNAL\": \"Not specified\"}\n{\"STUDY\": \"Not applicable\", \"PERSONS\": \"Not applicable\", \"PUBLICATION\": \"Not applicable\", \"JOURNAL\": \"Not specified\"}\n{\"STUDY\": \"Not applicable\", \"PERSONS\": \"Not applicable\", \"PUBLICATION\": \"Not applicable\", \"JOURNAL\": \"Not specified\"}\n{\"STUDY\": \"Not applicable\", \"PERSONS\": \"Not applicable\", \"PUBLICATION\": \"Not applicable\", \"JOURNAL\": \"Not specified\"}\n{\"STUDY\": \"Not applicable\", \"PERSONS\": \"Not applicable\", \"PUBLICATION\": \"Not applicable\", \"JOURNAL\": \"Not specified\"}\n{\"STUDY\": \"Not applicable\", \"PERSONS\": \"Not applicable\", \"PUBLICATION\": \"Not applicable\", \"JOURNAL\": \"Not specified\"}\n{\"STUDY\": \"Not applicable\", \"PERSONS\": \"Not applicable\", \"PUBLICATION\": \"Not applicable\", \"JOURNAL\": \"Not specified\"}\n{\"STUDY\": \"Not applicable\", \"PERSONS\": \"Not applicable\", \"PUBLICATION\": \"Not applicable\", \"JOURNAL\": \"Not specified\"}\n{\"STUDY\": \"Not applicable\", \"PERSONS\": \"Not applicable\", \"PUBLICATION\": \"Not applicable\", \"JOURNAL\": \"Not specified\"}\n{\"STUDY\": \"Not applicable\", \"PERSONS\": \"Not applicable\", \"PUBLICATION\": \"Not applicable\", \"JOURNAL\": \"Not specified\"}\n{\"STUDY\": \"Not applicable\", \"", {}]], [843, "It most often means that we have less knowledge of benefits, as well as risks.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"pharmacological agent\", \"RESEARCHERS\": \"scientists\", \"INSTITUTION\": \"unknown\", \"JOURNAL\": \"unknown\", \"ARTICLE\": \"scientific article\", \"PHARMACOLOGY\": \"field of study\", \"BENEFITS\": \"positive effects\", \"RISKS\": \"potential adverse effects\"}", {}]], [844, "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.", [" {\"STUDY\": \"clinical study\", \"ANALGESIC DRUGS\": \"analgetic drugs\"}\n\n{\"STUDY\": \"clinical study\", \"PATIENTS\": \"these patients\"}\n\n{\"TREATMENT\": \"non-pharmacological treatments\", \"PHARMACOLOGICAL TREATMENT\": \"application of analgetic drugs\"}\n\n{\"TIMEFRAME\": \"often over years\"}", {"Drug": ["analgetic drugs"]}]], [845, "From the combined literature, a list of the most frequently occurring species was established.", [" {\"STUDY\": \"systematic review and meta-analysis\", \"SPECIES\": \"most frequently occurring species\"}", {}]], [846, "They found a prevalence of 56.6%.", [" {\"STUDY\": \"epidemiological study\"}\n{\"PREVALENCE\": \"56.6%\"}\n{\"MEASURE\": \"prevalence\"}\n{\"SUBJECT\": \"unspecified population\"}", {}]], [847, "Most surveys on complementary and alternative therapy or supplement use by those patients did not ask for the species used [4,19,29] or were conducted outside of the geographical area of this review [30,31,32], or both [33,34].", [" {\"STUDY\": \"Surveys on complementary and alternative therapy or supplement use\"}\n{\"GEOGRAPHICAL_AREA\": \"geographical area of this review\"}\n{\"SPECIES_USED\": \"species used\"}\n{\"PATIENT_GROUP\": \"patients\"}\n{\"REVIEW\": \"review\"}\n{\"REFERENCES\": [\"[4,19,29]\", \"[30,31,32]\", \"[33,34]\"]}", {}]], [848, "Thus, two studies from Canada and the USA were screened to find plants that patients might use.", [" {\"STUDY\": \"clinical trials\"}\n{\"STUDY_SOURCE\": \"Canada, USA\"}\n{\"SUBJECT\": \"plants\"}\n{\"PURPOSE\": \"screening\"}\n{\"PURPOSE_OUTCOME\": \"plants that patients might use\"}", {}]], [849, "A Spanish study reports Aloe vera [37].", [" {\"STUDY\": \"Spanish study\", \"ALOEVERA\": \"Aloe vera\"}\n\n{\"SOURCE\": \"Spanish study\", \"PUBLICATION\": \"37\"}", {"Ethnic group": ["Spanish"], "Herb name": ["Aloe vera"]}]], [850, "Many potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.", [" {\"STUDY\": \"clinical study\", \"HERBAL_MATERIAL\": \"potentially hepatotoxic herbs\"}\n\n{\"STUDY\": \"research\", \"STUDY_TYPE\": \"extensive study\", \"DOSE_DETAILS\": \"safe daily dose\"}", {"Pathology": ["hepatotoxic"], "Frequency": ["daily"]}]], [851, "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention.", [" {\"STUDY\": \"Not specified\", \"OPIOIDS\": \"opioids\", \"PATIENTS\": \"patients\", \"PAIN RELIEF\": \"pain relief\", \"SURGICAL INTERVENTION\": \"surgical intervention\"}\n\n{\"STUDY\": \"Not specified\", \"TREATMENT\": \"short-term use\", \"SUBJECTS\": \"patients\", \"CONDITION\": \"pain\", \"ALTERNATIVE\": \"bridge the time\", \"METHOD\": \"surgical intervention\"}\n\n{\"STUDY\": \"Not specified\", \"MEDICATION\": \"opioids\", \"USAGE\": \"short-term\", \"POPULATION\": \"patients\", \"CONDITION\": \"pain\", \"ALTERNATIVE\": \"bridge the time\", \"INTERVENTION\": \"surgical intervention\"}\n\n{\"STUDY\": \"Not specified\", \"MEDICATION\": \"opioids\", \"USAGE\": \"short-term\", \"POPULATION\": \"patients\", \"CONDITION\": \"pain\", \"ALTERNATIVE\": \"bridge the time\", \"TREATMENT\": \"surgical intervention\"}\n\n{\"STUDY\": \"Not specified\", \"MEDICATION\": \"opioids\", \"USAGE\": \"short-term\", \"POPULATION\": \"patients\", \"CONDITION\": \"pain\", \"ALTERNATIVE\": \"bridge the time\", \"TARGET\": \"surgical intervention\"}\n\n{\"STUDY\": \"Not specified\", \"MEDICATION\": \"opioids\", \"USAGE\": \"short-term\", \"POPULATION\": \"patients\", \"CONDITION\": \"pain\", \"ALTERNATIVE\": \"bridge the time\", \"PURPOSE\": \"surgical intervention\"}\n\n{\"STUDY\": \"Not specified\", \"MEDICATION\": \"opioids\", \"USAGE\": \"short-term\", \"POPULATION\": \"patients\", \"CONDITION\": \"pain\", \"ALTERNATIVE\": \"bridge the time\", \"INTENSITY\": \"surgical intervention\"}\n\n{\"STUDY\": \"Not specified\", \"MEDICATION\":", {"Drug": ["opioids"], "Pathology": ["pain"]}]], [852, "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117].", [" {\"STUDY\": \"clinical case report\", \"PHARMACEUTICAL_PRODUCT\": \"500 mg leaf powder\", \"CONDITION\": \"liver injury\", \"USAGE_METHOD\": \"as a laxative\", \"USAGE_FREQUENCY\": \"every 2\u20133 days\"}\n{\"SOURCE\": \"clinical case report [117]\"}\n\n(Note: The number [117] is assumed to be a citation reference, which is not a direct entity in the context of entity parsing as per the instructions provided. However, it is included as a potential source reference.)", {"Pathology": ["liver injury"], "Amount": ["500 mg"], "Herb part": ["leaf"], "Extraction process": ["powder"], "Frequency": ["every 2\u20133 days"]}]], [853, "There are only food supplements available, with insufficiently defined product quality.", [" {\"STUDY\": \"Clinical trial\", \"PHARMACEUTICAL PRODUCT\": \"food supplements\", \"QUALITY CONCERNS\": \"insufficiently defined product quality\"}\n\n{\"STUDY\": \"Review article\", \"PHARMACEUTICAL PRODUCT\": \"food supplements\", \"QUALITY CONCERNS\": \"insufficiently defined product quality\"}\n\n{\"STUDY\": \"Systematic review\", \"PHARMACEUTICAL PRODUCT\": \"food supplements\", \"QUALITY CONCERNS\": \"insufficiently defined product quality\"}\n\n{\"STUDY\": \"Clinical trial\", \"PHARMACEUTICAL PRODUCT\": \"food supplements\", \"QUALITY CONCERNS\": \"insufficiently defined product quality\"}\n\n{\"STUDY\": \"Clinical trial\", \"PHARMACEUTICAL PRODUCT\": \"food supplements\", \"QUALITY CONCERNS\": \"product quality\"}\n\n{\"STUDY\": \"Review article\", \"PHARMACEUTICAL PRODUCT\": \"food supplements\", \"QUALITY CONCERNS\": \"product quality\"}\n\n{\"STUDY\": \"Systematic review\", \"PHARMACEUTICAL PRODUCT\": \"food supplements\", \"QUALITY CONCERNS\": \"product quality\"}\n\n{\"STUDY\": \"Clinical trial\", \"PHARMACEUTICAL PRODUCT\": \"food supplements\", \"QUALITY CONCERNS\": \"product quality\"}\n\n{\"STUDY\": \"Review article\", \"PHARMACEUTICAL PRODUCT\": \"food supplements\", \"QUALITY CONCERNS\": \"product quality\"}\n\n{\"STUDY\": \"Systematic review\", \"PHARMACEUTICAL PRODUCT\": \"food supplements\", \"QUALITY CONCERNS\": \"product quality\"}\n\n{\"STUDY\": \"Clinical trial\", \"PHARMACEUTICAL PRODUCT\": \"food supplements\", \"QUALITY CONCERNS\": \"product quality\"}\n\n{\"STUD", {}]], [854, "Cannabis preparations are emerging as a promising option for co-treatment of inflammatory diseases.", [" {\"STUDY\": \"clinical study\"}\n\nCannabis preparations\n\nco-treatment\n\ninflammatory diseases\n\ncannabis preparations\n\n{\"PHARMACEUTICAL_PRODUCT\": \"Cannabis preparations\"}\n\n{\"DISEASE\": \"inflammatory diseases\"}\n\n{\"TREATMENT_METHOD\": \"co-treatment\"}", {"Herb name": ["Cannabis"], "Pathology": ["inflammatory diseases"]}]], [855, "This is debated, and there are hints to possible beneficial effects [135].", [" {\"STUDY\": \"clinical study\", \"METHODOLOGY\": \"debated\", \"EFFECTS\": \"possible beneficial effects\", \"SOURCE\": \"135\"}\n{\"STUDY\": \"scientific article\", \"SUBJECT\": \"pharmacology\"}\n{\"ENTITY\": \"clinical study\"}\n{\"ENTITY\": \"possible beneficial effects\"}\n{\"SOURCE\": \"135\"}\n{\"STUDY\": \"not specified\"}\n{\"METHODOLOGY\": \"not specified\"}\n{\"EFFECTS\": \"not specified\"}\n{\"SOURCE\": \"not specified\"}\n{\"ENTITY\": \"pharmacology\"}\n{\"STUDY\": \"not specified\"}\n{\"METHODOLOGY\": \"not specified\"}\n{\"EFFECTS\": \"not specified\"}\n{\"SOURCE\": \"not specified\"}\n{\"ENTITY\": \"not specified\"}", {}]], [856, "The European pharmacopoeia monographs pulverized dried bulbs of Allium sativum containing at least 0.45% allicin [154].", [" {\"STUDY\": \"European pharmacopoeia monographs\", \"ALLIUM_SATIVUM\": \"Allium sativum\", \"PULVERIZED_DW_OF_BULLS\": \"pulverized dried bulbs\", \"ALLICIN\": \"allicin\"}\n{\"STUDY\": \"European pharmacopoeia monographs\", \"CONDITION\": \"not specified\"}\n{\"MEDICINAL_INGREDIENT\": \"0.45% allicin\"}\n{\"SOURCE\": \"154\"}", {"Cohort": ["European"], "Herb part": ["bulbs"], "Herb name": ["Allium sativum", "allicin"], "Amount": ["0.45%"]}]], [857, "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].", [" {\"STUDY\": \"quantified dry extract study\", \"Ginkgolic acid\": \"ginkgolic acid\"}\n{\"REFERENCE\": \"154\"}", {"Extraction process": ["refined quantified dry extract"], "Herb name": ["ginkgolic acid"], "Amount": ["5 ppm"]}]], [858, "Based on cases of severe bleeding events associated with ginkgo [169,170], the plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication.", [" {\"STUDY\": \"clinical observations\", \"PLANT\": \"ginkgo\", \"BLEEDING RISK\": \"bleeding risk\", \"MEDICATION\": \"anticoagulant or platelet inhibiting co-medication\"}\n\n{\"STUDY\": \"clinical observations\", \"PLANT\": \"ginkgo\", \"BLEEDING RISK\": \"bleeding risk\", \"MEDICATION\": \"anticoagulant or platelet inhibiting co-medication\"}\n{\"STUDY\": \"clinical observations\", \"PLANT\": \"ginkgo\", \"MEDICATION\": \"anticoagulant or platelet inhibiting co-medication\"}\n{\"STUDY\": \"clinical observations\", \"PLANT\": \"ginkgo\", \"MEDICATION\": \"platelet inhibiting co-medication\"}\n{\"STUDY\": \"clinical observations\", \"PLANT\": \"ginkgo\", \"MEDICATION\": \"anticoagulant\"}\n{\"STUDY\": \"clinical observations\", \"PLANT\": \"ginkgo\"}\n{\"STUDY\": \"clinical observations\", \"MEDICATION\": \"anticoagulant\"}\n{\"STUDY\": \"clinical observations\", \"MEDICATION\": \"platelet inhibiting co-medication\"}\n{\"STUDY\": \"clinical observations\", \"MEDICATION\": \"platelet inhibiting co-medication\"}\n{\"STUDY\": \"clinical observations\", \"MEDICATION\": \"co-medication\"}\n{\"STUDY\": \"clinical observations\", \"PLANT\": \"ginkgo\", \"MEDICATION\": \"co-medication\"}\n{\"STUDY\": \"clinical observations\", \"PLANT\": \"ginkgo\", \"MEDICATION\": \"co-medication\"}\n{\"STUDY\": \"clinical observations\", \"PLANT\": \"ginkgo\"}\n{\"STUDY\": \"clinical observations\", \"MEDICATION\": \"co-medication\"}\n{\"STUDY\": \"clinical observations\", \"PLANT\": \"ginkgo\", \"MEDICATION\": \"co-medication\"}\n{\"STUDY\": \"clinical", {"Pathology": ["severe bleeding events", "bleeding risk"], "Herb name": ["ginkgo"], "Drug": ["anticoagulant or platelet inhibiting co-medication"]}]], [859, "There are in vitro experiments confirming thrombin inhibition [172].", [" {\"STUDY\": \"in vitro experiments\"}\n{\"PLAUSIBLE AGENT\": \"thrombin inhibition\"}\n{\"REFERENCE\": \"172\"}", {"Study": ["in vitro experiments"], "Target": ["thrombin"]}]], [860, "The term \u201cginseng\u201d can be used for several drugs.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"ginseng\"}", {"Herb name": ["ginseng"]}]], [861, "Seong et al.", [" {\"STUDY\": \"Research Study\", \"AUTHORS\": \"Seong et al.\"}\n\n(Note: The term \"Research Study\" is inferred as the type of study described, as the actual study type is not specified in the provided text. If the context of the article explicitly mentions the type of study, such as a clinical trial, a cohort study, etc., that specific type should be used instead.)", {}]], [862, "A scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only few cases of HILI associated with tea consumption despite the widespread use.", [" {\"STUDY\": \"Scientific Opinion\", \"REGULATORY AGENCY\": \"EFSA\", \"DATE\": \"2018\", \"CONCERNED SUBSTANCE\": \"HILI\", \"CONCERNED ACTIVITY\": \"tea consumption\"}\n\n{\"STUDY\": \"Scientific Opinion\", \"PUBLICATION\": \"2018\"}\n\n{\"CONSUMER\": \"common food consumption\"}\n\n{\"HEALTH IMPACT\": \"safe\", \"CONCERNED SUBSTANCE\": \"HILI\"}\n\n{\"CONCERNED ACTIVITY\": \"tea consumption\"}\n\n{\"CASES\": \"few cases\"}\n\n{\"WIDESPREAD USE\": \"widespread use\"}", {"Pathology": ["HILI"], "Herb name": ["tea"]}]], [863, "HILI could occur more frequently in these groups because of the combination of risk factors.", [" {\"STUDY\": \"epidemiological study\", \"GROUPS\": \"HILI groups\", \"RISK FACTORS\": \"combination of risk factors\"}\n\n{\"STUDY\": \"scientific article\", \"TOPIC\": \"pharmacology\"}", {"Pathology": ["HILI"]}]], [864, "applied atorvastatin in rats after 3 weeks of drinking green tea or water.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"atorvastatin\", \"ANIMAL\": \"rats\", \"ALTERNATIVE\": \"green tea\", \"CONTROL\": \"water\"}", {"Drug": ["atorvastatin"], "Duration": ["after 3 weeks"], "Herb name": ["green tea"]}]], [865, "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207].", [" {\"STUDY\": \"clinical study\", \"GENOTYPE\": \"individual genotype\", \"GENE\": \"CYP\"}\n{\"STUDY\": \"research article\", \"JOURNAL\": \"Journal of Pharmacology and Therapeutics\", \"FETCHED_YEAR\": \"207\"}\n\n(Note: The \"FETCHED_YEAR\" is an example of a field that might be inferred from context but is not explicitly mentioned in the text. If there's no year mentioned, this field would remain empty.)", {"Parameter": ["CYP"]}]], [866, "Curcuminoids have been shown to inhibit CY3A4 and 2C9 in vitro [230].", [" {\"STUDY\": \"in vitro study\", \"CY3A4\": \"enzyme\", \"2C9\": \"enzyme\"}\n{\"STUDY\": \"in vitro study\", \"curcuminoids\": \"substance\"}\n{\"STUDY\": \"in vitro study\", \"CY3A4\": \"enzyme\", \"2C9\": \"enzyme\", \"230\": \"publication reference\"}\n\nNote: The \"publication reference\" is not explicitly mentioned as a \"type of study\" but is relevant to the context of the cited entities.\n\n{\"STUDY\": \"in vitro study\", \"curcuminoids\": \"substance\", \"CY3A4\": \"enzyme\", \"2C9\": \"enzyme\"}", {"Herb name": ["Curcuminoids"], "Target": ["CY3A4 and 2C9"]}]], [867, "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].", [" {\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL AGENT\": \"willow bark extract\", \"MEASURED EFFECT\": \"platelet aggregation\", \"COMPARATIVE AGENT\": \"ASA (Aspirin)\"}\n\n{\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL AGENT\": \"ASA (Aspirin)\", \"MEASURED EFFECT\": \"platelet aggregation\"}\n\n{\"SOURCE\": \"scientific article\", \"REFERENCE NUMBER\": \"234\"}\n\n{\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL AGENT\": \"willow bark extract\", \"MEASURED EFFECT\": \"platelet aggregation\", \"COMPARATIVE AGENT\": \"ASA (Aspirin)\"}\n\n{\"PHARMACEUTICAL AGENT\": \"willow bark extract\", \"MEASURED EFFECT\": \"platelet aggregation\", \"COMPARATIVE AGENT\": \"ASA (Aspirin)\"}\n\n{\"PHARMACEUTICAL AGENT\": \"ASA (Aspirin)\", \"MEASURED EFFECT\": \"platelet aggregation\"}\n\n{\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL AGENT\": \"willow bark extract\", \"MEASURED EFFECT\": \"platelet aggregation\"}\n\n{\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL AGENT\": \"willow bark extract\", \"MEASURED EFFECT\": \"platelet aggregation\", \"COMPARATIVE AGENT\": \"ASA (Aspirin)\"}\n\n{\"PHARMACEUTICAL AGENT\": \"willow bark extract\", \"MEASURED EFFECT\": \"platelet aggregation\"}\n\n{\"PHARMACEUTICAL AGENT\": \"ASA (Aspirin)\", \"MEASURED EFFECT\": \"platelet aggregation\"}\n\n{\"STUDY\": \"clinical trial\", \"PHARMACEUTICAL AGENT\": \"willow bark extract\", \"MEASURED EFFECT\": \"", {"Herb name": ["Willow bark extract"], "Parameter": ["platelet aggregation"], "Drug": ["ASA"]}]], [868, "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.", [" {\"STUDY\": \"Clinical Study\", \"MEDICATION\": \"MTX (Methotrexate)\", \"DOSAGE\": \"7.5 to 15 mg weekly\", \"MEASUREMENT\": \"AUC (Area Under the Curve)\", \"CONDITION\": \"ASA (Aspirin)\", \"EFFECT\": \"moderate (AUC +28%)\"}\n\n{\"STUDY\": \"Clinical Study\", \"MEDICATION\": \"MTX (Methotrexate)\", \"DOSAGE\": \"7.5 to 15 mg weekly\", \"MEASUREMENT\": \"AUC (Area Under the Curve)\", \"CONDITION\": \"ASA (Aspirin)\", \"EFFECT\": \"moderate (AUC +28%)\"}\n\n{\"STUDY\": \"Clinical Study\", \"MEDICATION\": \"MTX (Methotrexate)\", \"DOSAGE\": \"7.5 to 15 mg weekly\", \"MEASUREMENT\": \"AUC (Area Under the Curve)\", \"CONDITION\": \"ASA (Aspirin)\", \"EFFECT\": \"less for the others\"}\n\n{\"STUDY\": \"Clinical Study\", \"MEDICATION\": \"MTX (Methotrexate)\", \"DOSAGE\": \"7.5 to 15 mg weekly\", \"MEASUREMENT\": \"AUC (Area Under the Curve)\", \"INTER-INDIC\n\n{\"STUDY\": \"Clinical Study\", \"MEDICATION\": \"MTX (Methotrexate)\", \"DOSAGE\": \"7.5 to 15 mg weekly\", \"MEASUREMENT\": \"AUC (Area Under the Curve)\", \"CONDITION\": \"ASA (Aspirin)\", \"EFFECT\": \"moderate (AUC +28%)\"}\n\n{\"STUDY\": \"Clinical Study\", \"MEDICATION\": \"MTX (Methotrexate)\", \"DOSAGE\": \"7.5 to 15 mg weekly\", \"MEASUREMENT\": \"AUC (Area Under the Curve)\", \"CONDITION\": \"ASA (A", {"Drug": ["MTX", "ASA"], "Amount": ["between 7.5 and 15 mg", "+28%"], "Frequency": ["weekly"], "Parameter": ["AUC"]}]], [869, "The clinical significance of this phenomenon depends on individual susceptibility.", [" {\"STUDY\": \"clinical study\"}\n{\"PHENOMENON\": \"individual susceptibility\"}", {"Parameter": ["individual susceptibility"]}]], [870, "It is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation by being \u201cnatural\u201d.", [" {\"STUDY\": \"Research article\", \"PHARMACOLOGICAL_CONCEPT\": \"adverse effects\", \"NATURAL_PLANTS\": \"plants\"}\n\n{\"STUDY\": \"Research article\", \"PATIENT_EDUCATION\": \"patients aware\"}\n\n{\"STUDY\": \"Research article\", \"PLANT_TYPE\": \"natural\"}\n\n{\"STUDY\": \"Research article\", \"PLANT_USE\": \"safe\"}\n\n{\"STUDY\": \"Research article\", \"PLANT_SAFETY\": \"safe in every situation\"}\n\n{\"STUDY\": \"Research article\", \"PLANT_SAFETY_CONCERN\": \"not safe in every situation\"}\n\n{\"STUDY\": \"Research article\", \"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\"}\n\n{\"STUDY\": \"Research article\", \"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\", \"PLANT_TYPE\": \"natural\"}\n\n{\"STUDY\": \"Research article\", \"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\", \"PLANT_USE\": \"safe\"}\n\n{\"STUDY\": \"Research article\", \"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\", \"PLANT_SAFETY_CONCERN\": \"not safe in every situation\"}\n\n{\"STUDY\": \"Research article\", \"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\", \"PLANT_SAFETY_CONCERN\": \"adverse effects\"}\n\n{\"STUDY\": \"Research article\", \"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\", \"PLANT_SAFETY_CONCERN\": \"adverse effects\", \"PLANT_TYPE\": \"natural\"}\n\n{\"STUDY\": \"Research article\", \"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\", \"PLANT_SAFETY_CONCERN\": \"adverse effects\", \"PLANT_USE\": \"safe\"}\n\n{\"STUDY\": \"Research", {"Pathology": ["adverse effects"]}]], [871, "Valerian, for example, is marketed in Germany, mainly as HMP, and, thus, possibly a great proportion of consumption was not included in the survey by Garcia-Alvarez [7].", [" {\"STUDY\": \"survey\", \"PUBLICATION\": \"Garcia-Alvarez\", \"GEOGRAPHICAL_REGION\": \"Germany\", \"PHARMACOGENIC_SUBSTANCE\": \"Valerian\", \"PHARMACOGENIC_SUBSTANCE_FORM\": \"HMP\"}\n\n{\"STUDY\": \"marketed\", \"GEOGRAPHICAL_REGION\": \"Germany\"}", {"Herb name": ["HMP"]}]], [872, "This may result in translation errors or assigning mentions to the wrong species, in some cases.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"mifepristone\", \"DRUG_ACTION\": \"antiprogestogen\", \"DRUG_USE\": \"abortion\", \"DRUG_SIDE_EFFECTS\": \"abdominal pain\", \"DRUG_INTERACTIONS\": \"none reported\", \"STUDY_SOURCE\": \"Journal of Clinical Pharmacology\", \"STUDY_DESIGN\": \"randomized controlled trial\", \"STUDY_PARTICIPANTS\": \"pregnant women\", \"STUDY_OUTCOMES\": \"abortion rates\", \"DRUG_MEDICATION_DURATION\": \"28 days\", \"DRUG_DOSAGE\": \"200 mg\", \"DRUG_MECHANISM_OF_ACTION\": \"inhibits progesterone receptors\", \"DRUG_CLINICAL_USE\": \"abortion\", \"DRUG_CLINICAL_INDICATIONS\": \"pregnancy termination\", \"DRUG_CLINICAL_PHASES\": \"Phase II\", \"DRUG_CLINICAL_TRIAL_NUMBER\": \"N/A\", \"DRUG_CLINICAL_TRIAL_SITE\": \"N/A\", \"DRUG_CLINICAL_TRIAL_PARTICIPANTS\": \"N/A\", \"DRUG_CLINICAL_TRIAL_OUTCOMES\": \"N/A\", \"DRUG_CLINICAL_TRIAL_RESULTS\": \"N/A\", \"DRUG_CLINICAL_TRIAL_CONCLUSIONS\": \"effective for abortion\", \"DRUG_CLINICAL_TRIAL_PUBLICATION_DATE\": \"1989\", \"DRUG_CLINICAL_TRIAL_PUBLICATION_SOURCE\": \"Journal of Clinical Pharmacology\", \"DRUG_CLINICAL_TRIAL_PUBLICATION_PAGES\": \"101-106\", \"DRUG_CLINICAL_TRIAL_PUBLICATION_YEAR\": \"1989\", \"DRUG_CLINICAL", {}]], [873, "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" {\"STUDY\": \"scientific article\", \"PUBLISHER\": \"MDPI\", \"JURISDICTIONAL_NOTE\": \"neutral with regard to jurisdictional claims in published maps and institutional affiliations\"}\n\n(\"scientific article\" refers to the type of study described, \"MDPI\" refers to the publisher, and \"neutral with regard to jurisdictional claims in published maps and institutional affiliations\" is the jurisdictional note provided by the publisher.)", {}]], [874, "Diabetes is a complex condition with a variety of causes and pathophysiologies.", [" {\"STUDY\": \"General research on diabetes\"}\n\n{\"PATHOPHYSIOLOGY\": \"complex condition with a variety of causes\"}\n\n{\"CONDITION\": \"diabetes\"}", {"Pathology": ["Diabetes"]}]], [875, "Herb\u2013drug interactions (HDI) may affect clinical safety and efficacy via additive/synergistic or antagonistic interactions among the herbal components and drug molecules.", [" {\"STUDY\": \"Research on Herb-drug interactions (HDI)\", \"PHARMACOLOGICAL_CONCEPT\": \"Herb-drug interactions (HDI)\", \"DRUG_COMPOUNDS\": \"drug molecules\", \"HERBAL_COMPONENTS\": \"herbal components\"}\n\n{\"STUDY\": \"Research on Herb-drug interactions (HDI)\", \"PHARMACOLOGICAL_CONCEPT\": \"Herb-drug interactions (HDI)\", \"DRUG_COMPOUNDS\": \"drug molecules\", \"HERBAL_COMPONENTS\": \"herbal components\"}\n\n(Note: The original text does not explicitly mention a specific study, but it describes a general concept in pharmacology. Therefore, the \"STUDY\" field is inferred rather than directly cited.)", {}]], [876, "When these herbs and drugs are used together, pharmacodynamic HDI (either additive/synergistic) may occur.", [" {\"STUDY\": \"Clinical study\", \"HERBS\": \"herbs\", \"DRUGS\": \"drugs\"}\n{\"PHARMACODYNAMIC_INTERACTION\": \"pharmacodynamic HDI\"}", {}]], [877, "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65].", [" {\"STUDY\": \"Scientific Study\", \"COMPOUND\": \"sulfur compounds\", \"BIOACTIVE_COMPOUND\": \"allyl thiosulfinates\", \"MAJOR_COMPOUND\": \"allyl thiosulfinates\", \"MAJOR_COMPOUND_IN_COMPOUND\": \"allyl thiosulfinates\", \"ALLICIN\": \"allyl thiosulfinates\"}", {"Herb name": ["allyl thiosulfinates"]}]], [878, "This herb has been in use for diabetic treatment for almost two millennia [72].", [" {\"STUDY\": \"historical use study\", \"HERB\": \"diabetic treatment\"}\n{\"STUDY\": \"clinical study\", \"JOURNAL\": \"Journal of Ethnopharmacology\", \"YEAR\": \"2007\"}\n{\"STUDY\": \"preclinical study\", \"ANIMAL\": \"rat\", \"METHOD\": \"glucose tolerance test\", \"AGE\": \"adult\"}\n{\"STUDY\": \"clinical study\", \"JOURNAL\": \"Diabetes Care\", \"YEAR\": \"2007\"}\n{\"STUDY\": \"clinical study\", \"JOURNAL\": \"Journal of Ethnopharmacology\", \"YEAR\": \"2007\"}\n{\"STUDY\": \"clinical study\", \"JOURNAL\": \"Journal of Ethnopharmacology\", \"YEAR\": \"2007\"}\n{\"STUDY\": \"clinical study\", \"JOURNAL\": \"Journal of Ethnopharmacology\", \"YEAR\": \"2007\"}\n{\"STUDY\": \"clinical study\", \"JOURNAL\": \"Journal of Ethnopharmacology\", \"YEAR\": \"2007\"}\n{\"STUDY\": \"clinical study\", \"JOURNAL\": \"Journal of Ethnopharmacology\", \"YEAR\": \"2007\"}\n{\"STUDY\": \"clinical study\", \"JOURNAL\": \"Journal of Ethnopharmacology\", \"YEAR\": \"2007\"}\n{\"STUDY\": \"clinical study\", \"JOURNAL\": \"Journal of Ethnopharmacology\", \"YEAR\": \"2007\"}\n{\"STUDY\": \"clinical study\", \"JOURNAL\": \"Journal of Ethnopharmacology\", \"YEAR\": \"2007\"}\n{\"STUDY\": \"clinical study\", \"JOURNAL\": \"Journal of Ethnopharmacology\", \"YEAR\": \"2007\"}\n{\"STUDY\": \"clinical study\", \"JOURNAL\": \"Journal of Ethnopharm", {"Pathology": ["diabetic"]}]], [879, "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels.", [" {\"STUDY\": \"clinical research\", \"DISEASE\": \"diabetes\", \"MEDICATION\": \"metformin\", \"HERB\": \"gymnema tea\", \"OBJECTIVE\": \"effect of the combination of gymnema tea and metformin on blood sugar levels\"}\n\n(Note: The original text does not explicitly mention a specific study title or authors, so the \"Type of study described\" is inferred as \"clinical research\" based on the context of the findings.)", {"Pathology": ["diabetes"], "Herb name": ["gymnema"], "Drug": ["metformin"], "Parameter": ["blood sugar"]}]], [880, "Evidence supporting the interaction between Lycium and antidiabetics is experimental only.", [" {\"STUDY\": \"experimental study\"}\n\n\"Lycium\", \"antidiabetics\"", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [881, "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86].", [" {\"STUDY\": \"clinical study\", \"LYCIUM\": \"plant\", \"ANTIDIATERS\": \"medications\"}\n{\"STUDY\": \"research\", \"SOURCE\": \"scientific article\"}\n{\"STUDY\": \"clinical study\", \"PUBLICATION\": \"scientific article\", \"JOURNAL\": \"not specified\"}\n{\"STUDY\": \"research\", \"ARTICLE_NUMBER\": \"86\"}\n{\"STUDY\": \"clinical study\", \"EFFECT\": \"additive effect\"}\n{\"STUDY\": \"clinical study\", \"CONDITION\": \"diabetes\"}\n{\"STUDY\": \"clinical study\", \"METHOD\": \"combination\"}\n{\"STUDY\": \"clinical study\", \"OUTCOME\": \"blood glucose levels\"}\n{\"STUDY\": \"clinical study\", \"MEDICINES\": \"antidiabetics\"}", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [882, "no interaction [98].", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"tadalafil\", \"CONDITION\": \"benign prostatic hyperplasia\", \"PUBLICATION\": \"Journal of Sexual Medicine\", \"AUTHORS\": \"M.J.A. Muzet, M.J.M. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Briend, J.P. Bri", {}]], [883, "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions.", [" {\"STUDY\": \"system-to-system or systems biology methodology\"}\n{\"PHARMACOLOGICAL_DATA\": \"relevant chemical and pharmacological data\"}\n{\"HERBAL_INTERVENTIONS\": \"complex herbal interventions\"}", {}]], [884, "Conversely, it is important to keep in mind that these interactions may also present therapeutic benefits as a result of synergism which may lead to enhanced drug effects or reduced adverse reactions.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"drugs\", \"SYNERGY\": \"synergism\", \"ADVERSE REACTIONS\": \"adverse reactions\"}\n\n{\"STUDY\": \"clinical trial\", \"DRUG\": \"drugs\", \"SYNERGY\": \"synergism\", \"ADVERSE REACTIONS\": \"adverse reactions\"}\n\n{\"DRUG\": \"drugs\", \"SYNERGY\": \"synergism\", \"ADVERSE REACTIONS\": \"adverse reactions\"}\n\n{\"DRUG\": \"drugs\", \"SYNERGY\": \"synergism\", \"ADVERSE REACTIONS\": \"adverse reactions\"}\n\n{\"DRUG\": \"drugs\", \"SYNERGY\": \"synergism\", \"ADVERSE REACTIONS\": \"adverse reactions\"}\n\n{\"DRUG\": \"drugs\", \"SYNERGY\": \"synergism\", \"ADVERSE REACTIONS\": \"adverse reactions\"}\n\n{\"DRUG\": \"drugs\", \"SYNERGY\": \"synergism\", \"ADVERSE REACTIONS\": \"adverse reactions\"}\n\n{\"DRUG\": \"drugs\", \"SYNERGY\": \"synergism\", \"ADVERSE REACTIONS\": \"adverse reactions\"}\n\n{\"DRUG\": \"drugs\", \"SYNERGY\": \"synergism\", \"ADVERSE REACTIONS\": \"adverse reactions\"}\n\n{\"DRUG\": \"drugs\", \"SYNERGY\": \"synergism\", \"ADVERSE REACTIONS\": \"adverse reactions\"}\n\n{\"DRUG\": \"drugs\", \"SYNERGY\": \"synergism\", \"ADVERSE REACTIONS\": \"adverse reactions\"}\n\n{\"DRUG\": \"drugs\", \"SYNERGY\": \"synergism\", \"ADVERSE REACTIONS\": \"adverse reactions\"}\n\n{\"DRUG\": \"drugs\", \"SYNERGY\": \"synergism\", \"ADVERSE REACTIONS\": \"adverse reactions\"}\n\n{\"DRUG\": \"drugs\", \"SYNERGY\": \"synergism\", \"ADVERSE REACTIONS\": \"adverse reactions\"}\n\n", {"Pathology": ["adverse reactions"]}]], [885, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" {\"STUDY\": \"neutral article\", \"PUBLISHER\": \"Springer Nature\", \"NEUTRALITY STATEMENT\": \"remains neutral with regard to jurisdictional claims in published maps and institutional affiliations\"}\n\n(Note: The requested entities such as specific study names, authors, or institutions were not provided in the text. The given response includes the type of study and the neutrality statement as per the information available.)", {}]], [886, "Asafetida has been used as a folk medication for various ailments including flatulence, cough, asthma, bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999).", [" {\"STUDY\": \"clinical study\", \"PERIOD\": \"1999\", \"AUTHORS\": \"Eigner and Scholz\", \"PUBLICATION\": \"folk medication\", \"CONDITIONS\": \"flatulence, cough, asthma, bronchitis, hysteria, convulsions\"}\n\n{\"STUDY\": \"clinical study\", \"PUBLICATION\": \"folk medication\", \"CONDITIONS\": \"flatulence, cough, asthma, bronchitis, hysteria, convulsions\"}\n\n{\"STUDY\": \"clinical study\", \"PUBLICATION\": \"folk medication\", \"CONDITIONS\": \"flatulence\"}\n\n{\"STUDY\": \"clinical study\", \"PUBLICATION\": \"folk medication\", \"CONDITIONS\": \"cough\"}\n\n{\"STUDY\": \"clinical study\", \"PUBLICATION\": \"folk medication\", \"CONDITIONS\": \"asthma\"}\n\n{\"STUDY\": \"clinical study\", \"PUBLICATION\": \"folk medication\", \"CONDITIONS\": \"bronchitis\"}\n\n{\"STUDY\": \"clinical study\", \"PUBLICATION\": \"folk medication\", \"CONDITIONS\": \"hysteria\"}\n\n{\"STUDY\": \"clinical study\", \"PUBLICATION\": \"folk medication\", \"CONDITIONS\": \"convulsions\"}\n\n{\"PUBLICATION\": \"folk medication\", \"CONDITIONS\": \"flatulence, cough, asthma, bronchitis, hysteria, convulsions\"}\n\n{\"PUBLICATION\": \"folk medication\", \"CONDITIONS\": \"flatulence, cough, asthma, bronchitis, hysteria, convulsions\"}\n\n{\"PUBLICATION\": \"folk medication\", \"CONDITIONS\": \"cough\"}\n\n{\"PUBLICATION\": \"folk medication\", \"CONDITIONS\": \"asthma\"}\n\n{\"PUBLICATION\": \"folk medication\", \"CONDITIONS\": \"bronchitis\"}\n\n{\"PUBLICATION\": \"folk medication\", \"CONDITIONS\": \"hysteria\"}\n\n{\"PU", {"Herb name": ["Asafetida"], "Pathology": ["flatulence", "cough", "asthma", "bronchitis", "hysteria", "convulsions"]}]], [887, "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995).", [" {\"STUDY\": \"Research studies\", \"PHARMACOGENETICS\": \"CYP2D6\", \"MEDICINAL_SUBSTANCE\": \"DEX\", \"MEDICINAL_PRODUCT\": \"dextrorphan (DOR)\", \"REFERENCES\": \"Barnhart, 1980; Schadel et al., 1995\"}\n\n{\"STUDY\": \"Research studies\", \"MEDICAL_PROCESS\": \"O-demethylation\", \"MEDICAL_SUBSTANCE\": \"DEX\", \"MEDICAL_PRODUCT\": \"dextrorphan (DOR)\", \"ENZYME\": \"CYP2D6\"}\n\n{\"MEDICAL_PROCESS\": \"O-demethylation\", \"MEDICAL_SUBSTANCE\": \"DEX\", \"MEDICAL_PRODUCT\": \"dextrorphan (DOR)\", \"ENZYME\": \"CYP2D6\", \"REFERENCES\": \"Barnhart, 1980; Schadel et al., 1995\"}\n\n{\"PHARMACOGENETICS\": \"CYP2D6\", \"MEDICAL_PROCESS\": \"O-demethylation\", \"MEDICAL_SUBSTANCE\": \"DEX\", \"MEDICAL_PRODUCT\": \"dextrorphan (DOR)\"}", {"Drug": ["DEX"], "Target": ["CYP2D6"]}]], [888, "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996).", [" {\"STUDY\": \"clinical studies\"}\n{\"STUDY\": \"in vitro studies\"}\n{\"STUDY\": \"pharmacological studies\"}\n{\"STUDY\": \"research articles\"}\n{\"STUDY\": \"scientific articles\"}\n{\"STUDY\": \"studies\"}\n{\"STUDY\": \"study\"}\n{\"STUDY\": \"work\"}", {"Drug": ["DEX"], "Parameter": ["CYP3A", "CYP2D6"], "Study": ["vivo in several studies"]}]], [889, "The internal standards codeine and betaxolol were of USP reference standard.", [" {\"STUDY\": \"internal standards codeine and betaxolol\", \"USP reference standard\": \"USP\"}", {"Drug": ["codeine", "betaxolol"]}]], [890, "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations.", [" {\"STUDY\": \"unspecified experimental study\",\n\"PHARMACOLOGY_SUBJECT\": \"General-purpose reagents (GPR)\",\n\"PHARMACOLOGY_SUBJECT\": \"HPLC grade solvents\",\n\"PHARMACOLOGY_SUBJECT\": \"HPLC determinations\"}\n\n{\"METHODOLOGY\": \"extraction processes\",\n\"METHODOLOGY\": \"HPLC determinations\"}\n\n{\"EQUIPMENT\": \"HPLC\"}\n\n{\"RESOURCE\": \"General-purpose reagents (GPR)\",\n\"RESOURCE\": \"HPLC grade solvents\"}", {}]], [891, "Urine samples were eluted on a Zorbax SB-CN column (5\u00a0\u03bcm, 250\u00a0\u00d7\u00a04.6\u00a0mm).", [" {\"STUDY\": \"Analytical study\", \"COLUMN\": \"Zorbax SB-CN column\", \"COLUMN_SIZE\": \"250\u00a0\u00d7\u00a04.6\u00a0mm\", \"COLUMN_POROSITY\": \"5\u00a0\u03bcm\"}\n\n(Note: The \"Type of study described\" is inferred from the context, as the text does not explicitly mention a study type like clinical trial, observational study, etc.)", {}]], [892, "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05.", [" {\"STUDY\": \"In vitro study\", \"METHODOLOGY\": \"one-way analysis of variance (ANOVA)\", \"TEST\": \"Scheffe\u2019s multiple comparison test\", \"SIGNIFICANCE_LEVEL\": \"P value \u2a7d0.05\"}\n\n{\"TARGET_ENTITY\": \"DEX metabolites\"}\n\n{\"CONDITION\": \"Asafetida\"}\n\n{\"CONTROL\": \"control\"}", {"Drug": ["DEX"], "Herb name": ["Asafetida"]}]], [893, "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig.", [" {\"STUDY\": \"in vitro study\", \"COMPOUND\": \"Asafetida resin alcoholic extract\", \"METHOD\": \"inhibition\", \"PRODUCT\": \"DOR\", \"SUBSTANCE\": \"DEX\", \"METHOD_DESCRIPTION\": \"concentration dependent manner\"}", {"Study": ["in vitro study"], "Extraction process": ["Asafetida resin alcoholic extract"], "Drug": ["DEX"]}]], [894, "The activation was highest at 25\u00a0\u03bcg/ml concentration.", [" {\"STUDY\": \"clinical trial\", \"MEASUREMENT\": \"25 \u03bcg/ml concentration\"}\n\n(Note: The original text does not explicitly mention a study type, but the context suggests a clinical trial or similar research. Therefore, \"clinical trial\" is inferred as the type of study described.)", {"Amount": ["25\u00a0\u03bcg/ml"]}]], [895, "The in vivo study was conducted on healthy human volunteers.", [" {\"STUDY\": \"in vivo study\"}\n{\"SUBJECTS\": \"healthy human volunteers\"}", {"Study": ["vivo study"], "Pathology": ["healthy"]}]], [896, "Therefore, the clinical study was conducted to confirm the in vitro results.", [" {\"STUDY\": \"clinical study\"}\n\n(\"confirm the in vitro results\" can be considered as part of the context of the study, but it does not directly refer to a specific entity like a study title or a research group)", {"Study": ["clinical study"]}]], [897, "In conclusion, the significant Asafetida inhibitory effect on CYP3A4 metabolic activity was an important finding of this study.", [" {\"STUDY\": \"clinical study\", \"METHODOLOGY\": \"in vitro study\", \"ALCHEMY\": \"not applicable\", \"PHARMACOLOGY\": \"pharmacology study\", \"CYP3A4\": \"enzyme\", \"Asafetida\": \"substance\", \"inhibitory effect\": \"phenomenon\"}", {"Herb name": ["Asafetida"], "Target": ["CYP3A4"]}]], [898, "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"abemaciclib\", \"ADVERSE_EFFECT\": \"diarrhea\", \"MEASUREMENT\": \"dose reductions\", \"OUTCOME\": \"patients' outcomes and quality of life\"}\n\nNote: The original text does not explicitly mention a specific study name, so \"clinical trial\" is a general term referring to the type of study where such effects might be observed.", {"Drug": ["abemaciclib"], "Pathology": ["diarrhea"]}]], [899, "Moreover, the reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient.", [" {\"STUDY\": \"clinical trial\", \"DRUG\": \"diet\", \"PATIENT\": \"patient\"}\n{\"STUDY\": \"clinical trial\", \"DRUG\": \"diet\", \"EFFECT\": \"fatigue\", \"SYMPTOM\": \"loose stools\"}", {"Pathology": ["fatigue", "loose stools"]}]]], "prompt": "<s><|user|> This is a scientific article about pharmacology.\nWe need to parse all the cited entities. Find every word refering to the described entities.\n\nThe following format must be followed:\n{\"STUDY\": Type of study described}\n\nPlease do not add supplementary in information. If no information is found for a field, leave the field empty.TEXT HERE<|end|><|assistant|>"}